Insulin Analogues for Insulin Receptor Studies and Medical Applications by Watson, Christopher John
  
Insulin Analogues for Insulin Receptor 
Studies and Medical Applications 
 
 
 
Christopher John Watson 
 
 
 
 
PhD 
 
 
 
 
University of York 
Department of Chemistry 
 
 
September 2012 
 
  
  
2 
 
Abstract 
The structure of insulin molecule was determined by Dorothy Hodgkin in 1969. 
Subsequently, it has been established that insulin must rearrange upon binding to its 
receptor (Insulin Receptor – IR). However, all known structures of the hormone depict its 
storage or inactive form. It has been shown that some residues, key for IR binding, are 
buried inside the insulin molecule and must be exposed for an efficient insulin-IR complex 
formation. It has been postulated that the C-terminal region of the B-chain (~B
20
-B
30
) is 
dynamic in this process, and that the detachment of the B
20
-B
30
 β-strand leads to the 
activation of insulin. However, the understanding of the molecular basis of the insulin 
regulatory role is hindered by the lack of the structure of the insulin-IR complex; only 3-D 
description of the apo-form of the IR ectodomain is known. The very complex molecular 
biology behind expression and production of IR fragments also hampers progress in this 
field. 
             In order to facilitate progress towards determination of the insulin-IR complex 
crystal structure this work delivered: (i) structural characterisation of highly-active insulin 
analogues for stable hormone-IR complexes, (ii) development of various attempts for an 
alternative production of L1 domain of human IR, (iii) structural characterisation of the role 
of residues B
24
 and B
26 
for
 
insulin function, (iv) clarification of individual contributions of 
hydrogen bonds stabilising the insulin dimer, (v) understanding of the structural basis of 
different functionality of click-chemistry based novel insulin analogues.  
            This work established that: 
(i) the structural signature of the highly active insulin analogues is new -turn at the C-
terminus of the B-chain (the B26 turn) achieved by trans-to-cis isomerisation of the Phe
B25
-
Tyr
B26
 peptide bond. This conformational change exposes residues responsible for IR 
binding, (ii) the production of the L1 domain in E. coli, instead of the usual mammalian 
expression system, is not feasible, (iii) the structural invariance of the Phe
B24
 is fundamental 
to the formation of the insulin-IR complex. It acts as an anchoring and side-chain pivot for 
the B26 turn, (iv) removal of the NH
B25
-CO
A19
 dimer interface hydrogen bond is sufficient 
for a complete disruption of the dimer, whilst the other four hydrogen bonds had a less 
marked effect in this process, (v) the formation of the B26 turn can be efficiently mimicked 
by click-chemistry based intra-B-chain crosslinks.  
             These results provide a wealth of information about the active form of insulin, they 
provide important tools towards the first insulin-IR complex, and deliver novel insulin 
analogues. 
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Summary of Aims 
The main aims for the project are: 
 To determine the crystal structures of series of highly-active insulin analogues in 
order to delineate the active conformation of the hormone  
 To develop alternative methods of expression of the L1 domain of human IR  
 To identify clear structural and functional roles of Phe
B24
 and Phe
B26
: two
 
key 
invariant amino acids in vertebrate insulins, important for IR binding 
 To clarify the individual contributions of hydrogen bonds that stabilise the insulin 
dimer 
 To explore the application of click-chemistry in making new generations of insulin 
analogues 
As this thesis consists of multidirectional, and in some cases independent lines of 
research, with structural biology of insulin as the only common feature, an additional 
summary is also presented at the beginning of every appropriate chapter.  
This work also included attempts in the production of Insulin-like Growth Factor-1 
(IGF-1) core for future semi-syntheses. Crystallisation and preliminary structural work on 
complex of Drosophila DLP-5 insulin-like peptide with its IMPL-2 insulin binding protein 
have also been undertaken within this project. However, as these subjects are side- (or late) 
tracks of the main aspects of this thesis they are described in the appendix. 
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Chapter 1. Introduction 
1.1. Summary of Insulin Molecular Data 
 
Insulin is a 51 amino acid protein hormone, which plays an important role in many key 
cellular processes. It exerts its regulatory function (e.g. uptake of glucose into cells) through 
a signalling pathway initiated by binding of hormone in its monomeric form to its dimeric, 
tyrosine-kinase type membrane receptor (insulin receptor – IR (see chapter 1.4)). Insulin 
governs the intermediary metabolism of glucose along with the regulation of carbon 
sources. It is also responsible for stimulating lipogenesis, glycogen and protein synthesis 
whilst inhibiting their reverse conversions (Figure 1)
1
. Moreover, insulin is also involved in 
the stimulation of cell growth and differentiation. 
 
Figure 1. The main pathways of insulin-dependent regulation of metabolism. 
Insulin is the most potent anabolic hormone, promoting the synthesis and storage of 
carbohydrates, lipids and protein whilst inhibiting their catabolism. Insulin stimulates the 
uptake of glucose, amino acids and fatty acids into cells, whilst also increasing the 
expression or activity of enzymes that are responsible for these processes. Insulin inhibits 
the activity or expression of those that are responsible for catalysing degradation
1
. 
 
The mature form of human insulin consists of 51 amino acids arranged into an A-
chain (Gly
A1
-Asn
A21
) and a B-chain (Phe
B1
-Thr
B30
) of total molecular mass of 5808 Da ( 
Figure 2). The molecule is stabilised by two inter-( A
6
-A
11
, A
7
-B
7
) and one intra-
chain disulphide bonds (A
20
-B
19
). 
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Figure 2. The amino acid sequence of mature human insulin. 
 
The first insulin crystal structure was determined in 1969 by Dorothy Hodgkin
2
 
who studied hexameric crystals of pig insulin, which differs from the human hormone by 
only the B-chain C-terminal residue (Thr
B30→AlaB30)2-4. It has been discovered that in the 
A-chain residues A
2
-A
8
 and A
13
-A
19
 form α-helices, whilst the B-chain is organised by B9-
B
19
 α-helix, B19-B22 β-turn and B23-B30 that form a β-sheet (Figure 3).  Subsequently, it has 
been discovered that the B-chain N-terminus (B
1
-B
8
) can exist in two different 
conformations: R and T
5
. The so-called R-state of the hormone corresponds to more 
‘relaxed’ and allosterically more active form of this protein, in which an additional α-helical 
region is created by the B
1
-B
19
 residues (i.e.
 
B
9
-B
19
 α-helix is extended). The ‘tense’ T-state 
state is less active, with residues B
1
-B
19
 residues not forming a regular secondary structure 
and folding away from the core of the hormone.  The overall arrangement of the A and B 
chains results in the A-chain N-terminus and B-chain C-terminus being brought into close 
proximity.  This forms a hydrophobic core buried within the molecule, consisting of Ile
A2
, 
Val
A3
, Cys
A11
, Leu
A16
, Leu
B11
 and Leu
B15
 
3,6
. 
 
Figure 3. The T- and R-states of insulin monomer. 
The A-chain is shown in red, whilst the B-chain is in blue. (pdb used: 1mso [T-state] and 
1znj [R-state]); the monomers showed here are derived from hexamer oligomers present in 
these crystals. 
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Insulin can exist in three oligomeric forms: hexameric, dimeric and monomeric. 
Hexameric insulin is the main storage form of the hormone with Zn
2+
 ion located at its 
centre of the hexamer, and coordinated by His
B10
. Upon the dilution of hexamer containing 
crystals into the local environment (e.g. during excretion of insulin into the bloodstream) 
the hexamer disassociates into three dimers, which subsequently split into monomers 
(Figure 4).  The insulin hexamer (Figure 5) contains two or four (even number) Zn
2+
 ions 
coordinated at its centre 
3
.  In the 2-Zn
2+
 structure, all six monomers are in the T-state 
(denoted as (T6))
2
. In the 4-Zn
2+
 hexamer (stabilised by a high Cl
-
 concentration), three of 
the monomers are in the T-state and three are in the R-state (R3T3)
7
. A similar state to R3T3 
has been found 
8
 termed T3R3
f
, where in the R
f
 conformer the B
4
-B
19
 residues are R-like, α-
helical, but the B
1
-B
3
 are in an extended form. A fully R6 form exists in phenol-(or phenol-
like compounds) containing crystals 
5
 There are currently over 100 structures of insulin in 
the Protein Data Bank, though there are none of monomeric wild type (WT) insulin, nor a 
complex between monomeric insulin and IR. 
 
 
Figure 4.  The hexamer-to-monomer disassociation of insulin. 
The hexameric form, upon the loss of the Zn
2+
 ions at its centre breaks down into a 
monomer via a dimeric state. 
 
Figure 5. The general organisation of the insulin hexamer. 
The insulin hexamer comprises three distinct dimers. One of the monomers has its chains 
coloured as per Figure 3, with the rest shown in green. The Zn
2+
 ions are located at the 
centre of the hexamer. (pdb used: 1ZNJ). 
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The insulin hexamer is formed by three dimers that are arranged in a 32 point 
symmetry (Figure 5). The dimer interface is stabilised by strong interactions, mostly 
hydrogen bonds, between the two anti-parallel β strands at the C-terminus of the B-chain 
provided by each of the monomers (~B
21
-B
27
) (Figure 6). 
 
 
 
 
 
 
 
 
Figure 6. A close up view of the β-strands region of 
two monomers at the dimer interface. 
(A) An overview of the dimer interface, chains coloured as 
per Figure 3. (B) A close up view of the hydrogen bonds in 
the dimer interface (pdb used: 1ZNJ). Carbon atoms in 
green, oxygen - red and nitrogen - blue. 
 
 
The Insulin-like Growth Factors 1 and 2 (IGF-I and IGF-II) are insulin-related 
small single-chain hormones with molecular masses of 7.6 kDa and 7.5 kDa 
respectively
9,10
(Figure 7). IGFs are major growth factors in the embryonic-puberty phase of 
development
11
.  The IGFs are also involved in the induction of differentiation of whole 
cells, and processes within cells
12
. The actions of IGF are tightly controlled by growth 
factors
13
. 
 
Figure 7. Amino acid sequence of the mature human insulin, IGF-I and IGF-II 
hormones. 
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1.2. Discovery and Genetic Engineering of Insulin 
In 1869, Paul Langerhans identified some previously undiscovered tissue clumps 
scattered throughout the pancreas 
14
.  Whilst the functions of these clumps were initially 
unknown, they later became known as the Islets of Langerhans. The name insulin has its 
origins in Insel, the German word for islet/island. Edouard Laguesse subsequently 
suggested that these cells might be involved in the production of secretions that could have 
a role in digestion
15
. 
Oscar Minkowski, in collaboration with Joseph von Mering, established the relationship 
between the pancreas and diabetes 
14,16
.  Soon after in 1901, Eugene Opie showed the link 
between the Islets of Langerhans and diabetes, stating “Diabetes Mellitus … is caused by 
destruction of the Islets of Langerhans and occurs only when these bodies are in part or 
wholly destroyed” 17. 
During the next two decades various attempts were made to isolate the secretion of the 
Islets for application in the treatment of diabetes. Zuelzer was first to apply a pancreatic 
extract, and was partially successful in the treatment of dogs with diabetes in 1906
14
. Insulin 
(called “pancrein”) was isolated for the first time by Paulesco in 192118.  The final 
breakthrough in early insulin research and clinical applications was provided by Frederick 
Banting, J. J. R. Macleod, Charles Best, James Collip and Clark Noble in 1922 when the 
first injection of the purified insulin on January 11
th
 1922 was given to a 14 year old 
diabetic patient
16
.  They scaled up their biochemistry with the involvement of Eli Lilly & 
Co, and in November 1922 the first large amounts of highly refined, pure insulin were 
available for clinical and widespread treatments of diabetes
15
.  
Further understanding of the insulin molecule was provided by Frederick Sanger who 
determined the primary structure of insulin in 1951 
19
.  This was the first determination of 
any protein primary structure, an achievement for which Frederick Sanger was awarded the 
1958 Nobel Prize in Chemistry. This work lead to the first full synthesis of insulin by 
Panayotis Katsoyannis
20
 and Helmut Zahn
21
 in the 1960s.  Finally, Dorothy Hodgkin made 
the pioneering structural breakthrough in 1969, when after decades of work she determined 
the crystal structure of insulin utilising X-ray diffraction methods
4
, for which she was 
awarded the Nobel prize in Chemistry in 1964.   
Sanger’s discovery, along with advancements in molecular biology, allowed Herbert 
Boyer to insert the human insulin gene into genetically engineered E.coli, and produce this 
hormone in large and pure amounts in 1978
22
. Genetech (founded by Boyer), along with Eli 
Lilly and Co, delivered the first commercial biosynthetic human insulin called Humulin in 
1982
22
.  Currently, there are there are 1.4 million people in the UK alone who rely upon 
daily injections of recombinant insulin to control their diabetes. 
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1.3. Insulin Biosynthesis and Bioavailability 
 
There are three types of stimulus that are responsible for the release of insulin.  The first 
is the detection of an increase in blood sugar levels. Insulin secretion can also be stimulated 
in response to an increased blood concentration of alternative carbon sources such as amino 
acids and fatty acids, and neural stimuli such as the sight and taste of food. 
A prolonged increase in blood sugar levels is detected by both the hypothalamus 
and pancreatic beta-cells
23
, which triggers the translation of insulin mRNA in the Islets of 
Langerhans, the beta-cells in the pancreas.  The insulin mRNA is translated as a single chain 
molecule called preproinsulin, which consists of 110 amino acids. The preproinsulin is 
transported to the rough endoplasmic reticulum, where its signal peptide is removed during 
insertion into the cisternal space, forming proinsulin (Figure 8).   
 
Figure 8. The process of insulin biosynthesis and maturation. 
 
The processing of preproinsulin is an important step in the formation of the mature 
hormone. The signal peptide removed from the preproinsulin is packaged where it is 
accumulated prior to being recycled in the cytoplasm.  Proinsulin consists of three domains; 
an amino-terminal B-chain, a carboxy-teminal A chain, and B-A connecting peptide known 
as the C-peptide. The endoplasmic reticulum contains several specific endopeptidases, 
which excise the 31 amino acid C-peptide chain from the proinsulin to create the mature 
insulin molecule.  Insulin is prevented from possibly becoming misfolded, by formation of a 
hexameric assembly with Zn
2+
 ions. The insulin hexamer is stabilised further by 
microcrystallisation
24
.  The C-peptide and mature insulin are packaged into secretory 
granules, which accumulate in the cytoplasm.  Once the beta-cells are stimulated (Figure 9), 
the insulin is secreted from the cell by exocytosis of the secretory granules; the dilution-
caused leakage of Zn
2+
 ions from hormone hexamers/dimers leaves an insulin zinc-free 
monomer
25
 in the bloodstream
26
. The C-peptide is also secreted (Figure 9), but its biological 
activity has not yet been identified.  
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Figure 9.  Insulin biosynthesis within beta-cells of the pancreas.   
The major steps involved in insulin biosynthesis, from the expression of preproinsulin to the 
secretion of mature insulin.  Preproinsulin is converted to proinsulin in the rough 
endoplasmic reticulum, which is then followed by the folding of the molecule and formation 
of the correct pattern of disulphide bonds.  Proinsulin is then transported to the Golgi, from 
which it is secreted in granules, in which the conversion of the pro-hormone to the mature 
insulin takes place.  Fusion of the granules with the plasma membrane leads to the eventual 
secretion of mature insulin from the beta-cell.  A small proportion of unprocessed proinsulin 
is also secreted via an unregulated pathway
27
. 
 
The pathway by which insulin is secreted is known, but not fully understood.  
Glucose enters the beta-cells by facilitated diffusion utilising a glucose transporter, GLUT2. 
The glucose molecule is then phosphorylated by the rate-limiting enzyme glucokinase. 
Simultaneously, insulin inhibits glucose-6-phosphatase to prevent the phosphates from 
being removed. This causes the glucose molecule to become trapped within the beta-cells, 
where its metabolism increases the ATP:ADP  ratio, causing the closure of the ATP-gated 
cell membrane potassium channels. This prevents the escape of potassium ions from the 
cell, and its subsequent depolarisation, which then activates the voltage gated calcium 
channels. Subsequently, a rapid increase in intracellular calcium triggers the exocytosis of 
insulin-containing granules
28
. 
Release of insulin stimulates the uptake of glucose into cells by the sequestration of 
intracellular vesicles containing GLUT4 from intracellular stores to the cell membrane
29
.  
The exact mechanism by which a GLUT4-vesicle reaches the membrane is unknown, but it 
is believed that this vesicle is attached to an intracellular site that is linked to the membrane 
by a microtubule network
30
. The GLUT4-vesicles are untethered from their intracellular site 
and are transported along the microtubules towards the membrane in response to insulin:IR 
The Beta Cell 
20-40 min 
Rough 
Energy Dependent 
Transfers 
Unregulated Secretion 
Proinsulin ~ 1-2% 
Membrane Proteins 
+ 
Constitutive Pathway 
  
23 
 
binding and the resultant IR-initiated phosphorylation cascade. The docking and fusion of 
the vesicles with the membrane makes the GLUT4 available for glucose uptake.  It has been 
postulated that insulin may also regulate the docking and fusion of the GLUT4 vesicle with 
the cell membrane by a direct regulation of the v/t-SNARE proteins that are required for an 
efficient fusion of the vesicle and the cell membrane
29
. The time-dependent decrease in the 
insulin blood level results in a smaller number of stimulated IRs, which leads to the reverse 
endocytosis of GLUT4 transporters from the membrane back into vesicles, and their return 
to the cytoplasm
31
. 
Stimulation of insulin release is readily observed in animals and humans. The 
normal fasting blood glucose concentration in humans is tightly controlled at 80-90 mg/100 
ml (~5 mM)
1
 (Figure 10), and is associated with very low levels of insulin secretion (Figure 
11) and its short (4-6 min) half-life in the blood 
32
.  The serum levels of insulin increase 
dramatically almost immediately after the meal. This initial increase is due to secretion of 
preformed/stored insulin, which is quickly depleted. A secondary rise in insulin is assured 
by newly synthesised insulin that is immediately released 
27
. 
 
Figure 10. The general network of regulation of blood glucose levels.   
The increase of the blood sugar level leads to secretion of insulin by the pancreas. The 
body-circulation of this hormone, and its binding to the IR results in the uptake of glucose 
into cells, causing the blood sugar level to decrease.  Consequently, glucagon  - a hormone 
that works in tandem with insulin reversing its actions - is excreted by the pancreas to 
breakdown glycogen into glucose in the liver.  This glucose is then released into the 
bloodstream to raise the blood sugar level. 
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Figure 11.  Daily profile of NEFA (non-esterified fatty acid) concentrations and 
serum insulin concentrations. 
The NEFA levels are an indicator of blood glucose levels. Adapted from Daly
33
. 
 
After initiation of the intracellular signalling the insulin:IR complex is 
endocytosed
34
.  The complex is transported along the endocytic pathway, where is either 
recycled back to the cell surface, or targeted to the lysosome for degradation via the late 
endosomes 
35
. Internalisation of the IR depends on the IR autophosphorylation state, and is 
followed by downstream effects through the clathrin-mediated pathway
31
. There is also 
evidence for other, alternative pathways of IR internalisation 
34,36
. 
The overall maintenance of the plasma glucose level is achieved by balancing the 
glucose intake into the plasma from the intestine and its uptake to peripheral tissue. A drop 
of the blood glucose level below ~2.5 mM threshold level results in the stoppage of 
glycogen synthesis in the liver, and simultaneous activation of its breakdown. Insulin has a 
versatile role in the maintenance of blood glucose levels
1
 as it is also responsible for the 
inhibition of hepatic glucose production. Moreover, the metabolic effects resulting from the 
insulin actions depend on the type of the tissue, e.g. some tissues take up glucose 
independently of insulin.  For example, the brain relies upon glucose as its sole energy 
source
37
 and utilises a non insulin-dependent glucose transporter.  The skeletal muscle is the 
primary tissue responsible for insulin-regulated glucose uptake, while only a small fraction 
of glucose is taken up by adipose tissue
38
.  
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1.4. Molecular Organisation of the Insulin Receptor 
 
The first indication that insulin does not play an ‘enzymatic’ role in carbohydrate 
metabolism, but rather it interacts with the cell membrane was postulated by Levine in 
1949, who proposed that insulin facilitates the uptake of hexoses into cells
39
. Subsequently 
House and Weidemann showed binding of insulin to liver cells using radio-labelled 
insulin
40
.  Only in 1980-1981 was it demonstrated that the IR is a dimer with an apparent 
molecular weight of ~350 kDa and comprised of two α-subunits (~120-130 kDa) and two β-
subunits (~90 kDa) interconnected by disulphide bonds
41,42
. 
Soon, it was discovered that the intracellular parts of the β-subunits contain tyrosine 
kinase (TK) that is activated upon insulin binding
43,44
. This led to the subsequent 
identification of an intracellular substrate for this kinase - IR substrate 1, IRS1
45,46
. 
Two laboratories determined the cDNA of the human IR independently in 1985
47,48
 
revealing two different isoforms (IR-A, IR-B) of the receptor. They arise from alternative 
splicing, which results in different (12 amino acids) lengths of the IR at the C-terminus of 
the α-subunit.  In IR-A exon 11, consisting of 36 base pairs, is excised whilst being 
preserved in the IR-B. Further studies led to the discovery of 18 potential N-linked 
glycosylation sites
49
, with a further six O-linked glycosylation sites
50
. The structure of the 
unphosphorylated human TK was determined in 1994 by Hubbard et al.
51
, elucidating its 
activated, phosphorylated structure. This revealed the auto-phosphorylation of three 
tyrosines (Tyr
1158
, Tyr
1162
, Tyr
1163
) in the activation loop (A-loop) leads to a dramatic change 
of the IR conformation
52
. The crystal structure of the IR ectodomain dimer was solved in 
2006, a major achievement in insulin research
53
. The structure solution was facilitated by 
co-crystallisation with monoclonal antibodies (Fabs)
54,55
. 
IRs share very similar domain organisation to the Epidermal Growth Factor receptors 
(EGFR). In both families of these receptors an aberrant signalling has been implicated in 
different types of cancers. Study of the EGFRs can lead to important information in the 
study of the IR
56
. 
The IR (Figure 12) is a member of a sub-family of receptors that contain a TK, whose 
other members include the Insulin-Like Growth Factor (IGF)-I receptor  (IGF-1R) and 
insulin receptor-related receptor (IRR)
57
. These receptors are dimeric receptors which 
contain two α- and two β-subunits that function as allosteric enzymes, where the apo-form 
of an α-subunit inhibits the TK activity of the β-subunit 1. Binding of insulin to the IR 
abolishes the repression of TK activity, resulting in cross-phosphorylation of the β-subunit 
that induces further conformational changes and an increase of its activity 
58
.  The similar 
structure of the substrates of the IR, IGF-I and IRR receptors, results in their functional 
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hybrids, hence a mutation in one type of the receptor can have a functional consequences 
for the other types 
57
. The hormone binding sites of the receptor are located within the fully-
extracellular α-subunits.  
The IR ectodomain consists of the complete α-chain and 194 residues (Ser724-Lys917) of 
the β-chain.  Each IR monomer contains several structural domains (Figure 12) including a 
leucine-rich repeat domain (L1 residues 1–157), a cysteine-rich region (CR, residues 158–
310), a second leucine-rich repeat domain (L2, residues 311–470), and three fibronectin 
type-III domains (FnIII-1 residues 471–595, FnIII-2 residues 596–808, and FnIII-3 residues 
809–906). The FnIII-2 region includes a 118-residue insert domain (ID, residues 638–756) 
that contains the α∕β cleavage site at residues 720–723, which creates the α- and β-chains. 
The segments of the ID that lie within the α- and β-chains are identified as IDα and IDβ, 
respectively. The C-terminus of the α-subunits consists of residues 704-719 (CT peptide). 
The C-terminus of the FnIII-3 domains consists of a single transmembrane helix, followed 
by a ~40 residue intercellular juxtamembrane region (JM), a tyrosine kinase (TK) catalytic 
domain, and a ~100-residue C-terminal tail (Figure 13) 
59-61
. The IR receptor assembles into 
an inverted “V” shape53,61, with the L1-CR-L2 domains forming one side of the V, whilst the 
three FnIII domains form the other.  When the receptor dimerises, a two-fold rotation about 
the inverted V axis is formed by the L1-CR-L2 side packing against the three FnIII domains 
in the other monomer
59
.   The IGF-1R has a very similar domain organisation. 
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Figure 12. (A) An overview of the organisation of the IR. (B) A close up of the α-
subunit of the IR. 
In (B) The arrows indicate insulin binding locations, as determined by single amino acid-
directed mutagenesis
60. The majority of these binding “hotspots” are located in the L1 
region. The black spots are sites of N-glycosylation. 
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Figure 13. Modular structure of the IR aligned against known structures of its 
domains. 
The supra-molecular domain organisation of the IR. The structures shown do not imply the 
actual structure of the IR, but are shown to indicate the domain structures known. Adapted 
from De Meyts and Whittaker
62
. 
 
The IR L1 domain contains the majority of residues involved in insulin binding and 
consists of a series of β-sheets 55. Mutations in these residues lead to insulin binding 
defects
63
, making it the key domain of binding
60
 (Figure 14).  
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Figure 14  Main chain fold of the IR L1 region observed in apo-IR ectodomain 
crystal structure. 
Two different views of the L1 domain of the human apo-IR ectodomain crystal structure. 
The β-strands are colour through in rainbow style (pdb used : 2hr7). 
 
There have been many unsuccessful attempts to achieve a stable insulin:IR complex 
for structural studies. Interestingly, the CT peptide has been shown to be vital for effective 
binding of insulin to the IR
64
 .   Despite its location at the end of the -subunit it interacts 
with the L1 domain and insulin molecule, although their structural 3-D arrangement is 
unknown
65
. 
The isoforms of the IR have been identified in various human cells
66
, as well as in 
the cells of rats, rhesus monkeys and sheep 
67
.  The expression of IR-A and IR-B is tissue-
dependent.  The liver almost entirely expresses IR-B, whilst muscle, isolated adipocytes and 
cultured fibroblasts preferentially express IR-B over IR-A
67
.  IR-A is found predominantly 
in leukocytes, whilst similar amounts of both isoforms are found in placenta, skeletal 
muscle and adipose tissue
68
.  The steady-state binding of insulin is significantly higher in 
IR-A than in IR-B
69
.  Importantly, the ability of IGF-I to compete with insulin for binding is 
significantly higher for IR-A than IR-B 
67
, and IGF-II binds preferentially to the A isoform 
over the B form with a very high nanomolar affinity (Figure 15, Table 1). The effects of 
IGF-II via IR-A are mitogenic compared to the metabolic effects of insulin 
70
. Upon 
activation of the IR by insulin and phosphorylation of the IRS-1, this IR substrate acts as a 
docking centre where other enzymes and substrates can be activated to transduce further the 
effects of insulin
45,46
. 
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Figure 15.  The divergence of IGF and insulin, and their various effects. 
 
Table 1.  The binding affinity of insulin, IGF-I and IGF-II towards IR-A, IR-B 
and IGF-1R. 
KD is measured in nM
71
. 
 Insulin IGF-II IGF-I 
IR-A 0.2-1.0 1.0-6.6 9.0->30.0 
IR-B 0.5-1.6 36.3 >30.0 
IGF-1R >30.0 0.5-4.4 0.2-2.5 
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1.5. Molecular Action of Insulin 
 
There is a general consensus within the literature that the conformation of the active 
form of insulin monomer, i.e. its structure in the complex with IR must be different from the 
currently known structures of the hormone. This is evident as the residues that are crucial 
for the interaction with the IR are hidden under the B-chain C-terminus (Figure 16), in 
which conformational flexibility has also been indicated
4,72
. 
This observation results from a plethora of structural and functional data that focused on 
the structure-function relationship within the insulin molecule
73
. They have shown that the 
B
24
-B
26
 part of the β-strand region, the central part of the B-chain α-helix, and the N-
terminal α-helix of the A-chain are important for high affinity binding between insulin and 
its receptor
74
.  As mentioned before, insulin exists in either the T- and R-state
8
, though it is 
possible that neither of these states are adopted upon receptor binding
75
.   Insulin NMR 
studies have shown that the C-terminus of the B-chain is flexible
4
, but the chemical 
crosslinking of Gly
A1
 and Lys
B29
 resulted in fully inactive hormone with a structure that is 
similar to the known storage form
3
. 
This indicates that upon binding of insulin to the IR, the C-terminus of the B-chain must 
move away exposing the hydrophobic core of the hormone (Figure 13) 
3,6
.  The importance 
of the movement of the B-chain C-terminus is highlighted as its removal can increase the 
binding affinity of an analogue
76
. The ability of the C-terminal region of the B-chain to 
move has led to a so-called induced-fit hypothesis in which the B-chain is required to move 
during binding to the IR in order to expose the hydrophobic core beneath
46,47
.  It has also 
been shown that residues B
24
-B
27
 have an alternating pattern of interaction with the IR (L1 
and ID-α)77. This alternating pattern is caused by the side chains in the β-strand projecting 
outwards in opposite directions.  This indicates that for binding to occur, following the 
detachment, the C-terminus of the B-chain becomes inserted between the L1 and ID-α 
domains
77
. 
The ‘active’ hydrophobic core buried within the molecule consists of IleA2, ValA3, 
Cys
A11
, Leu
A16
, Leu
B11
 and Leu
B15
 
3,6
 (Figure 16). This hydrophobic core may represent the 
IR binding epitope; the flexibility of the C-terminus of the B-chain
4
 would allow this core to 
be exposed. 
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Figure 16. The end of the B-chain hides the insulin binding epitope. 
Residues B
24
-B
30
 hide the insulin binding epitope, preventing any interaction with the 
insulin receptor. Residues A
1-3
, A
19-20
, B
11-12
, B
15
 and B
19
 (shown in magenta)form the 
classical binding epitope
65
.  
 
Alanine-scanning mutagenesis helped to identify the receptor-binding epitopes 
within insulin molecule
78
.  The crucial epitope consists of Ile
A2
, Val
A3
, Tyr
A19
, Gly
B23
, 
Phe
B24
, Val
B12
, and Tyr
B16 78
. However, residues Leu
B6
, Gly
B8
, Leu
B11
, Glu
B13
 and Phe
B25
, 
though not believed initially to be part of the binding site, were also identified as important 
for IR binding
78
. 
However, the residues predicted to be the binding epitope differ to some extent 
depending upon the method employed in the analysis. Mutagenesis and modifications
44,51
 
has identified Gly
A1
, Gln
A5
, Tyr
A19
, Asn
A21
, Val
B12
, Tyr
B16
, Gly
B23
, Phe
B24
, Phe
B25
 and Tyr
B26
 
as the binding epitope.  This is in some contradiction to the crystal structure derived model
74
 
which involves Gly
A1
, Glu
A4
, Gln
A5
, Tyr
A19
, Asn
A21
 Gly
B23
 and Tyr
B26
, whilst alanine-
scanning alone has shown Ile
A2
, Val
A3
, Tyr
A19
, Gly
B23
 and Phe
B24
 
78
 as the IR epitope. It is 
clear that the correct composition of the IR binding epitope within insulin cannot be 
confirmed until the crystal structure of the insulin:receptor complex is attained.  
It has been shown that particular insulin analogues with substitutions at positions 
A
13
 and B
17
 – not considered as important for IR binding by several studies - exhibit an 
unusual correlation between binding affinity and biological potency
79
. Therefore, it was 
proposed by Schäffer et al
79
 that these observed differences in binding affinities indicate a 
second binding epitope. This so-called site 2 must employ the above residues in addition to 
those in the classical binding site 1. A model of high affinity binding is proposed where the 
insulin molecule site 1 binds to the IR site 1, whilst the insulin site 2 of the same monomer 
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binds to site 2 on the other receptor α-subunit (Figure 17)60. It is believed that the binding of 
the insulin molecule to the IR causes a conformational change within the receptor. This 
change activates the kinases’ activity in the β-subunits, resulting in their 
autophosphorylation
79
. 
 
 
Figure 17.  A representation of the two receptor-binding domains on the insulin 
molecule and two binding sites on each α-subunit of the IR, demonstrating high 
affinity binding between the two. 
 
Insulin has been shown to form stable dimers and hexamers in the presence of Zn
2+
.  
The dimer interface is formed of Gly
B8
, Ser
B9
, Val
B12
, Tyr
B16
, Gly
B23
, Phe
B24
, Phe
B25
, Tyr
B26
, 
Thr
B27
 and Pro
B28
, whilst Phe
B1
, Val
B2
, Gln
B4
, Glu
B13
, Ala
B14
, Leu
B17
, Val
B18
, Gly
B20
, Leu
A13
, 
Tyr
A14
 and Glu
A17
 are engaged in hexamer formation.   However, the most important residue 
for integrity of the hexamer is His
B10
, the key side chain for coordination of the Zn
2+
 ions
80
.    
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1.6. The Causes of and Treatment of Diabetes Mellitus 
 
Diabetes Mellitus affects 194 million people worldwide
81
, and can be characterised by a 
marked decrease in the efficiency with which blood glucose levels are controlled.  Diabetes 
mellitus can be categorised into two classes, idiopathic and secondary. Idiopathic diabetes is 
further divided into two sub-classes, type I and type II
82
, although this definition has not 
always been a clear division
83
.   
Idiopathic diabetes type I, or insulin dependent diabetes mellitus (IDDM) normally 
appears in childhood (juvenile-onset diabetes) as a result of the pancreatic beta-cells being 
destroyed in an autoimmune response.  This autoimmune response results in an insufficient 
amount of insulin being present within the body; this can be rectified by regular injection of 
the hormone.  The root of this disorder is believed to be genetic, although the actual onset 
can be caused by a viral infection.   
Idiopathic diabetes type II, or non-insulin dependent diabetes mellitus (NIDDM) is 
characterised by constant high levels of blood sugar, or hyperglycaemia despite usually 
near-normal insulin secretion levels. NIDDM usually appears in patients over the age of 40 
(adult-onset diabetes).  Hyperglycaemia in these cases is caused by insulin resistance, 
although a normal rate of glucose uptake can be achieved by artificially high levels of 
insulin.  The achievable maximum rate of glucose uptake is reduced.  There are usually two 
main reasons for the onset of NIDDM, insulin resistance, usually caused by a genetic defect 
or obesity, or insulin deficiency
84
.   
Secondary diabetes comprises a broad range of different health problems, all of which 
individually produce the symptoms of diabetes.  These health problems damage, injure or 
cause destruction of the pancreas.  The diabetes symptoms are a secondary condition 
produced as a result of the main illness, and if treated, they may disappear 
85
. 
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1.7. Chemical Synthesis of Insulin 
 
The study of the interaction between insulin and the IR required the development of 
insulin analogues, and a synthetic method for their production was developed 
73
. The 
solution based peptide approach of full synthesis of insulin uses successive steps of 
protection and deprotection. This was the standard method used to produce insulin 
analogues in the early research into insulin:IR
73
, in a variety of labs
86,87
. This method 
required several steps to produce insulin or a single chain, which meant that the yield was 
severely limited. 
Solution based peptide synthesis was improved upon by the use of solid-phase 
polypeptide synthesis. A polymer gel support is used to brace a growing polypeptide chain, 
which is added to by ligating a series of protected amino acids. This method has a greater 
efficiency that the solution based peptide synthesis
88
. 
Advancements in the methodology of chemical synthesis led to a simpler method for 
the condensation of modified polypeptide fragments into longer polypeptides, which is 
known as native chemical ligation
89
. This method is beneficial because native peptide bonds 
are formed. An advantage of this method is that non-natural amino acids can be 
incorporated
90
. 
Insulin analogues can also be prepared by a semi-synthetic method which is much more 
efficient than a total synthesis method, allowing larger quantities to be produced in a more 
rapid manner. The total synthesis of insulin involves full synthesis of a single chain 
followed by disulphide bond formation with the other chain 
73,86,87
The semi-synthesis is 
based on the unique feature of insulin that the B
23
-B
30
 region (that contain side chains 
crucial for binding to the IR) can be proteolytically and selectively removed, and a modified 
synthetic peptide can be enzymatically ligated back onto the hormone
73,91,92
 (Figure 18). A 
significant advantage of the semi-synthesis is that all insulin disulphide bonds are 
maintained in this process hence formation of non-native -S-S- isomers that tamper full 
synthesis of the hormone is avoided. This problem can be also overcome by the use of ester 
insulin intermediates
93
. Peptide excision is limited to areas that are outside the core of the 
insulin molecule, as defined by the disulphide bonds. The use of enzymes results in high 
yields, which can then be utilised by the enzyme for the reverse reaction
92,94
. 
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Figure 18. Semi-synthesis of human insulin from porcine.  
The A-chain is coloured red, the B-chain is coloured blue. Reaction 1: Trypsin is used to 
cleave the B-chain C-terminal octapeptide at pH 9-9.5, yielding desoctapeptideinsulin 
(DOI). Reaction 2: Both the A-chain and B-chain N-termini are protected using Boc-N3. 
Reaction 3: (Boc)2-DOI is coupled to a protected octapeptide sequence resembling that of 
the human insulin B-chain N-terminal octapeptide. Reaction 4: Product is deprotected using 
TFA and anisole to yield native human insulin
91
 (modified from Mayer 2007)
73
. 
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1.8. Insulin Analogues 
 
The purification of insulin was greatly advanced by the discovery that it could be 
crystallised 
95
 and that insulin formulations could be greatly improved 
96
 by the addition of 
zinc. 
Insulin-based treatments have to balance the ability to mimic normal glucose profiles 
(Figure 11), avoiding hypo- and hyperglycaemia, whilst causing minimal disruption to 
patients.   
Generally, there is a need for two types of insulin; a rapid acting insulin which would 
mimic an insulin peak that occurs after a meal, and a long acting insulin that is maintained 
at low level concentrations, for extended periods of time, e.g. very important in overnight 
glucose control (Figure 11)
97-99
.   
Insulin analogues are modified versions of human insulin
100
 by the substitution of 
amino acids, and thus have for example, a different absorption period or length of duration.  
New pharmaceutical preparations require knowledge of factors such as temperature, site 
of injection, exercise, massage, dosage levels and insulin formulation 
98,101
.  The initial rate 
of absorption of insulin is low as the injection is followed by an initial lag phase; this can be 
reduced by decreasing insulin concentration and injection volume. Diffusion into capillaries 
also limits the rate of absorption. Insulin is absorbed across the capillary barrier after the 
insulin hexamer has disassociated into dimers or monomers.  For insulin to start taking 
effect, the zinc ions have to be removed and the injection volume diluted. 
The development of recombinant DNA techniques led to the shift from animal sources 
to a more reliable and safe source of insulin. The first biosynthesis of human insulin was 
described by Goeddel et al.
102
, using an E. coli expression system to produce separate A- 
and B-chains, followed by an exchange reaction between S-sulphonates and thiols 
20,103
 to 
form the correct disulphide bonds.  Yeast has also been used in the production of insulin as 
it has a plasmid that codes for a single polypeptide chain, the insulin precursor, where the 
A- and B-chain are linked by a few amino acids.  Due to the complex machinery present in 
yeast, the correct disulphide bonds are formed during fermentation.  The linking amino 
acids were then cleaved to produce the mature insulin molecule
104
. 
Pharmaceutical companies use Zn
2+
-stabilised hexamers in their formulations to delay 
release
98
.  The treatment of diabetes is becoming increasingly dependent on analogues 
which utilise altered pharmacokinetics
105
.  Rapid acting analogues have been designed to 
limit self-assembly 
106
 or to accelerate disassembly from their storage form, whilst long term 
acting analogues have been designed to promote self-assembly or slow disassembly
107
. 
Insulin is soluble at a wide range of pH values, >7 and <5, although between these 
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values it undergoes isoelectric precipitation
108
.  At physiological pH insulin is less soluble in 
subcutaneous tissue, whilst still soluble in the acidic pH used in the pharmaceutical 
preparation. Insulin Glargine was designed to exploit the pH effect to become a long acting 
analogue 
107
.  The B-chain of the analogue is extended by the addition of paired Arg 
residues, whose positively charged side chains cause the pI to move 7.0 (insulin pI ~5.4)
107
.  
Glargine is formulated at pH 4.0, and upon injection undergoes pH-dependent precipitation, 
forming a deposit for slow release
107
. 
Dimer formation is a prerequisite to hexamer formation, residues involved in monomer-
monomer interactions are key in dimer formation.  There are several methods to make 
insulin monomeric at pharmaceutical concentrations
109
; an introduction of steric hindrance, 
abolition of metal binding sites, disruption of hydrophobic binding surfaces by the insertion 
of hydrophilic residues or the introduction of charge repulsion to residues in close proximity 
in the dimer interface. 
Protamine, surfen and zinc
99,108
 are all used to keep insulin in hexameric form.  
Protamines form complexes with insulin molecules as they are strongly basic proteins, 
consisting mainly of arginines.  Surfen is a urea derivative that is produced synthetically.  
Zinc is at the centre of the insulin hexamer, but it has also been shown
98
 that in a neutral pH 
solution lacking citrate or phosphate, zinc can slow down insulin uptake. 
Human insulin is available in many forms. Short- and intermediate-acting, called 
regular and Neutral Protaime Hagedorn (NPH) respectively.  The rapid-acting insulin 
analogues available currently are Lispro (Eli Lilly), Aspart (Novo Nordisk) and Glulisine 
(Sanofi-Aventis), whilst Glargine (Sanofi-Aventis) and Detemir (Novo Nordisk) are long-
acting insulin analogues.  The actions of insulins used for the treatment of diabetes are 
shown in Figure 19-A, whilst the profiles are shown in part B. 
In regular insulin, the formulation is clear at neutral pH, and has 0.4% zinc added to 
allow the insulin monomers to associate and form hexamers.  Phenol or m-cresol is added to 
the formulation to prevent micro-organism growth.  NPH (Hagedorn Laboratory, Denmark), 
has protamine added to regular insulin in a 1:6 ratio.  The positively charged protamine 
binds to the negatively charged insulin, in a neutral solution buffered with phosphate.  NPH 
also has zinc and m-cresol added 
98
.  These additions in solution at neutral pH buffered with 
acetate forms insoluble insulin-zinc complexes 
110
, and it is this that the Lente insulin 
formulation is based upon.  Insulin Detemir is a long-acting insulin analogue due to the 
addition of a fatty acid chain.  The combinations of human insulins and insulin analogues 
are shown in Figure 19
98
. 
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Figure 19.  Human insulins and analogues available with their course of action. 
(A) A table of various human insulin preparations and their time course.  (B) Profiles of 
human insulins and analogues
98
. 
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Since the introduction of insulin analogues, there have been improvements in 
glycemic control, a lowered risk of hypoglycaemia, lower glucose variability and for certain 
analogues, less weight gain
111
. Further developments in insulin analogues can further reduce 
these risks. 
Like almost all protein based medications, insulin cannot be taken orally, as it 
would be broken down into fragments during the digestive process, causing the loss of 
activity.  This means that insulin has to be administered subcutaneously, or inhaled. 
Currently insulin is delivered by injection, or directly by an insulin pump. Both of these 
methods allow the user to deliver a specific amount of insulin.  Injecting insulin requires the 
use of needles, creating wounds. An insulin pump requires a permanent “link” into the 
patient, removing the need for needles to inject insulin, and eliminates the wounds that they 
produce. Alternative methods for insulin delivery are being developed, such as oral and 
nasal. For oral delivery, insulin is encapsulated in nanoparticles made with a blend of 
biodegradable polyesters
112
. Nasal delivery is based upon a similar technique to that of the 
oral system, where insulin is complexed with chitosan, to form insulin-chitosan 
nanoparticles
113
. When the management of diabetes is under control, there are few side-
effects of taking insulin, though skin conditions from repeated injections are common
114
. 
Type II diabetes is characterised by a resistance to the effects of insulin. This resistance 
is normally restricted to the metabolic pathway, where the signalling pathway that affects 
cell proliferation and migration are uninduced
115
. It has been shown that the IR is over 
expressed in cancer cells
115,116
, which means that circulating insulin can affect the growth of 
cancerous cells. With high blood glucose levels, and therefore raised insulin levels, in type 
II diabetes, the mitogenic effects of insulin can be increased. As described previously, cross-
signalling is possible between insulin and IGF. A raised level of insulin is therefore more 
likely to produce uncontrolled mitogenic effects via IGF-R. 
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1.9. Importance of Insulin-Like Growth Factor in Insulin Biology 
 
The Insulin-like Growth Factors 1 and 2 (IGF-I and IGF-II) are single-chain 
polypeptides with molecular masses of 7.6 kDa and 7.5 kDa respectively
9,10
.  The names of 
the IGFs originate from their structural similarity to proinsulin and their similar metabolic 
effects, such as causing hypoglycemia
117
.  This hypoglycemic effect is seen through 
activation of the IR rather than the IGF-1R.  At high concentrations IGFs can induce effects 
through binding to the IR
117
. In a variety of tissues throughout the body, IGFs are 
synthesized de novo, and their mitotic effects can be seen in the local environment through 
intracrine, paracrine, and autocrine methods
11
.  The IGFs are also involved in the induction 
of differentiation of whole cells, and processes within cells
12
.   
IGFs can bind to two types of membrane bound, TK receptors (IGF-1R and IGF-2R)
63
. 
IGF-1R comprises two α- subunits and two β-subunits; the β-subunit contains a 
transmembrane region
65
.  IGF-1R preferentially binds IGF-I
65
, although it has been shown 
that at high concentrations insulin is also able to bind due to the structural similarity shared 
with IGF
11
 (Table 1). The preferential binding affinity of IGF-1R is IGF-I≥IGF-II>>Insulin.  
IGF-2R comparatively only binds IGFs with its preference being IGF-II>>IGF-I (Table 2), 
though this is not a signalling receptor with its functions still not fully understood. For 
example, its structure is identical to the mannose-6-phosphate receptor 
118
.  Most of the 
effects of both IGF-I and IGF-II are through IGF-1R, whilst in non-mammalian species the 
ability of IGF-II to bind to the mannose-6-phosphate receptor seems to have been lost
119
. 
The action of IGF-I, produced mainly in the liver, are growth hormone (GH) 
dependent
120
 and its production can be slowed down by GH insensitivity, lack of hormone 
receptor, malnutrition or a failure of the downstream signalling pathway. In contrast, the 
action of IGF-II is not GH dependent
120
.  Although IGF-II has no growth promoting effects 
in hypophysectomised rats
121
, it has been shown in rodents and other species to function as a 
foetal growth factor.  Deletion of the gene encoding IGF-II resulted in slowed intrauterine 
and perinatal growth
122
, though its role in humans remains unclear. IGF-II is involved in cell 
growth, proliferation and differentiation, and is important in embryonic growth and prenatal 
development
122
.  Mice embryos which lack the IR are only slightly affected, though severe 
growth problems occur if IGFR-I is missing
123
.  IGF signalling may affect the risk of cancer 
with increased levels of IGF having been implicated as a cause of lung cancer
124
. 
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 Table 2.  Binding affinities between insulin and IGFs, and their receptors
57,70,119
 
 
A characteristic of IGFs is that unlike other growth factors, their actions are 
regulated by a separate group of proteins known as Insulin-like Growth Factor Binding 
Proteins (IGFBPs), whose molecular weights vary from 17 to 43 kDa
11
.  IGFBPs show high 
affinity to IGFs, and can compete with the IGF receptor for binding of these molecules.  
The actions of IGFBPs have been shown to prevent the hypoglycemic response caused by 
IGFs
125
, along with prolonging the time taken to clear the IGFs
126
, the transportation of 
IGFs to the site of action and to take effect upon the action of the IGFs
127
.  Six IGFBPs have 
been identified and characterised (IGFBP-1 to IGFBP-6) (Table 3). 
 
Table 3. The effects caused upon binding of IGFBPs to IGFs. 
 
IGFBP-1 can cross the capillary barrier
128
 and regulate the actions of IGF at a cellular 
level
128
, whilst also regulating serum levels of IGF
11,129
.  IGFBP-2 is believed to inhibit all 
IGF action
130
, although it is also thought to stimulate IGF-I in certain cell types
11
.  IGFs are 
carried in the circulation by IGFBP-3, which is the main IGF carrier.  Large complexes of 
150 kDa in size have been seen consisting of IGFBP-3, IGF and the acid labile 
subunit
131,132
, which are unable to cross the capillary barrier
132
.  IGFBP-4 and IGFBP-5 are 
involved in controlling bone and cartilage growth
133,134
, whilst IGFBP-5 also has the ability 
to tightly adhere to fibroblasts extracellular matrix
135
.  A decrease in steroidogenesis is 
stimulated upon binding of IGFBP-6 with FSH and LH following the signalling of IGF-I
11
. 
  
Effect 
IGFBP-1 Regulate changes in serum IGFs and  
moderate IGFs actions at a cellular level 
IGFBP-2 Inhibit IGF (particularly IGF-II action upon  
particular cells) 
IGFBP-3 Major IGF carrier protein 
IGFBP-4 Control of growth in bone and cartilage 
IGFBP-5 Adheres tightly to fibroblast extracellular matrix (ECM). 
Control of growth in bone and cartilage 
IGFBP-6 Decreases steroidogenesis in response to IGF-I 
Type I receptor Type II receptor  Insulin receptor 
IGF-I  High  Very low  Very low 
IGF-II High or intermediate  High  Low 
Insulin Very low  None  High 
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1.10. Crystallography, X-Ray Diffraction and Current 
Approaches to X-Ray Crystallography 
 
The process from protein crystallisation to the final validation of its structure is a 
multifaceted and complex process. In this section, the main steps required for solution of the 
structure of a protein by X-ray crystallography will be described, and the specific methods 
applied in this thesis are covered in more detail (Figure 20).  
 
 
Figure 20. Flowchart of the steps from crystallisation to structure validation. 
The methods used in this project are highlighted in grey. 
 
1.10.1. Crystallography 
 
The procedures by which biological macromolecules are crystallised are complex 
and poorly understood, despite the registration of the first X-ray diffraction pattern from 
protein crystal (pepsin) in 1934
136
. This leads to a seemingly unscientific approach of trial 
and error, i.e. screening the target protein with a large array of conditions, followed by 
optimisation of any resulting suitable conditions. 
The formation of crystals relies upon changes of protein solubility that allow 
protein molecules to move from the solution- to solid- phase.  There is a solubility limit at 
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an equilibrium at which the number of molecules entering solution equal those that are 
being lost from solution to solid
137
.  Below the solubility limit the solute is said to be an 
undersaturated solution, and at the solubility limit it is a saturated solution (Figure 21).  
Crystals cannot grow in either of these states as they requires a system where 
thermodynamic forces are driving molecules from solution into the solid state, a 
supersaturated solution
137
.  This transition comes when an activation energy barrier has been 
overcome
137
, which could occur with the formation of nuclei by a number of aggregated 
protein molecules, or by the appearance of an ordered region.  The more supersaturated the 
solution can become, the more likely the nuclei will form.   
 
 
Figure 21. A simplified phase diagram for protein crystal growth. 
At supersaturation there is high probability that critical nuclei will form, this is the labile 
region. At lower values of supersaturation, the metastable region, nuclei are not formed, but 
if already formed will continue to grow. Crossing the equilibrium line of saturation into 
undersaturation causes the solid phase to dissolve and molecules will be monomeric and 
disperse.  
 
The population of protein molecules must be in the labile region in order for crystal 
growth to be initiated, by the formation of nuclei. Obtaining fewer but larger crystals is 
more desirable, which requires the crystal systems to move to the metastable region.  The 
selection of crystallisation conditions is crucial in obtaining a balance between the two.  If 
very high supersaturation is achieved, protein precipitation may occur, or a large number of 
microcrystals may form.  Once crystals start growing in the metastable zone, 
supersaturation will decrease as the concentration of protein in solution drops meaning large 
crystals can be formed. 
A supersaturated system can be achieved by several methods, though the system 
must be altered from its undersaturated state to supersaturated gradually to avoid 
precipitation
137
.  The most commonly used methods include increasing salt concentration, 
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mixing the protein with a precipitant, and altering the pH or temperature of the system.  
Increasing salt concentrations causes competition between ions and protein molecules for 
water molecules to form hydration shells.  If the salt concentration is increased, the water 
will be displaced from the protein, which promotes the protein molecules to self-associate to 
fulfil their electrostatic potential, causing solubility to be reduced
137
.  Precipitating agents 
such as polyethylene glycols (PEGs) and organic solvents can be used in a similar way
138
.  
PEGs dehydrate a protein causing the protein molecules to push together and become 
excluded from the solution. 
 
1.10.2. X-Ray Diffraction 
 
When a protein crystal is exposed to an intense X-ray beam, the incident X-rays are 
diffracted by the 3D array of atoms that form the crystal, producing a diffraction pattern.   
Incoming X-rays are scattered by the electrons in each atom of the crystal.  X-rays are 
electromagnetic waves that interact with the electrons and the same coherent frequency 
radiation is emitted to that of the incoming wave
139
.   
 
 
Figure 22. The schematic representation of relationship between some main 
crystallographic terms. 
The terms used in this figure are X-product, *-convolution and FT-Fourier transform 
 
This so-called reciprocal lattice is related to the crystal lattice and the diffraction 
pattern (Figure 22).  This lattice is imaginary, yet is a helpful concept for determining the 
direction of the diffracted beam
139
.  The unit cell dimensions in the reciprocal lattice are 
approximately reciprocal to the dimensions of the real unit cell, and correspond to the 
positions of the measured reflections in the diffraction pattern.  Using the position of the 
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spots on the diffraction image, the repeating distances between the reflecting planes in the 
crystal lattice can be determined.  Bragg’s Law relates the wavelength of the incident 
radiation to the angle of reflection and distances between the reflecting planes (Figure 23). 
 
 
Figure 23. Representation of Bragg’s Law. 
The incoming X-ray beam is reflected from the lattice planes.  The distance between the 
planes (d) can be determined from the wavelength (λ) of the beam and the angle of 
reflection (θ).  The order of diffraction is (n).  Adapted from J. Drenth, Principles of Protein 
X-ray Crystallography
139
. 
 
When the crystal is rotated in the X-ray beam, the reciprocal lattice also rotates.  
This allows other points on the lattice to produce diffraction spots, which are represented by 
the Ewald sphere (Figure 24). 
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Figure 24. The Ewald Sphere. 
The reciprocal lattice points will only produce diffraction when the points contact the 
surface of the Ewald sphere.  The direction of the incoming beam is denoted by s0, the 
reflected beam by s, and the sphere has a radius of 1/λ.  Adapted from J. Drenth, Principles 
of Protein X-ray Crystallography
139
. 
 
It can be seen from the Ewald sphere that not all reciprocal lattice points can 
produce diffracting beams at the same time.  The reciprocal lattice points, denoted hkl, must 
be in contact with the surface of the sphere to produce a reflection
139
.  The reflecting planes 
giving rise to the observed diffraction are crystal lattice planes.  These (imaginary) lattice 
planes divide up the a, b and c axes of the unit cell into a number of equal planes.  These 
planes are denoted by their indices, h, k and l.  Therefore, each reflection that is recorded on 
the diffraction images, also has coordinates or indices of h, k and l. 
Determination of the arrangement of the molecules within the unit cell (crystal 
motive) that can be expressed by coordinates (xj,yj,zj) of the j-atom, utilises not only the 
directional information of reflections (e.g. θ angle) but the intensities of the reflections as 
well. They are necessary for calculation of the electron density of the crystal structure in 
later stages of crystal structure analysis
139
. 
X-rays interact with all electrons in the protein molecule, producing scattered 
waves.  Every wave produced by every atom in every unit cell in the crystal adds up to 
obtain the scattering produced by the crystal.  This is called the Structure Factor (F), 
because it relies upon the structure of the crystal forming motif of the atoms in all unit 
cells
139
.  A factor that affects the intensity of the scattered X-rays is the temperature–related 
vibration of atoms within the crystal structure.  Atoms vibrate around an equilibrium point, 
which means that the X-rays do not meet the equivalent atoms in the same position within 
each unit cell.  This can reduce the intensity of the scattered X-rays.  To account for this 
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effect, the atomic scattering factor of the atoms must be multiplied by a temperature-
dependent factor (B)
139
.  This results in four unknown parameters per atom in a structure; its 
coordinates (xj,yj,zj) and B. 
The intensity I(hkl) of the diffracted reflection is proportional to the square of the 
amplitude of the structure factor F(hkl), so therefore its modulus |F| can be calculated 
directly from the collected X-ray data (Equation 1). 
 
                            
Equation 1. 
 
The structure factor is related to the electron density, as it is a function of the 
electron density distributed over the unit cell (from the atomic scattering of X-rays).  In 
principle, once F(hkl) has been reconstructed, the electron density ρ at every position x, y, z 
in the unit cell can be calculated.  This is done by a Fourier transform, as F(hkl) is the 
Fourier transform of ρ(xyz) of the entire unit cell.  The reverse is also true, so ρ(xyz) can be 
written as a function of the F(hkl)
139
. Using the experimentally derived information 
(Equation 1), this equation can be re-written (Equation 2).  
 
       
 
 
         
   
                     
Equation 2. 
 
 
Equation 3. 
 
A new equation (Equation 3) allows the electron density ρ(xyz) at every position 
within the unit cell to be calculated.  However, one key problem remains, and that is the 
unknown phase angle of the diffracted X-rays.  These values cannot be derived from the 
diffraction pattern, giving rise to the phase problem, which must be solved for a successful 
determination of atomic coordinates ((xj,yj,zj)) of each atom. 
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1.10.3. Data Processing 
 
The collected X-ray data needs to be processed to provide working, main X-ray 
data set. The HKL2000
140
programme, which uses DENZO and SCALEPACK, was used to 
process the data in this thesis.  Initially the unit cell dimensions, indexing of the data and 
determination of its Laue point group symmetry must be determined first.  Indexing 
comprises searching for peaks on a single diffraction image, followed by comparing the 
angles and distances of the observed diffraction spots to match the relationships 
characteristic for each of the seven crystal systems.  The crystal system which has the 
highest symmetry and best fit between the observed and predicted diffraction patterns is 
chosen
141
.  Following indexing, and refinement of the cell parameters the images are 
integrated to give measured intensities of the X-ray reflections.  The correct integration 
includes several additional corrections, for example reflection positional refinement, 
accurate assessment of the background, absorption and anisotropy resulting from crystal  
shape, size and properties, etc
141
.  After integration, the data are scaled and if there is more 
than one data set, merged as well.  Scaling puts all images and symmetry equivalent 
reflections on the same scale.  Differences can occur here due to unequal exposures in high 
and low resolution, beam decay and crystal decay
141
.  The quality of the data is usually 
assessed by checking the ratio of intensity to error of intensity <I/σ(I)>, and the agreement 
between symmetry related reflections, Rmerge
141
 (Equation 4).  Rpim  (precision indicating 
merging R-factor) is an alternative, and more accurate, measure of data quality as that it 
takes account of multiplicity in the data
142
. 
 
       
                         
              
 
Equation 4.  
 
The exact type of the space group (e.g. taking into account occurrence of some 
systematic absences) can be adjusted at the last stage of data processing
141
. 
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1.10.4. Solution of the Phase Problem 
1.10.4.1. Molecular Replacement 
 
If a suitable model of a studied protein already exists (with minimum sequence 
homology/similarity ca. 30%), molecular replacement is the fastest and most convenient 
method to solve the phase problem for an unknown structure.  An appropriate model is 
chosen based upon its sequence homology or belonging to the same fold family as the 
target.  The non-crystallographic symmetry of the model can also be considered to account 
for a particular oligomeric state of the protein.  The placement of the model molecule in the 
new unit cell comprises of two separate steps:  rotational and translational searches
141
.  
Computational methods are used to search all possible orientations and positions of the 
model in the new unit cell.  MOLREP
143
 is an example of one of these programs and was 
used in this thesis.  The rotation step is carried out first, using Patterson maps of the known 
model and unknown protein.  A Patterson map is a vector map, where vectors between 
atoms in the structure are represented as vectors from the origin to peaks in the Patterson 
map
139
.  As all phases are set to zero, no prior phase knowledge is required.  The rotation 
function calculates the relationship between Patterson vectors of the model and unknown 
structure, rotating the model until the two different maps overlap giving the best 
superposition
139
.  The subsequent translational search requires calculation when the two 
molecules to overlap in real space.  The simplest way to do this is trial and error approach, 
where the model is moved through the whole asymmetric unit of the unknown protein, with 
the comparison of the fits of Fcalc and Fobs structure factors monitored by calculation of the 
R factors
144
 (Equation 5).  
 
   
                    
          
 
Equation 5. 
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1.10.4.2. Isomorphous Replacement and Anomalous 
Scattering 
 
If a suitable molecular replacement model is not available or molecular replacement 
fails even with an appropriate model, then another method of solving the phase problem is 
required. Isomorphous replacement is a technique that involves attaching heavy atoms such 
as Hg, Pt or Au (or their compounds) to the protein by either soaking native protein crystals 
in solutions of complexes of such metals, or co-crystallisation of a protein solution with 
heavy atom compounds. Data sets are collected for both the native crystal and the heavy 
atom ones. Since heavy atoms have a large number of electrons, there are differences in the 
diffraction data that can lead to identification of heavy atom sites in the unknown structure. 
Their coordinates facilitate preliminary estimation of the phases.  
Anomalous scattering-based approach relies upon utilisation of so called anomalous 
scattering that is especially pronounced at wavelengths similar atom absorption range. 
Single wavelength anomalous dispersion (SAD) and multi-wavelength anomalous 
dispersion (MAD) are two techniques used. MAD uses the same crystal with anomalous 
diffraction collected at different wavelengths. SAD uses two crystals collected at a single 
wavelength, with one crystal used to collect a native data, and another with a heavy atom 
Since C, N and O atoms do not give strong anomalous scattering, a selenomethionine 
derivative is often used when native Met side chains are replaced by SeMet amino acids on 
the protein expression level. Alternatively, soaking of atoms known for their anomalous 
diffraction properties (e.g. Sm) can be used here as well. The SeMet approach has a great 
advantage over any soaking method as it alleviate potential changes of unit cell dimensions 
(i.e lack of so-called isomorphism) upon soaking of the heavy atoms. 
 
1.10.5. Refinement of the Model using Maximum Likelihood 
Method 
 
Following the solution of the phase problem, the process of model building and 
refinement of its structure can follow.  When the first model has been produced, the 
calculated structure factors generally are in poor agreement with the observed structure 
factors
139
.  Refinement improves and completes the model closing the gap between the 
calculated and observed structure factors.  The method of refinement used in this thesis was 
maximum likelihood, implemented in REFMAC
145
.  Maximum likelihood is a statistical 
method for fitting a mathematical model to some data, by stating that the best set of 
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parameters on the evidence of the data is the one that explains the observations with the 
highest probability
137
.  In crystallography, this means the likelihood for a reflection is the 
probability of the observed structure factor amplitude, given the current model
137
.  The 
correlation between the data and the model is optimised by adjustment of the model to the 
observed electron density.  This involves changing the positional parameters and 
temperature factors of all non-hydrogen atoms in the structure
139
.  Stereochemical 
information on bond lengths, angles and Van der Waals contacts can be applied to make an 
important contribution to refinement.  This most commonly involves restrained refinement 
where these parameters are allowed to vary around standard values, allowing easy 
movement of small parts of the model
139
.  Molecular graphics programmes, such as Coot
138
 
used in this work, allow manual manipulation and intervention into the model to achieve 
better fit to the electron density map.  Two types of calculated maps are output from 
refinement, usually 2mFo-DFc map, which represents the content of the crystal, and mFo-
DFc which represents the difference between the contents of the crystal and the current 
atomic model
145
.  Refinement is monitored by calculation of the R factor and Rfree factors.  
These values measure the fit of the calculated structure factors to the observed data, where 
the values will decrease as the observed and calculated structure factors agree more 
closely
144
. 
The Rfree factor is a more reliable measure of the refinement quality than the R 
factor, as it is calculated using a small subset of reflections (usually 5%) that are randomly 
removed from the data before refinement is started.  If the Rfree value is decreasing steadily 
then it can be regarded as an unbiased improvement of the model
144
; its increase may 
suggest over-fitting of the maps. The Rfree will always be slightly larger than the R factor, 
and at the end of refinement they should ideally be within a few percent of each other. 
 
 
1.10.6. Structure Validation 
 
Once a structure has been solved and refined, it is likely that it contains some errors 
that have been introduced through fitting of the model to the electron density maps.  These 
errors have to be corrected before the structure can be published or deposited in the Protein 
Data Bank (PDB).  One measure of the reliability and quality of the model is the 
Ramachandran Plot, where the stereochemistry of the protein main chain is investigated.  
The dihedral angles of φ and Ψ for each residue are plotted against each other, and are 
clustered into regions of preferred, allowed and outlier values
139
.  Other measures for the 
removal of errors of the model (implemented in programmes such as MolProbity
146
) is 
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checking residues with unusually high B factors, close Van der Waals contacts, 
unfavourable or unlikely hydrogen bonds, and unusual side chain rotamers.   
 
1.10.7. Current Approaches to X-Ray Crystallography 
 
Modern synchrotrons allow more data set to be collected for smaller and worse quality 
crystals. Diffraction images at synchrotron are collected charge couple device (CCD) 
detectors. These detectors produce a charge every time photon hits the detector. The total 
charge is calculated at the end of the image. CCD detectors are being replaced with 
PILATUS detectors. PILATUS (pixel apparatus for the SLS) has many advantages over 
CCD detectors as it uses single photon counting instead of an accumulative method in CCD 
detectors. When a photon hits the PILATUS detector, it immediately produces a charge, 
which is recorded if it exceeds a predetermined threshold. This results in no read-out noise 
associated with the accumulative method used in CCD detectors. Due to lack of background 
noise, a superior signal-to-noise ratio is achieved, and a readout time of in a range of 5 ms 
(compared to 1-120 s in CCD detectors) allows data sets to be collected in a formidable 
short periods of time
147
. 
New generation synchrotrons produce light with such a low divergence that it gives 
micro-beams smaller than 10 µm
148
. It has a great impact on data collection strategy as the 
intra-crystal variations within one single mounted crystal can be explored. A mesh-scan 
probes the diffraction quality across the entire crystal and produces a diffraction contour 
map allowing the best data to be collected
149
. 
Future developments at synchrotron beam-lines are challenging existing technological 
setups. For example, crystals are currently vitrified following cryoprotection in liquid (or 
gaseous) nitrogen. There are plans to locate the entire environment of an X-ray experiment 
in vacuum, which should reduce the air-related absorption of X-rays and result in a more 
intense and clearer image at longer wavelengths. This would require a new way of mounting 
crystals. The advancements of the PILATUS-like detectors leads to development of semi-
spherical detectors that will be able detect X-rays scattered at large diffracting angles 
expanding the resolution of the data even further. 
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Chapter 2. High Affinity Insulin Analogues as Tools for 
Insulin:Insulin Receptor Studies 
2.1. Summary 
 
The current crystal structures of insulin describe the inactive, storage form of the 
hormone. The hydrophobic core of insulin contains the residues A
1-3
, A
19-20
, B
11-12
, B
15
 and 
B
19
 that are involved in binding the IR
3,6
. Various studies have shown that the B-chain C-
terminus is mobile
4,72
 and must move to allow the binding epitope to become exposed
3,6
.  
This chapter describes efforts that probed whether a change or modification of an amino 
acid that would help induce a turn in the B20-B30 chain would expose the binding epitope, 
and increase the chance of finding the active form of insulin. Subsequently novel mutations 
can lead to improved insulin binding affinity
100
.  To achieve these series of unique semi-
synthetic insulin analogues were created to expose the binding epitope; previously 
described semisynthetic methods have been employed in making of these analogues
73,92,150
.   
As the result high affinity (~200-500%) analogues truncated at B
26
 were produced to 
explore the nature of the transition of the B-chain C-terminus. The high affinity analogues 
presented in this chapter show a structural convergence in the form of a new β-turn in the B-
chain at position B
26
, the B26 turn. The formation of the B26 turn at B
24
-B
26
 is associated 
with the trans-to-cis isomerisation of the B
25
-B
26
 peptide bond, which is initiated by the N-
methylation of B
26
. This turn and the resulting high affinity associated with these analogues 
is in agreement with the literature. With this I propose that the B26 turn is the active 
conformation of insulin upon binding to the IR. 
Subsequently, click-chemistry was used to create a cross-linked analogue that is 
permanently fixed in an active conformation. The 1,2,3-triazole ring chemically links side 
chains in an aim to mimic the B26 turn. A longer cross-link causes structural rigidity, which 
obscures the binding epitope and causes a greatly reduced binding affinity (0.13%). 
Shortening the cross-link reduces the rigidity and results in a binding affinity close to WT 
insulin (101.5%). 
The resulting conformation arising from the presence of the B26 turn causes the 
previously buried amino acids, important in IR binding to become unmasked. High affinity 
analogues provide key structural details vital for a new approach in the design of future 
insulin analogues.  
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2.2. Crystallisation, Structure Determination and Refinement of 
Insulin Analogues to Probe the Active Conformation of 
Insulin 
 
The insulin analogues crystallised and studied in this chapter are displayed in Table 4 with 
their sequence change from WT insulin illustrated along with their binding affinity. 
Table 4.  A comparison of insulin analogues structure and their relative receptor 
binding affinity. 
Changes in the B-chain sequence are indicated in bold.  [NMeXaaB
n
]: methylation of the N-
peptide atom preceding Xaa B
n 
amino acid; -NH2 : C-terminal carboxy amide. 
 
 
Insulin analogue [NMeTyr
B26
]-insulin was dissolved in 20 mM HCl to a 
concentration of 10 mg/ml. The best crystal identified from the screening was obtained from 
drops equilibrated 1:3 (protein:well) in well solution consisting of 0.055 M Na2SO4 pH 3.0 
(0.5 ml well volume), and grown at 21°C. The crystal was flash-cooled in liquid nitrogen 
without any cryoprotection. The X-ray data were collected at ESRF on station ID29, and 
processed using HKL2000
140
. The crystal structure of [NMeTyr
B26
]-insulin was solved by 
molecular replacement using default settings in Molrep
143
. The search model consisted of a 
truncated model of monomeric insulin 1mso.pdb
151
, which involved the removal of residues 
B
1
-B
5
 and B
25
-B
30
. Subsequent manual model building and refinement with Coot
138
 and 10 
cycles of REFMAC5
145
, resulted in a final model which was validated by MolProbity
146
. 
Data collection, reduction and refinement statistics are detailed Table 5. Crystal conditions 
are documented in Table 6. 
The other insulin analogues were crystallised (in monomeric form), and had their 
structure determined and refined as per [NMeTyr
B26
]-insulin. The differences in the crystal 
conditions and data collection, reduction and refinement conditions are detailed in Table 6 
and Table 5 respectively. 
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Table 5. Data collection, reduction and refinement statistics for monomeric 
insulin analogues. 
 
 
 [NMeAla
B26]-DTI-
NH2 
[NMeAlaB26]-insulin 
pH 3.0 
[D-ProB26]-DTI-NH2 [NMeTyrB26]-insulin 
monomer 
PDB code 2wru 2wrx 2wrw 2ws1 
Data collection Beamline ESRF, ID23-1 ESRF, ID14-1 ESRF, ID14-2 ESRF, ID29 
Wavelength (Å) 1.071  1.0723 0.9330 0.9762 
Space group I4122  P41212 I4122 I4122 
Cell dimensions     
    a, b, c (Å) 38.7 38.7 123.1  39.2 39.2 124.9 39.4 39.4 123.9 38.2 38.2 124.0 
 ()  90.0 90.0 90.0  90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 
Resolution (Å) 
50–1.57(1.63–1.57)  
30.0–1.50(1.55–
1.50) 
50.0–2.41(2.45–
2.41) 
30.0–1.5(1.53–1.50) 
Rsym 0.057(0.162)  0.063(0.469) 0.055(0.217) 0.051(0.424) 
I / I 23.0(11.0)  9.2(5.5) 14.6(9.2) 19.2(9.5) 
Completeness (%) 95.0(61.6)  94.6(60.5) 98.5(98.1) 95.1(52.2) 
Redundancy 10.6(2.0)  13.4(1.5) 6.0(5.0) 9.1(5.5) 
Refinement     
Resolution (Å) 37.0–1.57  37.4–1.50 25–2.41 30–1.6 
No. reflections 6339  14801 1977 6145 
Rwork / Rfree 0.179/0.255  0.180/0.250 0.236/0.300 0.184/0.247 
No. atoms 438  862 385 445 
    Protein 376  760 259 404 
    Ligand/ion 8 1 - - 
    Water 61  101 26 41 
B-factors     
    Protein 21.1  35.2 23.8 21.5 
    Ligand/ion 34.7  35.4 - - 
    Water 18.8  30.2 22.5 28.3 
R.m.s. deviations     
    Bond lengths (Å) 0.022  0.023 0.017 0.022 
    Bond angles () 1.744  1.980 1.632 1.707 
Ramachandran statistics 
(%) 
    
Preferred/Allowed/Outliers 97.2/2.8/0  94.0/4.8/0 95.24/4.76/0 100.0/0/0 
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Table 6. Crystal conditions for monomeric insulin analogues. 
 [NMeAla
B26
]-
DTI-NH2 
[NMeAla
B26
]-
insulin 
[NMeTyr
B26
]-
insulin 
[D-Pro
B26
]-
DTI-NH2 
[NMeHis
B26
]-
DTI-NH2 
Well Condition 
0.32 M 
Na2SO4, pH 
3.0 
0.18 M 
Li2SO4,      
0.1 M NaAc 
pH 3.0 
0.055M 
Na2SO4      
pH 3.0 
0.015M 
Cs2SO4      
pH 3.0 
0.1M NaCit, 
0.3M Tris 
pH8.2, 0.6 
mM ZnAc, 
0.06% 
phenol 
Drop Ratio 
(Protein:Well) 
1:3 1:3 1:3 1:3 1:3 
Temperature 21°C 21°C 21°C 21°C 21°C 
Cryoprotectant None None None None None 
 
 
 
  
 [NMeHis
B26]-
DTI-NH2 
Cyclo[G-
PrgFYTPK(N3)T]-
insulin 
Cyclo[GFFY-
Pent(N3)-P-G-Prg]-
insulin 
PDB code 2wrv   
Data collection Beamline ESRF, ID14-2 Diamond, i03 ESRF 
Wavelength (Å) 0.9330 0.9763 0.8726 
Space group I4122 P21212 P31 
Cell dimensions    
    a, b, c (Å) 39.2 39.2 
123.6 
55.4 56.9 60.0 61.0 61.0 82.0 
 ()  90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 120.0 
Resolution (Å) 27.0–
2.15(2.19–
2.15) 
27.72-1.57 (1.61-1.57) 
50.00-1.54 (1.57-
1.54) 
Rsym 0.067(0.269) 0.079 (0.309) 0.068 (0.488) 
I / I 14.5(6.8) 11.9 (2.3) 7.5 (3.6) 
Completeness (%) 97.8(97.4) 82.4 (40.1) 100.0 (100.0) 
Redundancy 7.2(7.0) 5.9 (3.2) 5.7 (5.7) 
Refinement    
Resolution (Å) 37.34–2.15 27.72-1.57 52.82-1.54 
No. reflections 2686 21129 48163 
Rwork / Rfree 0.199/0.277 0.203/0.265 0.167/0.207 
No. atoms 413 1778 2968 
    Protein 367 1491 2492 
    Ligand/ion 1 15 95 
    Water 45 272 381 
B-factors    
    Protein 20.6 18.759 18.690 
    Ligand/ion 30.0 31.611 12.603 
    Water 21.1 30.671 31.727 
R.m.s. deviations    
    Bond lengths (Å) 0.021 0.025 0.033 
    Bond angles () 1.677 2.141 3.081 
Ramachandran statistics 
(%) 
   
Preferred/Allowed/Outliers 90.48/9.52/0 96.9/3.1/0 98.7/0.4/0.9 
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2.3. The Formation of a Unique β-Turn in High Affinity 
Analogues 
 
The most potent (465%) insulin analogue [NMeAla
B26
]-DTI-NH2 which contains a N-
methylation at position B
26
 with the B-chain truncated after the Ala
B26
, was crystallised as a 
monomer revealing a new conformation in the B
24
-B
26
 position.  This feature resembles a 
type II β-turn at PheB24-NMeAlaB26, referred to here as the B26 turn (Figure 25).  Within this 
turn a cis conformation of the Phe
B25
-NMeAla
B26
 peptide bond is formed, causing the B-
chain residues B
22
-B
30
 to move away from its usual position seen in WT dimers and 
hexamers, exposing the insulin binding epitope.  The B26 turn in stabilised by the presence 
of a 2.8 Å hydrogen bond that is formed between the CO group of the B
24
 residue and the 
NH2 terminus of the B
26
 position, which mimics the main chain NH.  The hydrogen bond 
that is formed between the ί and ί+3 residues results in the truncated B-chain C-terminus 
pointing away from the main receptor binding epitope.  This confirms previous work which 
showed that the flexibility of the B-chain C-terminus
4
 is required during the induced-fit 
hypothesis upon binding to the IR
3,6
 to expose the hydrophobic core
73,77
. 
The B26 turn causes a structural re-arrangement of the B-chain. A rotation of the Phe
B25
 
side chain occurs, which results in an overhang of the A-chain part of site one (~7.7 Å from 
Ile
A2
) (Figure 26). This rotation is in contrast to Phe
B24
, which remains in place. Along with 
the B26 turn the A-chain N-terminal helix rotates by ~40°, causing a displacement of ~3 Å. 
Tyr
A19
 is shifted by 2.9 Å, enabling a hydrogen bond to be formed with Gln
A5
, which results 
in the non-polar receptor binding surface being extended (Figure 26). The crystal structure 
of [NMeHis
B26
]-DTI-NH2, another highly active insulin analogue (214%), contains the same 
geometries (Cβ of both are only 0.3 Å different from each other) and have the same 
hydrogen bond network. 
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Figure 25.  Structural features of crystallised insulin analogues. 
(A) An overlay of the general fold of crystal structures of the highly-active and other 
insulins: Red: wild-type insulin, Cyan: [NMeAla
B26
]-DTI-NH2, Purple: [NMeHis
B26
]-DTI-
NH2, Green: [D-Pro
B26
]-DTI-NH2, Coral: [NMeTyr
B26
]-insulin, and Yellow: [NMeAla
B26
]-
Insulin. (B) A close-up view of the B26 turn in the most representative analogues: Green: 
wild-type, Cyan: [NMeAla
B26
]-DTI-NH2, Yellow: [NMeAla
B26
]-insulin, and Coral 
[NMeTyr
B26
]-insulin. Oxygen atoms in red and nitrogen in blue. W – water molecule, 
hydrogen bonds (dashed lines) lengths in Å, and Me – methylation. 
 
Figure 26. The main structural changes in insulin upon activation. 
Human insulin (red
151
) and [NMeTyr
B26
]-insulin (coral), which is isomorphous to the 
highly-active [NMeAla
B26
]-DTI-NH2.  Magenta Star-Phe
B24
 side-chain structural pivot 
point, Red Star – PheB25 main chain structural pivot, Black Star – Ile42 Cα main chain pivot 
point, Green Star – Tyr A19 shift and formation of a hydrogen bond (dashed lines) with 
Gln
A5
, Blue Star – rotation of A1 helix, Cyan Star – translation of the A1 helix75. Oxygen 
atoms in red and nitrogen in blue. 
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The analogue [D-Pro
B26
]-DTI-NH2 is also a high affinity (359%) insulin analogue 
that possesses the B26 turn (Figure 27).  The D-Pro mimics the cis Phe
B25
-Xaa
B26
 N-
methylated peptide bond in the B26 turn. The ί+3 β-turn hydrogen bond is not formed here 
(CO
i
-NH
i+3
 distance ~4.00 Å), although the D-Pro causes the B-chain C-terminal CONH2 to 
adopt a conformation and position similar to the analogues with B26 turn.  The C-terminal 
NH2 group is displaced ~1.1 Å from hydrogen-bonded equivalents in other highly active 
analogues. 
The structures presented here suggest the conservation of specific structural features 
that may be present in WT insulin upon binding to the insulin receptor.  The high affinity 
insulin analogues may convey an active structural conformation that allows the buried 
biologically important residues to be exposed, allowing insulin:IR binding.  Although the 
structures presented here are not WT insulin, the information extracted from these structures 
gives indirect information about the active motif of insulin. 
The formation of the ί+3 hydrogen bond in the high affinity analogues is one of the 
most important events to occur during activation of the insulin molecule (Figure 25).  This 
formation causes other hydrogen bonds to be created (Figure 25), which results in a strong 
hydrogen bonding network, further stabilising the B26 turn. 
The most striking piece of information from the structures is the B26 turn, which is 
caused by the trans-to-cis isomerisation of the Phe
B25
-Tyr
B26
 peptide bond.  The presence of 
the strong 2.8 Å hydrogen bond between Phe
B24
(CO)-Thr
B27
(NH) indicates that the 
formation of the B26, or a turn similar to that seen here, is more than likely the preferred 
direction for the movement of the C-terminus of the B-chain following detachment of the 
Tyr
B26
-Thr
B30
 region.  Chemical crosslinking of Gly
A1
 and Lys
B29
 produces a crystal 
structure and displays assembly properties very similar to that of WT insulin, despite these 
similarities the cross linked insulin was biologically inactive
3
.  This implies that upon 
binding of insulin to the IR, the C-terminus of the B-chain must move away, exposing the 
hydrophobic core
3,6
.  This research suggests that it is the requirement for the C-terminus of 
the B-chain to be rearranged, as per the B26 turn, for IR binding to occur. 
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Figure 27. The B26 turn and B26-like turn in truncated analogues. 
Super positioning of the B
23
-B
26
 region in [NMeAla
B26
]-DTI-NH2 (carbons in cyan), [D-
Pro
B26
]-DTI-NH2 (carbons in green) and [NMeHis
B26
]-DTI-NH2 (carbons in purple).  The 
dashed line indicates the COB
24
-NHB
26
 hydrogen bond in [NMeAla
B26
]-DTI-NH2 which is 
characteristic of the B26 turn. Oxygen atoms in red and nitrogen in blue. 
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2.4. The Appearance of the B26 Turn in Full Length Insulin 
Analogues 
 
The two insulin analogues described previously are truncated in the B-chain after the 
B
26
 position, whilst the capabilities of full length analogues have not been investigated. 
Both [NMeTyr
B26
]-insulin and [NMeAla
B26
]-insulin have a binding affinity of 21%, despite 
the possession of the B26 turn and the structural characteristics seen in the truncated 
analogues (Figure 28).  The B26 turn in the full length analogues contains the same ί and 
ί+3 hydrogen bond between the CO in PheB24 and NH in ThrB27 with a bonding distance 
(~3.0-3.3 Å [NMeTyr
B26
]-insulin).  In the full length analogues the Thr
B27
 peptide bond NH 
groups are in an equivalent spatial position to that of the NH2 group in the CONH2 terminus, 
making hydrogen bond formation possible. In a typical type II β-turn, the Cαί-Cαί+3 distance 
is ~7 Å, in the full-length analogues the C
αί
-C
αί+3
 distance is ~6 Å, which makes hydrogen 
bonds more likely to form.  The C-terminal region of the B-chain is well defined (Lys
B29
-
Thr
B30
 are disordered), following the direction forced by the B26 turn, allowing the full 
exposure of binding site one in insulin (Figure 28). The B26 turn is further stabilised in this 
conformation by the formation of additional hydrogen bonds between Phe
B24
 CO with the –
OH in the side chain of Thr
B27
, and water molecules. [NMeTyr
B26
]-insulin was also 
crystallised in hexameric form, showing that despite the presence of the NMe group on 
residue B
26
, it is still capable of forming a hexamer. The full length analogue [NMeAla
B26
]-
insulin was unable to be crystallised as a hexamer, only as a monomer, indicating that the 
change of the amino acid removes an important interaction in the dimer interface.  
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Figure 28. The B26 turn in full length insulin analogues. 
A view of the B
24
-B
27
 region of two insulin analogues forming the B26 turn.  [NMeTyr
B26
]-
insulin (C-atoms in coral) and [NMeAla
B26
]-insulin form the B26 turn with an ί+3 hydrogen 
bond (3.0Å and 3.3Å), which is comparable to the 2.8Å seen in the highly active analogue 
[NMeAla
B26
]-DTI-NH2. Oxygen atoms in red and nitrogen in blue. 
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2.5. The Structural Signatures of Active Insulin Analogues 
 
Both truncated and full length analogues, showing high affinity, possess a novel 
conformation in the N-terminus of the B-chain.  Working from C to N-terminus, the main 
chain follows the path taken by the T-state of insulin, until the Cα in HisB5, at which point it 
deviates.  A pseudo type II β-turn (Figure 29) is formed, which is stabilised as in the C-
terminus, by a ί+3 hydrogen bond (3.0 Å) between the NH in the main chain of HisB5 (ί+3) 
and the side chain of Asn
B3
. Further stabilisation is achieved by a hydrogen bond (3.0 Å) 
with the Nδ2 in AsnB3.  The importance of the B5 side chain in this unique formation is 
further reinforced by the close proximity (~3.3 Å) of the Nδ1 of HisB5 to the main chain C 
in Thr
A8
.  This deviates from the T-state B-chain N-terminus causing the network of 
interactions between A- and B-chain to become almost entirely destroyed, leaving only the 
NHB
6
 – COA6 bond (2.8 Å).  
 
 
Figure 29. The unique conformation of high affinity insulin analogues at the B-
chain N-terminus. 
A representation of the pseudo β-turn at the B-chain N-terminus from [NMeAlaB26]-DTI-
NH2 (C-atoms shown in cyan).  All atoms are shown for B
2
-B
5, and a Cα trace for B6-B19.  
The Cα trace of insulin in the T-(red trace) and R-states (blue trace) are derived from 
1mso.pdb and 1znj.pdb respectively. Oxygen atoms in red and nitrogen in blue. 
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 The three-dimensional structural traits presented here show the conservation and 
convergence of key structural elements across multiple analogues.  The elements discussed 
here may be those present when insulin becomes active upon IR binding, or during an 
activation process. The structures present a conformation of what I believe to be the 
active/activated insulin conformation, although the evidence is indirect. The B26 turn is 
associated with the trans-to-cis isomerisation of the Phe
B25
-Tyr
B26
 peptide bond, which 
results in the most striking structural feature of the active/activated form of insulin. Another 
critical structural feature of the B26 turn is the formation of a hydrogen bond between 
Phe
B24
 (CO) and Thr
B27 
(NH). This hydrogen bond is likely to be critical to the stability of 
the turn, as when the B
24
 CO group is reduced to CH2, the insulin molecule loses its 
activity
152
. NMR shows that the potent [D-Ala
B26
]-DTI-NH2 analogue
153
 has mobility in the 
B
26
 region, indicating that the formation of the B26 turn can easily be achieved. 
        These structures and observations led to the proposal that for binding of insulin to the 
IR to occur, the C-terminus of the B-chain (Tyr
B26
-Thr
B30
) must be detached allowing the 
B26 turn to be formed along with the trans-to-cis isomerisation of the Phe
B25
-Tyr
B26
 peptide 
bond. This theory is consistent with the induced-fit theory and peptide bond 
isomerisation
61,154
. Detachment of the C-terminus exposes the hydrophobic core of insulin, 
so the protein environment supplied by the IR must be involved in the stabilisation of the 
insulin molecule. Due to this detachment and isomerisation, structures of high affinity 
analogues are more representative of the conformation that insulin adopts upon binding to 
the IR, than of the native hormone in its storage form. If these structural changes and re-
arrangements are correct, this indicates that the IR acts as a chaperone in the activation of 
insulin
61
, especially for the trans-to-cis isomerisation. 
        A striking structural feature is the invariance seen in the Cα in all of these structures. 
The re-arrangement of the B-chain and the concerted changes seen in the N-terminal A-
chain helix cause a large hydrophobic area (consisting of Gly
A1
, Ile
A2
, Val
A3
 and Tyr
A19
) to 
be exposed for direct interactions with the IR (Figure 26). In receptor binding, the 
importance of Ile
A2
 is illustrated by it being completely exposed on the large hydrophobic 
area. The structural conservation of the Cα in IleA2 suggests that it may act as a pivot point 
for the A-chain during activation. The A-chain IR-binding surface is further stabilised by the 
movement of Tyr
A19
 to form a hydrogen bond with Gln
A5
. The movement of Tyr
A10
 causes a 
transformation of the Gly
A1
-Ile
A2
-Val
A3
 hydrophobic surface into a binding epitope. 
        It has been shown that Phe
B24
 and Phe
B25
 play key structural roles in insulin activity
73
, 
which is confirmed by the structures of the high affinity insulin analogues presented here. In 
WT insulin and all other insulin analogues the aromatic ring of Phe
B24
 is spatially invariant, 
which is in contrast to the high affinity analogues that possess a ~90° rotation of Phe
B25
. 
This causes an overhang of ~7 Å of the A-chain over the binding epitope. Although there is 
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considerable movement of the side chain, the Phe
B25
 Cα position is well conserved in a 
variety of analogues. This observation further reinforces the need of Phe
B24
 to assist the 
detachment of the C-terminus of the B-chain in a stereo-specific manner
77
. The importance 
and role played by the Phe
B24
 side chain leads to it being described as an important pivot 
point during the activation of the insulin molecule (Figure 26). The ability of Phe
B25
 to be 
the initiation point for the formation of the B26 turn relies upon the structural stability of the 
Phe
B24
 side chain. The Phe
B24
 side chain is anchored by a hydrophobic cavity, lined by 
residues Leu
B15
, Val
B12
, Tyr
B16
 (whose side chains seal off the cavity by collapsing into it 
during activation) and Cys
B19
. This is then further complemented by the spatial stability of 
Phe
B25
 Cα, which allows this and PheB24 to act as an anchor, enabling the pivot to cause the 
formation of the B26 turn, and therefore IR binding. 
        Along with the structural convergence seen in the B
24
-B
26
 region of the highly-active 
analogues, there is also a consistent presence of a unique B
3
-B
5
 pseudo β-turn in the high 
affinity analogues. This causes the N-terminus of the B-chain to be in a conformational state 
between that of the T- and R-states. 
        The high affinity analogues described here present an interesting insight into structure-
function relationship, not only of the whole active conformation, but also of the local 
structures that can be involved in binding of insulin to the IR. When insulin becomes 
activated, the B26 turn, along with Phe
B25
 causes a hydrophobic knob to form along with the 
A-chain epitope. This forms a highly hydrophobic IR-binding cleft lined with Leu
B15
, Leu
B11
 
and Val
B12
 side chains. The shape of the cleft is reminiscent of a hydrophobic hand that 
ensures a good grip on the receptor, the thumb (Phe
B25
 and the B26 turn), a hydrophobic 
palm (Leu
B15
, Leu
B11
, Val
B12
) and hydrophobic fingers (Tyr
A19
, Gly
A1
-Ile
A2
 and Val
A3
). 
        The high affinity insulin analogues presented here show unique molecular features and 
structural elements in the conformational landscape of the insulin molecule. These give 
appreciable insight into the activation and the active form of insulin. 
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2.6. Application of Click Chemistry in the Development of Novel 
Insulin Analogues 
 
A structural re-arrangement of the C-terminus of the B-chain
61,75,77
  exposes the binding 
epitope of insulin, allowing effective binding of the IR. Cyclo[G-PrgFYTPK(N3)T]-insulin 
was designed to mimic the conformation seen in high affinity analogues such as 
[NMeTyr
B26
]-insulin, by fixing the B26 turn-like conformation by chemically cross-linking 
amino acid from the B20-B30 region
75
.  
The Cyclo[G-PrgFYTPK(N3)T]-insulin was crystallised as a tetramer of two 
dimers, which are not related along the normal dimer interface..  The low binding affinity 
(0.13%) of Cyclo[G-PrgFYTPK(N3)T]-insulin can be explained by the structure at the B-
chain C-terminus of the analogue. The B26 turn is not present in Cyclo[G-
PrgFYTPK(N3)T]-insulin (Figure 30).  The chemical cross-link causes conformational and 
structural rigidity, which results in the conversion of the B
25
-B
26
 peptide bond from trans-to-
cis being impossible. 
 
Figure 30. An overview of  the structure of Cyclo[G-PrgFYTPK(N3)T]-insulin. 
Left: An overview of Cyclo[G-PrgFYTPK(N3)T]-insulin, against T-state insulin (shown in 
blue, PDB used was 1mso.pdb) and [NMeTyr
B26
]-insulin (shown in red). Right: The C-
terminus of the B-chain Cyclo[G-PrgFYTPK(N3)T]-insulin, against T-state insulin (shown 
in blue, PDB used was 1mso.pdb) and [NMeTyr
B26
]-insulin (shown in red). Oxygen atoms 
in red and nitrogen in blue. 
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The conformation adopted by B
25
 and B
26
 protrudes towards the insulin binding 
epitope. This structure results in the limited exposure of the binding epitope to the IR, which 
is reflected in the reduced binding affinity. 
It is possible that tethering residues in the B
24
-B
30
 region may cause conformational 
rigidity in insulin, which reduces its ability to bind to the IR. Photo cross-linking studies 
have found that the active form of the insulin B-chain C-terminus may be an extended β-
strand which inserts itself between different subunits of the IR
77
. Conformational locking of 
this section of insulin eliminates the possibility of such a transition occuring. 
Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin was crystallised as a hexamer, similar to 
the R-state of WT insulin (Figure 31), which explains the almost native binding affinity, 
101.5%. The chemical cross-link at the B-chain C-terminus causes a small nodule to be 
formed. This structure was stabilised by a weak hydrogen bond between COB
27
 and NHB
30
. 
 
Figure 31. The cross-link of Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin. 
Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin is shown in green and R-state insulin is shown in 
red. PDB used was 1znj.pdb. Oxygen atoms in red and nitrogen in blue. 
 
The structural rigidity induced by the cross-link in Cyclo[G-PrgFYTPK(N3)T]-insulin 
caused a vastly reduced binding affinity (0.13%). The same structural rigidity caused by the 
chemical cross-link in Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin produced a slightly raised 
binding affinity (101.5%), as it does not interfere with the structural re-arrangement of the 
C-terminus of the B-chain required for binding to the IR.  
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2.7. Conclusion and Future Use of Click-Chemistry in the 
Development of Insulin Analogues 
 
The aim behind creating chemically cross-linked insulin analogues was to artificially 
maintain the structural conformation seen in the high affinity insulin analogues such as 
[NMeTyr
B26
]-insulin.  The conformational rigidity seen in Cyclo[G-PrgFYTPK(N3)T]-
insulin is a result of the chemical cross-link between residues B
24
 and B
29
, preventing the 
formation of the B26 turn.  This causes the binding epitope to be partially masked, 
impairing IR binding. These two factors combined result in the low binding affinity.  These 
structural features act upon binding affinity along with the chemical effect caused by the 
positive charge of the triazole ring, which is in contrast to the hydrophobic environment 
present in WT insulin. The 1,2,3-triazole ring at the centre of the chemical cross-link in 
Cyclo[G-PrgFYTPK(N3)T]-insulin introduces a positive charge, where in WT insulin Phe
B24
 
has a neutral charge and forms part of the binding epitope
61
.  It is believed that B
24
 interacts 
with the leucine-rich repeat of the IR
61
, and is part of a hydrophobic surface.  The chemical 
difference observed by the IR upon binding may be the reason that the binding affinity is 
reduced. 
Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin  shows very high structural symmetry with the 
R-state seen in WT insulin. The cross-linked C-terminus of the B-chain causes a nodule to 
form that is further stabilised by a weak hydrogen bond. Due to the location of this nodule, 
away from the B
26
 position, the B26 turn can still form and allow binding to the IR
75
. 
The chemical cross-link for Cyclo[G-PrgFYTPK(N3)T]-insulin created negative effects 
such as structural rigidity and a partial obscuring of the binding epitope. The location of the 
cross-link in Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin allows the B26 turn
75
 to form upon 
binding with the IR, meaning that the binding epitope would not be obscured. Structural 
rigidity in the nodule caused by the cross-link reduces the overal flexibility in the C-
terminus of the B-chain. The nodule acts as a handle for the IR to “grab onto” during 
binding to negate any negative effect and effectively restore binding affinity. 
The ability to fix the B-chain C-terminus into a conformation resembling the B26 turn 
would require further design to reduce the negative effects seen in Cyclo[G-
PrgFYTPK(N3)T]-insulin and to a lesser effect Cyclo[GFFY-Pent(N3)-P-G-Prg]-insulin. 
Structural flexibility in the C-terminal region is important for the re-arrangement of the 
region upon binding to the IR, therefore inserting a cross-link would require the formation 
of a structured turn similar to the B26 turn, whilst still maintaining structural flexibility in 
this region. 
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Chapter 3. The Role of Residues B24 and B26 in Insulin Dimer 
Formation and Hormone Activity 
3.1. Summary 
 
Insulin residues B
24
-B
26
 of the B-chain C-terminus play key roles in the interactions 
with the IR, as well as in insulin self-association into dimers.   
The role of Phe
B24
, Phe
B25
 and Tyr
B26
 in dimer formation have been studied 
previously
155
, although the individual contribution of each amide hydrogen has not been 
fully established.  The work described in this chapter addresses two outstanding issues 
concerning the role of B24 and B26 sites: (i) the role of B
24
/B
26
 main chains in the stability 
of the dimer interface, and (ii) the role of the Phe
B24
 Tyr
B26
 side chains in insulin activity. 
The C-terminus of the B-chain of insulin, along with its role in IR binding
156,157
 is also 
responsible for the formation and stabilisation of insulin dimers. The dimerisation of insulin 
is biologically important as it is vital step in the storage and bloodstream delivery of the 
hormone
24,73
.  Dimerisation occurs by the formation of an anti-parallel β-sheet between the 
B-chain C-terminal segments of two insulin monomers
2,80,151
. These secondary structures 
are stabilised four reciprocal but complementary hydrogen bonds that are formed between 
the carbonyl oxygen of Tyr
B26
 (Phe
B24
) of the first molecule, to the amide hydrogen of 
Phe
B24
 (Tyr
B26
) in the opposite molecule (Figure 32).  The amide hydrogen of Phe
B25
 forms a 
hydrogen bond with the carbonyl Tyr
A19
. Both molecules are linked by two-fold symmetry. 
 
Figure 32. The hydrogen bonding network at the insulin dimer interface. 
Carbon atoms in green, oxygen - red and nitrogen - blue. 
 
The second part of this chapter focuses on the two amino acids Phe
B24
 and Tyr
B26
 and 
the role of these side chains and their conformations.  The aromatic residues Phe
B24
 and 
Tyr
B26
 are invariant and believed to be involved in the first contact upon binding between 
insulin and the IR, with each having its own contribution in insulin:IR interactions
100,72
.  The 
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replacement of Phe
B24
 or Tyr
B26
 produces analogues with a wide range of activities.  When 
Phe
B24 
is replaced by an L-amino acid (except Gly), the analogues possess low binding 
affinities and biological activity
100
.  Whilst the incorporation of any D-amino acid (side 
chain independent), yields enhanced analogues with increased binding affinity in most 
cases
150,153
, except D-Pro.  The replacement of Tyr
B26
 displays less extreme effects on their 
binding affinity, with Trp
B26
-insulin
72
 displaying 18%, and Glu
B26
-insulin showing 125%
106
 
(compared to WT insulin). 
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3.2. Crystallisation, Structure Determination and Refinement of 
Insulin Analogues to Probe the Role of Residues B24 and B26 
 
The insulin analogues crystallised in this chapter are displayed in Table 7 with their 
sequence change from WT insulin illustrated along with their binding affinity. 
Table 7. A comparison of insulin analogues structure used in this chapter and 
their relative receptor binding affinity. 
Changes in the B-chain sequence are indicated in bold.  [NMeXaaB
n
]: methylation of the N-
peptide atom preceding Xaa B
n 
amino acid; -NH2 : C-terminal carboxy amide. 
 
 
Insulin analogue [NMePhe
B26
]-insulin was dissolved in 20 mM HCl to a 
concentration of 10 mg/ml. The best crystal identified from the screening was obtained from 
drops equilibrated 1:3 (protein:well) in well solution consisting of 0.6 M Na2SO4, 0.3 M 
Tris pH 8.2, 0.6mM ZnAc, 0.06% phenol (0.5 ml well volume), and grown at 21°C. The 
crystal was flash-cooled in liquid nitrogen without any cryoprotection. The X-ray data were 
collected in house on a Rigaku RUH3R with a MAR345 detector, and processed using 
HKL2000
140
. The crystal structure of [NMePhe
B26
]-insulin was solved by molecular 
replacement using default settings in Molrep
143
. The search model consisted of a truncated 
model of hexameric insulin 1znj.pdb, which involved the removal of residues B
1
-B
5
 and 
B
25
-B
30
. Subsequent manual model building and refinement with Coot
138
 and 10 cycles of 
REFMAC5
145
, resulted in a final model which was validated by MolProbity
146
. Data-
collection, reduction and refinement statistics are detailed Table 8. Crystal conditions are 
documented in Table 9. 
The other insulin analogues that were crystallised as hexamers had their structure 
determined and refined as per [NMePhe
B26
]-insulin. For crystals of monomeric insulins the 
molecular replacement was conducted using a truncated (removal of residues B
1
-B
5
 and B
25
-
B
30
) model of monomeric insulin 1mso.pdb
151
. The differences in the crystal conditions and 
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data collection, reduction and refinement conditions are details in Table 9 and Table 8 
respectively. 
Table 8. X-ray date and refinement statistics for the insulin analogues used in this 
chapter. 
 [NMeTyr
B26]-
insulin hexamer  
[TyrB25,NMePheB26,LysB28,ProB29]-
insulin 
[NMePheB25]-
insulin 
PDB code 2ws6  3zs2 3zqr 
Data collection Beamline 
ESRF, ID14-1  
ESRF, ID23-1, ADSC Q315 
detector 
In-house 
MAR345, Rigaku 
RUH3R 
Wavelength (Å) 0.9340  1.0712 1.54178 
Space group P21  P21 P21 
Cell dimensions    
    a, b, c (Å) 58.7 61.9 47.3  46.7 62.2 57.6 46.6 61.8 58.2 
 ()  90.0 111.9 90.0  90.0 111.3 90.0 90.0 111.2 90.0 
Resolution (Å) 40.0–1.50(1.55–
1.50)  
30.0-1.97 (2.04-1.97) 
20.0-1.9 (1.93-
1.90) 
Rsym 0.048(0.479)  0.109 (0.205) 0.047 (0.164) 
<I / I> 11.7(5.0)  13.5 (8.5) 16.3 (10.0) 
Completeness (%) 99.8(99.9)  90.2 (61.7) 95.3 (74.7) 
Redundancy 3.9(3.0)  2.3 (1.5) 3.2 (2.0) 
Refinement    
Resolution (Å) 40.0 - 1.50  50.0 – 2.60 20.0 – 19.0 
No. reflections 47779  18615 22062 
Rwork / Rfree 0.150/0.199 0.188/0.240 0.223/0.281 
No. atoms 2775  2440 2460 
    Protein 2523 2244 2250 
    Ligand/ion 6  46 46 
    Water 246  150 164 
B-factors    
    Protein 22.3  36.4 38.17 
    Ligand/ion 31.9  32.1 29.64 
    Water 30.2  46.6 39.10 
R.m.s. deviations    
    Bond lengths (Å) 0.025  0.019 0.022 
    Bond angles () 2.173  1.72 1.838 
Ramachandran statistics 
(%) 
   
Preferred/Allowed/Outliers 98.6/1.4/0  99.2/0.8/0 95.6/4.4/0 
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 [His
B24]-insulin [AsnB26]-insulin [PheB26]-insulin 
monomer 
PDB code    
Data collection Beamline Diamond i24 Diamond, i02 ESRF id232 
Wavelength (Å) 0.9686 0.9795 0.8726 
Space group I422 P41212 P212121 
Cell dimensions    
    a, b, c (Å) 57.5 57.5 56.2 45.6 45.6 90.0 43.9 45.8 51.3 
 ()  90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 
Resolution (Å) 40.62-1.70 (1.76-
1.70) 
45.63-1.81 (1.85-
1.81) 
50.00-1.60 (1.63-
1.60) 
Rsym 0.157 (0.559) 0.11 (0.817) 0.092 (0.467) 
<I / I> 10.2 (4.1) 19.1 (4.2) 5.2 (2.9) 
Completeness (%) 99.6 (95.0) 99.0 (99.6) 100 (100) 
Redundancy 6.5 (6.0) 14.2 (15.6) 7.1 (7.2) 
Refinement    
Resolution (Å) 40.62-1.70 36.06-1.81 34.15-1.59 
No. reflections 5182 11459 13606 
Rwork / Rfree 0.179/0.217 0.185/0.238 0.163/0.202 
No. atoms 340 936 998 
    Protein 300 813 802 
    Ligand/ion 5 5 15 
    Water 35 118 181 
B-factors    
    Protein 32.562 19.241 10.556 
    Ligand/ion 41.190 12.582 37.221 
    Water 50.511 28.677 23.131 
R.m.s. deviations    
    Bond lengths (Å) 0.025 0.028 0.024 
    Bond angles () 2.543 2.081 2.388 
Ramachandran statistics 
(%) 
   
Preferred/Allowed/Outliers 94.4/5.6/0 98.6/1.4/0 98.9/1.1/0 
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Table 9. Crystal conditions for the insulin analogues used in this chapter. 
 
 [NMeTyr
B26
]-
insulin hexamer 
[Tyr
B25
,NMePhe
B26
,Lys
B28
,Pro
B29
]-
insulin 
[NMePhe
B25
]-
insulin 
Well Condition 
0.3 M Tris pH 
8.2, 0.1 M NaCit, 
0.02% ZnAc, 
0.06% phenol 
0.1M NaCit, 0.3M Tris pH 8.2, 
0.6mM ZnAc, 0.06% phenol 
 
0.6M Na2SO4, 
0.3M Tris pH 8.2, 
0.6mM ZnAc, 
0.06% phenol 
Drop Ratio 
(Protein:Well) 
1:3 1:2 1:2 
Temperature 21°C 21°C 21°C 
Cryoprotectant None None None 
 
 
 [His
B24
]-insulin [Asn
B26
]-insulin [Phe
B26
]-insulin 
monomer 
Well Condition 
2M NaCl, 3M Urea, 
0.1M phosphate 
buffer pH 6.5, 6mM 
ZnAc, 0.5% 
resorcinol 
0.15M (NH4
+
)2SO4 
pH 3.0 
0.15M Na2SO4    
pH 3.0 
Drop Ratio 
(Protein:Well) 
1:3 1:3 1:3 
Temperature 21°C 21°C 21°C 
Cryoprotectant None None None 
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3.3. The Physical-Chemical Properties of Insulin in Various 
Association States 
 
The role of the amino acids at positions B
24
, B
25
 and B
26
 in dimer formation was 
elucidated here by the characterisation of several novel full-length insulin analogues that 
each has N-methylated peptide bonds at these positions. The dimerisation capability of each 
insulin analogue was determined was determined in collaborators’ laboratory in Institute of 
Organic Chemistry and Biochemistry (IOCB), in order to identify contribution of amide 
nitrogen of each of these amino acid towards insulin association. WT insulin (capable of 
forming dimers) and des(B
23
-B
30
) octapeptide (DOI, incapable of dimer formation
158
) were 
used as references for the dimeric and monomeric forms of insulin respectively. 
The ability of an insulin analogue to dimerise was measured by ITC dilution 
measurements that detect heat energy changes upon the dissociation of insulin dimers 
(Table 10)
159
.  Human/porcine insulin and DOI were used as references for normal and non-
dimerisable insulin respectively.   
Table 10. ITC analysis of dimerisation capabilities of insulin and insulin 
analogues. 
The number of repetitions of a measurement is indicated in brackets. The experimental 
values are taken from Antolikova et al.
159
. 
 
 
ITC experiments show that the Kd of human and porcine insulin (Table 10) are in 
close agreement, with previously reported values (8.8 μM and 9 μM respectively)160.  
Strazza et al.
161
 used concentration spectroscopy to determine the Kd of porcine insulin at 
pH 2 (Kd = 15μM) and pH 7 (Kd = 18 μM).  This reliability therefore allows a systematic 
look at the individual hydrogen bonds role in the B
24
-B
26
 dimer stability, evaluating their 
roles.  No heat effect could be detected for DOI, confirming that insulin dimerisation is 
caused by interactions at the B-chain C-terminus of insulin.  The analogue [NMeTyr
B26
]-
  
77 
 
insulin has a Kd of 142 μM, which is 15-fold weaker than that of insulin.  The removal of 
the phenolic hydroxyl ([NMePhe
B26
]-insulin) further suppresses the dimerisation ability to 
Kd = 1.24 mM.  [NMePhe
B24
]-insulin caused a 65-fold higher Kd compared to insulin of 587 
μM, but the greatest observed effect was for [NMePheB25]-insulin, which gave no heat 
effect, like DOI. pH has little effect upon insulin dimerisation experiments
161
, so all ITC 
experiments were performed at a pH of 2.5 to avoid reduced solubility of insulin at a more 
physiological pH
160
.   
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3.4. The Structural Properties of Insulin in Various Association 
States 
 
The crystal structure of [NMePhe
B25
]-insulin was obtained in the hexameric form (R6). 
[NMeTyr
B26
]-insulin was obtained in both monomeric and hexameric (R6) forms, whilst 
[Tyr
B25
,NMePhe
B26
]-insulin was in hexameric (R6) form
75,162
. 
[NMePhe
B25
]-insulin adopted the R6 hexamer conformation (such as 1znj.pdb), with six 
phenol ligands located at the type I site, with two Zn
2+
 cations and two Cl
-
 anions as their 
axial ligands. The type I site is located at the dimer interface, with the phenol forming 
hydrogen bonds with CO
A6
 and NH
A11
 as well as loose Van der Waals contacts (~3.7 Å) 
with the imidazole of His
B5
 
163
.  The hydrogen bonds in the dimer interface are not 
significantly disrupted (Figure 33-A) by the N-methylation of the Phe
B25
 peptide bond.  All 
four hydrogen bonds (B
24
-B
26
) were preserved, with just an increase of ~0.2 Å of the CO
B24
-
NH
D26
. The position of the N-methylation is outside the dimer interface, which maintains 
these hydrogen bonds. The NMe
B25
 is accommodated in the A
19
-A
21
 region.  
The most dramatic disruption of the ability of insulin to dimerise, based upon ITC data, 
is caused by the N-methylation of the B
25
 amide in [NMePhe
B25
]-insulin.  The dimer 
interface is very similar to WT insulin (Figure 33-A) with the N-methylations easily 
accommodated, by pointing outwards from the dimer interface.  The lack of an amide 
hydrogen bond at B
25
 resulted in no heat effect, the same as the negative control.  This 
hydrogen bond is usually donated to COA
19
 (Figure 34), which when released from the C-
terminal region of the B-chain will result in the higher mobility of this region.  This 
increased mobility can be observed in the side chain of Phe
B25
 as only one can be seen.  The 
monomeric nature of [NMePhe
B25
]-insulin can be attributed to the detachment of Phe
B25
 
from the A chain (Tyr
A19
)
159
. 
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Figure 33. The effect upon the dimer interface by the introduction of an N-
methylation. 
Reference wild type insulin is in grey (1znj.pdb) with hydrogen bonds indicated by dashed 
black lines, distances are in Å. (A) Is the dimer interface of [NMePhe
B25
]-insulin. (B) Is the 
dimer interface of [NMeTyr
B26
]-insulin. (C) Is the dimer interface of [Tyr
B25
,NMePhe
B26
]-
insulin . (D) Is the dimer interface of [Tyr
B25
,NMePhe
B26
,Lys
B28
,Pro
B29
]-insulin. Carbon 
atoms in green, oxygen - red and nitrogen - blue. The methyl groups on N-methylated atoms 
are coloured in purple and are indicated by a purple asterisk. 
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Figure 34. The effect of the intrachain coupling of the NH
B25
-CO
A19
 hydrogen 
bond. 
Wild type insulin (T6) 1mso.pdb is shown in grey, wild type insulin (R6) 1znj.pdb is shown 
in cyan, [NMePhe
B25
]-insulin is shown in green and [NMeTyr
B26
]-insulin is shown in 
yellow. Dashed lines indicate hydrogen bonds (distances given in Å). 
 
[NMeTyr
B26
]-insulin was obtained in both the R6 hexameric and monomeric forms, 
under the appropriate condition. The hexamer crystals appeared very similar to those of 
[NMePhe
B25
]-insulin (as well as the crystallisation conditions). The N-methylation of Tyr
B26
 
caused a much more disturbed dimer interface, where both groups point towards the dimer 
interface, causing only one of the original four hydrogen bonds to remain intact, CO
B26
-
NH
D24
 (Figure 33-B). The disturbance caused by the N-methylation is not uniform in the 
two β-strand; one follows the path of WT insulin, whilst the other β-strands experience a 
bulge in the B
24
-B
26
 region, to allow the N-methyl group to be accommodated. This bulging 
of the dimer interface causes structural stress that is seen in the higher mobility of B
28
-B
30
. 
The bulge in the β-sheet to accommodate the N-methylations causes the NHB25 peptide to 
move closer to CO
A19
, resulting in a unique 2.9 Å hydrogen bond, unseen in R6 hexamers 
(Figure 34).  It could be this hydrogen bond that is responsible for the lower dimerisation 
capability. 
[Tyr
B25
,NMePhe
B26
]-insulin was crystallised as an R6 hexamer form similar to those 
of [NMeTyr
B26
]-insulin and [NMePhe
B25
]-insulin, though the bulge at the dimer interface of 
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this analogue is apparent in both β-sheets (Figure 33-C). The structural consequences of the 
N-methylation are the same as those discussed for [NMeTyr
B26
]-insulin, whilst the side 
chain substitutions of residues B
25
 and B
26
 has little effect. 
[Tyr
B25
,NMePhe
B26
,Lys
B28
,Pro
B29
]-insulin was crystallised as an R6 hexamer.  The 
multiple changes to the analogue from insulin WT allow extensive probing and 
characterisation of the dimer interface and its hydrogen bonding network. The B
25
-B
26
 
Tyr↔Phe and B28-B29 Lys↔Pro substitutions along with the N-methylation of B26 cause the 
dimer interface to become fully disrupted (Figure 33-D), meaning that R1R1 dimer 
formation here is entirely dependent upon phenol induced interactions. The disruption of the 
dimer interface is similar to that seen in [NMeTyr
B26
]-insulin, where the two β-sheets aren’t 
uniformly displaced. One of the β-strands follows the conformation shown by WT insulin, 
whereas the counter β-strand departs from the dimer interface dramatically from D23 
onwards and becomes fully disordered crystallographically after D
27
. 
Analogues that have peptide bonds at the B
24
-B
25
 or B
25
-B
26
 position reduced CH2-
NH have extremely low binding affinities.  Their binding affinities can be attributed to the 
loss of the carbonyl oxygens that form hydrogen bonds with the IR.  [NMeTyr
B26
]-insulin
75
 
shows a reduced binding affinity (21%) to WT insulin. This is reduced less than in 
analogues that are N-methylated in the B
24
 and B
25
 positions (3 and 0.17% respectively). 
This indicates that the NH of B
26
 (and its hydrogen bond) are less important in the binding 
of insulin to the IR than those in positions B
24
 and B
25
, or has a different role. It has been 
shown
75
 that a N-methylation of Tyr
B26
 causes the induction of a novel type II β-turn at 
positions B
24
-B
26
 (the B26 turn), which causes the departure of the C-terminus of the B-
chain (the B
22
-B
30
 β-strand) from the usual hexamer/dimer conformation. There are several 
reasons to explain the reduced binding affinity of [NMeTyr
B26
]-insulin. The first is that the 
arrangement of B
27
-B
30
 caused by the N-methylation may be non-optimal.  The reduced 
affinity may also be due to the loss of the NH
B26
 hydrogen bonds that are required for 
binding to the IR. 
The analogue [Phe
B26
]-insulin shows the importance of the phenolic character of Tyr
B26
 
to binding affinity, with reduced binding affinity (46%)
71
.  An analogue that combines the 
loss of the phenolic character of the side chain along with a N-methylation of this peptide 
bond, [NMePhe
B26
]-insulin, results in a binding affinity of 4%.  This accumulation of 
multiple unfavourable modifications is further demonstrated by [NMePhe
B25
,NMePhe
B26
]-
insulin, which has a binding affinity of 0.44% due to the two N-methylations and the loss of 
the phenolic nature of the B
26
 side chain.          
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In summary, the evidences resulting from the dimerisation capabilities of the 
[NMePhe
B24
]-insulin and [NMePhe
B26
]-insulin analogues and their crystal structures, 
indicate that the loss of the NHB
24
-COB
26
 hydrogen bond has the greatest impact on dimer 
formation.  This is due to its flanking position in the dimer interface, allowing solvent to 
more easily penetrate the β-sheet, resulting in the solvation/breaking of the two remaining 
central hydrogen bonds
164
.  Unzipping of the two remaining hydrogen bonds could also be 
due to this lack of the flanking hydrogen bonds combined with the highly mobile B
27
-B
30
 
region.  The insulin analogue [NMePhe
B25
]-insulin displays a dimerisation capability 
identical to that of DOI.  This N-methylation results in the loss of the hydrogen bond with 
the carbonyl Tyr
A19
.  Consequently the C-terminus of the B-chain is no longer held in place, 
and is allowed to move freely in solution.        
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3.5. The Importance of the B24 and B26 sites in Insulin Activity 
3.5.1. The Steric Importance of the B24 Site 
 
The role played by Phe
B24
 in insulin activation was probed by a combination of crystal 
and NMR structures (all NMR structures have been determined at IOCB).  Phe
B24
 is an 
invariant residue in all vertebrate insulins.  In the storage forms of the hormone the side 
chain of Phe
B24
 points towards the hydrophobic core of the protein. The main chain CO and 
NH of Phe
B24
 are crucial for the activity of insulin and for its ability to dimerise
152,159
. 
[His
B24
]-insulin analogue is almost inactive (1.5%) and was crystallised as a monomer 
with the C-terminus of the B-chain being completely disordered (B
22
-B
30
) (Figure 35-A). 
The side chain of Tyr
B16
 is flipped from its usual position into the B
24
 pocket, which is 
stabilised by van der Waals contacts with the Val
B12
 side chain. This indicates that the Phe
B24
 
pocket needs to be occupied in the native hormone. 
The NMR structure of [His
B24
]-insulin at pH 2 shows great disorder at the C-terminus of 
the B-chain, similar to the crystal structure (Figure 35-B). This may be attributed to the 
disruptive effect of double protonated His side chain
165
 that cannot be maintained in Phe
B24
 
hydrophobic cavity. 
In contrast the NMR structure of [His
B24
]-insulin at pH 8 is well ordered (Figure 35-C). 
The His side chain is accommodated in the B
24
 pocket. The Nɛ is protonated and forms a 2.4 
Å hydrogen bond with CO
B12, whilst Nδ is deprotonated and forms a 2.9 Å hydrogen bond 
with NH
B26
. The NMR structure indicates that the dimer interface had been disrupted, which 
explains its inability to dimerise. Moreover, the monomeric character of this analogue may 
results from quite visible increased compactness of the hole insulin molecule; the B20-B30 
chain is closer to the core to the hormone than in WT insulin. In addition, the side chain of 
Tyr
B26
 is shifted, and forms a π stacking interaction with ProB28, whilst the side chain 
hydroxyl forms hydrogen bonds with the main chain CO
B8
 (2.8 Å) and/or NH
B8
 (3.3 Å).  
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Figure 35. The crystal and NMR structures of [His
B24
]-insulin at different pHs. 
(A) The crystal structure of [His
B24
]-insulin at pH 3. (B) NMR structure of [His
B24
]-insulin 
at pH 2. (C) NMR structure of [His
B24
]-insulin at pH 8. The A-chain is coloured red in all 
part, and the B-chain blue. NMR structures were produced by collaborators in Prague. 
 
The [D-His
B24
]-insulin analogue is a high affinity insulin (217%) that is monomeric 
in NMR structures at pH 2 and pH 8. At pH 2 the NMR structure shows disorder at the C-
terminus of the B-chain (B
22
-B
30
) as seen in [His
B24
]-insulin (Figure 36-A). The pH 8 NMR 
structure of [D-His
B24
]-insulin is more ordered in the C-terminus of the B-chain than L-His 
or WT insulin (Figure 36-B). The D-His side chain is oriented out of the insulin core, 
exposed to the solvent. As a result of this transition, the side chain of Phe
B25
 has turned and 
downshifted towards the Phe
B24
 pocket, partially taking its place. This clearly indicates the 
importance of the maintenance of the integrity of the B
24
 pocket. The B
21
-B
23
 turn is more 
open that that seen in WT insulin. The presence of D-His, a non-naturally occurring amino 
acid may result in an artificial structure, however the enhanced flexibility of the B
25
-B
30 
due 
to the lower chance of hydrogen bonds forming, results in a higher affinity of this analogue. 
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Figure 36. NMR structures of [D-His
B24
]-insulin at different pHs. 
(A) NMR structure of [D-His
B24
]-insulin at pH 2. (B) NMR structure of [D-His
B24
]-insulin 
at pH 8. The A-chain is coloured red in all part, and the B-chain blue. NMR structures were 
produced by collaborators in Prague. 
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3.5.2. The Steric Importance of the B26 Site 
 
Tyrosine at position B
26
 is invariant in many species, although its role in the interaction 
with the IR is unclear.  Replacing the Tyr with another amino acid can lead to analogues 
with a range of affinities between less than 1%, up to 4-5 times higher than that of WT 
insulin
150
. 
A reduction in the binding affinity of an analogue can be accounted for by an increase in 
the size of the amino acid in the B
26
 position in shortened analogues ([NMePhe
B26
]-DTI-
NH2 
150
, [NMeTyr
B26
]-DTI-NH2) or in full length analogues ([NMeTyr
B26
]-insulin and 
[NMeAla
B26
]-insulin)
150
.  The increase in the size of the amino acid at the B
26
 position 
results in binding affinities of 21-72%.  
The full length analogues [NMeTyr
B26
]-insulin and [NMeAla
B26
]-insulin both possess 
the same structural features around the B26 turn
75
 as with the high affinity analogues, 
despite their low affinity (21 % for both analogues).  The structures show that the N-
methylated group is located on the outside of the B
26
 position, causing the B26 turn.  
Residues B
27
-B
30
 are stabilised by hydrogen bonds between amino acids located at ί and ί+3 
positions. 
The structural importance of the B
26
 position is chiral dependent as indicated by its 
replacement with [D-Pro
B26
]-DTI-NH2 (359%).  The chirality of the D-Pro is important at 
the Cα of the amino acid., as it mimics the cis PheB25-XaaB26 N-methylated peptide bond in 
the high affinity analogues such as [NMeAla
B26
]-DTI-NH2.   
Some B
26
 truncated analogues, [NMeTyr
B26
]-DTI-NH2 and [NMePhe
B26
]-DTI-NH2 
show much lower affinities than their higher affinity relatives (72% and 36% respectively).  
In these analogues the presence of a bulky side group Phe
B26
/Tyr
B26
 or the N-methylation of 
the B
26
 peptide bond in [NMeTyr
B26
]-DTI-NH2 could result in a detrimental entropic effect.  
This causes a destabilising effect on the formation of the B26 turn.  The lack of a crystal 
structure suggests increased flexibility, which has been observed using NMR in a related 
truncated insulin analogue
166
.  
In full length WT insulin, substitution of Tyr
B26
 with Ala
B26
 results in reduction of 
binding affinity to ~36%
78
.  The crystal structure of monomeric [NMeAla
B26
]-insulin was 
obtained under both monomeric and hexameric conditions, whilst [NMeTyr
B26
]-insulin was 
obtained as a monomer and hexamer, under relevant monomeric and hexameric conditions.  
The presence of Ala infers a preference in state towards the monomer, whereas Tyr doesn’t 
preferentially crystallise in a particular form.  The low potencies of [NMeTyr
B26
]-insulin and 
[NMeAla
B26
]-insulin (~21%) confirm the trend seen that full length analogues are generally 
less active than their truncated homologues
73
. This could result from the B
27
-B
30
 region 
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causing detrimental effects to the structure, such as steric and entropic factors. A reason for 
this could be that in order to stabilise the B
27
-B
30
 segment, the IR could be required to 
provide significant contacts. Also, it is possible that the structural restraints enforced by 
formation of the B26 turn may not be the optimal conformation for the B
27
-B
30
 residues, or 
may not even be the final conformation. 
 
Table 11. The Kd and relative IR binding affinity of human insulin and insulin 
analogues. 
The Kd is a representation of the dissociation constant of binding of insulin/insulin analogue 
to the IR. Each value shown indicates the mean ± the standard error. The number in 
parentheses indicates the number of replications. The relative binding affinity is defined as 
(Kd of human insulin/Kd of analogue) x 100. The experimental values are taken from 
Antolikova et al.
159
. 
 
 
The ability of insulin, [Phe
B26
]-insulin and [Asn
B26
]-insulin to dimerise are all 
different.  The ability of [Asn
B26
]-insulin, and [Phe
B26
]-insulin to dimerise is reduced 
approximately 86 and 3 fold respectively, compared to insulin, as determined by ITC (Table 
12). 
Table 12. ITC analysis of the dimerization capabilities of insulin and insulin 
analogues. 
Each value shown indicates the mean ± the standard error. The number in parentheses 
indicates the number of replications. The experimental values are taken from Antolikova et 
al.
159
. 
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Both [Phe
B26
]-insulin and [Asn
B26
]-insulin were crystallized under dimeric 
conditions, which gave rise to an unusual monomer-monomer crystal organisation (Figure 
37). In [Phe
B26
]-insulin and [Asn
B26
]-insulin, an unusual pseudo-dimer is formed by rotation 
of the α-helix in the B-chain by 50˚, where the only close contact between the monomers is 
between the –OH of serine A12 of one monomer, and the –NH2 of glutamine B
4
 in the 
second.  These form a hydrogen bond of ~2.6 Å (Figure 37).  Whilst the spatial 
arrangements of [Asn
B26
]-insulin and [Phe
B26
]-insulin are similar, there are also some 
different features (Figure 38). 
 
Figure 37. A representation of the unusual dimer interface in [Asn
B26
]-insulin. 
(A) The main chain representation (chains B and D only) of the dimer interface in human 
insulin (1znj.pdb in grey) and of [Asn
B26
]-insulin (red). (B), The close contact between two 
molecules in the unusual dimer interface of [Asn
B26
]-insulin (chains B and C, in red) and 
[Phe
B26
]-insulin (Chains B and C, in blue). Dashed lines indicate hydrogen bonds.  
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Figure 38. An overlay of the main chain of T- and R-state insulin, [Asn
B26
]-
insulin and [Phe
B26
]-insulin. 
T-state insulin (1znj.pdb in grey), R-state (1mso.pdb in grey), [Asn
B26
]-insulin (in red) and 
[Phe
B26
]-insulin (in blue).  
 
Both substitutions at the B
26
 position have a similar effect on the N-terminus of the 
B-chain, which occupies a conformation similar to that in [NMeAla
B26
]-DTI-NH2, which is 
between the T- and R-states.  This conformation is formed by a type II β-turn, which is 
stabilised by a pseudo i+3 hydrogen bond between the main chain NH of His
B5
 and the side 
chain of Asn
B3
 
75
.  The hydrogen bond formed by the side chain hydroxyl of Tyr
B26
 via a 
bridging water molecule with Gly
B8
 is lost in both analogues.  This causes the disruption of 
an apolar area consisting of Gly
B8
, Val
B12
, Tyr
B16
, Phe
B24
 and Tyr
B26
 (Figure 39), and 
therefore a switch of conformation to the intermediate state.  This intermediate state was 
previously described in several insulin analogues
75,167,168
, however without any thorough 
discussions of its relevance.   
In contrast, the C-terminus of the B-chain of [Asn
B26
]-insulin is in a different 
conformation.  In [Phe
B26
]-insulin, the C-terminus of the B-chain occupies a similar 
conformation to that seen in WT insulin.  The phenyl ring of Phe
B26
 occupies the same 
position as that of the tyrosine in WT insulin, though the Phe
B25
NH-Tyr
A19
CO hydrogen 
bond, which is crucial to insulin dimerisation
159
 is missing in both monomers with the 
distance now 4.65 and 4.20 Å. 
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Figure 39. A view of the interactions of Tyr
B26
 and its surrounding residues in the 
T-state of human insulin. 
Carbon atoms in green, oxygen - red and nitrogen - blue. Dashed lines indicate hydrogen 
bonds. PDB used: 1znj.pdb. 
 
[Asn
B26
]-insulin has a novel conformation in the C-terminus of the B-chain 
compared to [Phe
B26
]-insulin.  The polar residue asparagine is forced out of the hydrophobic 
pocket, causing a new C-terminal conformation to form, which causes new intramolecular 
interactions to be created.  The C-terminal turn is stabilised by close contacts with Asn
A21
, 
where three hydrogen bonds are created with several C-terminal residues (Figure 40).  The 
hydrogen bond between Gly
B23
CO and Asn
A21
NH in WT insulin is 3.0 Å, whilst in [Asn
B26
]-
insulin it is decreased to 2.8 Å.  The side chain of Asn
A21
 forms two hydrogen bonds that are 
not seen in WT insulin.  The first is a bifureated hydrogen bond, between the carbonyl of 
the Asn
A21
 side chain and the main chain amides of Phe
B25
 (3.3 Å) and Asn
B26
 (2.7 Å).  The 
second hydrogen bond is between the amide of the Asn
A21
 side chain, and the Asn
B26
 main 
chain carbonyl (2.8 Å) (Figure 40).  The Phe
B25
NH-Tyr
A19
CO hydrogen bond that is crucial 
to insulin dimerisation
159
 is missing in both monomers, with the distance now 5.22 and 4.68 
Å. 
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Figure 40. The bent conformation of the C-terminus of the B-chain of [Asn
B26
]-
insulin, stabilised by interactions with Asn
A21
. 
Carbon atoms in green, oxygen - red and nitrogen - blue. Dashed lines indicate hydrogen 
bonds. 
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3.6. Conclusion 
 
All the N-methylated full-length analogues showed a significant reduction in binding 
affinity, which confirmed the role of the amide hydrogens direct interaction/involvement 
with the IR. The systematic N-methylation of the individual residues caused a reduction in 
dimerisation ability. 
The dramatic loss in dimerisation capability was caused by the N-methylation of B
25
, 
which disrupted the NHB
25
-COA
19
 hydrogen bond that links the β-strand to the core of 
insulin.  Greater mobility of the C-terminus of the B-chain causes insulin to tend towards 
the monomeric state.  
The analogue [NMePhe
B24
]-insulin produced the greatest loss of dimerisation ability 
from the loss of a hydrogen bond in the dimer interface. This analogue lost the flanking 
hydrogen bonds, allowing the solvent easy penetration into the dimer β-sheet. The increased 
accessibility of the dimer interface allows easier break of the two remaining hydrogen 
bonds
164
. 
These analogues helped to determine the importance and contribution of the NHB
24
-
COB
26
, NHB
26
-COB
24
 and NHB
25
-COA
19
 hydrogen bonds in the formation and stabilisation 
of insulin dimers. Positions B
24
 and B
26
 in the dimer interface have been shown integral to 
stability of the insulin dimer
159
. Substitutions of each of these residues has created 
analogues of both high and low affinities
75,100,150
. 
The functional and structural observations lead to a greater understanding of the 
association-dissociation pathways of insulin.  This may allow the design of more controlled 
insulin drugs for the treatment of diabetes
159
. 
This work also provides a more systematic investigation of the role of individual B
24
 
and B
26
 side chain for insulin:IR binding. 
Substitution of B
24
 with His causes structures that are pH and chirality dependent. In 
both isomers at low pH the C-terminus of the B-chain is disordered, whilst at pH 8, the 
region becomes structured.  The low pH in both the crystal and NMR structures causes the 
side chains in [His
B24
]-insulin, [D-His
B24
]-insulin and surrounding residues to become 
protonated.  This results in hydrogen bonds not being formed, preventing the B
24
 position 
from becoming an anchor point at the C-terminus of the B-chain, resulting in the disorder 
seen in the structures. 
The B
24
 side chain of [His
B24
]-insulin sits in a similar position to that observed in WT 
insulin, pointing towards the hydrophobic core. Due to the presence of N atoms in [His
B24
]-
insulin, hydrogen bonds are able to be formed with neighbouring amino acids that would 
not be possible in WT insulin. This causes the B
24
 pocket to be more tightly bound. During 
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the activation of insulin, the C-terminus of the B-chain becomes detached from the core of 
the insulin molecule, though in [His
B24
]-insulin this is greatly reduced due to the tighter 
binding in the B
24
 pocket. 
The NMR structure of [D-His
B24
]-insulin at pH 8 shows an arrangement that is more 
flexible than [His
B24
]-insulin yet ordered. Contradictory to that seen in insulin and [His
B24
]-
insulin, the B
24
 side chain of [D-His
B24
]-insulin points away from the hydrophobic core. 
This increases the ability of the C-terminus of the B-chain to move, which is shown by the 
increased binding affinity, 217%. This increase in flexibility has ramifications on the ability 
of insulin to form dimers
159
, so changing the residue would have other detrimental effects 
on insulins method of action. This indicates that Phe is the optimum residue at B
24
, as it 
does not bind too tightly or weakly. 
The Glu, Asn and Asp B
26
 analogues were designed based upon the work of 
Brange
106,169
.  The binding affinities of these analogues are close to that of WT insulin 
(Table 11).  They indicate that a substitution by a polar residue is better incorporated at the 
B26 site
78
. 
The main chain and side chain of Tyr
B26
 play roles in monomer:monomer interactions
80
.  
The side chain of Tyr
B26
 is part of a polar region consisting of Gly
B8
, Val
B12
, Tyr
B16
 and 
Phe
B24
, that is involved in the stabilisation of the structure of insulin
170
.  A small change in 
the amino acid at B
26
 could disrupt these interactions, and cause a change in the insulin 
structure. 
ITC data (Table 12) supports the inability to form dimer or hexamer crystals for 
[Asn
B26
]-insulin and [Phe
B26
]-insulin.  [Asn
B26
]-insulin shows a bent structure in the C-
terminus of the B-chain, caused by the repulsion of the Asn
B26
 side chain from the 
hydrophobic pocket.  The loss of the Tyr
B26
OH-Gly
B8
CO hydrogen bond as described 
previously, led to the intermediate conformation seen at the B-chain N-terminus which has 
been seen previously
75,168
.  This may play a role in insulin:IR interaction. 
In [Phe
B26
]-insulin the Phe
B26
 occupies the same space as the tyrosine ring in WT 
insulin, meaning that the hydrophobic core is maintained.  The loss of the Tyr
B26
OH-water-
Gly
B8
CO hydrogen bond leads to the intermediate conformation seen at the N-terminus of 
the B-chain.  The loss of this hydrogen bond has a knock-on effect on the structurally 
important Phe
B25
NH-Tyr
A19
CO hydrogen bond, which is lost
159
, causing an enhanced 
mobility of the C-terminal β-strand of the B-chain. 
[Asn
B26
]-insulin forms a new C-terminal turn in the B-chain similar to the B26 turn
75
, 
and retains near full binding affinity.  This new turn may be closer to the actual 
conformation of WT insulin complexed with the IR, than seen in analogues with B
26
 N-
methylation due to the lack of a non biological addition. 
The susceptibility of the C-terminus of the B-chain to form a turn indicates that this 
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plays an important part in IR binding.  Initial binding may induce detachment of the Tyr
B26
 
side chain from the hydrophobic pocket, causing the formation of the B-chain C-terminus 
turn, and the loss of the previously described hydrogen bonds, causing the formation of the 
intermediate conformation of the N-terminus.  These conformational changes allow both N-
and C-terminal residues to interact with the IR. The B
24
 pocket acts as an anchoring point 
allowing the B-chain C-terminus turn to form. The local structures at either termini of the 
B-chain possess the structural signatures of activated insulin, which imply an activation 
scheme (Figure 41).  The formation of the active conformation of the insulin molecule and 
binding to the IR is simultaneous. 
 
 
Figure 41. A hypothetical scheme of insulin-IR binding. 
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Chapter 4. Insulin Receptor Expression 
4.1. Summary 
 
The IR has been expressed many times previously
63,50,171,172
 using mammalian cell 
cultures. The IR L1 domain contains the majority of residues involved in insulin 
binding
55,63,60
. This makes it a key target for expression with the aim of achieving a 
‘workable’ and compact insulin:IR complex. The IR consists of a series of well-defined 
domains, linked by flexible linker regions (Figure 13). Removal of these flexible regions 
would increase the likelihood of obtaining a crystal structure of the complex thus 
facilitating more systematic studies on this hormone:receptor system. Therefore the work in 
this chapter focused on cloning and expression of soluble L1 domain of IR for structural 
studies. 
Initial protein expression was attempted in E. coli using Rosetta-Gami 2, to aid the 
correct formation of disulphide bond but an insoluble protein expression was produced here. 
As the expression in TUNER cells produced high levels of protein expression, in vitro 
refolding was attempted. Following on-column and redox refolding of the L1 domain 
soluble protein was achieved. Analysis of the disulphide bonds, indicated that they had 
formed in an intermolecular manner, rather than intramolecular. This meant that the L1 
domain had to be expressed in a higher organism. However, expression in S. cerevisiae and 
P. pastoris failed to produce soluble, correctly formed protein. 
The L1 domain had not been previously expressed alone, but instead as part of a larger 
IR construct. There may be interactions between the L1 domain and other domains that are 
important for protein stability that are absent by removing these other domains. Mammalian 
cells contain complex post-translational machinery that aid disulphide bond formation, and 
other post-translational modification hence they may be ultimately needed for more 
successful expression of the l1 domain.  
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4.2. The L1 Region and Previous Expression 
 
The L1 region of the IR comprises the amino acid sequence shown in Figure 42, which 
contains four disulphide bonds Cys
8
-Cys
26
, Cys
126
-Cys
155
, Cys
159
-Cys
182
and Cys
169
-Cys
188
.   
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Figure 42.  The amino acid sequence of the L1 region in the human IR. 
 
The L1 region of the IR has been expressed previously as part of a larger construct. 
Using mammalian expression systems, Lou et al.
63
 expressed the L1-CR-L2 regions in Lec8 
cells, which are Chinese Hamster Ovary (CHO) cells that have limited protein glycosylation 
abilities. Sparrow et al.
50
 produced the entire ectodomain of the IR in CHO-K1 (CHO cells 
that require proline in the medium for growth) and Lec8 cells. Kristensen et al.
171
 expressed 
the L1-CR-L2 regions with various lengths of C-terminal sequences in Baby Hamster 
Kidney cells (BHK), which give stable transformations. Huang et al.
172
 expressed the L1-
CR-L2-FnIII-1 and C-terminal insert domain-derived segment in 293H cells, which give 
good growth and transfection efficiency. 
Two constructs were considered: full length of L1 (as Figure 42) and a short 
construct. The short construct, residues 5- 157 (Figure 42), has an apparent molecular 
weight of 17819.6 Da and a theoretical pI of 4.98, whilst the full length construct (entire L1 
region) has an apparent molecular weight of 21928.4 Da, and a theoretical pI of 5.80. The 
constructs were designed after analysing the available structure of L1 (pdb 2hr7.pdb). The 
structure of the full length L1 region (Figure 43-A and B) is a barrel consisting of a series of 
β-sheets. The main binding residues are located on the larger β-sheet side, and are 
responsible for insulin binding
55,60,63
.  The C-terminus lacks secondary structure, apart from 
small regions of β-strands (Figure 43-A). The short construct (Figure 43-B) was designed to 
remove this region, along with the two disulphide bonds closest to the C-terminus. The 
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benefit of removing these in an E. coli expression system is that the likelihood of the correct 
formation of the remaining disulphide bonds is increased. The disulphide bonds are at 
opposing termini, which increases the probability of the bonds forming correctly during 
translation of the L1 mRNA. 
 
Figure 43. Main chain comparison of the full length and short construct of the L1 
region. 
(A) Residues 4-190 from Figure 42. (B) Residues 4-157 from Figure 42. (pdb used is 
2hr7.pdb). Disulphide bonds are coloured in yellow.  
 
The binding between insulin and the IR is dependent upon the CT peptide
64
. Various 
constructs of the IR were investigated by Kristensen et al., where it was shown that the 
addition of the CT peptide restored binding. I will aim to repeat this approach later on by 
adding the CT peptide to the expressed L1 region. 
The most appropriate E. coli cell strains for expression of the L1 region would aid in the 
formation of the disulphide bonds. Rosetta-Gami 2 combines the advantages of two 
different strains; Rosetta 2 and Origami 2. Rosetta2 is designed to enhance expression of 
eukaryotic proteins that contain rare codons, whilst Origami 2 have mutations in 
thioredoxin reductase (trxB) and glutathione reductase (gor) genes, which greatly enhance 
disulphide bond formation in the cytoplasm by making it a more reducing environment. 
ArcticExpress cells express the chaperone proteins Cpn10 and Cpn60 from the 
psychrophilic bacterium Oleispira Antarctica, which aid protein folding between 4-12 °C. 
BL21 cells are an all-purpose strain for high-level protein expression and easy induction. 
Lemo21 has the basic features of BL21 whilst also allowing tuneable expression. The 
expression level can be controlled by varying the level of lysozyme (lysY), which is the 
natural inhibitor of T7 RNA polymerase. The level of lysozyme is controlled by the addition 
of L-rhamnose to the expression culture at levels up to 2000 µM. TUNER cells have a 
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deletion of lacZY which means that an adjustable level of protein expression is possible. The 
lacY allows a uniform entry of IPTG into all cells in culture, producing a concentration-
dependent level of induction.  
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4.3. Methods 
4.3.1. Ligation-Independent Cloning of the L1 Region 
 
The L1 protein was expressed using a ligation-independent cloning (LIC) 
expression vector (pET-YSBLIC3C).  The LIC site contains a N-terminal His6 tag and a 3C 
protease cleavage site.  Primers were used to amplify the target gene by PCR, leaving the 
LIC additions as an overhang. The full method, primers and LIC-specific sequence are 
given in the appendix. After purification, LIC-specific overhangs were created by 
incubating the insert with a T4 DNA polymerase (T4 pol) in the presence of dATP.  The 
vector was cleaved and linearised using BseRI and 5’-single-stranded overhangs were 
generated with T4 pol and dTTP.  The vector and target gene overhangs, which were 
designed to be complementary to each other, were allowed to anneal and then directly 
transformed into competent E. coli cells, where nicks can be repaired 
173
.  
 
4.3.2. Creation of L1 Region Constructs 
 
Production of the L1 region was attempted using various pET and pMAL vectors. 
Vector specific primers were used to amplify the target gene (see appendix).  The plasmid 
was linearised using restriction enzymes, which left specific sticky ends (see appendix for 
details). Complementary sticky ends were also produced on the target gene.  Ligation and 
transformation was performed. Full details of this method and primers are given in the 
appendix. 
 
4.3.3. On-Column Refolding of Expressed L1 Protein 
 
The target insoluble protein (L1 region) was solubilised using a denaturing solution 
consisting of 6 M guanidine hydrochloride, 20 mM Tris pH 8.0 and 10 mM β-
mercaptoethanol (buffer A). Ni-NTA resin was equilibrated with buffer A before binding 
with the solubilised protein overnight, whilst being continually rocked in a sealed container.  
The column was washed with buffer A, followed by buffer A with 20 mM imidazole to 
remove any non-specific column-bound proteins.  The column was then washed with a 
detergent solution of 0.1% Triton X-100, 20 mM Tris pH 7.5 and 0.5 M NaCl to remove any 
contaminating protein molecules bound to the target protein or column.  The detergent was 
removed with 5 mM β-cyclodextrin, 20 mM tris pH 7.5 and 0.1 M NaCl.  The column was 
then washed with a solution of 0.1 M NaCl, 20 mM Tris pH 7.5 before the target protein 
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was eluted over an increasing imidazole gradient (0 – 1M) in 20 mM Tris pH 7.5, 0.1 M 
NaCl
174
. 
 
4.3.4. Redox Refolding of L1 Expressed Protein 
 
The L1 protein was buffer exchanged from the final on-column refolding buffer into 
0.1 M NaCl, 0.1 M Tris (pH 7.5).  The refolding of L1 was performed by dilution with 20 
mM Na2HPO4 (pH 7.3), 1 M L-arginine, 20% v/v glycerol, 10 mM reduced glutathione and 
1 mM oxidised glutathione, to an L1 concentration of approximately 10 mg/ml, followed by 
dialysis against 20 mM Na2HPO4 (pH 7.3), 0.5 M L-arginine and 10% v/v glycerol for 12 
hours at 4
o
C.  Further dialysis against 20 mM Na2HPO4 (pH 7.3), 0.2 M L-arginine and 5% 
v/v glycerol for 12 hours at 4
o
C was then followed by two dialysis steps against 20 mM 
Na2HPO4 (pH 7.3) for 12 hours at 4
o
C 
175
. 
 
4.3.5. Cloning, Transformation and Antibiotic Selection in S. 
cerevisiae 
 
The L1 protein was cloned into the pYES2/CT vector. Sequence specific primers 
were used to amplify the L1 gene (see appendix).  The pYES2/CT plasmid was linearised 
using restriction enzymes which left sticky ends specific to the L1 gene.  Specific sticky 
ends were also produced on the L1 gene.  The plasmid and L1 gene sticky ends were 
complementary to each other so they were ligated and then directly transformed into 
competent E. coli cells, where nicks can be repaired.  The plasmid was isolated from the E. 
coli cells and then used to transform S. cerevisiae cells.  Yeast extract peptone dextrose 
medium (YPD) was inoculated with a single S. cerevisiae colony and left to grow at 30
o
C 
overnight.  The overnight culture was used to further inoculate a larger volume of YPD, 
which was then incubated for another 2-4 hours at 30
o
C.  Following incubation, the cells 
were pelleted and re-suspended in 1X TE (1 mM EDTA and 10 mM Tris, pH 7.5), and then 
re-pelleted and re-suspended in a reduced volume of 1X LiAc (pH 7.5) / 0.5X TE, before 
being incubated at room temperature for 30 min.  Plasmid DNA, 1 mg, was mixed with 100 
µg thermally denatured salmon sperm DNA and 100 µl of the S. cerevisiae suspension.  1X 
LiAc / 40% v/v PEG3350 / 1X TE was added (700μl) and left at 30oC for 30 min.  DMSO 
was added (to a final concentration of ~10 %) before the cells were heat shocked at 42
o
C for 
7 min.  The cells were pelleted immediately and re-suspended in 1X TE before being re-
pelleted and re-suspended in a small volume of 1X TE.  The cell suspension was spread on 
  
101 
 
SC uracil selective plates containing glucose (SC is synthetic minimal defined medium for 
yeast) before being incubated at 30
o
C to allow colonies to grow.  
 
4.3.6. Cloning, Transformation and Antibiotic Selection in P. 
pastoris 
 
The L1 protein was cloned into the pPICZαA vector. Creation of L1 constructs, 
ligation and transformation were performed as described previously (Full methods and 
primers can be found in the appendix).  The plasmid was isolated from the E. coli cells and 
used to transform P. pastoris X-33 cells.  YPD medium was inoculated with a single P. 
pastoris X-33 colony, which was left to grow at 30
o
C overnight.  This overnight culture was 
then used to inoculate a larger volume of YPD and left to grow again at 30
o
C overnight.  
The overnight culture was centrifuged (1000 x g, 5 min), after which the cells were re-
suspended in 50 ml sterile water and re-centrifuged (1000 x g, 5 min).  The cells were then 
re-suspended in 20 ml sterile water, and re-centrifuged (1000 x g, 5 min) before being re-
suspended again in 5 ml ice cold 1 M sorbitol.  Following a final centrifugation the cells 
were re-suspended in 300 μl 1 M sorbitol and stored on ice. 
The L1-pPICZαA plasmid was linearised by incubating 10 μg of the plasmid with 
10 μl SacI.  The linearisation reaction was stopped by heating the sample to 65oC for 15 
min.  The linearised DNA was then purified using a PCR clean up kit. 
An aliquot of cell suspension, 80 μL, and the linearised DNA were mixed gently and 
left to incubate in an electroporation cuvette on ice for 5 min.  The cells were electroporated 
(30 s, 25 μF, 200 Ω, 2000 V) and then, after the addition of 1 ml ice-cold sorbitol the cells 
were left to incubate at 30
o
C for 2 hours.  The cells were then plated out on YPDS plates 
containing 100 μg/ml Zeocin and incubated at 30oC until colonies appeared. 
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4.4. Results and Discussion 
4.4.1. Expression of the L1 Region in E. coli 
 
The L1 region of the IR is one of the main parts of the IR involved in insulin 
binding.  Rosetta-Gami 2 cells were used initially to produce the L1 protein and were grown 
and induced as described in the appendix. 
 
Figure 44. A time course expression trial and solubility test of L1 expressed in 
Rosetta-Gami 2. 
(A) A 15%  reduced SDS-PAGE of a time course expression test of L1 in Rosetta-Gami 2. 
Lane 1: Broad range molecular weight marker.  Lane 2: 0.5 h post-induction sample.  Lane 
3: 1 h post-induction sample.  Lane 4: 2 h post-induction sample.  Lane 5: 4 h post-
induction sample.  Lane 6: 6 h post-induction sample.  Lane 7: overnight sample. (B) A 15% 
SDS-PAGE of a solubility test of L1 produced in Rosetta-Gami 2.  Lane 1: Low range 
molecular weight marker.  Lane 2: Media sample.  Lane 3: Total sample.  Lane 4: Soluble 
fraction.  Lane 5: Insoluble fraction. (C) A 15% SDS-PAGE of a solubility screen using L1 
produced in Rosetta-Gami 2.  Lane 1: Low range molecular weight marker.  Lane 2: Control 
sample.  Lane 3-12: Soluble fractions from buffers used in buffer trial. 
 
The expression of the L1 protein was monitored at various intervals throughout an 
overnight expression, and analysed by SDS-PAGE (Figure 44-A). The L1 protein with the 
His6 tag, has a molecular weight of 20.191 kDa.  The presence of bands on the gel around 
the expected molecular weight indicates that the protein is being produced post induction, 
although the weakness of the bands suggests that the protein is only being expressed in low 
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levels.  The target protein was not present in the soluble fraction (Figure 44-B).  This could 
be a result of an unsuitable re-suspension buffer. A buffer screen has been designed, by 
Lindwall et al., that utilises a range of reagents and conditions in an attempt to improve 
protein solubility 
176
. Out of the 30 conditions tried, none resulted in the L1 region 
becoming soluble (Figure 44-C).  Due to the difficulties in expressing soluble L1 protein in 
Rosetta-Gami 2 cells, alternative methods to improve solubility were investigated. 
There were various methods that would increase protein solubility. Three methods 
were utilised within this study.  The first technique, the Eco construct, utilised the pMAL-p2 
plasmid to fuse the L1 protein to a maltose binding protein.  The soluble maltose binding 
protein should result in a more soluble L1 construct.  The maltose binding protein is 
purified using an amylose column and is engineered to be cleavable (this construct has a 
molecular weight of ~64 kDa).  Two more constructs of the short L1 region construct, 
termed Nco and Xho, utilised the pET22 plasmid to add a pelB signal sequence to the L1 
protein (molecular weight of 21.5 and 20.0 kDa respectively).  pelB is responsible for 
translocation of the protein to the periplasmic space, where the environment is much more 
reducing and so more favourable to the formation of disulphide bonds.  The L1 protein is 
still being produced in small amounts and is present in the insoluble fraction (Figure 45-A). 
 
Figure 45.  A solubility trial of the L1 region of various constructs and different 
cell strains. 
(A) A 15% reduced SDS-PAGE of a solubility check of Eco, Nco and Xho constructs. Lane 
1: Low range molecular weight marker.  Lanes 2-13 contain soluble samples.  Lane 2: 
Uninduced Eco sample.  Lane 3: Eco induced with 0.2 mM IPTG.  Lane 4: Eco induced 
with 0.5 mM IPTG.  Lane 5: Eco induced with 1 mM IPTG.  Lane 6: Uninduced Nco 
sample.  Lane 7: Nco induced with 0.2 mM IPTG.  Lane 8: Nco induced with 0.5 mM 
IPTG.  Lane 9: Nco induced with 1 mM IPTG.  Lane 10: Uninduced Xho sample.  Lane 11: 
Xho induced with 0.2 mM IPTG.  Lane 12: Xho induced with 0.5 mM IPTG.  Lane 13: Xho 
induced with 1 mM IPTG. (B) A 15% SDS-PAGE of a solubility test of L1 produced in 
TUNER and BL21 cells.  Lane 1: Low range molecular weight marker.  Lane 2: Reference 
sample.  Lane 3: BL21 uninduced.  Lane 4:  BL21 total sample.  Lane 5: BL21 soluble 
sample.  Lane 6: TUNER uninduced.  Lane 7: Total sample of TUNER induced with 1 mM 
IPTG.  Lane 8: Soluble sample of TUNER induced with 1 mM IPTG.  Lane 9:  Total sample 
of TUNER induced with 0.5 mM IPTG.  Lane 10: Soluble sample of TUNER induced with 
0.5 mM IPTG.  Lane 11: Total sample of TUNER induced with 0.2 mM IPTG.  Lane 12: 
Soluble sample of TUNER induced with 0.2 mM IPTG. 
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TUNER cells are a strain of E. coli that has been modified to be “tuneable” with 
respect to the amount of target protein produced in response to induction by IPTG. The 
wide bands seen for the TUNER cells indicate that markedly more protein has been 
expressed (Figure 45-B). An increased level of over-expression was achieved, although the 
protein was still insoluble.  Despite this, the ability to produce L1 in increased amounts 
meant that an in vitro method of solubilisation could be investigated. 
It is possible to purify and re-fold target proteins using a nickel affinity column
174
.  
This method binds denatured protein to the Ni column using the target’s His6 tag.  While 
non-target proteins can also bind to the target protein via non-specific interactions, various 
solutions can be applied to the column to remove these unwanted proteins. Varying salt 
solutions are used to refold the protein, before elution over an imidazole gradient (Figure 
46-A). The results of the SDS-PAGE of fractions across the elution peak indicate that the 
target protein has been purified to a relatively high level and is also soluble (Figure 46-B).  
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Figure 46. Analysis of on-column (Ni
2+
 affinity) refolding purification of the L1 
region.  
(A) The blue trace indicates a UV 280nm reading and the green trace shows the percentage 
imidazole concentration of the eluting solution. The labels on the x-axis show the points at 
which the new solutions were added. (B) A 15% reduced SDS-PAGE of the analysis of the 
fractions from the elution peak in Figure 46-A.  Lane 1: Low range molecular weight 
marker.  Lanes 2-9: Fractions across the elution peak in Figure 46-A. 
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Figure 47. MALDI of purified L1 protein. 
 
A mass spectrometry (MALDI) analysis of the L1 sample was performed to check 
that the protein produced was correct (Figure 47). The mass of the L1 region expressed is 
20.191 kDa, where the observed mass from MALDI is 20.113 kDa; a difference of 80 Da 
which is not an issue as the L1 mass is theoretical and does not account for pH effects of the 
buffer or the harsh purification method used.  
The L1 protein was expressed to form complexes with a range of insulin analogues, 
and allow determination of the crystal structure.  To test binding, L1 was mixed with 
various insulin analogues and WT insulin in a 1:5 ratio of L1:insulin, and after being 
incubated at room temperature for 3 hours, the samples were run on a native gel (Figure 48). 
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Figure 48. Complexation trials of various insulin analogues and WT insulin each 
with the L1 region expressed in TUNER cells, and an investigation of disulphide 
bond formation in the L1 region. 
(A) A 7.5% native gel of the complexations each of LZ30, 33 and 45 insulin analogues and 
WT insulin with the TUNER L1 receptor.  Lane 1: IR.  Lane 2:  LZ30.  Lane 3: LZ30 and 
IR.  Lane 4: LZ33.  Lane 5: LZ33 and IR.  Lane 6: LZ45.  Lane 7: LZ45 and IR  Lane 8: 
WT insulin.  Lane 9: WT insulin and IR. (B) A 15% SDS-PAGE of the TUNER L1 
disulphide formation.  Lane 1: Low range molecular weight marker.  Lane 2: Redox 
refolded material in a reducing buffer.  Lane 3: Redox refolded material in a non-reducing 
buffer. 
 
The L1 protein precipitated out of solution and was unable to enter the gel (Figure 
48-A). To check the protein, an SDS-PAGE was run with a sample of the protein in both 
reducing and non-reducing sample buffers.  The protein only appears as a normal band in 
the presence of the reducing sample buffer (Figure 48-B).  The smearing of the sample in 
the non-reducing sample buffer suggests that the disulphide bonds formed incorrectly and 
had cross-linked with other protein molecules. 
Although the disulphide bonds were incorrectly formed due to the relatively large 
amount of soluble L1 protein, a re-folding experiment could be attempted.  A redox method 
of re-folding other proteins that is based on redox potentials has been described by Walter et 
al.
175
.  A sample of the on-column refolded material was subjected to this method (Figure 
49-B). 
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Figure 49. Native gel electrophoresis investigating the correct disulphide bond 
formation in redox refolded L1 protein. 
(A) A 15% SDS-PAGE of redox refolded L1 material disulphide.  Lane 1: Low range 
molecular weight marker.  Lane 2: Redox refolded material in a reducing buffer.  Lane 3: 
Redox refolded material in a non-reducing buffer. (B) A 15% SDS PAGE of 100X redox 
refolded L1 material disulphide.  Lane 1: Low range molecular weight marker.  Lane 2: 
Control sample prior to redox re-folding in reducing sample buffer. Lane 3: Sample of L1 in 
a reducing sample buffer.  Lane 4: Sample in a non-reducing buffer. (C) A 15% SDS-PAGE 
of a disulphide check of fresh TUNER L1 material.  Lane 1: Low range molecular weight 
marker.  Lane 2: Sample in a reducing sample buffer.  Lane 3: Sample in a non-reducing 
buffer. 
 
The refolded material was not formed correctly and thus unable to enter the gel 
(Figure 49-A).  A small band is present in the third lane, at approximately 30 kDa, 
indicating that a small fraction of the material was correctly refolded. A higher level of 
dilution (100x) was attempted, which resulted in the majority of the sample successfully 
refolding (Figure 49-B). As the solubilisation and refolding of the L1 protein took place 
over several weeks, a fresh preparation of L1 protein was made. This preparation followed 
the on-column refolding protocol before being passed through a gel filtration column, 
followed by the redox protocol. There appears to be a large proportion of protein in the non-
reducing sample buffer compared to that in the reducing buffer (Figure 49-C).  The 
preparation also seems to be relatively free from contamination.  A mass spectrometry 
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analysis of this sample indicated that the protein matched the predicted molecular weight of 
the L1 protein. When the protein was used to complex with insulin analogues, it was unable 
to enter the native gel. 
The over-expression of a protein can lead to it being insoluble and targeted towards 
inclusion bodies. It has been shown that if protein synthesis is halted, the equilibrium 
between protein solubilisation and aggregation can be shifted towards protein solubilisation. 
Protein synthesis can be halted by the addition of chloramphenicol
177
. This was attempted 
using BL21 and TUNER cells (Figure 50), although no soluble protein was obtained. 
 
 
Figure 50.  SDS-PAGE of chloramphenicol shock-based expression method to 
induce re-folding of the L1 protein. 
(A) A 15% reducing SDS-PAGE of the chloramphenicol shock upon BL21 and TUNER 
cells.  Lane 1: Low range molecular weight marker.  Lane 2: BL21 control total sample.  
Lane 3: BL21 control soluble sample.  Lane 4: BL21 induced total sample.  Lane 5: BL21 
induced soluble sample.  Lane 6: TUNER control total sample.  Lane 7: TUNER control 
soluble sample.  Lane 8: TUNER induced soluble sample.  Lane 9: TUNER induced soluble 
sample. (B) A 15% SDS-PAGE of the chloramphenicol shock upon BL21 and TUNER 
cells. Lane 1: Low range molecular weight marker.  Lane 2: BL21 control soluble sample.  
Lane 3: BL21 induced soluble sample.  Lane 4: TUNER control soluble sample.  Lane 5: 
TUNER induced soluble sample.  Lane 6: Control sample from E. coli. 
 
Lemo21 and ArcticExpress were used to try and express soluble L1 protein with the 
correct disulphide bonds. It is apparent that for Lemo2,1 there is an over-expressed soluble 
protein of a similar weight to the expected molecular weight of the L1 protein.  
ArcticExpress appears to have one clone that has over-expressed a correctly sized insoluble 
protein, whilst another clone has also over-expressed a correctly sized partially-soluble 
protein (Figure 51). 
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Figure 51.  Solubility trial of the L1 protein expressed in ArcticExpress and 
Lemo21 cells. 
A 15 % reducing SDS-PAGE of the solubility trail undertaken in ArcticExpress and 
Lemo21.  Gel (A) ArcticExpress, Gel (B) Lemo21 total samples and Gel (C) Lemo21 
soluble samples. Gel (A) Lane 1: Low range molecular weight marker.  Lane 2: S1 
uninduced total sample.  Lane 3: S1 uninduced soluble sample.  Lane 4: S1 induced total 
sample.  Lane 5: S1 induced soluble sample.  Lane 6: L1 uninduced total sample.  Lane 7: 
L1 uninduced soluble sample.  Lane 8: L1 induced total sample.  Lane 9: induced soluble 
sample.  Gel (B) Lane 1: Low range molecular weight marker.  Lane 2:  uninduced sample. 
Lane3: 0 µM Rhamnose.  Lane 4: 100 µM Rhamnose.  Lane 5: 250 µM Rhamnose.  Lane 6: 
500 µM Rhamnose.  Lane 7: 750 µM Rhamnose.  Lane 8: 1000 µM Rhamnose.  Lane 9: 
2000 µM Rhamnose. Gel (C) Lane 1: Low range molecular weight marker.  Lane 2:  
uninduced sample. Lane 3: 0 µM Rhamnose.  Lane 4: 100 µM Rhamnose.  Lane 5: 250 µM 
Rhamnose.  Lane 6: 500 µM Rhamnose.  Lane 7: 750 µM Rhamnose.  Lane 8: 1000 µM 
Rhamnose.  Lane 9: 2000 µM Rhamnose. 
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Figure 52.  Comparison of the best results from the solubility of L1 domain 
expressed in ArcticExpress and Lemo21, using comassie and His6-tag stains. 
(A) A 15% reducing SDS-PAGE of the solubility of ArcticExpress and Lemo21.  Lane 1: 
Low range molecular weight marker.  Lane 2: ArcticExpress S1 total sample.  Lane 3: 
ArcticExpress S1 soluble sample.  Lane 4: ArcticExpress L1 total sample.  Lane 5:  
ArcticExpress L1 soluble sample.  Lane 6: Lemo21 2000 µM Rhamnose total sample.  Lane 
7: Lemo21 2000 µM Rhamnose soluble sample. (B and C) A 12% reducing SDS PAGE of 
the best results from the solubility of ArcticExpress and Lemo21 expressed before and after 
Ni
2+
 column.  Gel (B) is comassie stained, and Gel (C) is His6-tag stained, both gels have 
the same layout.  Lane 1: Low range molecular weight marker.  Lane 2: Lemo21 soluble 
load.  Lane 3: Lemo21 elution fraction.  Lane 4: ArcticExpress L1 soluble load.  Lane 5:  
ArcticExpress L1 elution fraction.  Lane 6: ArcticExpress S1 soluble load.  Lane 7: 
ArcticExpress S1 elution fraction.  Lane 8: 25 kDa positive control. 
 
The total and soluble fractions of both the Lemo21 and ArcticExpress cells were 
assessed (Figure 52-A) to confirm the presence of a His6-tag on the target protein using a 
His6-tag stain.  It appears that both of the bands in Lemo21 give a positive response (Figure 
52-B&C). 
Both Lemo21 colonies, along with one from ArcticExpress were grown in 50 ml 
volumes and subjected to a Ni
2+
 affinity chromatography purification.  The cells were lysed 
in 125 mM NaCl, 100 mM HEPES pH 7.4, and only the soluble fraction loaded onto the 
column and purified (Figure 53). 
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Figure 53.  Elution fractions from small scale Ni
2+
 purification from 
ArcticExpress and Lemo21 cells expression trials. 
(A) A 12% reducing SDS-PAGE of the elution fractions from ArcticExpress and Lemo21 
Ni
2+
 purification.  Lane 1: Low range molecular weight marker.  Lane 2: Lemo21 elution 
fraction.  Lane 3: ArcticExpress L1 elution fraction.  Lane 4: ArcticExpress S1 elution 
fraction. (B and C) A 12% reducing SDS PAGE of the purification of L1 from Lemo21. (B) 
Ni
2+
 purification of L1 from Lemo21. Lane 1:  Low range molecular weight marker.  Lane 
2: Pre-induction total sample.  Lane 3:  Soluble load.  Lanes 4-8: elution fractions. (C) Gel 
filtration purification of S1 from Lemo21. Lane 1: Low range molecular weight marker.  
Lanes 2-7: elution fractions. 
 
The best approach to obtain soluble protein would be Lemo21, as neither of the 
ArcticExpress clones have the correct molecular weight for L1 protein (Figure 53-A).  The 
major protein to have bound to the column is at 25 kDa (lane 2), whilst the band at 
approximately 20 kDa has bound at a much lower level.  The Lemo21 construct was grown 
in a 2 L culture, then purified by Ni
2+
 affinity followed by gel filtration (Figure 53-B&C). 
Both proteins that potentially correspond to L1 as identified by the His6-tag stain 
bound to the Ni
2+
 column and were separated by gel filtration.  A sample of each was mixed 
with the high affinity analogues LZ29 and LZ30 to ascertain whether a complex could be 
formed.  From the native gel (Figure 54-A) it appears that the larger protein binds to the 
analogue.  To check that this result was not an artefact of the high affinity analogue, a 
second complexation was set up using WT insulin (Figure 54-B), to which the protein 
bound.  The two bands were sent for protein identification (trypsin digest of the protein 
sample followed by LC-MS with the results searched against a database) and the results 
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showed that the larger protein was a chloramphenicol acetyltransferase mutant, whilst the 
smaller protein was lysozyme. 
 
 
Figure 54.  Native gel of insulin-complex formation trials of Lemo21 produced L1 
material and various insulin analogues. 
(A) A 10 % native gel of the complexation of both Lemo21 peaks with LZ29 and LZ30.  
Lane 1: Higher peak.  Lane 2: Higher peak and LZ29.  Lane 3: Higher peak.  Lane 4: 
Higher peak and LZ30.  Lane 5: Lower peak.  Lane 6: Lower peak and LZ29.  Lane 7: 
Lower peak.  Lane 8: Lower peak and LZ30. (B) A 10% native gel of the complexation 
between the higher Lemo21 peak with WT insulin and LZ30.  Lane 1: Higher peak.  Lane 2: 
WT insulin.  Lane 3: Higher peak and WT insulin.  Lane 4: LZ30.  Lane 5: Higher peak and 
LZ30. 
 
The clone of ArcticExpress, S1, that gave the larger expression of the protein at 
approximately 20 kDa was grown and subjected to a 30 condition solubility screen 
176
 
(Table 13 Figure 55). 
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Table 13. Thirty Reagents for Solubilisation of Over-Expressed Proteins
176
 
Condition Contents 
1. 100 mM Tris, 10% glycerol, pH 7.6 
2. 100 mM Tris, 50 mM LiCl, pH 7.6 
3. 100 mM HEPES, 50 mM (NH4)2SO4, 10% glycerol, pH 7.0  
4. 100 mM HEPES, 100 mM KCl, pH 7.0 
5. 100 mM Tris, 50 mM NaCl, 10% isopropanol, pH 8.2 
6. 100 mM K2HPO4/KH2PO4, 50 mM (NH4)2SO4, 1% Triton X-100, pH 6.0  
7. 100 mM triethanolamine, 100 mM KCl, 10 mM DTT, pH 8.5 
8. 100 mM Tris, 100 mM sodium glutamate, 10 mM DTT, pH 8.2 
9. 250 mM KH2PO4/K2HPO4, 0.1% CHAPS, pH 6.0  
10. 100 mM triethanolamine, 50 mM LiCl, 5 mM EDTA, pH 8.5 
11. 100 mM sodium acetate, 100 mM glutamine, 10 mM DTT, pH 5.5 
12. 100 mM sodium acetate, 100 mM KCl, 0.1% n-octyl-β-D-glucoside, pH 5.5  
13. 100 mM HEPES, 1 M MgSO4, pH 7.0  
14. 100 mM HEPES, 50 mM LiCl, 0.1% CHAPS, pH 7.0 
15. 100 mM KH2PO4/K2HPO4, 2.5 mM ZnCl2, pH 4.3  
16. 100 mM Tris, 50 mM NaCl, 5 mM calcium acetate, pH 7.6 
17. 100 mM triethanolamine, 50 mM (NH4)2SO4, 10 mM MgSO4, pH 8.5  
18. 100 mM Tris, 100 mM KCl, 2 mM EDTA, 1% Triton X-100, pH 8.2 
19. 100 mM sodium acetate, 1M MgSO4, pH 5.5  
20. 100 mM Tris, 2M NaCl, 0.1% n-octyl-β-D-glucoside, pH 7.6  
21. 100 mM Tris, 1 M (NH4)2SO4, 10 mM DTT, pH 8.2  
22. 100 mM sodium acetate, 50 mM LiCl, 5 mM calcium acetate, pH 5.5 
23. 100 mM HEPES, 100 mM sodium glutamate, 5 mM DTT, pH 7.0 
24. 100 mM triethanolamine, 100 mM sodium glutamate, 0.02% n-octyl-β-D-glucoside, 10% glycerol, pH 8.5  
25. 100 mM Tris, 50 mM NaCl, 100 mM urea, pH 8.2 
26. 100 mM triethanolamine, 100 mM KCl, 0.05% dextran sulfate, pH 8.5 
27. 100 mM KH2PO4/K2HPO4, 50 mM (NH4)2SO4, 0.05% dextran sulfate, pH 6.0  
28. 100 mM HEPES, 50 mM LiCl, 0.1% deoxycholate, pH 7.0 
29. 100 mM Tris, 100 mM KCl, 0.1% deoxycholate, 25% glycerol, pH 7.6 
30. 100 mM potassium acetate, 50 mM NaCl, 0.05% dextran sulfate, 0.1% CHAPS, pH 5.5 
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Figure 55.  Solubility screen for the L1 domain expressed in ArcticExpress cells. 
A 15 % reducing SDS-PAGE of the ArcticExpress solubility screen.  Gel (A) Lane 1: Low 
range molecular weight marker.  Lane 2: Total ArcticExpress sample.  Lanes 3-12: 
conditions 1-10.  Lane 1: Low range molecular weight marker.  Lane 2: Total ArcticExpress 
sample.  Lanes 3-12: conditions 1-10.  Gel (B) Lane 1: Low range molecular weight marker.  
Lane 2: Total ArcticExpress sample.  Lanes 3-12: conditions 11-20.  Gel (C) Lane 1: Low 
range molecular weight marker.  Lane 2: Total ArcticExpress sample.  Lanes 3-12: 
conditions 21-30. 
 
 
Samples with the highest solubility were seen in conditions 1, 7, 8 and 10 (Table 
13), although conditions 7 and 8 contain DTT which would reduce the disulphide bonds 
present in the protein.  These samples were re-tested in the buffer without DTT, but also 
with EDTA, due to its presence in condition 10. 
 
 
 
 
  
116 
 
 
Figure 56.  Comparison of the best conditions achieved for expression of soluble 
L1 protein in ArcticExpress, and the test for DTT requirment in conditions 7 and 
8. 
A 15% reducing SDS-PAGE exploring the solubility of L1 in condition 1, 7, 8 and 10.  Lane 
1: Low range molecular weight marker.  Lane 2: Total sample.  Lane 3: soluble sample.  
Lane 4: insoluble sample.  Lane 5: condition 1 soluble fraction.  Lane 6: condition 7 soluble 
fraction.  Lane 7: condition 7 soluble fraction without DTT.  Lane 8: condition 7 soluble 
fraction without DTT.  Lane 9: condition 8 soluble fraction without DTT with EDTA.  Lane 
10: condition 8 soluble fraction without DTT.  Lane 11: condition 8 soluble fraction without 
DTT with EDTA.  Lane 12: condition 10 soluble fraction. 
 
It appears that DTT is required in conditions 7 and 8 for soluble protein, however 
conditions 1 and 10 give comparable results to one another based upon solubility levels 
(Figure 56). Protein identification showed that the expressed protein was not L1. 
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4.4.2. Expression of the L1 Region in S. cerevisiae 
 
Due to the problems encountered in expression of the L1 region in E. coli, S. 
cerevisiae was used to express L1 protein. The L1 gene was successfully cloned into the 
pYES2/CT plasmid (MW = ~25 kDa).  Small scale (15 ml) culture volumes were grown 
with the cells lysed by digesting the cell walls, followed by homogenisation (see appendix).  
The soluble fraction was then passed over a Ni column (Figure 57-A). 
 
Figure 57. Purification of the L1 region produced in S. cerevisiae. 
(A) A 15% reducing SDS-PAGE of the Ni
2+
 purification of L1 in S. cerevisiae.  Lane 1: 
Low range molecular weight marker.  Lane 3: Run through sample. Lanes 5-7: Samples 
from the Ni column elution peak. (B) A 15% reducing SDS-PAGE of the disulphide check 
of the L1 region produced in S. cerevisiae.  Lane 1: Low range molecular weight marker. 
Lane 2: Sample in a reducing sample buffer.  Lane 3: Sample in a non-reducing buffer. (C) 
A 15% reducing SDS-PAGE of the Ni column purification of the L1 region produced in S. 
cerevisiae.  Lane 1: Low range molecular weight marker.  Lane 2: Run through sample.  
Lanes 3-5: Samples of non-specific binding washed off by wash buffer. Lanes 6-8: Samples 
from the Ni column elution peak. (D) A 15% reducing SDS-PAGE of gel filtration 
purification of the L1 region produced in S. cerevisiae.  Lane 1: Low range molecular 
weight marker.  Lanes 2-5: Samples from the gel filtration column elution peak. 
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There is a band present at ~25 kDa which could correspond to the predicted 
molecular weight of the L1 protein. Lanes 5 and 6 show a high level of contamination 
meaning further purification was required.  The correct formation of the disulphide bonds 
was assessed by using both reducing and non-reducing sample buffer (Figure 57-B). The 
disulphide bonds may be correctly formed, as both the reducing and non-reducing samples 
ran identically on an SDS gel (Figure 57-B).  A larger preparation of L1 expressed in S. 
cerevisiae was then prepared and purified by a Ni
2+
 column (Figure 57-C) followed by gel 
filtration (Figure 57-D). There is a distinct double band present on the gel (Figure 57-D).  A 
mass spectrometry analysis of this sample indicated the presence of a single species present 
at 25 kDa, which matched the predicted molecular mass of the L1 protein. When the protein 
was used in an attempt to form a complex with insulin analogues, it was unable to enter the 
gel. A fresh preparation of the protein was used for protein identification of these bands.  
The results indicated that neither corresponded to the L1 protein. 
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4.4.3. Expression of the L1 Region in P. pastoris 
 
Following the lack of success of the S. cerevisiae studies, P. pastoris was used to 
express the L1 protein.  The vector, pPICZαA, has a signal sequence that targets the protein 
for secretion to the media and has a C-terminal His6 tag.  A 3C protease site was added 
using the reverse primer to allow the removal of the His6 tag.  A long construct was trialled 
along with the short construct, (see appendix for primers and constructs).  The plasmid was 
transformed into P. pastoris X-33 cells as per the method described in the appendix.  
Colonies were picked and grown in a 48 well plate containing BMGY media (Figure 58).  
The cultures were then used to produce induction/expression cultures of OD600=2 at 
induction in BMMY. 
 
 A B C D E F 
1 L3 L3 S1 L3 L3 S1 
2 L3 L3 S1 L3 L3 S1 
3 L3 L1 S1 L3 L1 S1 
4 L3 L1 S1 L3 L1 S1 
5 L3 S1 Empty L3 S1 Empty 
6 L3 S1 Empty L3 S1 Empty 
7 L3 S1 Empty L3 S1 Empty 
8 L3 S1 Empty L3 S1 Empty 
Figure 58.  P. pastoris 48 well expression layout. 
The wells in columns A, B and C were used to produce starter cultures from single colonies. 
The starter cultures were used to inoculate the induction media in the corresponding well in 
columns D, E and F to an OD600=2. 
 
Following 96 hours of induction, the cultures were spun down (12,000 x g, 5 min) 
and a sample of the supernatant was used for a dot blot experiment to test for the presence 
of a His6 tag (Figure 59). 
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Figure 59.  A dot blot experiment to probe for expression of the L1 region in P. 
pastoris. 
A dot blot experiment of the expression trial for L1.  Square A1: Uninduced Media.  Square 
A2: 100 ng/μl His6-tagged protein.  Square A3: 50 ng/μl His6-tagged protein.  Square A4: 10 
ng/μl His6-tagged protein.  Square A5: 1 ng/μl His6-tagged protein.  Square B1-E5 contain 
samples from Figure 58.  Squares B1-B5: Samples D1-D5.  Squares C1-C5: Samples D6-
E2.  Squares D1-D5: E3-E7.  Squares E1-E5: E8-F4.  
 
Positive results were seen for squares E1, E2, E7 and E8, with the strongest result 
being that of E7 so this clone was taken forward (Figure 59).  A small scale expression trial 
(150 ml) was carried out on this clone (E7-L1) to produce, identify and purify the L1 
protein. 
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Figure 60.  The Ni
2+
 purification trace for the small scale production of L1 from 
E7-L1. 
The blue trace is the A280 reading and the green line is the percentage of elution buffer from 
0% to 100%. 
 
The expressed L1 protein bound to the Ni column and eluted upon application of 
the imidazole gradient (Figure 60).  Samples were run on an SDS-PAGE gel to ascertain 
whether the protein purified (gel not shown).  No bands were present, which could be due to 
the low levels of protein produced owing to the small volume of culture.  To increase the 
amount of material produced a 3 L expression was performed, followed by a Ni column 
purification. 
The fractions across the elution peak (chromatograph not shown) were pooled and 
run on an SDS-PAGE gel to assess the success of the expression.  There were no bands 
present, which indicated that the protein was either at a concentration too low to be detected 
or was not present.  To increase sensitivity, a copper stain was applied to the gel and 
revealed bands of approximately 37 and 42 kDa (gel not shown). The bands could be the L1 
protein, but this cannot be stated with confidence.  A dot blot of samples taken from various 
points across the purification was conducted to indicate if the bands detected were those of 
the L1 protein. 
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Figure 61.  Dot blot analysis of L1 purification after expression in P. pastoris. 
A dot blot for the elution of L1 from a Ni column and gel filtration.  Square A1: H2O.  
Square A2: 100 ng/μl His6-tagged protein.  Square A3: 10 ng/μl His6-tagged protein.  Square 
A4 and A5: Elution peak sample.  Square B1-B5: Elution peak sample. Square C1-C5: 
Elution peak sample. Square D1-D4: Elution peak sample.  Square D5: Concentrated 
elution peak 1.  Square E1: Concentrated elution peak 2.  Square E2: Concentrated gel 
filtration peak 1.  Square E3: Concentrated gel filtration peak 2.  Square E4: Media sample. 
 
The dot blot shows positive results for 1B and 1C which correspond to the positive 
control, whilst also giving a positive result for E4, the media sample (Figure 61).  This 
indicates that the L1 protein was produced although it did not bind to the column.  The 
media sample was analysed by coomassie, copper and silver staining methods (Figure 62), 
showing inconclusive results. 
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Figure 62.  A SDS-PAGE staining analysis of L1 protein expressed in P. pastoris. 
A 12 % reducing SDS-PAGE of the P. pastoris media following expression.  Gel (A), 
stained with Coomassie, gel (B) copper stained and gel (C)  silver stained.  All gels; lane 1: 
Low range molecular weight marker.  Lane 2: Media sample. 
 
To ascertain whether the positive signal from the dot blot was of the L1 protein, a 
western blot was run. 
 
 
Figure 63.  A western blot of the purification of the L1 protein expressed in P. 
pastoris. 
A 12 % reducing SDS-PAGE western blot of the purification of L1.  Membrane (A) shows 
the result following transfer and staining with Ponceau red, (B) shows the western blot 
results.  (A) lane 1: Low range molecular weight marker.  Lane 2: Positive control sample.  
Lane 3: Sample buffer only.  Lane 4: Empty.  Lane 5: Media sample.  Lane 6: Media 
sample.  Lane 7: Empty.  Lane 8: Elution peak concentrated sample.  Lane 9: Elution peak 
concentrated sample.  (B) lane 1: Low range molecular weight marker.  Lane 2: Positive 
control sample.  Lane 3: Sample buffer only.  Lane 4: Empty.  Lane 5: Media sample.  Lane 
6: Media sample.  Lane 7: Empty.  Lane 8: Elution peak concentrated sample.  Lane 9: 
Elution peak concentrated sample. 
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The western blot shows that there is a positive signal to the anti-His6 tag antibody in 
the region of 18-29 kDa (Figure 63).  The band is difficult to distinguish on the western blot 
due to the high intensity of the band and the smearing present.  The predicted molecular 
weight of the L1 protein expressed in P. pastoris is ~23 kDa, which corresponds to the 
smeared band present.  It was considered that the media or a short loading time could be the 
cause of weak binding to the Ni column.  A 3 L culture was split four ways; one part was 
loaded onto a column overnight, whilst the others were dialysed overnight against 500 mM 
NaCl + 50 mM NaPO4 pH 7.4, 500 mM NaCl + 100 mM HEPES pH 7.4 and 125 mM NaCl 
+ 100 mM HEPES pH 7.4, before loading onto a Ni-affinity column. 
There are peaks present for all samples on the chromatogram upon elution with 
imidazole (chromatograph not shown).  Samples from all four peaks were concentrated ~10-
fold and run on an SDS-PAGE gel. 
 
 
Figure 64.  Analysis of media loading change of L1 protein expressed in P. 
pastoris. 
A 12 % reducing SDS-PAGE of the purification trial of the L1 protein.  Gel (A) lanes 2-4 
samples from overnight load, and lanes 6-8 samples from 500 mM NaCl + 50 mM NaPO4 
pH 7.4  Gel (B) lanes 2-4 samples from 500 mM NaCl + 100 mM HEPES pH 7.4, and lanes 
6-8 samples from 125 mM NaCl + 100 mM HEPES pH 7.4.  Gel (A), lane 1: Low range 
molecular weight marker.  Lane 2: Run through.  Lane 3 and 4: Samples from elution peak.  
Lane 5: Low range molecular weight marker.  Lane 6: Run through.  Lane 7 and 8: Samples 
from elution peak. Gel (B), lane 1: Low range molecular weight marker.  Lane 2: Run 
through.  Lane 3 and 4: Samples from elution peak.  Lane 5: Low range molecular weight 
marker.  Lane 6: Run through.  Lane 7 and 8: Samples from elution peak. 
 
There is possibly L1 protein in each of the purifications, although it cannot be 
identified due to the presence of other bands (Figure 64). 
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Figure 65.  Western blot analysis of media loading change following Ni
2+
 
purification of L1 expressed in P. pastoris. 
A 12 % reducing SDS-PAGE western blots of the purification trial of the L1 protein.  
Western blot lanes 2-4 samples from overnight load, and lanes 6-8 samples from 500 mM 
NaCl + 50 mM NaPO4 pH 7.4. Lane 1: Low range molecular weight marker.  Lane 2: Run 
through.  Lane 3 and 4: Samples from elution peak.  Lane 5: Low range molecular weight 
marker.  Lane 6: Run through.  Lane 7 and 8: Samples from elution peak. 
 
The western blots show two bands present in lanes 7 and 8 (Figure 65) at 
approximately 30 kDa.  Using Figure 65, the strong bands present in Figure 64 can be 
implied to be the L1 protein.  A 3 L scale fermentation was followed by concentration of the 
media and dialysed against 125 mM NaCl and 100 mM HEPES pH 7.5, followed by an 
overnight load onto the Ni column to maximise binding. An SDS-PAGE and western blot of 
the purification were run (Figure 66). 
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Figure 66.  Analysis of E7 L1 purification from P. pastoris following media 
loading change. 
A 15% reducing SDS PAGE of the purification and western blot of the L1 protein. Gel (A), 
lane 1: Low range molecular weight marker.  Lane 2: Run through.  Lanes 3-8: Samples 
from elution peak.  Gel (B), lane 1: Positive control sample. Lane 2: Low range molecular 
weight marker. Lanes 4-9: Samples from elution peak. 
 
The bands appear consistent in molecular weight to previous gels, and did not need to 
be concentrated to appear on the gel.  The samples that gave a positive result on the western 
blot were sent for protein ID.  The results identified beta-lactamase as a strong signal, whilst 
also having strong spectra that were unassigned.  Beta-lactamase is an enzyme attributed to 
the breakdown of the antibiotic Zeocin, upon which the electroporated P. Pastoris cells were 
selected. 
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4.5. Conclusion 
 
The expression of the L1 region in E. coli led to a good level of protein expression 
although it was insoluble. Following various attempts to express soluble protein, on-column 
refolding resulted in soluble protein. The soluble protein had incorrectly formed disulphide 
bonds, with intermolecular bonds rather than intramolecular ones. Attempts to express the 
protein in S. cerevisae and P. pastoris were unsuccessful. 
The presence of N-glycosylations is important in ensuring protein solubility
178,179
. The 
L1 region has four predicted N-glycosylation sites at positions Asn
16
, Asn 
25
, Asn
78
 and Asn 
111
. These N-glycosylations would not be present after expression in E. coli. All eukaryotic 
proteins are glycosylated to a certain level, with the process occurring through a complex 
series of steps, originating in the endoplasmic reticulum
180
.  The solubility of the expressed 
L1 in E. coli following on-column refolding brings the requirement of glycosylation for 
soluble protein into question. The refolded material was soluble in a solution that comprised 
20 mM Tris pH 7.5 and 0.1 M NaCl following on-column refolding, chemicals that are not 
shown to increase solubility. Expression in S. cerevisae and P. pastoris yielded no soluble 
protein indicating that the presence of N-glycans in this instance yielded no appreciable 
results. 
Previous expression of the IR
50,63,171,172
 was undertaken by using a variety of 
mammalian expression systems. This is preferred as the protein processing machinery 
possessed by these cells closely resembles that of human cells
181
, as the particular 
glycoform displayed on the protein surface can influence its effect
181
. This method of 
producing the L1 region could result in soluble protein, though the production of soluble 
protein from on-column refolding questions this assumption. 
The structure of L1 (Figure 43) shows a barrel with a series of β-sheets. At both the N- 
and C-terminus of the barrel there is a disulphide bond, which fixes the termini to the barrel. 
The correct formation of these disulphide bonds is therefore critical to a correctly folded 
and soluble protein. The re-solubilised expressed L1 protein in E. coli was shown to have 
incorrectly formed disulphide bonds, despite being soluble. It would be assumed that 
moving to an organism such as S. cerevisae, P. pastoris, or a mammalian system would 
solve this issue. It has been shown that the pathways and proteins employed in the correct 
disulphide formation show remarkable similarity between prokaryotes and eukaryotes
182
. 
This would indicate that if protein expression had been possible in either of the yeast 
systems, a similar result would be seen to that in E. coli. The high expression levels seen in 
E. coli may have caused an overload in these pathways, hence the lower expression levels in 
yeast and mammalian cell culture. This, coupled with the glycosylation effects discussed 
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previously, may result in soluble protein that is correctly formed. 
The expression of the IR described in the literature contains many different constructs, 
from L1-CR-L2 to the entire ectodomain
50,63,171,172
, however the L1 domain has not been 
expressed by itself. Expression of the “core” L1 region is a sensible strategy in obtaining a 
complex between insulin and the IR, because removing the flexible regions between the 
domains of the IR increases the possibility that crystals will form. Examining the crystal 
structure of  L1-CR-L2 from 2hr7.pdb
63
, it can be seen that there are hydrogen bonds 
formed between the L1 and CR regions (Figure 67). 
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Figure 67. Interaction between the L1 and CR regions in the IR. 
(A) An overview of the L1-CR contacts. (B) A close up of the L1-CR interactions. The L1 
region is coloured green, and the CR in red. (pdb used: 2hr7.pdb). The dashed line indicates 
a hydrogen bond. Carbon atoms in green, oxygen – red and nitrogen – blue. Disulphide 
bonds are in yellow. 
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The side chains of both domains form six hydrogen bonds between them. These 
hydrogen bonds could help stabilise the regions that lack secondary structure, (the areas 
between the series of β-sheets), and could be important in the formation of a soluble protein. 
The glycosylation of the L1 region, its interactions with the CR, the choice of 
expression systems and construct design are inconsequential to the correct formation of the 
disulphide bonds. As demonstrated in E. coli soluble protein can be achieved, but it is the 
formation of the disulphide bonds that prevented the future use of this protein. Solving the 
disulphide bond formation issue should result in the production of large amounts of the L1 
region that are correctly formed. 
  
  
131 
 
Chapter 5. Insulin:Insulin Receptor Complex Formation 
5.1. Summary 
 
The ultimate aim of this project was to obtain the crystal structure of insulin-IR 
complex.  Successful complexation and structure derivation could lead to a new rationale 
for the design of new insulin analogues and drugs for the treatment of diabetes. This can be 
achieved by analysis of the insulin- IR interface and the nature of conformational changes 
occurring in this hormone and its receptor upon binding.  Insulin analogues that expose the 
main IR binding epitopes have the highest affinity for IR and are therefore most likely to 
form complexes, thus making them the most promising candidates for structure solution of 
the complex
4,75
. 
The selection of the best IR construct for the formation of an effective complex 
with insulin is not clear. Various constructs were investigated by Kristensen et al.
64
, all had 
insulin binding affinities in a range of 9.3-11 nM (Figure 68). All three constructs 
investigated that lacked the 704-719 CT segment in the receptor construct showed no 
insulin binding, but the addition of 10 µM of the CT peptide, resurrected normal levels of 
insulin binding. This indicates that the presence of the CT peptide in solution (or its 
inclusion in the IR construct) is vital for an effective engagement of insulin and IR. The 
structural location of the CT peptide in the complex is believed to be on the binding face of 
the L1-domain
53
. Two constructs, which were supplied by WEHI collaborators, IRB17dB 
and IRB13 (Figure 68), were used in attempts to make complexes with various insulin 
analogues (Table 14). Fabs were associated with the IR constructs and were added for 
crystallisation to facilitate crystal contacts.  The CT peptide consisting of 709-719 residues 
of the IR -subunit was synthesised and delivered by IOCB Prague collaborators. 
 
Figure 68. Schematic of previously investigated IR constructs. 
The receptor constructs IR468, IR309 and IR255 were with and without their C-terminal CT 
peptide by Kristensen et al.
64
. The L1 region expression was described in Chapter 4. 
IRB17dB and IRB13 were supplied by Australian collaborators. 
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The mechanism behind the formation of a complex between insulin:IR:CT peptide is 
unknown.  
Various attempts were also undertaken to obtain a direct, binary complex between 
insulin and the CT peptide to obtain any insight into the nature of interactions of these 
proteins. These trials were unsuccessful, which indicates that insulin and the CT peptide do 
not interact directly or interaction between the two is dependent upon the presence of 
domains of the IR
183
. 
The IR-binding abilities of various insulin analogues to constructs IRB17dB and IRB13 
were assessed by a native gel electrophoresis. Several high affinity analogues were 
identified as being able to form a IR-complex and were used in crystal trials. Diffraction-
quality crystals of some complexes were obtained using the short IR construct IRB13. 
These crystals lead to the first crystal structure of the insulin:IR complex. 
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5.2. Methods Used for Trials for a Direct, Binary Insulin:CT 
Peptide Complex Formation and Insulin:IR:CT Complexes 
 
The formation of insulin analogue and the CT peptide putative binary complexes were 
studied by 1:5 (insulin:CT) molar ratio mixing of the proteins BUFFER?. They were 
incubated overnight at 37
o
C. 
The binary complexes of the IR constructs IRB17dB and IRB13 with insulin were 
formed by mixing the IR and insulin analogue in a 1:1 molar ratio in TBSA (25 mM Tris pH 
8.0, 25 mM NaCl and 2 mM KCl). A tertiary complex of insulin analogues, IR and the CT 
peptide was formed by mixing the IR and CT peptide, then incubating at RT for 1 hour 
before adding the insulin analogue and leaving for a further 3-4 hours at RT. The reaction 
was buffered against TBSA, with the proteins mixed at final ratio of 1:1.5:3 (IR, CT peptide 
and insulin respectively). 
The insulin analogues used to form complexes in this chapter are shown in Table 
14. 
 
Table 14. A comparison of insulin analogue structures and their relative receptor 
binding affinities used in this chapter. 
Changes in the B-chain sequence are indicated in bold.  [NMeXaaB
n
]: methylation of the N-
peptide atom preceding Xaa B
n 
amino acid; -NH2 : C-terminal carboxy amide. 
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5.3. Study on Binary, Direct Insulin:CT Peptide Complexes 
5.3.1. Results and Discussion 
 
If the CT peptide is absent from a complex between insulin and the IR, binding 
cannot occur
64
. Therefore an ‘intermediate’ step in insulin-IR interaction was studied here 
by following a putative binary insulin:CT interaction monitored by the native gel 
electrophoresis (Figure 69). 
 
Figure 69. Initial screening of binary insulin:CT peptide complex formation. 
A 17.5% native gel analysing complexation between insulin analogues and the CT peptide.  
Lane 1: WT insulin. Lane 2: WT insulin and CT peptide. Lane 3: LZ30.  Lane 4: LZ30 and 
CT peptide. Lane 5: LZ33.  Lane 6: LZ33 and CT peptide.  Lane 7: LZ59.  Lane 8: LZ59 
and CT peptide.  Lane 9: CT peptide. 
 
The absence of new bands present in the lanes containing both an analogue and the 
CT peptide indicates that a complexes have not been formed (Figure 69). As insulin 
analogues were dissolved in 20 mM HCl, whilst the CT peptide was in 50 mM Tris pH 9.0, 
the non-optimum pH resulting from the mixing of these buffers could be the reason for a 
lack of detectable complexes.  Therefore Dynamic light scattering (DLS) was employed to 
gain more physic-chemical information about high affinity insulin analogue LZ30 and the 
CT peptide both independently and together, was performed. The hydrodynamic size, 
indication of possible interactions and aggregation state of the proteins were obtained. The 
molecular weights of insulin and the CT peptide are 5.6 and 1.8 kDa respectively, and thus 
the theoretical weight of a 1:1 complex between insulin and the CT peptide is 7.4 kDa. 
However, the only stable/interpretable DLS result for measurements of the insulin:CT 
solutions was approximately three orders of magnitude larger than the size of monomeric 
insulin (Table 15). 
  
 
 
 
  
135 
 
Table 15.  DLS data of complexation between LZ30 and CT peptide under varying 
conditions. 
A table showing the results of DLS data for LZ30 conducted with and without the CT 
peptide.  - indicates no readings were able to be recorded. 
  MW (kDa) Rh (nm) Pol Baseline 
LZ30 
pH 3.0 
RT - - - - 
37
o
C - - - - 
CT 
pH 9.0 
RT 5.95 x 10
3
 24.1 0.40 1.000 
37
o
C - - - - 
LZ30 + CT 
pH 7.6 
RT - - - - 
37
o
C - - - - 
LZ30 + CT 
~pH 2.0 
RT - - - - 
37
o
C - - - - 
 
The failure to obtain any results in the expected range (~7.4 kDa) could indicate 
aggregation of insulin in the solution. To prevent this, small amounts of denaturants (urea 
and guanidinium-hydrochloride [Guan-HCl]) were added to the same conditions. This 
resulted in the DLS data now falling within the expected range (Table 16). 
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Table 16.  DLS data of complexation between LZ30 and CT peptide with various 
denaturants. 
A table showing the results of DLS assessments conducted in solutions containing the 
insulin analogue LZ30 and the CT peptide, both independently and together, in the presence 
of a denaturing agent.  “-” indicates no readings were able to be recorded. 
Condition Name  MW (kDa) Rh (nm) Pol Baseline 
LZ30 pH 3.0 
50 mM Urea 
1A I Peak 2 18.36 0.17 0.46 1.001 
  M Peak 2 17.07 0.22 0.46 1.001 
CT pH 9.0 
50 mM Urea 
1B  1.16 x 10
5
 55 0.52 0.999 
LZ30 + CT pH 7.6 
50 mM Urea 
1C - - - - - 
LZ30 + CT ~pH 2.0 
50 mM Urea 
1D - - - - - 
LZ30 pH 3.0 
50 mM Guan-HCl 
2A - - - - - 
CT pH 9.0 
50 mM Guan-HCl 
2B - - - - - 
LZ30 + CT pH 7.6 
50 mM Guan-HCl 
2C - - - - - 
LZ30 + CT ~pH 2.0 
50 mM Guan-HCl 
2D I Peak 2 8.12 1.46 0.48 1.000 
  M Peak 2 7.09 1.38 0.48 1.000 
 
The molecular weights indicated in condition 2D: 8.12 and 7.09 kDa indicate that a 
complex may have been formed between LZ30 (insulin analogue) and the CT peptide.  
Upon running this sample on a native gel (Figure 70), the indication that a complex had 
been formed was further supported by the absence of the LZ30 band and the presence of a 
new band. 
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Figure 70. The complexation of LZ30 and the CT peptide in condition 2D of Table 
16 (presence of 50 mM Guan-HCl 
A 12% native gel of the complexation of LZ30 and the CT peptide in 2D conditions.  Lane 
1: CT peptide.  Lane 3: LZ30.  Lane 5: LZ30 and the CT peptide in solution under condition 
2D from Table 16. 
  
The next step undertaken was to investigate abilities of other, high- and low affinity 
insulins analogues to form a direct complexes with the CT peptide. 
Numerous bands present in lanes with the insulin analogue and CT peptide indicate 
some types of oligomerisation (Figure 71-A and –B). In a native or SDS-PAGE gel, the 
bands are usually blue in colour due to the Coomassie Blue stain, however the bands circled 
are those that were purple, which corresponds to the CT peptide.  There are also purple 
bands present in LZ30, 53 and 45, which could indicate an analogue:CT peptide complex 
being present.  The true importance and meaning of the purple bands is unknown and have 
not been studied here. 
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Figure 71. A range of insulin analogues and CT peptide complexed in 2D 
conditions from Table 16. 
(A) A 14% native gel of a range of insulin analogues complexed with the CT peptide in 2D 
conditions .  Lane 1: CT peptide.  Lane 2: LZ30.  Lane 3: LZ30 and CT peptide.  Lane 4: 
LZ53.  Lane 5: LZ53 and CT peptide.  Lane 6: LZ57.  Lane 7: LZ57 and CT peptide.  Lane 
8: LZ33. Lane 9: LZ33 and CT peptide. (B) A 14% native gel of a range of insulin 
analogues and CT peptide complexed in 2D conditions.  Lane 1: CT peptide.  Lane 2: LZ45.  
Lane 3: LZ45 and CT peptide.  Lane 4: LZ36.  Lane 5: LZ36 and CT peptide.  Lane 6: 
LZ38.  Lane 7: LZ38 and CT peptide.  The bands circled are purple in colour. 
 
A native gel was used to check whether these additional bands were the 
consequence of either a complex being formed, or as a by-product of the conditions (Figure 
72). Due to the presence of the same bands in lanes 2 and 3 it can been assumed that the 
extra bands were formed as a by-product of the conditions present in the samples and not 
those of a new complex formation. 
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Figure 72.  The complexation of LZ57 and the CT peptide in 2D conditions of 
Table 16. 
A 14% native gel of the complexation of LZ57 and the CT peptide in 2D conditions.  Lane 
1: CT peptide in 2D conditions.  Lane 2: LZ57 in 2D conditions.  Lane 3: LZ57 and CT 
peptide complexed in condition 2D.  Lane 4: the CT peptide in native conditions.  Lane 5:  
LZ57 in native conditions. 
  
Insulin is soluble at a pH <5 and >7
108
, so it was decided to investigate dissolving 
insulin at a higher pH, closer to pH 9.0 in which the CT peptide can only be dissolved.  The 
solubility of WT insulin was investigated in Tris buffers at a range of pH values (Table 17).  
The samples were then run on a native gel to assess their ability to enter the gel (Figure 73). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
140 
 
Table 17.  WT insulin solubility trial. 
A trial of various conditions to investigate the solubility properties of WT insulin in alkali 
conditions. 
Tris Buffer 
Concentration 
pH Soluble Notes 
1 M 10 Yes Clear 
1 M 9.6 Yes Clear 
1 M 9 Yes Minor precipitation, goes clear with time 
1 M 8.6 No/Yes Some precipitation, goes clear with time. 
1 M 8.4 No/Yes Some precipitation, goes clear with time. 
1 M 8.2 No/Yes Some precipitation, goes clear with time. 
1 M 7.5 No Precipitation 
0.5 M 10 Yes Clear 
0.25 M 10 No Still some precipitation with 2x dilution 
50 mM 9 No Insoluble 
 
 
Figure 73. A native gel assessment of soluble WT insulin at various pHs and Tris 
concentrations. 
A 12% native gel of WT insulin dissolved in a range of pHs and Tris concentrations.  All 
lanes contain WT insulin.  Lane 1: 1 M Tris pH 10.  Lane 2: 0.5 M Tris pH 10.  Lane 3: 1 M 
Tris pH 9.6.  Lane 4: 0.5 M Tris pH 9.6.  Lane 5: 1 M Tris pH 9.  Lane 6: 0.5 M Tris pH 9.  
Lane 7: 1 M Tris pH 8.6.  Lane 8: 0.5 M Tris pH 8.6.  Lane 9:1 M Tris pH 8.4.  Lane 10: 0.5 
M Tris pH 8.4.  Lane 11: 1 M Tris pH 8.2.  Lane 12: 0.5 M Tris pH 8.2.   
 
WT insulin is not able to fully dissolve at a range of pH values (Table 17).  At pHs 
and buffer concentrations in which insulin can fully dissolve, it is also able to enter a native 
gel (Figure 73). The ability to dissolve insulin at an alkaline pH (closer to pH 9 of the 
soluble CT peptide) could facilitate more likely formation of insulin:CT peptide.     
The initial complexation trial between LZ30 and LZ34 in an alkaline solution and 
WT insulin with the CT peptide (Figure 74-A) shows no obvious gel shift indicative of 
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complexation, although there is perhaps a difference between the lanes of LZ30 (lanes 4 and 
5) and LZ34 (lanes 6 and 7) before and after the addition of the CT peptide. 
 
Figure 74.  An initial complexation trial between WT insulin in an alkaline 
solution and the LZ30 and LZ34 insulin analogues, with CT peptide. 
(A) A 12% native gel of an initial complexation trial between WT insulin in an alkaline 
solution, LZ30 and LZ34 insulin analogues and CT peptide.  Lane 1: CT peptide.  Lane 2: 
WT insulin.  Lane 3: WT insulin and CT peptide.  Lane 4: LZ30.  Lane 5: LZ30 and CT 
peptide.  Lane 6: LZ34.  Lane 7: LZ34 and CT peptide. (B) A 12% native gel with a 
stacking gel of an initial complexation trial between alkali WT insulin with a stacking gel, 
LZ30 and LZ34 insulin analogues and CT peptide.  Lane 1: CT peptide.  Lane 2: WT 
insulin.  Lane 3: WT insulin and CT peptide.  Lane 4: LZ30.  Lane 5: LZ30 and CT peptide.  
Lane 6: LZ34.  Lane 7: LZ34 and CT peptide. 
 
The differences between the bands in Figure 74-A were hard to distinguish, so 
another gel was run using a stacking gel to increase band separation to determine whether a 
new species had been created (Figure 74-B). This indicated that the potential shift in Figure 
74-A was caused by smearing between the two bands, and not the creation of a new species 
(Figure 74-B). 
A 1:5 ratio between WT insulin or insulin analogues and the CT peptide has been 
used to investigate the complexation between these species.  This approach did not yield 
  
142 
 
any results.  The next step was an investigation of whether this ratio is appropriate.  Using 
the most potent insulin analogue, LZ30, a range of ratios from 1:7 to 7:1 (LZ30:CT peptide) 
were assessed. 
 
 
Figure 75.  A complexation trial between LZ30 (alkali) and CT peptide at different 
molar ratios. 
(A) A 12% native gel of a complexation trial between LZ30 (alkali) and CT peptide at a 
variety of ratios.  Lane 1: CT.  Lane 2: LZ30.  Lane 3: LZ30 and CT peptide at 1:7 ratio.  
Lane 4: LZ30 and CT peptide at 1:5 ratio.  Lane 5: LZ30 and CT peptide at 1:3 ratio.  Lane 
6: LZ30 and CT peptide at 1:1 ratio.  Lane 7: LZ30 and CT peptide at 3:1 ratio.  Lane 8: 
LZ30 and CT peptide at 5:1 ratio.  Lane 9: LZ30 and CT peptide at 7:1 ratio. (B) A 17% 
native gel of a complexation trial between LZ30 (alkali) and CT peptide at a 1:7 ratio 
respectively at two temperatures. Lane 1: CT peptide. Lane 2: LZ30.  Lane 3: LZ30 and CT 
peptide incubated at 37
o
C.  Lane 4: LZ30 and CT peptide incubated at RT. 
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No new major species appear to be present, although the circled band (lane 3) does 
appear in only one condition (Figure 75-A). This sample was re-run on a higher percentage 
gel, where it is no longer visible, indicating that it must have been an artefact of the gel 
(Figure 75-B). 
The change in pH of the insulin molecule could impede its ability to bind to the IR. 
The insulin molecule dissolved in 1.0 and 0.5 M Tris and was complexed with IR468, then 
run on a native gel (Figure 76). A gel shift occurred, which meant that despite a change in 
pH, binding between insulin and the IR still occurred. 
 
Figure 76.  Native gel electrophoresis of the initial complexation trials of the IR 
and WT insulin +/- CT peptide. 
A 7.5% native gel of the initial complexation between IR468 and WT insulin dissolved in 1 
M Tris pH 9.0 (gel A) and 0.5 M Tris pH 9.0 (gel B). Gel (A) Lane 1: WT insulin and 
IR468.  Lane 2: WT insulin, IR468 and CT peptide.  Lane 3: IR468. Gel (B) Lane 1: WT 
insulin and IR468.  Lane 2: WT insulin, IR468 and CT peptide.  Lane 3: IR468. 
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5.3.2. Conclusion 
 
The ability to form a complex between insulin and the IR is dependent upon the 
presence of the CT peptide
64
, which is believed to be located on the binding surface of the 
L1 region of the IR
53
. The nature of the interactions between insulin, the IR and the CT 
peptide are unknown; therefore a crystal structure of this complex would provide vital 
evidence. 
The inability of a complex to be formed between insulin and the CT peptide could be 
due to many reasons. For example, binding of the CT peptide to the IR could be required 
prior to insulin binding. The low resolution structure of the L1 domain of the IR
53
  shows 
electron density of the CT peptide binding to the face of the L1 region that is α-helical. IR 
could have a chaperone effect on folding of this peptide inducing its-helical conformation. 
This would allow its binding to the insulin molecule, meaning that the L1 region is 
necessary for the binding=active structure of the CT peptide and insulin. Another reason for 
the lack of complex formation may be that the insulin molecule and the CT peptide do not 
actually interact with each other, and that the CT peptide is involved in other interactions. 
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5.4. Formation of Stable Insulin:IR Complexes With and Without 
CT Peptide (Collaborators IR Constructs) 
5.4.1. Results and Discussion 
 
The ability of IRB17dB and IRB13 to form a binary IR-insulin complex was tested 
on a native gel. For IRB17dB it can be seen that a visible shift has occurred in lanes 2 
(LZ29), 4 (LZ33) and 6 (LZ45) (Figure 77-A). Of these, LZ29 (lane 2) is a highly active 
analogue (~214%), whilst LZ33 and LZ45 (lanes 4 and 6 respectively) are low affinity 
analogues (both ~20%). All analogues display a B26- or B26-like turn. It appears that 
reducing the size of the side chain in position B
26
, reduces the ability of the analogue to 
form a complex with IRB17dB, contrary to the binding affinity in cases. A full length 
analogue restores binding capability despite the reduced size of the side chain (LZ30 and 
LZ33). In all of the lanes with IRB17dB, a degree of oligmerisation seems to be present, 
and parts of some of the samples failed to enter the gel as well.  This oligomerisation could 
also explain why some of the analogues failed to bind to the receptor due to its not optimum 
conformation.  
There is a distinct shift for the high affinity analogues LZ29 (~214%, lane 2) and 
LZ59 (~360%, lane 7) (Figure 77-B).  A fairly high degree of smearing has occurred, 
possibly due to glycosylation, making the analysis more difficult. However the shifts seen 
for LZ29 and LZ59 indicating receptor binding is clear. 
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Figure 77. Native gel electrophoresis of the initial binary complexation of 
IRB17dB (A) and IRB13 (B) with insulin analogues. 
A 7.5% native gel of the initial complexation between IR-B17dB (A) and IR-B13 (B) with 
insulin analogues. Gel (A), all lanes contain IRB17dB.  Lane 1: Receptor only.  Lane 2: 
LZ29.  Lane 3: LZ30.  Lane 4: LZ33.  Lane 5: LZ36.  Lane 6: LZ45.  Lane 7: LZ59.  Lane 
8: Receptor only. Gel (B), all lanes contain IRB13.  Lane 1: Receptor only.  Lane 2: LZ29.  
Lane 3: LZ30.  Lane 4: LZ33.  Lane 5: LZ36.  Lane 6: LZ45.  Lane 7: LZ59.  Lane 8: 
Receptor only. 
 
Subsequently, the complexation of IRB17dB with insulin analogues and WT insulin 
was conducted comparing IRB17dB alone, or in the presence of the CT peptide (Figure 78). 
From the gel shifts it appears that LZ29 (gel A, lanes 4 and 5) and LZ30 (gel A, lanes 6 and 
7) are able to bind to the receptor with and without the presence of the CT peptide (Figure 
78-A). The LZ30 analogue had been unable previously to bind to the IR, though for this gel 
a fresh preparation was used, indicating that the age of the sample may play an important 
role. LZ45 seems to bind to the receptor (Figure 78-B). LZ59 (gel B, lanes 4 and 5) alone 
does not appear to be able to bind to the receptor, although upon addition of the CT peptide, 
a complex was formed. All +/- CT peptide lanes are smeared, which could indicate the 
dynamic character of the complexes. LZ33 appears to bind to the receptor (Figure 78-C, 
lanes 6 and 7). LZ36 binds upon the addition of IRB17dB, whilst upon the addition of the 
CT peptide there appears to be dissociation of the complex (gel C, lanes 4 and 5).  The band 
present corresponds to a transient state, indicating that the binding of LZ36 to the IR is 
dynamic and dependent upon the CT peptide. In all gels WT insulin appears to bind to the 
receptor, with the gel shifts indicating binding very similar to that of the insulin analogues 
(Figure 78). 
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Figure 78.  Native gel electrophoresis of the IRB17dB – insulin complexes in the 
presence or absence of the CT peptide. 
A 5% native gel of the complexation of IRB17dB with insulin analogues, investigating the 
effect of the CT peptide.  All lanes on all three gels contain IRB17dB.  Gel (A), lane 1: 
Receptor only.  Lane 2: WT insulin.  Lane 3: WT insulin with CT peptide.  Lane 4: LZ29.  
Lane 5: LZ29 with CT peptide.  Lane 6: LZ30.  Lane 7: LZ30 with CT peptide.  Lane 8: 
Receptor only.  Gel (B), lane 1: Receptor only.  Lane 2: WT insulin.  Lane 3: WT insulin 
with CT peptide.  Lane 4: LZ59.  Lane 5: LZ59 with CT peptide.  Lane 6: LZ45.  Lane 7: 
LZ45 with CT peptide.  Lane 8: Receptor only.  Gel (C), lane 1: Receptor only.  Lane 2: WT 
insulin.  Lane 3: WT insulin with CT peptide.  Lane 4: LZ36.  Lane 5: LZ36 with CT 
peptide.  Lane 6: LZ33.  Lane 7: LZ33 with CT peptide.  Lane 8: Receptor only. 
 
Native gels were run to investigate the complexation of IRB13 with insulin 
analogues and WT insulin comparing IRB13 alone, to IRB13 in the presence of the CT 
peptide (Figure 79).  For LZ30 (gel A, lanes 4 and 5) and LZ33 (gel B, lanes 6 and 7) 
(Figure 79) some upward smearing in the bands indicates that some binding has occurred.  
The addition of CT peptide does not show special effect upon IRB13 binding to any of the 
analogues. 
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Figure 79. Native gel electrophoresis of the complexation of IRB13 with insulin 
analogues, investigating the effect of the CT peptide. 
A 7.5% native gel of the complexation of IRB13 with insulin analogues, investigating the 
effect of the CT peptide. All lanes on all three gels contain IRB13.  Gel (A), lane 1: 
Receptor only.  Lane 2: WT insulin.  Lane 3: WT insulin with CT peptide.  Lane 4: LZ30.  
Lane 5: LZ30 with CT peptide.  Lane 6: LZ45.  Lane 7: LZ45 with CT peptide.  Lane 8: 
Receptor only. Gel (B), lane 1: Receptor only.  Lane 2: WT insulin.  Lane 3: WT insulin 
with CT peptide.  Lane 4: LZ59.  Lane 5: LZ59 with CT peptide.  Lane 6: LZ33.  Lane 7: 
LZ33 with CT peptide.  Lane 8: Receptor only. Gel (C), lane 1: Receptor only.  Lane 2: WT 
insulin.  Lane 3: WT insulin with CT peptide.  Lane 4: LZ36.  Lane 5: LZ36 with CT 
peptide.  Lane 6: Receptor only. 
 
The addition of certain organic compounds, notably TFEtOH and phenol, can 
promote α-helical formation of disordered proteins. It appears that low pH (pH 4.0) 
promotes an addition of the CT peptide to the analogue:receptor complex (Figure 80).  The 
promotion of the α-helix seems to be present with the addition of phenol because of the 
stabilisation of the complex, whilst TFEtOH appears to destabilise the complex. 
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Figure 80.  Native gel electrophoresis of the complexation between IRB13 with 
LZ29 and the CT peptide. 
A 7.5% native gel of the complexation of IRB13 with LZ29 and the CT peptide, 
investigating the effects pH and additives. All lanes contain IR-B13.  Gel (A), lane 1: 
Receptor only.  Lane 2: LZ29 and CT peptide.  Lane 3: LZ29 and CT peptide, pH 4.0.  Lane 
4: LZ29 and CT peptide, pH 6.5.  Lane 5: LZ29 and CT peptide, pH 8.5.  Lane 6: LZ29 and 
CT peptide with 0.1 % TFEtOH.  Lane 7: LZ29 and CT peptide with 0.1 % phenol.  Lane 8: 
LZ29. 
 
A systematic approach was taken to analyse the effect of addition of phenol during 
the complexation of insulin, insulin analogues and IRB13 (Figure 81).  The only clear 
difference upon the addition of phenol occurs when it is added to WT insulin and CT 
peptide (gel A, lanes 4 and 6).  This could indicate a good route upon which to try and form 
a ternary complex, with insulin, the IR and CT peptide. 
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Figure 81.  Native gel electrophoresis of the complexation between IRB13 with 
various insulins, investigating the effects of the CT peptide, pH and additives. 
A 7.5% native gel of the complexation of IR-B13 with various insulins, investigating the 
effects the CT peptide, pH and additives. All lanes on all three gels contain IR-B13.  Gel 
(A), lane 1: 0.15 % phenol.  Lane 2: Receptor only.  Lane 3: WT insulin.  Lane 4: WT 
insulin and 0.15 % phenol.  Lane 5: WT insulin and CT peptide.  Lane 6: WT insulin and 
CT peptide with 0.15 % phenol.  Gel (B), lane 1: 0.15 % phenol.  Lane 2: Receptor only.  
Lane 3: LZ29.  Lane 4: LZ29 and 0.15 % phenol.  Lane 5: LZ29 and CT peptide.  Lane 6: 
LZ29 and CT peptide with 0.15 % phenol.  Gel (C), lane 1: 0.15 % phenol.  Lane 2: 
Receptor only.  Lane 3: LZ30.  Lane 4: LZ30 and 0.15 % phenol.  Lane 5: LZ30 and CT 
peptide.  Lane 6: LZ30 and CT peptide with 0.15 % phenol. 
 
To gain physical information on binding between the IR and insulin analogues, the 
ITC measurements
184
 were conducted on LZ30. They were performed by collaborators at 
WEHI in Melbourne, Australia. LZ30 was injected into TBSA, which gave no heat of 
dilution, indicating a good negative control. When LZ30 was injected into IR-B13, it also 
gave no heat of dilution. The addition of LZ30 into IRB13 in the presence of the CT 
peptide, however gave a heat of dilution, with a Kd = 4.85 nM. WT insulin in this system 
has a Kd = 16.6 nM.  This indicates that the binding of the LZ30 analogue to IRB13 is CT 
peptide dependent.  The data of analogue binding previously published
150
 show different 
binding affinities, although still in the low nM range. The proportions between LZ30 and 
WT binding affinities remain consistent. 
The IRB13:insulin:CT peptide complex was buffered in TBSA. The best crystal 
identified from the screening was obtained from drops equilibrated 1:1 (protein:well) in 
well solution consisting of 1M tri-sodium citrate pH 8 (1 ml well volume), and grown at 
21°C. The crystal was flash-cooled in liquid nitrogen using paraffin oil as cryoprotectant. 
The X-ray data were collected at Diamond at station I24, and processed using XDS
185
. The 
data collection statistics are shown for three crystals (Table 18). 
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Table 18. X-ray data processing and refinement of the insulin:IR complex. 
 Data set 1 Data set 2 Data set 3 
Receptor / Fab IR310.T/Fab83-7 IR310.T/Fab83-7 IR310.T/Fab83-7 
Insulin Human [D-ProB26]-DTI-NH2 [D-Pro
B26
]-DTI-NH2 
CT peptide 704-719 704-719 697-719 
X-ray source Diamond Light 
Source 
Diamond Light 
Source 
Diamond Light 
Source 
No. of frames 180 400 200 
Oscillation range () 0.2 0.2 0.2 
Exposure / frame (s) 0.2 0.2 0.2 
Unit cell dimensions a = 168.91 Å a = 169.49 Å a = 169.22 Å 
Space group P23 P23 P23 
Solvent content (%) 80 80 80 
Data completeness 
(%) 
98.4 (99.6) 99.7 (100.0) 98.5 (98.1) 
Resolution (Å) 46.8 – 3.9  
(4.0 – 3.9) 
29.6 – 4.3  
(4.53 - 4.3) 
29.5 – 4.3  
(4.54 – 4.3) 
Rmerge 0.089 (1.32) 0.188 (2.69) 0.101 (1.09) 
Rpim 0.089 (0.83) 0.067 (0.97) 0.053 (0.59) 
<I/(I)> 8.95 (1.0) 7.8 (1.0) 8.2 (1.4) 
Redundancy 4.1 (4.2) 8.8 (8.8) 4.4 (4.3) 
1 
Numbers in parentheses refer to the statistic in the highest resolution shell. 
2 
Rmerge= | Ii(hkl) - <I(hkl)> | / Ii(hkl) 
3 
Rpim = [N/(N-1)]
1/2
 | Ii(hkl) - <I(hkl)> | / Ii(hkl) 
 
The data was processed and revealed the structures of complexes between insulin, 
IRB13 and the CT peptide. 
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5.4.2. Conclusion 
 
The sample of the IRB17dB construct showed some degree of aggregation even 
prior to formation of the insulin complexes.  This could be, for example, due to the CT 
peptides becoming dislodged from their own receptor and associating transiently with 
neighbouring homodimers, resulting in their oligomerisation. Domain swapping cannot be 
excluded here as well.  Obtaining a homogeneous mixture of IRB17dB would be required 
for more successful crystallisation attempts. 
Consistently, the LZ29 and LZ30 have shown successfully IR complex formation 
on native-PAGE analysis.  These insulins correspond to some of the highest affinity 
analogues (214% and 465% respectively).  It is therefore understandable that LZ59, another 
high affinity analogue (356%) formed a stable complex with IRB13 as well. LZ59 displays 
the same structural characteristics associated with the high affinity analogues seen in LZ29 
and LZ30. 
The resolutions obtained for the crystals of the complex between the IR, insulin 
(WT and LZ59) and the CT peptide are low, around 4 Å. This resolution is not high enough 
to produce detailed interactions between side chains, but it does show how and where the 
three components come together and form one of the most sought after complexes in 
structural biology. 
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Chapter 6. Conclusions and Future Perspectives 
6.1. Exploitation of the Conformation Associated with High 
Affinity Insulin Analogues 
 
For many years the 3-D structures of insulin were derived from its relatively similar 
storage forms. However, wealth of interdisciplinary data indicated reorganisation on the C-
terminus of the B-chain, needed for the exposure of the hydrophobic core of the insulin 
molecule upon binding to the IR. 
The development and structural characterisation of a wide range of high affinity insulin 
analogues led to the discovery of their structural signature - B26 turn
75
. The B26 turn fulfils 
the requirements of the active conformation of insulin. The C-terminus of the B-chain is 
detached from its position in proximity to the N-terminus of the A-chain exposing 
hydrophobic core of the hormone.  The side chains around the B25-B26 sites alternate their 
positions, forming pattern of interactions that facilitate effective interactions with L1 and 
ID-αCT regions of the IR upon hormone-receptor binding77. 
Future exploitations of in the B26 turn will involve rational modifications of the B24-
B30 C-terminal residues. For example, improvement of IR-binding affinity could require 
either increase of the stability of the B26 turn (e.g. by optimisation of the click-chemistry 
based crosslinking) or improvement of specific insulin side chains interactions with the IR. 
 
6.2. Further Investigation of the Dimer Interface 
 
The dimer interface is formed by a series of four parallel hydrogen bonds between two 
anti-parallel β-sheets at the C-terminus of the B-chain. Residues PheB24 and TyrB26 form two 
hydrogen bonds each from their carbonyl and amide groups
2,80,151
. However, Chapter 3 
shows that the most important interaction is that formed by the main chain amide from 
Phe
B25
 to Tyr
A19
, loss of which causes a dramatic reduction in dimerisation capability
159
. 
From all insulin aggregation forms (hexameric, dimeric and monomeric) it is the 
monomer of the hormone that binds to the IR. Current insulin analogues in diabetes-linked 
clinical applications have tailored characteristics for a specific (i.e. long- or rapid-aciting) 
use. An increasing of the strength of the dimer interface would lead to new insulin 
analogues that with more prolonged effects and low-level insulin release. This can be 
achieved by either increasing the amount of hydrogen bonds formed between the anti-
parallel main chain atoms, forming new interactions between side chains of the residues in 
the interface, or by forming new interactions with the core of the insulin molecule, such as 
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that seen between Phe
B25
 and Tyr
A19
. A reverse process would help to create a more rapid 
acting analogue. 
 
6.3. Improved Receptor Binding 
 
Insulin binds to the IR in its monomeric form following conformational changes of its 
storage form. The B26 turn at the C-terminus of the B-chain is characteristic of high affinity 
analogues, in which the N-terminus of the B-chain exhibits also an intermediate state 
between the R- and T-states. This type II-like pseudo turn could be of special importance 
for activation of insulin as well. A range of new analogues addressing the importance of the 
residues in the B1-B8 N-terminal region would lead to a greater understanding of the active 
form of insulin upon binding to the IR. Improvements in binding caused by the analogues 
probing the N-terminal turn could lead to analogues of increased binding affinity similar to 
those seen at the C-terminus of the B-chain. Coupling of the improvements to both termini 
of the B-chain would result in a super affinity analogue that would assist high resolution 
studies of the insulin:IR complex and may provide novel 3-D scaffold for insulin organic 
mimics. 
 
6.4. Improvements in the Crystals of Insulin:IR 
 
A high resolution structure of the complex between Insulin:IR was a key aim of this 
project. Attempts to express a correctly formed L1 construct were unsuccessful, but through 
collaboration with the group of Prof. Mike Lawrence (WEHI) a certain insulin:IR complex 
was crystallised that diffracted to 3.9-4.3 Å. 
The construct that produced these crystals consisted of L1-CR-L2, with each domain 
consisting of a stable individual element linked by a flexible linker region. These flexible 
regions could be disrupting the crystals ability to diffract to a high resolution. Using a 
construct that maintains the binding regions important in insulin:IR binding, whilst 
minimising the flexibility experienced (such as just the L1 region) could improve crystal 
quality, and therefore diffraction. 
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6.5. Insulin and Insulin-Like Growth Factor Relationship 
 
Insulin and IGF-I and -II are closely related protein hormones that have different 
biological functions. Insulin is a key metabolism controller, whilst IGF-I and -II are major 
growth factors. When released into the bloodstream they bind tightly and specifically to 
their homologous receptors. 
The ability of insulin and IGF to cross-bind to their receptors
117
 means that insulin 
can be implied in the regulation of proliferation and growth. IGF-I and -II have been 
identified as cancer specific growth factors
124
. The structural factors that signal for 
metabolic or cell growth need to be identified. 
The efficient production of an insulin-like core from the full-length IGFs facilitates 
semi-synthesis of novel IGFs and insulin-IGF hybrids for characterisation of their molecular 
and cellular specificities as well as IGF-1R and IR binding. This will allow the creation of 
designer insulin and IGF analogues with specific effects, for example an insulin analogue 
which has only metabolic effects, and is an antagonist of IGF-I and -II. 
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Appendix 1. General Materials and Methods 
A.1. General Materials and methods 
A.1.1. General Materials, Chemicals, and Bacterial and Fungal 
Strains 
 
Chemicals purchased for use in this project were of the highest purity available.  
Synthetic genes were purchased from GenScript.  PCR primers were ordered from MWG-
Eurofins (Germany).  KOD hot start DNA polymerase was obtained from Novagen.  The 
pET-YSBLIC3C vector was obtained from the Structural Biology Labratory (University of 
York).  Restriction enzymes EcoRI, HindIII, NcoI, NotI, SacI and XhoI were purchased from 
New England Bio Labs.  PCR clean-up and mini-prep kits were purchased from Qiagen, 
and a gel extraction kit from Sigma Aldrich.  Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was purchased from Melford Labs.  Methanol came from Fisher. Yeast nitrogen base was 
purchased from Sigma. 
The following bacterial and fungal cultures were acquired from collections within 
the University of York: E. coli; XL-10 gold, BL21, Tuner, Rosetta-Gami 2, lemo21 and 
ArcticExpress, and fungal; S. cerevisiae INVSc1, and P. pastoris X-33. 
 
A.1.2. SDS-PAGE Analysis of Proteins 
 
Cell extract samples were diluted in a 4x loading buffer (0.5 M Tris, pH 6.8) 
containing: glycerol 20 %, SDS 4 %, bromophenol blue 0.1 %, and β-mercaptoethanol 5 %.  
Resolving gels (15 or 17.5 % acrylamide) were set by adding tetramethylethtlenediamine 
(TEMED) to a resolving buffer (1.5M Tris, 0.4 % SDS, pH 8.8) containing acrylamide and 
ammonium persulphate (APS).  A stacking gel was poured from a 0.5 M Tris buffer (0.4 % 
SDS, pH 6.8) containing acrylamide, APS, and TEMED.  A BioRad low molecular mass 
marker mixture was used that contained phosphorylase B 97.4 kDa, serum albumin 66.2 
kDa, ovalbumin 45 kDa, carbonic anhydrase 31 kDa, Soybean trypsin inhibitor 21.5 kDa  
and lysozyme 14.4 kDa.  Following this gels were stained with Coomassie Blue dye, and 
de-stained using a 6:3:1 mixture of water : propan-2-ol : glacial acetic acid.  Samples and 
the molecular mass marker were boiled at 95 
o
C for 5 minutes prior to loading.  This 
method was based upon that described by Laemmli
186
. 
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A.1.3. Native Gel Analysis of Proteins 
 
Cell extracts samples were diluted in a 4x loading buffer (0.5 M Tris, pH 6.8) 
containing: glycerol 20% and bromophenol blue 0.01%.  Resolving gels (5 or 7.5% 
acrylamide) were set by adding tetramethylethtlenediamine (TEMED) to a resolving buffer 
(1.5M Tris, pH 8.8) containing acrylamide and ammonium persulphate (APS).  Gels were 
then stained with Comassie Blue dye and de-stained using a 6:3:1 mixture of water : 
propan-2-ol : glacial acetic acid.  This method was based upon that described by 
Laemmli
186
. 
 
A.1.4. Copper Staining of Acrylamide Gels 
 
A gel was run as described previously.  Following electrophoresis, the gel was 
momentarily washed in milliQ water.  The gel was then transferred to a 0.3 M CaCl2 
solution for 5 min.  The bands were then able to be visualised. Based upon the method 
described by Lee et al.
187
. 
 
A.1.5. Silver Staining of Acrylamide Gels 
 
A gel was run as described previously.  Following electrophoresis, the gel was 
washed twice for 5 min each time in ultra pure water.  The gel was fixed by immersion in a 
solution of 30% ethanol: 10% acetic acid for 15 min twice.  The fixant was washed away by 
two 5 min washes in 10% ethanol, followed by two washes for 5 min in ultra pure water.  
Sensitiser was applied to the gel for 1 min, and then washed for 1 min twice with water.  
The gel was stained for 30 min in the dark using the stain solution.  Following staining, the 
gel was washed twice for 20 sec with ultra pure water, then immersed in developer solution 
for 2-3 min until bands appear.  The reaction was stopped with a 5% acetic acid solution for 
10 min.  The kit used was Silver SNAP Stain Kit II. 
 
A.1.6. Western Blotting 
 
A gel was run, as described previously.  Layers of thick absorbent paper and 
nitrocellulose membrane were soaked in transfer buffer (25 mM Tris, 193 mM glycine, 20% 
v/v methanol, pH 8.3) for 10 min.  The transfer block was prepared from the anode 
consisting of thick absorbent paper, nitrocellulose membrane, polyacrylamide gel and thick 
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absorbent paper.  A transfer was performed for 25 min at 25 V, after which Ponceau Red 
was used to visualise transferred proteins.  The marker was marked using a pencil.  The 
membrane was washed twice for 10 min each time with 15 mL 1X TBS (150 mM NaCl, 10 
mM Tris, pH 7.5).  The membrane was then blocked for 1 h with 20 mL blocking solution 
prior to being washed twice for 10 min each time with 20 mL 1X TBSTT (500 mM NaCl, 
20 mM Tris, 0.2% v/v Triton X-100, 0.05% v/v Tween 20, pH 7.5). A 10 min wash followed 
with 15 mL 1X TBS, after which an anti-His antibody, diluted 1:1000 in blocking solution, 
was applied to the nitrocellulose for 1 h at room temperature.  The membrane was washed 
again twice for 10 min each time with 20 mL 1X TBSTT, and then for a further 10 min with 
15 mL 1X TBS. Excess solution was then drained away.  The substrate solution was 
prepared immediately before use by composing a solution comprising equal parts of 2X 
Luminol/Enhancer and 2X peroxide solution.  The substrate solution was applied to the 
membrane and allowed to develop for 1-2 min, with maximum luminescence occurring 
after 5 min, before taking white light and bioluminescence images, and combining them to 
form a composite image. 
 
A.1.7. Dot Blot 
 
The nitrocellulose was marked into a grid using a pencil, after which it was allowed 
to soak in methanol, causing the nitrocellulose to become permeable.  Samples were then 
applied to the nitrocellulose directly and allowed to absorb into the surface.  The membrane 
was washed twice for 10 min each time with 15 mL 1X TBS (150 mM NaCl, 10 mM Tris, 
pH 7.5).  The membrane was blocked for 1 h with 20 mL blocking solution prior to being 
washed twice for 10 min each time with 20 mL 1X TBSTT (500 mM NaCl, 20 mM Tris, 
0.2% v/v Triton X-100, 0.05% v/v Tween 20, pH 7.5). A 10 min wash followed with 15 mL 
1X TBS, after which an anti-His antibody diluted 1:1000 in blocking solution was applied 
to the nitrocellulose for 1 h at room temperature.  The membrane was again washed twice 
for 10 min each time with 20 mL 1X TBSTT, and then for 10 min with 15 mL 1X TBS. 
Excess solution was then drained away.  The substrate solution was prepared immediately 
before use by composing a solution comprising equal parts of 2X Luminol/Enhancer and 
2X peroxide solution.  The substrate solution was applied to the membrane and allowed to 
develop for 1-2 min, with maximum luminescence occurring after 5 min, before taking 
white light and bioluminescence images, and combining them to form a composite image. 
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A.1.8. Molecular Biology Techniques 
A.1.8.1. Ligation Independent Cloning (LIC) 
A.1.8.1.1. Preparation of LIC Vector using PCR Method 
 
Cleavable His-tagged pET-YSBLIC vector, 1 μg, was transformed into competent 
DH5α cells and plated onto Luria Bertani (LB) agar + kanamycin (30 μg/mL) before being 
incubated at 37 
o
C overnight.  The cells were harvested before a mini-prep was carried out 
to extract the vector DNA (20 μg), which was used as the template for PCR.  Each 50 μL 
PCR volume contained 0.4 μM of forward and reverse primers (ordered from MWG), 0.2 
mM dNTPs, 1 μL KOD hot start DNA polymerase (1 unit/μL), 1 mM MgSO4, 5 μL 10X 
buffer, 50 ng template DNA, 5% v/v DMSO, and water to 50 μL.  Thermocycling 
conditions were as follows: initial denature 3 min at 94 
o
C, followed by 35 cycles of: 
denature 30 s at 94
o
C, annealing 30 s at 60 
o
C, and extension 2 min at 72 
o
C, with a final 
extension step 3 min at 72 
o
C.  DpnI was added to the DNA and incubated at 37 
o
C for 2 h 
to digest the methylated DNA.  The reaction mixture was run on a preparative agarose gel 
and the bands corresponding to linear vector DNA were cut from the gel and extracted (7.5 
μg). 
 
A.1.8.1.2. Preparation of LIC Vector using BseRI Method 
 
1 μL LIC vector was transformed into competent NovaBlue cells, plated out onto 
LB + kanamycin (30 μg/mL) agar, and incubated at 37oC overnight.  A single colony was 
picked to inoculate 2 x 50 mL LB + kanamycin (30 μg/mL) and incubated 37oC overnight.  
All 100 mL culture was harvested before a mini-prep was carried out to extract the vector 
DNA.  A restriction digest comprising 66 μL vector DNA (7.9 μg), 8 μL BseRI, 16 μL 
10xbuffer (NEB2) and 70 μL water was incubated at 37oC for 1 h 50 min.  The sample was 
run on a preparative agarose gel.  The bands were cut out and purified to give linear LIC 
vector DNA, which was concentrated to 20 ng/μL. 
 
A.1.8.1.3. Vector LIC T4pol Reaction 
 
A mixture comprising the following: 3.75 μg linearised vector DNA, 15 μL T4pol 
buffer (10X), 15 μL dTTP (25 mM stock), 7.5 μL DTT (100 mM stock), 3 μL T4 
polymerase (2.5 U/μL LIC qualified – Novagen) and H2O to 150 μL, was incubated at 22
o
C 
for 30 min, and then at 75
o
C for 20 min. 
  
160 
 
A.1.8.1.4. Insert LIC T4pol Reaction 
 
A mixture comprising the following: 0.2 pmol PCR product (insert), 2 μL T4pol 
buffer (10x), 2 μL dATP (25 mM stock), 1 μL DTT (100 mM stock), 0.4 μL T4 polymerase 
(2.5 U/μL LIC qualified – Novagen) and H2O to 20 μL, was incubated at 22
o
C for 30 min, 
and then at 75
o
C for 20 min. 
 
A.1.8.1.5. LIC Annealing Reaction 
 
The annealing reaction comprised 1.5 μL of T4 treated vector (50 ng/μL) added to 
2.5 μL of the insert T4 reaction, and incubated at room temperature for 10 min.  The 
reaction then received an addition of 1.5 μL EDTA (25 mM stock) and was incubated for a 
further 10 min at r/t.  A negative control using water was also set up. 
 
A.1.8.1.6. Transformation of Competent E. coli Cells 
 
A transformation was performed by adding 5.5 μL of the LIC annealing reaction to 
50 μL of competent E. coli XL-10 gold cells, and was then incubated on ice for 5 min.  The 
cells were heat-shocked at 42 
o
C for 30 s, and then incubated on ice for a further 5 min.  0.2 
mL of LB medium was added and the cells were incubated at 37 
o
C for 1 h.  The cells were 
plated out onto LB agar + kanamycin (30 μg/mL) and incubated overnight at 37 oC.  
 
A.1.8.1.7. NdeI/NcoI Reaction Digest 
 
Colonies from the transformation of XL-10 gold cells were picked to inoculate 5 
mL cultures of LB + kanamycin (30 μg/mL) and were incubated overnight at 37oC before 
carrying out a mini-prep.  Extracted DNA was then digested in a solution comprising: 1 μg 
DNA, 1 μL NE buffer 2 (10x), 1 μL NcoI, 1 μL NdeI, and water up to 10 μL, before being 
incubated at 37
o
C for 3 h. The mixture was then run out on an agarose gel. 
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A.1.8.2. Traditional Molecular Biology 
A.1.8.2.1. Amplification of the Target Gene by PCR 
 
Each 50 μL PCR volume contained 0.4 μM of forward and reverse primers (ordered 
from MWG), 2 mM dNTPs, 1 μL KOD hot start DNA polymerase (1 unit/μL, 1 mM 
MgSO4, 5 μL 10X buffer, 10 ng template DNA, and water to 50 μL.  Thermocycling 
conditions were as follows: initial denature 3 min at 94
o
C, followed by 35 cycles of: 
denature 30 s at 94
o
C, annealing 30 s at 60
o
C, and extension 2 min at 72
o
C, with a final 
extension step 3 min at 72
o
C. The amplified target gene was cleaned using a PCR clean up 
kit. 
 
A.1.8.2.2. Preparation of the Plasmid 
 
1 μL vector was transformed into competent Nova Blue cells, plated onto LB + 
antibiotic agar and incubated at 37˚C overnight.  A single colony was picked to inoculate 10 
mL LB + antibiotic and incubated at 37˚C overnight.  All 10 mL culture was harvested 
before a mini-prep was carried out to extract the vector DNA.  A restriction digest 
comprising 10 μL vector DNA, 2.5 μL 10X buffer, 1 μL each restriction enzyme, made up 
to 25 μL with water, and incubated at 37˚C for 2 hours.  1 μL of phosphatase was added and 
incubated at 37˚C for 2 hours before heat activating the enzymes at 65˚C for 15 min before 
being stored at -20˚C. 
 
A.1.8.2.3. Preparation of the Insert 
 
20 μL of the target gene from PCR was incubated at 37˚C for 8.5 hours before being 
stored at -20°C. 
 
A.1.8.2.4. Ligation Reaction 
 
A ligation was setup with a solution comprising 5 μL digested vector, 2 μL digested 
insert, 1.5 μL 10X buffer, and 1.5 μL ligase, made up to 15 μL with water. 
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A.1.8.2.5. Transformation of Competent E. coli Cells 
 
A transformation was performed by adding 4 μL of the ligated vector to 50 μL of 
competent E. coli XL-10 gold cells, and then incubated on ice for 5 mins.  The cells were 
heat-shocked at 42
o
C for 30 s and then incubated on ice for a further 5 min.  0.2 mL of LB 
medium was added to the reaction and the cells were incubated at 37
o
C for 1 h.  The cells 
were then plated out onto LB agar + antibiotic and incubated overnight at 37
o
C  
 
A.1.8.2.6. Restriction Digest 
 
Colonies from the transformation of XL-10 gold cells were picked to inoculate 5 
mL cultures of LB + antibiotic and incubated overnight at 37
o
C before carrying out a mini-
prep.  Extracted DNA was then digested in a solution comprising: 1 μg DNA, 1 μL 10X 
buffer, 1 μL restriction enzyme 1, 1 μL restriction enzyme 2, and water up to 10 μL, before 
being incubated at 37
o
C for 3 h. The mixture was then run out on an agarose gel. 
 
A.1.9. DNA Sequencing 
 
Sanger sequencing of cloned genes and PCR products was carried out by the 
Technology Facility (University of York). 
 
A.1.10. Purification of Plasmid DNA Using a Mini-Prep Kit 
 
A single colony was picked from an antibiotic selective plate and used to inoculate 
a 5 mL overnight culture.  The 5 mL culture was harvested using a microcentrifuge for 1 
min at 13,000 x g, and the cell pellet resuspended in 250 μL of P1 (resuspension buffer).  
250 μL of P2 (lysis buffer) was added to the suspension and mixed thoroughly before the 
addition of 350 μL N3 (neutralisation buffer).  The solution was centrifuged for 10 min at 
13,000 x g and the supernatant applied to a QIAprep spin column.  Following centrifugation 
for 1 min at 13,000 x g, the spin column was washed with 0.5 mL PB (binding buffer) and 
0.75 mL PE (wash buffer), before eluting the DNA with 50 μL water after 1 min incubation. 
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A.1.11. Agarose Gel Analysis of DNA 
 
An agarose gel was created by heating 0.5 g of agarose in a 50 mL solution of Tris-
acetate buffer pH 8.0 containing EDTA, using a microwave until dissolved to create a 1% 
gel.  Upon cooling and prior to the gel setting, 2 μL of the DNA stain Sybr safe® was added.  
8 μL samples were mixed with 2 μL of loading buffer (New England Biolabs) prior to 
loading onto the gel in addition to a DNA ladder (New England Biolabs), before the gel was 
run at 100 V and 400 mA for 1 h. 
 
A.1.12. Extraction of DNA from Agarose Gels 
 
DNA bands were cut from agarose gels with a scalpel and extracted using a gel 
extraction kit (Sigma).  The gel slice was then dissolved using a gel solubilisation solution 
(300 μL solution / 100 mg gel) at 55oC for 10 min before precipitating the DNA with 
isopropanol (100 μL / 100 mg gel).  The DNA binding column was prepared by adding 0.5 
mL of preparation solution and centrifuging (13,000 x g, 1 min) before binding the DNA 
and further centrifuging for 1 min.  The column was washed and the DNA eluted in 50 μL 
of distilled water at 65
o
C before the concentration was determined using a nanodrop 
spectrophotometer. 
 
A.1.13. Preparation of Competent Cells 
 
A single colony was picked from an antibiotic selective plate and used to inoculate 
an overnight culture.  This was used to create a new 20 mL culture following a 1:100 
dilution and incubation for 2 hours at 37
o
C.  Following incubation on ice for 15 min the 
cells were harvested (4,000 x g, 10 min, 4
o
C).  The cells were resuspended in 1 mL ice-cold 
TSS (10% PEG 3.35K, 50 mM MgCl2, 5% DMSO, pH 6.5) before being aliquoted into 50 
μL fractions, following which they were snap frozen in liquid N2 and stored at -80
o
C. 
 
A.1.14. Expression of Cloned Genes in E. coli 
 
A 4 μL sample of the LIC construct containing the insert was added to 50 μL of 
competent E. coli cells (BL21, TUNER or Rosetta-Gami 2), and then incubated on ice for 5 
min.  The cells were heat-shocked at 42
o
C for 30 s and then incubated on ice for a further 5 
min.  0.2 mL LB medium was added to the cells, which were then incubated at 37
o
C for 1 h.  
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The cells were plated out onto LB agar + kanamycin (30 μg/mL) (also + chloramphenicol 
30 μg/mL when using Rosetta-Gami 2 cells) or ampicillin (100 µg/mL), and incubated 
overnight at 37
o
C.  Expression tests were carried out by picking colonies from these plates 
to inoculate 5 mL overnight cultures of LB + kanamycin (+ chloramphenicol).  Cultures 
were set up with a 1:100 overnight culture:media dilution, and incubated at 37
o
C until 
reaching an optical density of A600 = 0.7 when they were induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG) (0.1-1 mM).  Cultures were then incubated overnight at a 
range of temperatures between 16 and 37
o
C. 
 
A.1.15. Lysis of S. cerevisiae 
 
A S. Cerevisiae cell pellet was re-suspended (to a OD600 50-100) in a breaking 
buffer consisting of 50 mM sodium phosphate, pH 7.4, 5% glycerol and 1 mM PMSF.  An 
equal volume of acid-washed glass beads was added, before vortexing the mixture for 30 
sec, followed by 30 sec on ice.  This was repeated four times to lyse the cells by shear force. 
 
A.1.16. Purification Techniques 
A.1.16.1. Immobilised Metal Affinity Chromatography 
 
The purification was carried out using Hi Trap Chelating HP columns with a 5 mL volume 
from GE Healthcare charged with Ni
2+
.  The column was equilibrated with 5 column 
volumes of starting buffer, followed by 5 column volumes of the starting buffer with 20mM 
imidazole.  The bound protein was eluted by an increasing gradient of the starting buffer 
with 20mM imidazole and the starting buffer with 1 M imidazole, over 20 column volumes. 
 
A.1.16.2. Size Exclusion Chromatography 
 
The gel filtration column was pre-incubated in 150 mM NaCl prior to the protein 
sample being injected onto the column.  The column was run at a constant rate until all 
proteins had been eluted. 
 
 
 
 
  
165 
 
A.1.16.3. Ion Exchange Chromatography 
 
The purification was carried out using Hi Trap Q HP columns with a 1 mL volume 
from GE Healthcare.  Prior to use, the column was equilibrated with 5 column volumes of 
buffer (20 mM Na2HPO4, pH 7.3), followed by 5 column volumes of buffer B (20 mM 
Na2HPO4, pH 7.3, 1 M NaCl) followed by 5 column volumes buffer A.  The protein sample 
was loaded onto the column.  The column was washed with 5 column volumes prior to the 
protein being eluted with an increasing gradient to buffer B over 20 column volumes. 
 
A.1.17. Protein Analytical Techniques 
A.1.17.1. Matrix-Assisted Laser Desorption/Ionisation 
(MALDI) 
 
Samples were sent for MALDI mass spectrometry analysis at Central Science 
Laboratory (York). 
 
A.1.17.2. Electrospray Mass Spectrometry 
 
Samples were sent for Electrospray mass spectrometry analysis at the Technology 
Facility (University of York). 
 
A.1.17.3. Protein Identification 
 
Protein samples were analysed using protein identification (protein fingerprinting) 
by the Technology Facility (University of York). 
 
A.1.18. Crystal Cryoprotection 
 
Crystals were cryoprotected by soaking sequentially in cryoprotectants (glycerol-
mother liquor solutions) or straight into various oils, prior to being vitrified in liquid 
nitrogen.  Alternatively, crystals were vitrified without a cryoprotectant. 
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B.1. Molecular Biology 
B.1.1. L1 Expression in E. coli 
B.1.1.1. Ligation Independent Cloning 
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Figure 82. The amino acid sequence of the L1 region of the human IR. 
The expressed region consists of residues Gly
5
-Ile
158
. 
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TACGGGGTCATTCCCCTCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGG
CAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAGC
AGGTGAAGTTTGTCCGGGTATGGATATTCGTAATAATCTGACCCGTCTGCATGAACTGGAA
AATTGCAGCGTGATTGAAGGTCATCTGCAAATTCTGCTGATGTTTAAAACCCGTCCGGAA
GATTTTCGTGATCTGAGCTTTCCGAAACTGATTATGATTACCGATATTCTGCTGCTGTTTCG
TGTTTATGGTCTGGAAAGCCTGAAAGACCTGTTTCCGAATCTGACCGTTATTCGTGGTAGC
CGTCTGTTTTTTAATTATGCCCTGGTGATTTTTGAAATGGTGCATCTGAAAGAACTGGGTC
TGTATAATCTGATGAATATTACCCGTGGTAGCGTGCGTATTGAAAAAAATAATGAACTGTG
CTATCTGGCAACCATTGATTGGAGCCGTATTCTGGATTCTGTGGAAGATAATCATATTGTGC
TGAATAAAGATGATAATGAAGAATGCGGTGATTAACGCGCCTTCTCCTCACATATGGCTAG
CATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTT
GCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCG
AAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGA
ATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCG
TGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCTTCCTTTCTC
GCCACGTTCGCGGCTTTCCCCGTCAGCTCTAATCGGGGCTCCTTAGGTTCCGATTTATGCT
TACGCACTCGACCCAAAAACTTGATAGTGATGTCACGTATGGCATCGTTGATGACCGATTT
CGCCTTGAGCTGGATCAGTCTATATGACTGTCACTGACACCTACCTATTCCGGCAA 
Figure 83. The base pair sequence of the L1 region. 
Primer regions are indicated in red. 
 
Forward CCAGGGACCAGCAGGTGAAGTTTGTCCGGGTATGG 
Reverse GAGGAGAAGGCGCGTTAATCACCGCATTCTTCATTATCATCTTTATTCAGCAC 
Figure 84. Primers for LIC. 
 
  
  
168 
 
B.1.1.2. Molecular Biology 
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Figure 85. The amino acid sequence of the L1 region of the human IR. 
 
Nco ATCTGTCCATGGGTGAAGTTTGTCCGGGTATGG 
Eco CATCTGGAATTCGGTGAAGTTTGTCCGGGTATGG 
xho ACCCGGCTCGAGATCACCGCATTCTTCATTATCATCTTTATTCAG 
Hind CTGTACAAGCTTATCAATCACCGCATTCTTCATTATCATCTTTATTCAG 
Figure 86. Primers used with the pET22 and pMAL vectors. 
Primer pairs were Eco-Hind, Nco-Hind and Nco-Xho. 
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B.1.2. L1 S. cerevisiae 
 
 
Figure 87. Vector map for L1 expression in S. cerevisiae. 
 
CATTTGTATCCAGGTGAAGTTTGTCCTGGTATGGATATCAGAAACAACTTA
ACAAGATTGCATGAATTAGAAAACTGTTCTGTTATTGAAGGTCATTTGCAA
ATCTTGTTGATGTTCAAGACTAGACCAGAAGATTTCAGAGATTTGTTTTTC
CTAAGTTGATCATGATCACAGATATCTTGTTGTTGTTTAGAGTTTACGGTTT
GGAATCCTTAAAGGATTTGTTCCCAAATTTGACCGTTATTAGAGGTAGTAG
ATTATTTTTCAACTACGCTTTGGTTATTTTCGAAATGGTTCATTTGAAGGAA
TTGGGTTTGTACAATTTGATGAACATTACCAGAGGTTCCGTTAGAATCGAA
AAGAATAACGAATTGTGTTACTTGGCAACTATCGATTGGTCTAGAATTTTA
GATTCAGTTGAAGATAACCATATTGTTTTGAATAAGGATGATAACGAAGAA
TGTGGTGACATTTGTCCAGGTACTGCTAAAGGTAAAACAAATTGTCCTGC
AACCGTTATTAACGGTCAATTCGTTGAAAGATGTTGGACTCATTCACATTG
TCAAAAGTAA 
Figure 88. Optimised base pair sequence of the L1 region for expression in S. 
cerevisiae. 
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Forward TTTTAAGCTTAAAATGTCTGGTGAAGTTTGTCCTGGTATGG 
Reverse TTTTCTCGAGGTCACCACATTCTTCGTTATCATCC 
Figure 89. Primers used for S. cerevisiae L1 sequence. 
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B.1.3. L1 P. pastoris 
 
 
Figure 90. Vector map for L1 expression in P. pastoris. 
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Figure 91. Gene sequence of the L1 region in human IR. 
The expressed region consists of residues Gly
5
-Ile
158
. 
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CATTTGTATCCAGGTGAAGTTTGTCCTGGTATGGATATCAGAAACAACTTAACAA
GATTGCATGAATTAGAAAACTGTTCTGTTATTGAAGGTCATTTGCAAATCTTGTTG
ATGTTCAAGACTAGACCAGAAGATTTCAGAGATTTGTCTTTTCCTAAGTTGATCAT
GATCACAGATATCTTGTTGTTGTTTAGAGTTTACGGTTTGGAATCCTTAAAGGATT
TGTTCCCAAATTTGACCGTTATTAGAGGTAGTAGATTATTTTTCAACTACGCTTTG
GTTATTTTCGAAATGGTTCATTTGAAGGAATTGGGTTTGTACAATTTGATGAACAT
TACCAGAGGTTCCGTTAGAATCGAAAAGAATAACGAATTGTGTTACTTGGCAACT
ATCGATTGGTCTAGAATTTTAGATTCAGTTGAAGATAACCATATTGTTTTGAATAA
GGATGATAACGAAGAATGTGGTGACATTTGTCCAGGTACTGCTAAAGGTAAAAC
AAATTGTCCTGCAACCGTTATTAACGGTCAATTCGTTGAAAGATGTTGGACTCAT
TCACATTGTCAAAAGTAA 
Figure 92. Gene sequence of the L1 region for expression in P. pastoris. 
Primer locations are marked in red. 
 
Forward CTGAATTCGGTGAAGTTTGTCCTGGTATGG 
Reverse GTTCTAGAATGGTCCCTGGAACAAAACCTCCAATCCGTCACCA 
CATTCTTCGTTATCATCC 
Figure 93. Primers used for L1 expression in P. pastoris. 
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C.1. Insulin Screens 
 
 1 2 3 4 5 6 
A  
Na2SO4 
0.05M 
pH 3.0 
 
Na2SO4 
0.10M 
pH 3.0 
 
Na2SO4 
0.15M 
pH 3.0 
 
Na2SO4 
0.20M 
pH 3.0 
 
Na2SO4 
0.25M 
pH 3.0 
 
Na2SO4 
0.35M 
pH 3.0 
 
B  
Am2SO4 
0.05M 
pH 3.0 
 
Am2SO4 
0.10M 
pH 3.0 
 
Am2SO4 
0.15M 
pH 3.0 
 
Am2SO4 
0.20M 
pH 3.0 
 
Am2SO4 
0.25M 
pH 3.0 
 
Am2SO4 
0.35M 
pH 3.0 
 
C  
Li2SO4 
0.010M 
pH 3.0 
 
Li2SO4 
0.015M 
pH 3.0 
 
Li2SO4 
0.020M 
pH 3.0 
 
Cs2SO4 
0.01M 
pH 3.0 
 
Cs2SO4 
0.015M 
pH 3.0 
 
 
Cs2SO4 
0.020M 
pH 3.0 
 
D Hexameric 
Condition A 
0.1M Na 
Citrate, 
0.3M Tris pH 
8.2, 
0.6mM ZnAc, 
0.06% Phenol 
Hexameric 
Condition B 
0.6M Na2SO4, 
0.3M Tris pH 
8.2, 
0.6mM ZnAc, 
0.06% Phenol 
Hexameric 
Condition C 
0.1M Na 
Citrate, 
0.3M Tris pH 
7.5, 
0.6mM ZnAc, 
0.06% Phenol 
Hexameric 
Condition D 
0.6M Na2SO4, 
0.3M Tris pH 
7.5, 
0.6mM ZnAc, 
0.06% Phenol 
Hexameric 
Condition E 
5mM ZnAc, 
35mM Na 
Citrate, 
0.7% Phenol, 
0.7M NaCl, 
0.3M Tris pH 
7.5 
Hexameric 
Condition F 
5mM ZnAc, 
35mM Na 
Citrate, 
0.7% Phenol, 
1.1M NaCl, 
0.3M Tris pH 
7.5 
Figure 94. Insulin screen 1 
An insulin screen developed to form monomeric and hexameric insulin molecules. 
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Figure 95. Insulin screen 2. 
An insulin screen developed to form monomeric insulin molecules. 
  
 1 2 3 4 5 6 
A  
0.01M Mg 
Formate 
0.1M NaAc 
pH 3.0 
 
 
0.1M Na 
Formate 
0.1M NaAc 
pH 3.0 
 
0.1M Na 
Citrate 
0.1M NaAc 
pH 3.0 
 
0.01M Li 
Formate 
0.1M NaAc 
pH 3.0 
 
0.01M 
Rb2SO4 
0.1M NaAc 
pH 3.0 
 
0.01M K2SO4 
0.1M NaAc 
pH 3.0 
B  
0.02M Mg 
Formate 
0.1M NaAc 
pH 3.0 
 
 
0.2M Na 
Formate 
0.1M NaAc 
pH 3.0 
 
0.2M Na 
Citrate 
0.1M NaAc 
pH 3.0 
 
0.02M Li 
Formate 
0.1M NaAc 
pH 3.0 
 
0.05M 
Rb2SO4 
0.1M NaAc 
pH 3.0 
 
0.05M K2SO4 
0.1M NaAc 
pH 3.0 
C  
0.06M Mg 
Formate 
0.1M NaAc 
pH 3.0 
 
 
0.5M Na 
Formate 
0.1M NaAc 
pH 3.0 
 
0.5M Na 
Citrate 
0.1M NaAc 
pH 3.0 
 
0.06M Li 
Formate 
0.1M NaAc 
pH 3.0 
 
0.1M Rb2SO4 
0.1M NaAc 
pH 3.0 
 
0.1M K2SO4 
0.1M NaAc 
pH 3.0 
D  
0.1M Mg 
Formate 
0.1M NaAc 
pH 3.0 
 
 
0.8M Na 
Formate 
0.1M NaAc 
pH 3.0 
 
0.8M Na 
Citrate 
0.1M NaAc 
pH 3.0 
 
0.1M Li 
Formate 
0.1M NaAc 
pH 3.0 
 
0.3M Rb2SO4 
0.1M NaAc 
pH 3.0 
 
0.3M K2SO4 
0.1M NaAc 
pH 3.0 
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 1 2 3 4 5 6 
A 20% PEG 3350 
0.2M NaCl 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaCl 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaCl 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCl 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCl 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCl 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
B 20% PEG 3350 
0.2M NaBr 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaBr 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaBr 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaBr 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaBr 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaBr 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
C 20% PEG 3350 
0.2M NaCitrate 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaCitrate 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaCitrate 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCitrate 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCitrate 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaCitrate 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
D 20% PEG 3350 
0.2M NaNO3 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaNO3 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
20% PEG 3350 
0.2M NaNO3 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaNO3 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaNO3 
3mM ZnCl2 
+10%1M Tris.HCl 
pH 8.5 
40% MPD 
0.2M NaNO3 
3mM ZnCl2 
0.7% Phenol 
+10%1M Tris.HCl 
pH 8.5 
E 20% PEG 3350 
0.2M NaCl 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaCl 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaCl 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCl 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCl 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCl 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
F 20% PEG 3350 
0.2M NaBr 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaBr 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaBr 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaBr 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaBr 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaBr 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
G 20% PEG 3350 
0.2M NaCitrate 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaCitrate 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaCitrate 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCitrate 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCitrate 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaCitrate 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
H 20% PEG 3350 
0.2M NaNO3 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaNO3 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
20% PEG 3350 
0.2M NaNO3 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaNO3 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaNO3 
3mM ZnCl2 
+10%1M 
Glycine.HCl pH 3.0 
40% MPD 
0.2M NaNO3 
3mM ZnCl2 
0.7% Phenol 
+10%1M 
Glycine.HCl pH 3.0 
Figure 96. Insulin screen 3. 
An insulin screen developed to form monomeric and hexameric insulin molecules. 
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Appendix 2. The Use of Insulin-Like Growth Factor as a Basis for 
New Novel Insulin Analogues 
A.2.1. Summary 
 
IGF-I and IGF-II are single-chain polypeptides with molecular masses of 7.6 kDa and 
7.5 kDa respectively 
9,10
.  There is a cross-over between insulin and IGF, so it is important 
to investigate the relationship between these two molecules (Figure 97). Creating an insulin-
like core from IGF, could lead to an understanding of this cross signalling. 
 
Figure 97.  The domain layout of insulin, IGF-I and IGF-II. 
Regions labelled A and B are based upon the chain labels of insulin. Region C is the linking 
peptide of insulin that is proteolytically removed but remains in IGF, and region D is the 
signal peptide of insulin that is removed. 
 
The cleavage sites of trypsin in IGF (Figure 98) are spread throughout the molecule 
and it is possible to cleave IGF into an insulin-like core region using trypsin. This is because 
the disulphide bonds in insulin (A
6
-A
11
, A
7
-B
7
 and A
20
-B
19
) correspond almost identically to 
those seen in IGF (Figure 98). Following trypsin digest, part of chains C and D (Figure 97) 
are be removed leaving chains A and B.  
 
Figure 98.  IGF disulphide bonds and trypsin cleavage sites. 
The arrows indicate trypsin cleavage sites, and disulphide bonds are indicated by the joined 
cysteine residues. The letter colours correspond to the regions in Figure 97. 
 
A.2.2. Methods 
 
A IGF:trypsin digest was set up in a 50:1 molecular ratio respectively in 0.3 M Tris pH 9.2.  
The samples were incubated for a specified period of time at 37
o
C.  The digestion was 
halted using PMSF at a 0.2% w/v concentration. 
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A.2.3. Results and Discussion 
 
To ensure the starting material was at the expected molecular weight, a sample of IGF 
was analysed by electrospray mass spectrometry.  The mass of IGF was confirmed to be 
7649 Da (Figure 99). 
 
Figure 99.  Electrospray mass spectrometry of IGF. 
 
To promote the proteolytic cleavage, urea and guanidine hydrochloride were added at 
various concentrations to aid the availability of the tryptic cleavage sites.   The initial 
digestions were run on SDS-PAGE in a non-reducing sample buffer to ascertain the 
completeness of digestion (Figure 100 and Figure 101). 
 
Figure 100.  IGF digestion with various concentrations of urea.  
A 17.5% SDS-PAGE gel IGF digestion with various concentrations of urea with SDS in the 
running buffer (A) and without (B). Gels (A) and (B) lanes 2-9 contain IGF.  Gel (A), Lane 
1: Broad range molecular weight marker. Lane 2: IGF only.  Lane 3: no urea.  Lane 4: 50 
mM urea.  Lane 5: 100 mM urea.  Lane 6: 200 mM urea.  Lane 7: 500 mM urea.  Lane 8: 1 
M urea.  Lane 9: 2 M urea. Gel (B), Lane 1: Broad range molecular weight marker.  Lane 2: 
IGF only.  Lane 3: no urea.  Lane 4: 50 mM urea.  Lane 5: 100 mM urea.  Lane 6: 200 mM 
urea.  Lane 7: 500 mM urea.  Lane 8: 1 M urea.  Lane 9: 2 M urea. 
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Figure 101.  IGF digestion with various concentrations of guanidine 
hydrochloride. 
A 17.5% SDS-PAGE gel showing the digestion of IGF with various concentrations of 
guanidine hydrochloride with SDS in the running buffer (A) and without (B). Gels (A) and 
(B) lanes 2-9 contain IGF.  Gel (A), Lane 1: Broad range molecular weight ladder.  Lane 2: 
IGF only.  Lane 3: no guanidine hydrochloride.  Lane 4: 50 mM guanidine hydrochloride.  
Lane 5: 100 mM guanidine hydrochloride.  Lane 6: 200 mM guanidine hydrochloride.  Lane 
7: 500 mM guanidine hydrochloride.  Lane 8: 1 M guanidine hydrochloride.  Lane 9: 2 M 
guanidine hydrochloride.  Gel (B), Lane 1: Broad range molecular weight marker.  Lane 2: 
IGF only.  Lane 3: no guanidine hydrochloride.  Lane 4: 50 mM guanidine hydrochloride.  
Lane 5: 100 mM guanidine hydrochloride.  Lane 6: 200 mM guanidine hydrochloride.  Lane 
7: 500 mM guanidine hydrochloride.  Lane 8: 1 M guanidine hydrochloride.  Lane 9: 2 M 
guanidine hydrochloride. 
 
 
   Digestion occurs at all concentrations of urea, although further digestion also seems 
to occur past the desired level, with multiple breakdown products present in the sample. The 
samples containing guanidine hydrochloride seem to allow the trypsin to digest the IGF 
completely. The guanidine hydrochloride samples were investigated to determine at which 
point in a time course, the optimum digestion occurs (Figure 102). 
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Figure 102.  Time course digestion of IGF with the addition of various 
concentrations of guanidine hydrochloride. 
A 15% SDS-PAGE gel showing the digestion of a IGF time course in various 
concentrations of guanidine hydrochloride. Gels (A), (B) and (C) lanes 2-6 contain IGF, 
gels were run without SDS in the running buffer. Gel (A) contains no guanidine 
hydrochloride, Lane 1: Broad range molecular weight marker.  Lane 2: IGF only.  Lane 3: 
15 min digestion.  Lane 4: 30 min digestion.  Lane 5: 60 min digestion.  Lane 6: 120 min 
digestion. Gel (B) contains 1 M guanidine hydrochloride, Lane 1: Broad range molecular 
weight marker.  Lane 2: IGF only.  Lane 3: 15 min digestion.  Lane 4: 30 min digestion.  
Lane 5: 60 min digestion.  Lane 6: 120 min digestion. Gel (C) contains 2 M guanidine 
hydrochloride, Lane 1: Broad range molecular weight marker.  Lane 2: IGF only.  Lane 3: 
15 min digestion.  Lane 4: 30 min digestion.  Lane 5: 60 min digestion.  Lane 6: 120 min 
digestion. 
 
 
 It appears that the best digestion occurs at 2 M guanidine hydrochloride for 15 min, 
so this was used and then analysed by MALDI. Multiple peaks could be seen at 5589, 5745, 
5901 and 6057 Da (Figure 103).   The difference in the peaks was averaged to 156 Da.  This 
difference can be attributed to adducts of de-fluorinated PMSF.  The IGF fragment has 
multiple PMS adducts, leading to the observation of multiple peaks (Figure 103-A). The 
PMS adducts were removed by repeated washing steps with 2 mM Tris (Figure 103-B). 
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=  
 
Figure 103.  MALDI sample of IGF digested in the presence of 2 M guanidine-
hydrochloride for 15 minutes. 
(A) MALDI sample of IGF digested in 2 M guanidine hydrochloride for 15 min. (B) 
MALDI sample of IGF digested in 2 M guanidine hydrochloride for 15 min following 
washing, and containing an IGF internal calibrant. 
 
Trypsin digestion of the IGF molecule can lead to various length peptides 
dependent on where the trypsin cuts (Figure 98, Table 19). The major species present 
following digestion had a mass of 5585 Da (Figure 103-B), and were analysed to investigate 
which core fragments remained following cleavage (Table 20). 
Table 19.  Lengths and weights of all possible fragments of IGF. 
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Table 20.  Analysis of IGF MALDI digest data. 
MALDI Result 
(Da) Fragment/Identity 
Molecular Weight 
(Da) 
5585 
1-21 2193.4 
38-55 2013.20 
57-68 1363.70 
Hydroxylation 16.00 
Total 5586.3 
 
Following digestion, residues 1-21, 38-55 and 57-68 remain connected (Table 20). In 
comparison to the insulin molecule (Figure 97), where regions C and D have been partially 
removed from IGF leaving a core similar to insulin. 
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A.2.4. Conclusion 
 
The cross signalling of insulin and IGF requires more understanding. This knowledge 
could be gained by the creation of IGF-insulin hybrids. The cleavage of IGF with trypsin 
left an insulin-like core that comprised residues 1-21, 38-55 and 57-68 of IGF. The 
structural overlay of this core (representation) and insulin (Figure 104) show structures of 
high similarity, a good start for the study of the insulin-IGF cross signalling. The method 
has caused intra-chain cleavages to occur, so a crystal structure is required to confirm the 
actual structure of the IGF insulin-like core. 
  
 
Figure 104. Super positioning of insulin and the digested IGF. 
The insulin analogue (1mso.pdb) is coloured in green, and a representation of the digested 
IGF molecule (1imx.pdb) is superimposed in red. Disulphide bonds are shown in yellow. 
 
Using trypsin to digest away the C and D regions causes several problems for 
further applications due to the method used. Trypsin cleavage results in broken chains, for 
example between residues Arg
50
 and Ser
51
. There are also missing residues that would form 
secondary structures such as Arg
56
 (Figure 104). These cleavages and loss of residues could 
result in the loss of secondary structure, which could cause problems with receptor binding. 
The location of Arg
56
 is in the α-helix C-terminal region equivalent to the insulin A-chain, 
so its loss would cause the α-helix to be destroyed. Nicks in the peptide backbone could be 
repaired, such as between Arg
50
 and Ser
51
, by a condensation reaction using trypsin in an 
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organic solvent
92
. The ability of this method to retain/regenerate secondary structure is 
unknown. 
The C-peptide is cleaved from proinsulin whilst it is in hexameric form
24
. The C-
peptide is located on the outside of the spherical proinsulin hexamer, and is readily available 
to be cleaved by proteases. Due to the similarity between proinsulin and IGF, this could be 
repeated protecting the A- and B-chain equivalent regions from cleavage, allowing the 
removal of the C-peptide. However the ability of IGF to form a hexamer is doubted
188
. 
Following creation of the insulin-like IGF core there are various fragments present 
in the reaction mixture that need to be removed from the IGF. Following the creation of 
semi-synthetic insulin analogues as described by Zakova et al.
92
 the analogues are purified 
by RP-HPLC, a method which can be used here. Similarly gel filtration could also purify 
the IGF core. 
The method of producing semi-synthetic insulin analogues as described by Zakova 
et al.
92
 uses trypsin to remove the C-terminal octapeptide from the B-chain of the insulin. 
Changing the buffer to an organic solvent allows trypsin to attach a synthetic peptide to the 
C-terminus. The IGF insulin-like core was left in an equivalent state to insulin following 
cleavage using trypsin. The availability of IGF and trypsin, and the simplicity of the method 
used means that the IGF insulin-like core can be produced in large enough amounts to allow 
many custom peptides to be added to the B-chain C-terminus. This permits the investigation 
into the relationship between insulin binding
75
 and IGF binding, and the cross signalling 
relationship between them. 
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Appendix 3. Drosophila melanogaster Insulin-Like Peptide 5 and 
Insect Insulin Binding Protein 
A.3.1. Summary 
 
The genome of D. melanogaster contains seven insulin-like genes, dilp1-7, that are 
expressed in a highly tissue- and stage-specific pattern
189
. The gene dilp5 has 27.8 % 
identity to the human insulin gene
189
. 
Drosophila melanogaster insulin-like peptide 5 (DILP5) has a fold similar to other 
proteins in the larger insulin family such as human insulin, human relaxin and bombyxin II 
from Bombyx mori
190
. There is a greater degree of flexibility, and therefore disorder, in the 
C-terminus of the B-chain in DILP5 compared to insulin (Figure 105-A). The β-turn seen in 
insulin is in an extended conformation in DILP5 (B
20
-B
23
), which causes the C-terminus to 
be orientated differently from insulin (Figure 105-B). The B-chain N-terminus in DILP5 
exhibits a fold similar to that seen in the T-state of insulin. The A-chain of DILP5 is a close 
mimic of insulin
190
. 
 
Figure 105. A structural comparison of insulin and DILP5. 
Human insulin is shown in red (pdb used: 1mso), whilst DILP5 is in green (pdb used: 
2wfv). 
 
DILP5 is able to form dimers along a crystallographic 2-fold axis, similar to insulin. 
The dimerisation differs between the two. Insulin dimerises along the anti-parallel β-sheet at 
the B-chain C-terminus, whereas in DILP5 this occurs between the anti-parallel β-sheet 
present at the N-terminus of the B-chain
190
. 
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DILP5 is able to bind to insect insulin-binding proteins (IMPL-2) (Figure 106). It 
has been proposed that in vertebrates IMPLs are required for metabolism and growth 
control
191
. The binding of DILP5 to IMPL-2 from the fall armyworm S. frugiperda has been 
proven through assays and chemical cross-linking experiments, showing specific 
binding
190,191
. 
 
Figure 106. Structure of IMPL-2. 
The monomeric form of the IMPL-2 from unpublished data. 
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A.3.2. Crystallisation, Structure Determination and 
Refinement 
 
The DILP5:IMPL-2 complex was buffered in 20 mM HEPES pH 7.5 to a concentration 
of 9.3 mg/ml. The best crystal identified from the screening was obtained from drops 
equilibrated 1:1 (protein:well) in well solution consisting of 0.2M MgCl2, 8% PEG20k, 8% 
PEG550MME and 0.1M NaAc pH 4.5 (0.1 ml well volume), and grown at 4°C following 
equilibration at 21°C. The crystal was flash-cooled in liquid nitrogen using paraffin oil as 
cryoprotection. The X-ray data were collected at Diamond at station i24, and processed 
using XDS
185
. The crystal structure of DILP5:IMPL-2 complex was solved by molecular 
replacement using default settings in Molrep
143
. The search model consisted of DILP5 
2wfv.pdb
190
  and an unpublished structure for IMPL-2. Subsequent manual model building 
and refinement with Coot
138
 and 10 cycles of REFMAC5
145
, resulted in a final model which 
was validated by MolProbity
146
. Data collection, reduction and refinement statistics are 
detailed Table 21. 
. 
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Table 21. Data collection, reduction and refinement statistics for the DILP5:IMPL-2 
complex. 
 DILP5 + IMPL-2 
PDB code  
Data collection Beamline Diamond i24 
Wavelength (Å) 0.9150 
Space group P41212 
Cell dimensions  
    a, b, c (Å) 150.8 150.8 125.3 
 ()  90.0 90.0 90.0 
Resolution (Å) 20.00-3.50 
Rsym 0.162 (1.235) 
I / I 8.2 (1.4) 
Completeness (%) 99.5 (99.8) 
Redundancy 4.3 (4.4) 
Refinement  
Resolution (Å) 29.60-3.48 
No. reflections 17857 
Rwork / Rfree 0.273/0.315 
No. atoms 7387 
    Protein 7387 
    Ligand/ion - 
    Water - 
B-factors  
    Protein 60.321 
    Ligand/ion - 
    Water - 
R.m.s. deviations  
    Bond lengths (Å) 0.011 
    Bond angles () 1.754 
Ramachandran statistics 
(%) 
 
Preferred/Allowed/Outliers 86.4/6.6/7.0 
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A.3.3. Results and Discussion 
 
The DILP5:IMPL-2 complex was obtained  from our collaborators, where DILP5 and 
IMPL-2 were expressed separately and were purified to a high level prior to the formation 
of the complex. Prior to crystallisation the purity of the complex was ascertained (Figure 
107-A), with there being multiple bands present that equate to IMPL-2. 
 
Figure 107. Physical characterisation of the DILP5:IMPL-2 complex. 
(A) A 20% non-reduced SDS-PAGE of samples of DILP5 and DILP5:IMPL-2 complex. 
Lane 1: Broad range molecular weight marker. Lane 2: DILP5. Lane 3: DILP5 and IMPL-2. 
(B) A 20% native PAGE of sample of DILP5 and DILP5:IMPL-2 complex. Lane 1: DILP5. 
Lane 2: DILP5 and IMPL-2. 
 
The molecular weight of IMPL-2 is ~23 kDa, with a band approximately twice this 
size present, which indicates due to the non-reducing gel that some disulphide bonds are 
being formed intermolecularly rather than intramolecularly. This could result in there being 
multiple species present in the complex. The DILP5 sample has a band that has entered the 
gel and another that has just entered the gel (Figure 107-B). This band could indicate a high 
oligomeric state present in the sample. The native gel of the DILP5:IMPL-2 complex 
indicates one dominant species present, though this is contaminated with a secondary band 
above the main band. Tertiary bands are present on the gel at lower intensities. Due to the 
apparent formation of the complex and its prominence in solution, crystallography trials 
were undertaken. 
The complex crystallised in P41212 and diffracted to 3.5 Å with four molecules of 
the DILP5:IMPL-2 complex in the asymmetric unit (Figure 108). This complex shows a 
screwed 2-fold rotation axis around the central point in the unit cell. The DILP5 binds to the 
IMPL-2 in a groove formed by a series of β-sheets (Figure 109). 
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Figure 108. The complex of DILP5 and IMPL-2 
IMPL-2 is coloured green, DILP5 A-chains are red and DILP5 B-chains are blue. 
 
Figure 109. A view of the binding groove in IMPL-2 cause by the binding of 
DILP5. 
IMPL-2 is coloured green, DILP5 A-chain is red and DILP5 B-chain in blue. 
 
The low resolution of the structure causes many of the side chains to lack density 
entirely, or only having density available for Cγ. The result of this is that the interactions 
between DILP5 and IMPL-2 in the groove are missing. The distances between the main 
chain atoms of the B-chain in DILP5 and  IMPL-2 range between 7.5 and 9.1 Å (Figure 
  
190 
 
110). This is a size that could accommodate side chains easily and form hydrogen bonds. 
There is one weak hydrogen bond, 3.8 Å, present in the interface between DILP5 and 
IMPL-2, located between Val
237
 in IBP and Cys
A14
 in DILP5. These residues are located 
away from the 7.5 Å gap in the binding groove. This indicates that an increased resolution 
should lead to future elucidation of interactions further along the groove. 
 
Figure 110. The space available in the binding groove between IMPL-2 and 
DILP5. 
IMPL-2 is coloured green, DILP5 A-chain is red and DILP5 B-chain in blue. The dashed 
lines indicate the main chain to main chain distance. 
 
Figure 111. The hydrogen bond in the binding groove between IMPL-2 and 
DILP5. 
IMPL-2 is coloured green, DILP5 A-chain is red and DILP5 B-chain in blue. The dashed 
line indicates a hydrogen bond. Carbon atoms in green, oxygen – red, nitrogen – blue, and 
sulphur – yellow. 
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A.3.4. Conclusion 
 
The binding of DILP5 to IMPL-2 has been implicated in the regulation of metabolism 
and growth in vertebrates
191
. This binding has been proven in various assays and cross-
linking experiments
190,191
, but the molecular basis of this interaction had not been 
determined. 
The structure of the complex shows that the binding of DILP5 to IMPL-2 occurs in the 
centre of a β-sheet. The binding causes a groove to be created, increasing the surface area in 
which stabilising interactions can be formed. There are residues present in both DILP5 and 
IMPL-2 that can form hydrogen bonds between either side chain or main chain atoms. 
Higher resolution crystallographic data would elucidate the location of these hydrogen 
bonds. 
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Abbreviations 
 
Å   Ångström 
A
6
  Position 6 in the A-chain 
BMGY   Buffered Glycerol-complex Medium 
BMMY   Buffered Methanol-complex Medium 
CR   Cysteine rich region of the insulin receptor 
CT peptide The 18 amino acid region at the C-terminus of the α-subunit of the 
insulin receptor 
dATP   Deoxy Adenosine Triphosphate 
dTTP   Deoxy Thymidine Triphosphate 
Da   Dalton, the mass of 1/12 of a carbon atom 
DLS   Dynamic light scattering 
DNA   Deoxyribonucleic acid 
DOI   Des-octa insulin 
DTI   Des-tetra insulin 
FnIII   Fibronectin type III region of the insulin receptor 
ID   Insert domain 
IGF  Insulin-Like Growth Factor 
IGFBP   Insulin-Like Growth Factor Binding Protein 
IGF-1R   Insulin-Like Growth Factor Type 1 Receptor 
IPTG   Isopropylthiogalactoside 
IR   Insulin receptor 
IR-A   Insulin receptor isoform A 
IR-B   Insulin receptor isoform B 
IRR  Insulin receptor-related receptor  
ITC   Isothermal Titration Calorimetry 
JM   Juxtamembrane region 
Kd   Dissociation constant 
LIC   Ligation Independent Cloning 
L1   Leucine region 1 of the insulin receptor 
L2   Leucine region 2 of the insulin receptor 
MALDI  Matrix-Assisted Laser Desorption/Ionisation 
mg   Milligrams 
ml   Millilitres 
mM   Millimolar 
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mRNA   Messenger RNA 
NEFA   Non-esterified fatty acid 
Ni-NTA  Nickel-nitriloacetic acid 
NMe   A methylation on the main chain nitrogen 
NMR  Nuclear magnetic resonance 
PCR   Polymerase chain reaction 
pET-YSBLIC  YSBL Ligation Independent Cloning vector 
pH  Concentration of H
+
 ions 
Phe
B1
  Phenylalanine in position 1 in the B-chain 
pI   Isoelectric point 
RNA   Ribonucleic acid  
R6   The R-state of hexameric insulin 
R1R1   A dimer of insulin consisting of one R-state insulin and one T-state 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TK   Tyrosine kinase 
UV   Ultraviolet 
WT   Wild type 
YPD   Yeast Extract Peptone Dextrose Medium 
YPDS   Yeast Extract Peptone Dextrose Medium with Sorbitol 
3C   Protease 
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Insulin is a key protein hormone that regulates blood glucose levels
and, thus, has widespread impact on lipid and protein metabolism.
Insulin action is manifested through binding of its monomeric form
to the Insulin Receptor (IR). At present, however, our knowledge
about the structural behavior of insulin is based upon inactive,
multimeric, and storage-like states. The active monomeric struc-
ture, when in complex with the receptor, must be different as
the residues crucial for the interactions are buried within the multi-
meric forms. Although the exact nature of the insulin’s induced-fit
is unknown, there is strong evidence that the C-terminal part of the
B-chain is a dynamic element in insulin activation and receptor
binding. Here, we present the design and analysis of highly active
(200–500%) insulin analogues that are truncated at residue 26 of
the B-chain (B26). They show a structural convergence in the form
of a new β-turn at B24-B26. We propose that the key element in in-
sulin’s transition, from an inactive to an active state, may be the
formation of the β-turn at B24-B26 associated with a trans to cis iso-
merisation at the B25-B26 peptide bond. Here, this turn is achieved
with N-methylated L-amino acids adjacent to the trans to cis switch
at the B25-B26 peptide bond or by the insertion of certain D-amino
acids at B26. The resultant conformational changes unmask
previously buried amino acids that are implicated in IR binding
and provide structural details for new approaches in rational
design of ligands effective in combating diabetes.
β-turn ∣ diabetes ∣ peptide bond isomerisation ∣ protein ∣ structure
The peptide hormone insulin regulates blood glucose levelswith a widespread impact on lipid and protein metabolism.
It is a molecule of major therapeutic importance in the treatment
of diabetes. The mature form of insulin is formed by two chains
“A” and “B” with a B chain running from PheB1-ThrB30 and an A
chain GlyA1-AsnA21, stabilized by two inter and one intra chain
disulphide bonds. Insulin’s metabolic actions are expressed
through binding as a monomer to the insulin receptor (IR).
The structure of insulin, which has been known for four decades
(1), has not provided insight into the mode of receptor binding
and hormone activation. This is because detailed three-dimen-
sional knowledge of insulin’s complex structural behavior is lim-
ited to its inactive storage (hexameric, dimeric) states (2–4). The
NMR structures of the monomeric form of insulin facilitated by
mutations (5), applications of organic co-solvents (6) or trunca-
tion of the B-chain (7) merely confirm the conformations known
from the inactive forms but also indicate intrinsic mobility of the
N- and C termini of the B-chain. It has also been found that the
N terminus of insulin can exist in so called T (extended) or R
(helical) conformations, however, their role for insulin activation
is still ambiguous (3, 4).
It is widely acknowledged that insulin must therefore undergo
induced-fit structural changes upon binding to the IR because
residues crucial for receptor interactions are hidden in the known
structures of the native hormone (8–11). Although the exact
nature of the changes that expose these residues to the receptor
surface is unknown, there is strong evidence that the C-terminal
part of the B-chain is a dynamic element in the transition that
leads to IR binding (10, 12, 13). The structure of the insulin-
IR complex is not known but extensive insulin sequence and
mutagenesis studies have identified the likely functional sites re-
sponsible for key interactions with the receptor (4, 14–18). The
main IR-binding site one consists of LeuB11, ValB12, LeuB15,
GlyB23, PheB24, PheB25, and TyrB26 on chain B and GlyA1, IleA2,
ValA3, GlnA5, TyrA19, and AsnA21 on chain A (19, 20). The shield-
ing of the A-chain residues in site one by the ∼B25-B30 residues of
B-chain C terminus in native insulin structures led to a widely
accepted induced-fit hypothesis for insulin-IR binding, requiring
this part of the B chain to be displaced (3, 4, 10).
As the lack of structural detail of the active form of insulin
bound to the receptor restrains the progress in combating dia-
betes, we have tried to characterise the structural signatures of
the active conformation of this hormone employing partial chem-
ical synthesis/modification of highly-active (i.e., 200–500%) insu-
lins, IR-binding studies and x-ray crystallography. Two types of
“semisynthetic” insulins were prepared: one in which the nitrogen
atom in the PheB25-XaaB26 peptide bond was methylated
(NMeB26), and others in which the chirality at the B26 Cα was
changed to the D-enantiomer. The nine insulin crystal structures
reported here provide persuasive structural evidence concerning
the nature of the induced-fit changes upon receptor binding.
Results
Highly active B26-Shortened/N-Methylated Insulins. Chemical
changes were systematically introduced in the insulin molecule
to achieve high-activity. Semisynthesis (21) of several unique
and some previously reported (22, 23) insulin analogues with
an N-methylated (NMe) PheB25-XaaB26 peptide bond or with
a D-enantiomer at position B26 yielded insulins with various bind-
ing activities (Table 1, Figs. S1–S3). These modifications indicate
a clear pattern that correlates with high binding activity of the hor-
mone: (i) shortening of its B-chain by deletion of residues B27-
B30, (ii) the use of a carboxyamide (CONH2) C terminus at posi-
tion B26, and (iii) a concurrent incorporation of NMeB26 (22),
D-amino acid (23) or D∕L-Pro at position B26. In contrast, an in-
crease of the bulkiness of the B26 amino acid in shortened analo-
gues (½NMePheB26-DTI-NH2 (22), ½NMeTyrB26-DTI-NH2) or
similar modifications in the full-length analogues [½NMeTyrB26-
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insulin and ½NMeAlaB26-insulin (22)] resulted in low ormoderate
(21–72%) binding activities (Table 1).
B-Chain of the Highly Active Insulins Possess a Unique β-Turn. The
apparent correlation between chemical composition and binding
activity within the present insulin analogues prompted their
crystallographic characterization (Tables S1–S4) in order to iden-
tify the underpinning structural features and to get further insight
into the structural origins of the active conformation of insulin.
The most active (465%) insulin presented in this study: NB26-
methylated and B26-truncated analogue ½NMeAlaB26-
DTI-NH2 (22), was crystallized as a monomer with a unique con-
formation at B24-B26. Its most striking feature is a type II β-turn
at PheB24-NMeAlaB26 referred to here as the B26 turn (Fig. 1,
Fig. S4A). This turn is associated with a cis conformation of
the PheB25-NMeAlaB26 peptide bond. The B24 CO group
forms a 2.8 Å hydrogen bond with NH2 of the terminal AlaB26
carboxyamide, in which the NH2 group mimics the peptide
NH of the iþ 3 (B27) amino acid.
The most important consequence of the B26 turn is the depar-
ture of the B-chain B22-B30 β-strand from its typical hexamer/
dimer like conformation (Fig. 1). The truncated B-chain C-termi-
nal segment now points away from IR site one making the latter
accessible for a direct interaction with the IR. Another structural
consequence of the B26 turn is a rotation of the PheB25 side chain
that now overhangs the A-chain part of site one (∼7.7 Å from
nearest IleA2) (Fig. 2, 4). In contrast, PheB24 remains in place.
These B-chain changes are complemented by large movements
of the A-chain, most notably the N-terminal helix is displaced
by ∼3 Å and rotated by ∼40°, whereas TyrA19 shifts 2.9 Å away
to form a hydrogen bond with GlnA5 extending the non-polar
receptor binding surface (Fig. 2). These “high-activity motifs”
of the insulin structure were confirmed by the crystal structure
of an another highly-active (214%) truncated analogue
(½NMeHisB26-DTI-NH2) (22, Fig. S5). These both highly-active
insulins possess B26 turns with identical geometries (e.g., the cor-
responding Cβ atoms of HisB26 and AlaB26 are only ca. 0.3 Å from
each other) and hydrogen bond networks.
D-ProB26 Mimics β-turn Resulting in High Activity. To explain the
structural role of D-amino acid chirality at position B26 in achiev-
ing highly active (359%) insulin analogue (Table 1), the crystal
structure of the truncated ½D-ProB26-DTI-NH2 analogue was de-
termined. The change of the chirality at the B26 Cα center in this
Table 1. Comparison of relative receptor binding affinity of some insulin analogues
B-chain position: 24 25 26 27 28 29 30 Affinity, %
Human insulin: F F Y T P K T 100
½NMeAlaB26-DTI-NH2† F F MeA − CONH2 — — — — 465 (22)
½D − ProB26-DTI-NH2† F F D − P − CONH2 — — — — 359‡
½NMeHisB26-DTI-NH2† F F MeH − CONH2 — — — — 214 (22)
½NMeAlaB26-insulin† F F MeA T P K T 21 (22)
½NMeTyrB26-insulin†§ F F MeY T P K T 21‡
[ProB26]-DTI†§ F F P − COOH — — — — 81‡
½ProB26-DTI-NH2 F F P − CONH2 — — — — 359‡
½NMePheB26-DTI-NH2 F F MeF − CONH2 — — — — 36 (22)
½NMeTyrB26-DTI-NH2 F F MeY − CONH2 — — — — 72‡
½D − AlaB26-DTI-NH2 F F D − A − CONH2 — — — — ∼400ð1252Þ¶
Relative receptor binding affinity is defined as (IC50 of human insulin/IC50 of analogue) ×100.
†Crystal structures presented in this report,
‡data presented in this study (the values of IC50s are given in legends for Figs. S1–S3). Changes in B-chain sequence, high activities, and
nonstandard chemical groups in bold;
§analogue for which both monomer and hexamer crystal structures have been determined, DTI: des-tetrapeptide; ½NMeXaaBn: methylation of
the peptide bond N-atom preceding Xaa Bn amino acid; -NH2: C-terminal carboxyamide.
¶Only one analogue: ½D-AlaB26-DTI-NH2, 1,252% from ref. 23, was reevaluated here as it showed IR affinity within the range of other analogues
semisynthesised and presented in this work.
Fig. 1. Structural features of the highly-active insulin analogues. (A) An overlay of the general fold of crystal structures of the highly-active and other insulins
reported here: Magenta: ½NMeAlaB26-DTI-NH2, Coral: ½NMeHisB26-DTI-NH2, green: ½D-ProB26-DTI-NH2, Blue: ½NMeAlaB26-insulin, Yellow: ½NMeTyrB26-insulin
(monomer structure), Red: wild type human insulin (32); the location of the B26 turn is marked by the Star inMagenta. (B) A close-up view of the B26 turn in the
most representative analogues. N, O atoms in Blue and Red, resp. [except for normal human insulin (32) that is in White], C atoms color code: Green —
½NMeAlaB26-DTI-NH2, Yellow — ½NMeAlaB26-insulin, Pink — ½NMeTyrB26-insulin, W — water molecule, hydrogen bonds (Dashed Lines) lengths in Å. *Me
(Red) — NMeB26, Blue * — indicates the three-dimensional convergence of N atoms from the B26CONH2 and B26NH peptide groups. (C) Superposition
(on B23-B25 Cα) of B26 turns in ½NMeAlaB26-DTI-NH2 and ½D-ProB26-DTI-NH2 showing a conformational convergence of peptide methylation (NMeB26) and
D-ProB26 chirality.
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analogue caused by the introduction of D-Pro generates a local
structure similar to that seen in the cis PheB25-XaaB26 N-methy-
lated peptide bond high-activity insulin analogues. The absence
of the cis-peptide bond in ½D-ProB26-DTI-NH2 is compensated by
the D-Pro in attaining a conformation similar to the B26 turn
(Fig. 1C, Fig. S5). Although the iþ 3 β-turn hydrogen bond is
not formed here (COi-NHiþ3 distance of ∼4.0 Å), the D-Pro
residue positions the B-chain C-terminal CONH2 moiety in a
manner similar to that, observed in insulins containing a B26
turn; the NH2-terminal group is only ∼1.1 Å from its hydro-
gen-bonded equivalents in two other highly-active analogues.
Hence, the conformations of the B-chain C-termini are
associated with a β-turn in all three highly-active insulins and
are correlated with their similar high affinity receptor binding.
As a very similar high activity (∼360%) was also observed with
the truncated L-Pro containing analogue with the carboxyamide
group at the B-chain C terminus (½L-ProB26-DTI-NH2, Table 1),
the shortened L-Pro analogues were also investigated by x-ray
crystallography. However, only the monomeric and hexameric
structures of C terminus-amide lacking truncated L-Pro homo-
logue (½L-ProB26-DTI, 81% affinity) could be crystallized and
determined. They show that the B20-B26 segments are severely
disordered in both crystals forms.
Full-length Insulin Analogues Can Adopt B26 Turn. The capacity of
full-length insulin to adopt the B26 turn was investigated further
in the crystal structures of monomers of the full-length analogues:
½NMeTyrB26-insulin and ½NMeAlaB26-insulin (22). These
variants also possess the B26 turn and all other general structural
features characteristic for the most active truncated insulin
molecules including the exposure of site one (Fig. 1A and B,
Fig. 2, Fig. S4B). The B26 β-turn is stabilized in these analogues
by a typical iþ 3 β-turn hydrogen bond between PheB24 and
ThrB27 (COB24-NHB27 distances of ∼2.9–3.3 Å). As expected,
the ThrB27 peptide bond NH groups of the full-length analogues
are spatially equivalent to CONH2 terminus NH2 group of the
truncated insulins. The Cαi-Cαiþ3 distances of ∼6 Å are well
within the ∼7 Å limit typical for a type II β-turn. The section
of the C-terminal segment that is well defined, ThrB27-ProB28
(LysB29-ThrB30 is disordered) follows the direction enforced by
the B26 turn (identical to its conformation found in truncated
insulins), and departs further from site one (Fig. 1A and B, Fig. 2)
that is, thus, fully revealed. The B26 β-turn is further stabilized
here by additional hydrogen bonds between PheB24 CO with the
side-chain OH of ThrB27 and water molecules. As the crystalliza-
tion experiments were carried out in parallel in the monomer-
and hexamer-like conditions (pH 3.0 and pH 7.5–8.2 respectively)
(Fig. S6), the hexamer crystals of the full-length ½NMeTyrB26-
insulin have also been obtained. Despite the presence of NMe
group at position B26, this insulin analogue is still capable of
forming a typical hexamer, in which the dimer interface adapts
to the NMe-induced disruption as described before (24). Inter-
estingly, crystallizations of the full-length ½NMeAlaB26-insulin,
even under typical hexamer conditions, always yield the monomer
crystal form. It has to be noted that some crystal structures of
analogues described here are unique crystallographic descrip-
tions of the full-length monomeric form of insulin.
New Pseudo β-Turn Conformation of B-Chain N Terminus. All mono-
mers of the highly-active insulin analogues reported here also
show a structural convergence of their N termini that adopts a
unique conformation not previously seen. Here, the main chain
of B-chain N terminus follows the direction typical for the T-state
till the Cα atom of the PheB5 at which it deviates from the T-fold
forming, instead, a pseudo type II β-turn (Fig. 3). The turn is sta-
bilized by the iþ 3 hydrogen bond (3.0 Å) between main chain
NH of the HisB5 (iþ 3) and the side chain of the AsnB3 that mi-
mics the i- main chain CO group. This turn is stabilized further by
an additional side chain AsnB3- side chain (Nδ2) HisB5 hydrogen
bond (3.0 Å). The Nδ1 atom of the HisB5 is also close to the main
chain CO of the ThrA8 (∼3.3 Å) reflecting the importance of B5
side chain in this unique formation. Only the main chain hydro-
gen bond: NHB6-COA6 (2.8 Å) remains here from the network
of B-chain—A-chain interactions that contribute to the stabiliza-
tion of a typical T-state B chain N terminus.
Discussion
Structural Signatures of the Activated/Active Form of Insulin. The
conservation and three-dimensional convergence of specific
structural features that lead to the exposure of buried, biologi-
cally active residues in chemically modified, highly-active insulin
analogues discussed here suggest key structural traits that may be
present in insulin’s active conformation on the receptor or during
its activation process. Although the evidence for the conforma-
tional motifs of the activated/active insulin conformation is
indirect, the convergence of the structural signatures of highly-
active hormone analogues observed here is to our mind quite
persuasive.
Fig. 2. Main structural changes occurring in insulin during a transition from
ground-state to a proposed activated/active form based on the structures of
some highly-active analogues; Yellow — human insulin (32); Green —
½NMeTyrB26-insulin (isomorphous with the highly-active truncated
½NMeAlaB26-DTI-NH2 but with the almost full B-chain structural definition),
Magenta Star — PheB24 side-chain structural pivot, Red Star — PheB25 main
chain structural pivot, Black Star — IleA2 Cα main chain pivot, Green Star —
TyrA19 shift and formation of a hydrogen bond (Dashed Lines) with GlnA5,
Blue Star — rotation of the A1 helix (in degrees), Cyan Star — translational
move of the A1 helix (in Å).
Fig. 3. Unique conformation of B-chain N terminus in the highly-active in-
sulin analogues. One representative pseudo β-turn from the ½NMeAlaB26-DTI-
NH2 analogue is given in Green (only for the B2-B5 residues all atoms are
given; Cαs trace for the B6-B19 region, hydrogen bonds in Dash Lines,
distances in Å). Cα trace of the B1-B19 region typical for the T-state form
of insulin (1 mso.pdb) in Yellow; the same region representative for the
R-state of the hormone — derived from the hexamer form of the
½L-ProB26-DTI) — in Magenta.
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It can be envisaged that the most striking element of the acti-
vated/active form of insulin is the formation of B26 turn asso-
ciated with trans-to-cis isomerisation of the PheB25-TyrB26
peptide bond. The PheB24ðCOÞ-ThrB27ðNHÞ hydrogen bond—
crucial for the stabilization of B26 turn—is probably also critical
to the productive receptor binding in wild-type insulin because
the inhibition of its formation by selective reduction of the B24
CO group to ψðCH2-NHÞ in the native hormone molecule
abolishes its activity (25). The B26 turn conformation at B26 is
found in all three truncated, highly-active insulins described here.
Although the structure of the highly-active ½L-ProB26-DTI-NH2
insulin is not known the loss of potency in carboxyamide-lacking
½L-ProB26-DTI correlates well with a loss of B26 turn. Further-
more, the NMR structures of another very potent
½D-AlaB26-DTI-NH2 insulin (23) (reevaluated here) indicated
mobility of the B26 region. It is to be expected that there is
conformational freedom in this structural element and that the
formation of B26 turn can be readily achieved.
Therefore, we propose that these structural changes (forma-
tion of B26 turn and trans-cis isomerisation of the
PheB25-TyrB26 peptide bond) follow the detachment of the
TyrB26-ThrB30 segment from the insulin molecule during, or
on, binding to the receptor. These observations are consistent
with the induced-fit theory of insulin-IR binding and with
trans/cis peptide bond isomerisation analyses (26–29). The pro-
tein environment supplied by IR is important in the unmasking
and stabilisation of the active surfaces of insulin. We suggest that
the analogues with higher affinity described here have an active
surface more representative of the conformation of insulin bound
to the receptor than do the structures of the storage forms of the
native hormone. The scale and nature of the structural
rearrangements leading to highly active analogues underlines a
“chaperone-like” role of the IR in insulin activation (30), espe-
cially if trans-cis peptide isomerisation is one of the key steps.
The restructuring of the B-chain and the concerted changes to
the N-terminal helix of the A-chain reveal a large hydrophobic
area made up of GlyA1, IleA2, ValA3, and TyrA19 priming them
for direct interactions with the IR (Fig. 2, 4). The importance
of IleA2 to receptor binding is indicated by its complete exposure
on the IR-binding surface and by the striking spatial invariance of
its Cα atom in these transformations. The structural conservation
of the A2 Cα suggests its role as the A-chain main chain pivot in
insulin activation. The shift of TyrA19 into hydrogen bond contact
with GlnA5 further stabilises the A-chain IR-binding surface with
the edge of the TyrA19 ring transforming the GlyA1-IleA2-ValA3
hydrophobic surface into a three-rim (TyrA19, GlyA1-IleA2, and
ValA3) evenly spaced “epitope” (Fig. 4).
The key structural roles of PheB24 and PheB25 in insulin activ-
ity, well known from several studies (4, 15), are firmly confirmed
by structures of the highly-active insulins described here. The aro-
matic ring of PheB24 is spatially invariant in native hormone and
all other insulin analogues. This is in contrast to the ∼90° rotation
of PheB25 side chain that subsequently overhangs (by ∼7 Å) the
A-chain part of site one (TyrA19-GlyA1-IleA2-ValA3) “epitope” in
the highly active insulins. However, in spite of its considerable
side-chain movement the position of the PheB25 Cα atom is well
conserved in different forms of insulin, confirming further the
role of PheB24 in stereo-specific detachment of the B-chain
β-strand (10). Therefore, it may be suggested that the PheB24
is a B-chain side-chain pivot during insulin activation (Fig. 2).
PheB24 is structurally invariant side chain that, being anchored
into the hydrophobic cavity lined up by LeuB15, ValB12, TyrB16
(its side chain collapses on this cavity in the activation process
sealing it off) and CysB19, provides structural stability during re-
arrangement of the C-terminal segment of the B-chain. PheB25
complements the role of PheB24 in this process acting as the
B-chain main chain pivot with the B25 Cα as the first B-main
chain turning point in formation of the B26 turn and, subse-
quently, initiation of IR binding (Fig. S7).
In addition to the structural convergence of the B24-B26 region
in the highly active insulin analogues the consistent similarity of
the unique B3-B5 pseudo β-turn of B-chain N termini observed
there should be also noted. This turn locates the N terminus con-
formation in-between the T- and R-forms. However, the physio-
logical relevance of this unique state of the hormone (e.g., as a
snapshot of the T-R transition or as its more stable high-activity
related form) is unclear and requires further studies.
Lower Activity Insulin Analogues Fit the B26 Turn-Related Activation
Model. Interestingly, some of the B26-truncated analogues:
½NMeTyrB26-DTI-NH2 and ½NMePheB26-DTI-NH2 (22), show
lower activities, 72% and 36% respectively (Table 1). At present,
there is no straightforward structural explanation for this behav-
ior. In the native, full-length insulin the replacement of TyrB26 to
Ala (without any N-methylation) results in a lowering of its
activity to ∼36% (14). However, the presence of a more bulky
aromatic side chains (PheB26∕TyrB26) in the B26-truncated (and
N-methylated) analogues may result, for example, in a detrimen-
tal, entropic effect leading to the destabilization of the short B26
turn. It is interesting that these analogues have not crystallized,
suggesting an increased flexibility that has also been observed by
NMR for a related truncated insulin analogue (31).
The crystal structures of the full-length analogues result in
intriguing observations. Firstly, only the monomer structures of
½NMeAlaB26-insulin have been obtained under both “monomer”
and “hexamer” crystallization conditions whilst both monomer
and hexamer crystals of ½NMeTyrB26-insulin were grown in
the relevant monomer and hexamer crystallization environments.
This indicates that the monomer conformation is preferentially
stabilized by Ala in the B26 position, consistent with the high
Fig. 4. Molecular shape of a putative active form of insulin based on the electrostatic surface of the ½NMeTyrB26-insulin analogue as the representative of B26
turn-containing insulins. (A) A “side” view showing the formation of the hydrophobic IR-binding hand-like insulin shape composed of site one residues (Red
Numbering), and lined by LeuB11, LeuB15; labels for some residues of site two are inMagenta. (B) As (A) but with B25-B30 chain of the wild type human insulin
modeled in (32) (Yellow Surface, Blue-Italic Numbering) showing the obstruction of site one prior to the formation of the B26 turn. (C-D) “Top” views of insulin
surfaces equivalent to the (A and B) representations after 90° rotation.
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potency of the B26 truncated insulin. The reduced potencies
of ½NMeTyrB26-insulin and ½NMeAlaB26-insulin analogues
(∼21%, Table 1) confirm the trend that the full-length analogues
are generally less active than their truncated homologues (4) and
suggest that this may result from several disadvantageous steric
and entropic factors originating in the B27-B30 region. For exam-
ple, (i) the B27-B30 segment may require a significant contribution
from the IR to be induced to a fully active conformer of insulin,
(ii) the structural constrain of the B26 turn may not impose the
optimal conformation for the B27-B30 residues, and (iii) the B26
turn may not represent the final and the most optimum active
insulin conformation (Fig. S7).
Molecular Shape of Active Insulin. The structure-function relation-
ships of the highly-active insulin analogues described here not
only give an insight into detailed definition of the putative local
structural signatures of an active form of insulin, but shed also
light on the possible molecular shape of the hormone’s active
conformer. In the process of insulin activation the PheB25 and
the B26 turn form a hydrophobic knob that together with the
A-chain “epitope” defines a unique, highly hydrophobic IR-bind-
ing cleft, lined by LeuB15, LeuB11, and ValB12 side chains [Fig. 4; it
should be mentioned that the normal insulin B25-B30 substructure
modeled in Fig. 4B is actually in more intimate contacts with
other A- and B-chain residues in the ground-state insulin mole-
cule due to a different relative orientation of these chains in
highly-active insulin analogues and its ground form (Fig. 2)].
The shape of this cleft is reminiscent of a macromolecular hand
that ensures the grip on the receptor by a hydrophobic thumb
(PheB25 and B26 turn), a hydrophobic palm (LeuB15∕LeuB11∕
ValB12), and hydrophobic fingers (TyrA19, GlyA1-IleA2,
and ValA3).
The molecular features of several highly-active, and related,
insulin analogues discussed here provide unique structural
elements for the conformational landscape of the hormone. They
give considerable insight into the activation of human insulin and
should help in development of unique types of hormone ana-
logues for the treatment of diabetes mellitus.
Material and Methods
Semisynthesis of Insulin Analogues and Binding Assays. In general, solid-phase
synthesis of peptides, enzymatic semisynthesis of analogues, purification of
analogues, preparation of rat adipose membranes, and binding assays were
performed as described previously (21, 22) (SI Text).
Crystallization, Structure Determination, and Refinement. Crystallization con-
ditions (Table S1) were found initially by an in-house developed screen based
on the available insulin crystallization protocols and they were refined indi-
vidually by the hanging drop method. X-ray data (Tables S2–S4) were pro-
cessed by HKL2000 (33) and all computational crystallography was
performed by the CCP4 suite of programs (34). Structures were determined
by molecular replacement with differently truncated 1mso.pdb-derived
monomeric insulins as the model (32). Crystallization details, x-ray data, re-
finement statistics, and model building protocols are provided in SI Text.
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Non-equivalent Role of Inter- and Intramolecular Hydrogen
Bonds in the Insulin Dimer Interface*□S
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Apart from its role in insulin receptor (IR) activation, the C
terminus of the B-chain of insulin is also responsible for the
formation of insulin dimers. The dimerization of insulin plays
an important role in the endogenous delivery of the hormone
and in the administration of insulin to patients. Here, we inves-
tigated insulin analogues with selective N-methylations of pep-
tide bond amides at positions B24, B25, or B26 to delineate their
structural and functional contribution to the dimer interface.
AllN-methylated analogues showed impaired binding affinities
to IR, which suggests a direct IR-interacting role for the respec-
tive amide hydrogens. The dimerization capabilities of ana-
logueswere investigated by isothermalmicrocalorimetry. Selec-
tive N-methylations of B24, B25, or B26 amides resulted in
reduced dimerization abilities compared with native insulin
(Kd  8.8 M). Interestingly, although the N-methylation in
[NMeTyrB26]-insulin or [NMePheB24]-insulin resulted in Kd
values of 142 and 587M, respectively, the [NMePheB25]-insu-
lin did not form dimers even at high concentrations. This effect
may be attributed to the loss of intramolecular hydrogen bond-
ing between NHB25 and COA19, which connects the B-chain
-strand to the core of the molecule. The release of the B-chain
-strand from this hydrogen bond lock may result in its higher
mobility, thereby shifting solution equilibrium toward the
monomeric state of the hormone. The study was complemented
by analyses of two novel analogue crystal structures. All exam-
ined analogues crystallized only in the most stable R6 form of
insulin oligomers (even if the dimer interface was totally dis-
rupted), confirming the role of R6-specific intra/intermolecular
interactions for hexamer stability.
Insulin is an important polypeptide hormone that controls a
wide range of cellular processes such as the regulation of blood
glucose uptake and has a large impact on protein and lipid
metabolism. However, despite decades of intensive research,
many questions about the structure of insulin and its mecha-
nism of action remain. The solid state-based structural insight
into the insulin molecule is limited to inactive dimeric or hexa-
meric storage forms (1–3), whereas the insulin monomer rep-
resents the active form of the hormone when binding to the
insulin receptor (IR).3 It is also widely accepted that insulin
undergoes a profound structural change during this process
(4–6), a hypothesis supported by a plethora of highly dynamic
hormone conformers identified by NMR studies (7–13).
Attempts to determine the structure of the insulin-IR complex
have been unsuccessful so far. However, the regions of the insu-
lin molecule responsible for the interaction with the IR (3, 14)
or for its dimerization and hexamerization (15, 16) have been
functionally and structurally identified in a number of insulin
analogues.
The insulin molecule consists of two peptide chains, a 21-
amino acid A-chain and a 30-amino acid B-chain, intercon-
nected by two interchain and one intrachain disulfide bridges.
The C terminus of the B-chain of insulin, particularly residues
B24–B26, plays a substantial role in the initial contact with the
receptor. It is believed that the C terminus of the B-chain of
insulinmust be detached away from the central B-chain-helix
of insulin (2, 6). One of the main signatures of this so-called
“active form” of insulin should be the exposure of the previously
hidden amino acids Gly-A1, Ile-A2, and Val-A3, which are
important for the interaction with IR (3). Recently, we
described crystal structures of several shortened and full-length
insulin analogues with modifications at the B26 position (17).
The structural convergence of some of these highly active ana-
logues (200–400%) enabled us to postulate that the active form
of human insulin is characterized by a formation of a new type
II -turn at positions B24–B26.
Besides its role in IR activation and IR negative cooperativity
(18, 19), theC terminus of the B-chain is also responsible for the
formation and stabilization of the insulin dimers that are the
building blocks of storage hexamers. In addition, the dimeriza-
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Czech Republic Grant LC060777 (Research Centre for Chemical Genetics,
to J. J.), Research Project of the Academy of Sciences of the Czech Republic
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tion Facility (Grenoble, France).
The atomic coordinates and structure factors (codes 3ZQR and 3ZS2) have been
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Bioinformatics, Rutgers University, NewBrunswick, NJ (http://www.rcsb.org/).
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420220183571; E-mail: jiracek@uochb.cas.cz.
3 The abbreviations used are: IR, insulin receptor; DOI, des(B23–B30)-
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tion of insulin plays an important role in the endogenous deliv-
ery of the hormone from the pancreas to the circulatory system
and in the administration of insulin to diabetic patients (3,
20–22). The structures of insulin dimers and hexamers have
been determined from several crystal structures (e.g. Refs. 15,
23, 24). They revealed that the key interactions between insulin
molecules I and II of the dimer are complementary and involve
reciprocal hydrogen bonds between the carbonyl oxygen of
Tyr-B26 (Phe-B24) of one molecule and the amide hydrogen
of Phe-B24 (Tyr-B26) of the complementary second molecule
of the dimer. Hence, antiparallel -strands of the C termini of
B-chains are connected by four hydrogen bonds. It has also
been found that the amide hydrogen of Phe-B25 of molecule II
forms an intramolecular hydrogen bond with the carbonyl of
Tyr-A19. The side chains of Phe-B24, Tyr-B26, Tyr-B16, and
Pro-B28 reinforce further the stabilization of the dimer by a
network of Van der Waals contacts (15).
Our previous studies on the structural and functional rele-
vance of the B26 (17, 25, 26) and B25 (27) positions of insulin
focused onmodulation of hormone conformation by the incor-
poration of an N-methyl group on the amide nitrogen of the
peptide bond in shortened and full-length insulin analogues.
Subsequently, we investigated the selective application of this
N-methylation within the B24–B26 region of insulin by the
systematic elimination of the inter/intramolecular hydrogen
bonds, which are important for the stability and folding of the
insulin monomer, dimer formation, and interaction with IR.
Therefore, the approach reported here represents an applica-
tion of a very specific, chemically controlled molecular tool for
the functional assessment of the hydrogen bond network
related to the dimer interface.
Here, we present the synthesis and characterization of sev-
eral novel full-length insulin analogues with the selective
N-methylation of the peptide bond at position B24, B25, or B26
to delineate the role of each of these particular peptide units in
insulin dimer/hexamer assembly. In this process, we correlate
the binding affinities of the analogues to IR (determined in rat
adipose membranes) using isothermal titration microcalorim-
etry (ITC) dilution experiments, performed to assess the ther-
modynamic contributions toward hormone dissociation. The
wild-type insulin (capable of dimer formation) and des(B23-
B30)octapeptide insulin (DOI, not able to dimerize (28, 29))
were used as references for the dimeric and monomeric forms,
respectively. This study is also complemented by the analysis of
two novel crystal structures and two previously published ana-
logue crystal structures that have not been hitherto discussed in
the context presented here. This approach allowed us to shed
light on the contributions of individual peptide bond amides to
the dimerization and binding affinity of insulin.
MATERIALS ANDMETHODS
Materials—2-Chlorotrityl chloride resin, protected amino
acids, and reagents for solid phase synthesis of peptides were
purchased from Novabiochem Merck (Laufelfingen, Switzer-
land). Fmoc-Lys(phenylacetyl)-OH was prepared as described
previously (30). Tosyl phenylalanyl chloromethyl ketone-
treated trypsin was purchased from Sigma, and penicillin G
acylase was from Fluka. Human [125I]monoiodotyrosylA14-in-
sulin was purchased from PerkinElmer Life Sciences. Human
and porcine insulins were purchased from Sigma. All other
chemicals and solvents were obtained from Sigma-Aldrich.
Peptide Synthesis and Enzymatic Semisynthesis—The syn-
theses of peptides and the semisyntheses of analogueswere per-
formed according to Zakova et al. (30). The identity of peptides
and analogues was confirmed with a Fourier transform mass
spectrometer LTQ Orbitrap XL (Thermo Fisher).
Receptor Binding Studies—Receptor binding studies with
plasmamembranes prepared from epididymal adipose tissue of
adult male Wistar rats were performed according to Zakova et
al. (26).
Isothermal Titration Microcalorimetry—Human and por-
cine insulin (Sigma) were used without further purification.
DOI was prepared in our laboratory from porcine insulin by
tryptic cleavage (31). Purificationwas performed using reverse-
phase HPLC, and identification was confirmed with electros-
pray ionization mass spectrometry. The analogues were pre-
pared as described above.
Peptide solutions (1 mM) were prepared in 0.1 M glycine/
HCl buffer, pH 2.5 (total volume of 1 ml). Peptide solutions
were dialyzed in dialysis cassettes (Slide-A-Lyzer cut-off,
molecular weight 3,500, Pierce) against 600 ml of the buffer at
4 °C. The buffer was changed three times (after 3, 20, and 26 h).
Following dialysis, the concentrations of peptides were deter-
mined from UV absorbance at 280 nm (insulin,  5,840 M1
cm1; DOI,   4,560 M1 cm1). Concentrations were con-
firmed by amino acid analysis ( 10%). The final dialysis buffer
and peptide solutions were briefly degassed prior to ITC dilu-
tion titration.
Calorimetric experiments were performed using a VP-ITC
apparatus (MicroCal, Inc.) operated in dilution/dissociation
mode, with the reaction vessel (1.417 ml) held at 25 °C. The
instrument was temperature-equilibrated prior to the start of
injection. The sample contents were stirred at a speed of 307
rpm over the duration of the titration. A typical experiment
comprised of 20 injections of 12.5 l (first injection of 2 l) of
insulin solution into the reaction vessel, initially loaded with
dialysis buffer. The duration of each injection was 25 s, with a
time interval between injections of 300 s.
Integrated heat pulse datawere corrected for small injection/
mixing effects from controls that were performed separately
and analyzed under identical conditions by omitting the first
injection and using MicroCal LLC Origin software (version 7).
The software employed an updated and corrected (June 2008)
version of the dissociation analysis procedure andwas validated
by comparison with earlier analysis methods (32, 33). For
human insulin, the experimental values ( S.E.) were deter-
mined from eight parallel experiments. For porcine insulin,
DOI, and insulin analogues, the experimental values ( range)
were determined from two parallel experiments. The initial
concentrations in the injection syringe ranged from 0.208 to
1.220 mM (supplemental Table S1).
X-ray Studies—Crystallization of the analogues ([NMe-
PheB24]-insulin, [NMePheB25]-insulin, and [TyrB25,NMe-
PheB26,LysB28,ProB29]-insulin) were performed with the in-
house insulin crystallization screens covering most of the
reported crystal growth parameters of insulin. Crystallization
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conditions, data collection, and refinement andmodel statistics
are given in supplemental Table S2. X-ray data were processed
byHKL2000 (34), andmodel building and refinementwere per-
formed by the CCP4 suite of programs (35) and COOT (36).
Crystal structures were solved by Molrep (37) with B1–B6 and
B23–B30-truncated insulin hexamer or monomer as a model
(Protein Data Bank code 1MSO) (24) and refined by Refmac5.6
(38). All figures were made by CCP4mg (35). For structural
comparisons of the dimer interfaces, the best defined (i.e. with
the best electron density for typically very mobile Phe-B25 side
chain and B28–B30 amino acids) dimers (referred here as
chains AB and CD) from the relevant structures were superim-
posed on the B9–B19 and D9–D19 C atoms by the LSQKAB
program from the CCP4 suite. Both reported crystal structures
contain one full hexamer in the asymmetric unit. As the nature
of changes along the dimer interface observed here was virtu-
ally identical within each of the three dimers related by hex-
amer symmetry, only one dimer was selected for comparisons
as a fully representative structural entity.
RESULTS
Binding Affinities—Insulin analogues were prepared by tryp-
sin-catalyzed semisynthesis, and their binding affinities to the
insulin receptor in membranes from rat adipose tissue were
determined (Table 1 and Fig. 1). Four of these analogues are
novel molecules, with [PheB26]-insulin having been already
reported by Gauguin et al. (39). The crystal structure and bind-
ing affinity of [NMeTyrB26]-insulinwas recently reported by us
elsewhere (17). The first three analogues differ in the position of
N-methylation of the peptide bond amide at the B24, B25, or
B26 positions of human insulin. Additionally, two insulin ana-
logues were also produced in which Tyr at the B26 position was
replaced with either Phe or N-MePhe. The last analogue con-
tains twomutations, i.e. N-MePhe residue in both B25 and B26
positions.
All analogues showed diminished binding affinity compared
with human insulin. Themost drastic reduction in binding was
observed in the case of analoguesN-methylated at the B25 posi-
tion (1%). The N-methylation of the B24 amide also had a
highly negative effect on the binding affinity of the respective
analogue (3%). In contrast, the B26 position was much more
tolerant to the modifications, with [PheB26]-insulin displaying
only moderate reduction of the affinity (45.9%) (very similar to
its binding affinity (47.6%), determined using an IM-9 cells
binding assay (39)). N-Methylation of Tyr-B26 reduces the
binding affinity of the analogue to 20.7%, and the combination
of both N-methylation and the substitution of Phe for Tyr at
B26 results in a very weak binding of this insulin analogue
(4.2%).
ITCMeasurements—The key part of our study was devoted
to the investigation of the dimerization ability of insulin ana-
logues by ITC dilution measurements that detect heat
energy changes upon the dissociation of insulin dimers. The
dimerization properties of the analogues were set against
human/porcine insulin and DOI as benchmarks of regular and
non-dimerization hormone behavior. The results of titration
experiments are summarized in Table 2, and the complete data
from all titration experiments used for the calculation of kinetic
and thermodynamic parameters are shown in supplemental
Table S1. The dilution experiments with human or porcine
insulin yielded sequences of endothermic heat pulses charac-
teristic of molecular dissociation as described previously (32).
As the insulin concentration in the calorimeter cell increased
with successive injections, dissociation decreased, and themag-
nitude of the heat uptake diminished accordingly, giving heat
typical of dilution curves for human insulin, as shown in Fig. 2A.
The example of the dilution process giving no heat effect is
shown in Fig. 2B (dilution curve of [NMePheB25]-insulin).
Dilution curves for porcine insulin, DOI, [NMePheB24]-insu-
lin, [NMeTyrB26]-insulin, and [NMePheB26]-insulin are
TABLE 1
Values of IC50 and relative receptor binding affinities of human insulin
and insulin analogues
Peptide IC50 S.E.a Potencyb
nM (n) %
Human insulin 0.89 0.06 (3) 100c
NMePheB24-insulin 30.1 2.2 (3) 2.96c
NMePheB25-insulin 515 32 (3) 0.17c
NMeTyrB26-insulin 4.30 0.46 (3) 20.7d
PheB26-insulin 1.94 0.31 (3) 45.9c
NMePheB26-insulin 21.3 2.7 (3) 4.17c
NMePheB25,NMePheB26-insulin 201 39 (3) 0.44c
a IC50 values represent concentrations of insulin or the analogue that cause half-
maximal inhibition of binding of human 125ImonoiodotyrosylA14-insulin to
IR. Each value represents the mean S.E. of multiple determinations (n).
b Relative receptor binding affinity is defined as (IC50 of human insulin/IC50 of
analogue) 100.
c This study.
d From Ref. 17.
FIGURE 1. Inhibition of binding of human [125I]-insulin to adipose plasma
membranes by insulin and insulin analogues. A, human insulin (black cir-
cles), [NMePheB24]-insulin (blue triangles), and [NMePheB25]-insulin (red
squares). B, [PheB26]-insulin (black circles), [NMePheB26]-insulin (blue trian-
gles), and [NMePheB25,NMePheB26]-insulin (red squares). Quantitative infor-
mation is provided in Table 1. See “Materials and Methods” for details.
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shown in supplemental Fig. S2. The curves can be fit in terms of
amonomer-dimer equilibriummodel (Ins27 2Ins;	Hod;Kd
[Instot]2/[Ins2], where [Instot] represents the total free insulin
monomer concentration) yielding the apparent equilibrium
constant of insulin dissociation Kd and enthalpy of dissociation
	Hod (per mol of dimer). The values of the thermodynamic
parameters 	God and 	Sod were calculated from standard
expressions: 	God  RTlnKd and 	God  	Hod  T	Sod,
respectively.
The titration experiments with human insulin resulted in an
apparent dissociation constantKd of8.8M. This value is in a
very close agreement with Kd of9 M, which we determined
for porcine insulin (Table 2) and with the previous determina-
tions of the Kd under similar conditions (32). Human and por-
cine insulin represent molecules with native and full dimeriza-
tion potency. In contrast, the dilutions of DOI did not yield any
heat effect, indicating that this (B23–B30)-truncated insulin
analogue does not form dimers within the range of concentra-
tions tested here.
All investigated analogues showed considerably reduced
dimerization capabilities. The N-methylation of the B26 posi-
tion resulted in an analogue ([NMeTyrB26]-insulin) with Kd of
TABLE 2
ITC analyses of dimerization capabilities of insulin and insulin analogues
The experimental data were analyzed without first injection using LLC ITC Origin 7 software. The experimental values for human insulin are means of eight parallel
experiments S.E. (n 8). The experimental values for porcine insulin, DOI, and insulin analogues were determined from two parallel experiments and are provided as
means range (n 2) with the exception of DOI and NMePheB25-insulin, where no heat effect was observed. The ITC experiments were performed at injection syringe
concentrations of insulins ranging from 0.213 mM to 1.22 mM. The complete ITC data are shown in supplemental Table S1.
Insulin Kd Hod God Sod
M kJ/mol kJ/mol J/Kmol
Porcine insulin (n 2) 9.03 0.50 41.96 0.45 28.78 0.14 44.22 1.06
Human insulin (n 8) 8.81 1.05 56.93 2.56 28.95 0.28 93.90 8.15
DOI (n 2) No heat effect
NMePheB24-insulin (n 2) 587 99 10.82 0.46 18.47 0.42 25.68 2.97
NMePheB25-insulin (n 2) No heat effect
NMeTyrB26-insulin (n 2) 142 30 70.85 15.50 22.02 0.53 163.86 53.75
NMePheB26-insulin (n 2) 1240 10 37.84 8.34 16.58 0.02 71.34 28.07
FIGURE 2. Representative dilution ITC curves for human insulin (A) and [NMePheB25]-insulin (B).
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142 M, which was 
15-fold higher than the Kd of native
insulin. Moreover, the combination ofN-methylation and sub-
stitution of Phe for Tyr at the B26 position ([NMePheB26]-
insulin) suppresses the dimerization capacity even further to a
Kd of 1.24 mM. The N-methylation of B24 amide nitrogen
yielded the analogue ([NMePheB24]-insulin) with a low
dimerization capability (Kd of587M,which is 65-fold higher
than the Kd of native insulin). However, the most drastic effect
of the N-methylation on insulin dimerization was observed in
the case of the modification at the B25 position. The
[NMePheB25]-insulin analogue, similarly to DOI, gave no heat
effect and behaved solely as a monomer, even at millimolar
concentrations (Fig. 2B).
Structural Characterization of Analogues—The analogues
[NMePheB24]-insulin and [NMePheB25]-insulin were sub-
jected to intensive crystallization screening under a plethora of
monomeric, dimeric, and hexameric conditions. Only R6 hexa-
meric crystals of [NMePheB25]-insulin were obtained. The
monomeric and hexameric (R6) crystals of [NMeTyrB26]-insu-
lin and hexameric (R6) of [TyrB25,NMePheB26]-insulin, also
discussed in thiswork, were already reported by us (Refs. 17 and
27, respectively). However, their oligomeric organization was
not described there in detail, as these studies were focused on
the monomeric form of the hormone. In addition, the
[TyrB25,NMePheB26,LysB28,ProB29]-insulin analogue, not
investigated here by the ITC due to its Lys 7 Pro sequence
swap and, thus, likely monomeric properties, was also crystal-
lized in the hexameric (R6) form; we reported the synthesis and
binding affinity (4%) of this analogue elsewhere (30).
Crystal Structure of [NMePheB25]-Insulin—This analogue
yielded crystals only under hexameric conditions in the pres-
ence of Zn2 and phenol (see supplemental Table S2). The ana-
logue oligomer adopted a typical R6 conformationwith six phe-
nol ligands at the so-called type I site (located at the dimer
interface, with hydrogen bonds toCOA6 andNHA11, loose van
derWaals contacts (3.7 Å) with imidazole of His-B5 (40)) and
two Zn2 cations and twoCl anions as their axial ligands. The
overall structure of this hexamer followed general fold and
most of the structural details of a typical R6 hexamer such as
that of the insulin structure of Protein Data Bank code 1ZNJ.
In the [NMePheB25]-insulin R6 hexamer, theN-methylation
of the NHB25 did not result in significant disruption of the
dimer interface hydrogen bonds motifs (Fig. 3A). All four sym-
metrical B24–B26 hydrogen bonds were preserved there
despite a small weakening of the B24CO-NHD26 interaction by
0.2 Å. The conservation of these interactions is likely due to
an “outward” orientation of the NMeB25 groups, which point
out away from the dimer interface (Fig. 3A) and are thus easily
accommodated in the vicinity of the A19–A21 region. How-
ever, the introduction of twoNMeB25 groups resulted inmuch
greater mobility of the Phe-B25 side chains; only one B25 phe-
nyl moiety (with poor definition in the electron density maps)
could be located. Both C-terminal threonines B30 are not visi-
ble in the structure.
Crystal Structure of [NMeTyrB26]-Insulin Hexamer—Al-
though we already reported this structure elsewhere (17), the
nature of the dimer interface and its R6 hexamer structure was
not discussed in that report. Remarkably, it can be crystallized
both as a monomer and R6 hexamer under appropriate condi-
tions. The hexamer crystallization protocol, similar to condi-
tions for [NMePheB25]-insulin (see supplemental Table S2),
yielded crystals of the R6 oligomer very similar to that of
[NMePheB25]-insulin. However, the methylation of NHB26
resulted in a much more disturbed dimer interface than in the
[NMePheB25]-insulin structure. As both B26N-methyl groups
pointed into the dimer interface, its quartet of the hydrogen
bonds was almost lost; only one of them, COB26-NHD24,
remained in place (Fig. 3B). The disturbance created by
N-MeB26 groups had a non-symmetrical character. Only one
-strand of the two-strand dimer -sheet bulged out between
B24–B26 to accommodate the more bulky substitutions of the
NHB26hydrogen atoms; the otherD21–D27-strand followed
the typical fold of the wild-type insulin. However, it still exerted
FIGURE 3.Main chain representation of the dimer (chains AB inmolecule
I and chains CD inmolecule II) interface in [NMePheB25]-insulin (Protein
DataBank code3ZQR) (A), [NMeTyrB26]-insulin (ProteinDataBank code
2WS6) (B), [TyrB25,NMePheB26]-insulin (Protein Data Bank code 1W8P)
(C), and [TyrB25,NMePheB26,LysB28,ProB29]-insulin (Protein Data
Bank code 3ZS2) (D) analogues. The reference wild-type insulin (Protein
Data Bank code 1ZNJ) is in white with its dimer hydrogen bonds as black
dashed lines; hydrogen bonds of the analogues are colored magenta. The
methyl groups at N-methylated atoms are indicted by magenta asterisks;
hydrogen bond distances are in Å.
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some signs of induced structural stress, reflected in its higher
mobility, with B28–B30 residues being fully disordered. Inter-
estingly, the -strand bulge in the B-chain brought the B25NH
peptide unit closer to the COA19 group, resulting in the
unusual, for the R6 hexamer, B25NH-COA19 hydrogen (2.9 Å)
bond.
Crystal Structure of [TyrB25,NMePheB26]-Insulin—The
structure of our already reported (27) analogue with NHB26
N-methylation and the Tyr7 Phe B25–B26 swapwas also ana-
lyzed here in more detail. The main focus of the previous dis-
cussion of this structure was the impact of the IGF-like swap of
B25–B26 side chains, combined with simultaneous modifica-
tion of the main chain, on insulin and IGF-I structure-function
relationships. Here, we tried to extract the relevant structural
features in the context of the dimer interface. [TyrB25,
NMePheB26]-insulin formed an R6 hexamer that is quite sim-
ilar to [NMeTyrB26]-insulin and [NMePheB25]-insulin oligo-
mers. Although the bulging of the B24–B26 chain was “sym-
metrical” to that observed in the [NMeTyrB26]-insulin (Fig.
3C), its nature and structural meaning was practically identical
to the [NMeTyrB26]-insulin change, considering the 32 sym-
metry of the hexamer and the relativity of its chain
nomenclature.
Crystal Structure of [TyrB25,NMePheB26,LysB28,ProB29]-
Insulin—The crystal structure of [TyrB25,NMePheB26,LysB28,
ProB29]-insulin was obtained under hexameric conditions
(supplemental Table S2) in the pursuit of a very extensive char-
acterization of the dimer interface hydrogen bond network
of the B25–B26 side chains for the stability of this region.
The R6 hexamer was also very similar to all other R6 oligo-
mers described here. However, the B28–B29 Lys7 Pro and
B25–B26 Tyr7 Phe swaps, combined with N-MeB26, fully
disrupted the dimer interface, with none of its hydrogen
bonds being preserved (Fig. 3D). Hence, the remarkable sta-
bility of these R1R1 dimers depended entirely on the phenol-
induced and R-form specific inter- and intramolecular inter-
actions (see “Discussion”). The disruption of the dimer
interface was also very asymmetrical, in a fashion similar to
that observed in [NMeTyrB26]-insulin; one -strand fol-
lowed the wild-type conformation, whereas its counterpart
systematically departed from the dimer interface from D23
to become fully disordered from D27 onwards.
DISCUSSION
Impact of Modifications on Binding Affinity of Analogues—
Analogues N-methylated at the B24 position ([NMePheB24]-
insulin, 3%) or B25 ([NMePheB25]-insulin, 0.17%) showed
drastically reduced binding potency. To our knowledge,
[NMePheB24]-insulin represents the first insulin analogue
with a backbone modification at the B23–B24 peptide bond.
The low binding activity of [NMePheB25]-insulin is in agree-
ment with findings ofWollmer et al. (41) for an almost inactive
(3–4%) insulin analogue ([depsi(B24–B25)]-insulin) in which
the B24–B25 CO-NH peptide bond was replaced by a CO-O
ester bond. It seems that the very low binding affinity of
[NMePheB24]-insulin and [NMePheB25]-insulin results from
the lack of the respective peptide bond amides that may be
crucial for the direct interaction of insulinwith IR. These obser-
vations are also supported by findings of Nakagawa et al. (42)
concerning inactive insulin analogues in which peptide bonds
at the B24–B25 or B25–B26 positions were replaced by
reduced CH2-NH groups. They attributed the extremely low
activity of their analogues to the loss of respective carbonyl
oxygens involved in H-bonding with IR. Another possible rea-
son for the low binding affinity of [NMePheB24]-insulin and
[NMePheB25]-insulin, N-methylation-induced conforma-
tional changes in the structures of their B24–B30 strands, will
be discussed below.
Interestingly, the [NMeTyrB26]-insulin (17) also displayed
lower binding potency toward IR (21%, Table 1) than human
insulin, but significantly less reduced than that of analogues
N-methylated at the B24 and B25 positions (3 and 0.17%,
respectively). This may indicate that the NH of B26 is less
important for IR binding than its counterparts at the B24 and
B25 positions and/or has a different function. Our recent study
(17) demonstrated that N-methylation of Tyr-B26 induces a
new type II of -turn at positions B24–B26 (B26 turn), which
results in the departure of B-chain B22–B30 -strand from its
typical hexamer/dimer conformation. The B26 turn is stabi-
lized by a typical i3 -turn hydrogen bond between CO of
Phe-B24 and NH of Thr-B27. These large conformational
changes unmask previously buried amino acids Gly-A1, Ile-A2,
and Val-A3, which are implicated in IR binding. We proposed
(17) that similar conformational changes may occur in the
native insulinmolecule upon binding to IR. Hence, it is possible
that the reduced binding affinity of [NMeTyrB26]-insulin
(21%)may be caused by a non-optimal arrangement of residues
B27–B30. However, the reduced affinity of this analogue may
also result from the loss of NHB26 hydrogen bonding capabil-
ities, required in IR interactions, or by a combination of these
factors. The impact of some distinct (e.g. long range) N-meth-
ylation-induced conformational changes in the structures of
B24–B30 strands in [NMePheB24]-insulin and [NMePheB25]-
insulin cannot be excluded as well. However, their existence
still awaits structural proof as [NMePheB24]-insulin eluded all
crystallization trials so far, and [NMePheB25]-insulin has been
crystallized only in the formof a typical R6 hexamer (see below).
The last three analogues in Table 1 represent molecules with
single, double, or multiple modifications compared with native
human insulin, respectively. The [PheB26]-insulin analogue
was included in this study to examine the importance of the
Tyr-B26 hydroxyl group for insulin affinity, as the next ana-
logue studied here, [NMePheB26]-insulin, featured two com-
bined modifications: the loss of phenolic character of the B26
side chain with N-methylation of the B26NH. The [PheB26]-
insulin showed 46% binding affinity that was in full agreement
with data (47%) already reported for this analogue (39), clearly
indicating that the loss of Tyr-B26 hydroxyl group is responsi-
ble for the reduced binding affinity of this analogue. Therefore,
an even more drastic (actually to 4%) loss of affinity of the
[NMePheB26]-insulin was expected, as it results from a double
(side andmain chain) modification of the hormone at this posi-
tion. Subsequently, the practically total loss of affinity (0.44%)
of the [NMePheB25,NMePheB26]-insulin analogue is not sur-
prising, as it fosters the cumulative effect of three unfavorable
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modifications (two N-methylations and loss of a phenolic B26
side chain).
ITC Measurements and Dimerization Capabilities of Ana-
logues—ITC measurements of insulin dimer dissociation
require relatively high amounts of protein material. Their opti-
mum required concentration should be in the 0.2–1 mM range,
but concentrations closer to the high end yield more reliable
data (32). Hence, a typical ITC experiment in a 1.4-ml reaction
vessel requires 8 mg of insulin, which presents some experi-
mental challenges due to the relatively low yields of semisyn-
thetic reactions (30). Also, the recovery of analogues from reac-
tion mixtures after ITC experiments is not very efficient.
Therefore, we determined the dimerization capabilities of ana-
logues only at two replicates at different protein concentra-
tions. However, the complete ITC data presented in supple-
mental Table S1 indicate that duplicate measurements
performed here produced very consistent and reliable results.
As some reports (43, 44) have shown, pH has a rather small
effect on the outcomes of insulin-dimerization experiments;
thus, all ITCexperimentswere performedhere also at acidic pH
2.5 to avoid reduced insulin solubility at the physiological pH
(32). As expected, our ITC experiments with human and por-
cine insulin gave almost identical dissociation constants of
dimerization (Kd) of 9 M, and the changes in Gibbs free
energies of dissociation (	God) of29 kJ/mol (Table 2). These
results are close to the Kd and 	God of12 M and 28 kJ/mol,
respectively, measured by Lovatt et al. (32) for bovine insulin
under similar ITC conditions. Strazza et al. (43) used concen-
tration difference spectroscopy to determine the monomer-
dimer association constants of porcine insulin, finding only
minor differences in Kd at pH 2 (15 M) and at pH 7 (18 M).
Equilibrium sedimentation, an alternative assessment of insu-
lin dimerization, provided Kd of4.5 M for bovine insulin (at
pH 8.0) (28), whereas this approach for porcine insulin gave Kd
of 7 M (at pH 7.0) (44). Altogether, the dimerization disso-
ciation constants for human and porcine insulin determined in
this study fall well into the range ofKd values determined exper-
imentally by other groups and different techniques. The reli-
ability of the approach presented here therefore allows a more
systematic insight into the evaluation of the roles of individual
hydrogen bonds involving B24–B26 peptide units in dimer sta-
bility. They are discussed below in the context of structural
changes caused by their alternations.
Structure-Function Relationships in Insulin AnalogueDimers—
The resultant minor differences in equilibrium constants and
thermodynamic parameters of insulin dimerization at different
pHs led to the conclusion that insulin association is mainly
driven by the nonpolar interactions (44).However, Strazza et al.
(43) also indicated that insulin dimerization is under enthalpic
control and that the formation of four hydrogen bonds in the
apolar protein environment is the main driving force in the
assembly of insulin dimer. However, molecular dynamics sim-
ulations suggested that insulin dimerization results mainly
from nonpolar interactions (contributed mostly by residues
B24–B26) (45) and that the role of hydrogen bonds between
monomers is to provide a correct directional and spatial guid-
ance to prevailing non-polar interactions. Our experimental
data do not exclude any of these hypotheses but indicate more
clearly the important individual contributions of B24–B26
hydrogen bonds toward the stability of the dimer.
The individual knock-outs of the NHB24 ([NMePheB24]-
insulin) and NHB26 ([NMeTyrB26]-insulin) hydrogen bond
donors increasedKd from 9M to 587 and 142M, respectively
(Table 2). As the role of the B24–B26 side chains can, to some
extent, be decoupled in this process due to the 2-fold symmetry
of these regions, the B24NH–COB26 hydrogen bond can be
seen as a more important polar stabilizer of the insulin dimer.
Its loss causes a much larger (4-fold) dimer disruptive effect
than abolishing the B26NH-COB24 interaction. This can result
from its flanking positions on the dimer interface, closer to the
solvent exposed termini of the dimer -sheet (Fig. 3, A and B).
The lack of B24NH-COB26 interactions, linked with the
mobility-prone character of the B27–B30 terminal residues
(observed in many insulin crystal and NMR structures; see, for
example, Fig. 3, B–D), can lead to easier solvent penetration
through the dimer interface and to faster unzipping of the
-sheet via solvation/breaking of the remaining central pair of
B26NH–COB24 hydrogen bonds (46). The lower Kd of the
[NMeTyrB26]-insulin analogue, its higher dimeric stability
than the [NMePheB24]-insulin, can also result from the non-
typical (for the R-state) B25NH–COA19 hydrogen bond in one
of its monomers. It seems that it is a side effect of the -strand
bulge that brings NHB25 into the proximity of the Tyr-A19
main chain, allowing the formation of an intramolecular hydro-
gen bond (2.9 Å, Fig. 4), which may be important for insulin
dimerization (see “Discussion”). However, as this interaction is
not symmetrical (-strand bulge occurs only in onemonomer),
it cannot fully compensate for the instability of the interface in
this analogue. Therefore, it is possible that the lack of positive
crystallization results of the [NMePheB24]-insulin analogue
FIGURE 4. TheB-A (right panel) andC-D (left panel) insulin intrachain cou-
plingeffectof theB25NH-COA19hydrogenbond in thewild-type insulin
T6 dimer (Protein Data Bank code 1MSO) (in dark gray), wild-type R6
dimer (ProteinData Bank code 1ZNJ) (white), [NMePheB25]-insulin (Pro-
tein Data Bank code 3ZQR) (green), and [NMeTyrB26]-insulin (Protein
Data Bank code 2WS6) (yellow). The T state characteristic B25NH-COA19
hydrogenbond in the T6dimer is in redonbothpanels (distances inÅ); this AB
monomer-only hydrogen bond in the [NMeTyrB26]-insulin analogue is in
magenta. Phe-B25 side chains are disordered in [NMePheB25]-insulin and are
not represented here.
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(significant but rather indirect evidence) may result from the
rapid monomer-dimer kinetics that prevents a stable crystal
nucleation process. Moreover, it is interesting that the higher
stability of the [NMeTyrB26]-insulin dimer is also reflected in
its remarkable availability to form monomeric and hexameric
crystal structures (17); appropriate physicochemical solution
parameters can shift the monomer-oligomer equilibrium
toward one of the stable (crystallisable) forms of this analogue,
especially if themost stable (
8 h (47)) phenol-induced R-form
of the hexamer is assured.Although crystallization trials cannot
be considered as an unambiguous experimental proof, the15-
fold higher Kd of [NMeTyrB26]-insulin compared with native
insulin (Table 2) also agrees with the lack of its dimer crystals,
even under extensive dimer crystallization conditions (17).
Interestingly, the most dramatic/disruptive impact on insu-
lin dimerization properties, evident in the ITC data, is not pro-
vided by the knock-out of each of the intermonomer -sheet
hydrogen bonds pairs, but by the N-methylation of the B25
amide unit in the [NMePheB25]-insulin analogue. Despite the
almost wild-type nature of the dimer interface here (Fig. 3A)
and an easy spatial accommodation of the outward (from the
dimer -sheet interface) pointing B25N-Me groups, the lack of
intramolecular hydrogen bond donor properties of B25NH
group results in no-heat effects in the ITCmeasurements of this
analogue, in a fashion similar to the monomeric-benchmark
DOI insulin. The only direct hydrogen bond-related impact of
the loss of the B25NH proton is the lack of the B25NH-COA19
hydrogen bond that connects B-chain -strand with the core of
the molecule in the T-forms (dominant insulin state in the
metal/ligand-free ITC experiments) of the hormone (Fig. 4).
The release of the C-terminal-strand residues from this intra-
molecular hydrogen bond lockmay result in its higher mobility
shifting solution equilibrium toward the monomeric state.
Additionally, increased dynamics of this region can contribute
to, or be amplified further by, the Phe-B25 side chain mobility.
Indeed, the B25 phenyl ring can be located with difficulty (poor
electron density map definition) only for one of the B25 resi-
dues. Therefore, it is possible that the monomeric character of
[NMePheB25]-insulin can be associated with the detachment
of Phe-B25 (and surrounding B-chain) from the A-chain.
The -strand detachment-driven monomeric behavior
in the solution and formation of hexameric crystals of
[NMePheB25]-insulin are somehow reflected in the crystal
structure (and solution properties) of the [LysB28,ProB29]-in-
sulin, an analogue also with a very substantially diminished
(300) dimerization capacity (48). Its monomeric behavior
did not also prohibit its crystallization as the T3R3f hexamer in
the presence of zinc and phenol (16). The [NMePheB26]-insu-
lin was an additional step in probing of the resistance of the
dimer interface by prevention of the “central” B26NH-COB24
hydrogen bond of the dimer interface, combined with the loss
of B26 phenolic character. It is surprising that, although the
“peripheral” dimer-spanning B24NH-COD26 hydrogen bonds
are preserved here (like in the [NMeTyrB26]-insulin analogue),
the loss of the central pair (B26NH-COD24) of these interac-
tions, combined with a simultaneous loss of a Tyr-B26 OH
group, cannot prevent the further dramatic increase of the Kd
into the mM range (1.240 mM). It seems then that the phenolic
indirect hydrogen bonds of the Tyr-B26 side chain (e.g. to Tyr-
D16) and its multiple van der Waals interactions (e.g. Phe-B24,
Pro-B28, Ile-A2, Val-A3, Ile-B11, and Val-B12), multiple com-
bined contributions, are rather important for monomer (and
dimer) stability. This also indicates that the dimer-stabilizing
role of B24–B26 hydrogen bonds cannot be unambiguously
decoupled from the individual contributions of the associated
individual side chains.
Role of Hexameric Form in Dimer Stability—It has to be
stressed that all dimer-related comparisons and correlations
of structural information with the solution (ITC) studies pre-
sented here are based on different quaternary forms of insulin.
Structural data were derived exclusively from the R6 hexamers
(two Zn2, six phenol ligands), and none of the analogues dis-
cussed in this report attained the conformation of T3R3 (T3Rf3)
or T6 hexamers. In contrast, the ITC solution measurements
were performed in ametal/ligand-free environment, with the T
state being the likely form of the hormones.
Considering the dimer -sheet disruptive character of the
chemical changes in analogues studied here, it is not surprising
that the most stable form of the hexamer (R6) (47, 49, 50) was
found to be adopted by all modified insulin. The dominance of
the R6 hexameric form likely originates from the additional
reinforcement of dimer stability provided the B1–B6 helical
extension. It not only delivers typical phenol site I-generated
interactions (40) but also a few new, strong (2.7 Å) intermo-
lecular dimer-spanning protein-protein hydrogen bonds such
as Tyr-B16NH-COHis-D5. It seems that these interactions
must also compensate for a loss of the B25NH-COA19 intra-
molecular hydrogen bond, which occurs only in the T state of
insulin. Hence, the changes in dimer interfaces in various ana-
logues are displayed here against virtually the same reference-
like core of the R6 oligomer.
It is interesting that even very disruptive effects on the
dimer interface (i) resulting from the interference with the
B24-B26 intermolecular hydrogen bonds, (ii) amplified fur-
ther by some mutations in this region, and (iii) leading, for
example, to a full detachment of dimer -strands (i.e.
[TyrB25,NMePheB26,LysB28,ProB29]-insulin, Fig. 3D), are
still compensated and accommodated in a stable R6 hexamer.
Energy-driven superiority of the R6 oligomer is especially visi-
ble in the already reported (17) crystal structure of the trun-
cated [ProB26]-DTI analogue, in which the dimer interface is
totally disrupted beyond B/D21–22 residues (Fig. 5). Themain-
tenance of the hexameric form there, despite the lack of the
entire dimer -strand interface, is somehow compatible with
the association of DOI into a R6 hexamer observed in the
presence of Zn2 and cyclohexanol (29). Although the
T63 T3R33 R6 dynamic transitions are rather well described
by the SMB model (51–56), the conformational events on the
monomer3 dimer3 hexamer pathway are much less under-
stood. Our results presented here provide further evidence that
the nature of the changes on the insulin dimer interfaces (and
associated other parts of the insulin molecule) is quite asym-
metrical (Fig. 3, B–D); thus, they fit and support well the occur-
rence of structural asymmetries that are important features of a
SMB model for the allosteric behavior of insulin (57).
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Undoubtedly, the formation and dissociation of insulin hex-
amers and dimers into active monomers plays an essential role
in the endogenous delivery of the hormone (20, 22). First, the
release of insulin hexamers from secretory granules (pH 5.5)
into the bloodstream (pH 7.4) results in the loss of zinc (due to
the higher pH) and in the dissociation of hexamers to insulin
dimers (21). The process of dimer dissociation is likely concen-
tration-driven (Kd of insulin dimerization is9M). Therefore,
the dissociation of insulin dimers into monomers in the blood-
stream is a dilution-driven phenomenon. The clinically used
and fast acting [LysB28,ProB29]-insulin (Humalog) (58) or
[AspB28]-insulin (Novolog) (59, 60) are not able to form
dimers, but still associate into hexamers (16), providing evi-
dence that the disruption of insulin dimerization has a funda-
mental impact on the endogenous action of this hormone.
CONCLUSIONS
The C terminus of the B-chain, namely, residues B24–B26
and B28–B29, is a crucial part of insulin for its interaction with
IR and for its self-association into dimers. The importance of
Phe-B24, Phe-B25, and Tyr-B26 residues in the formation of
dimers is well established; however, the contribution of their
respective individual amide hydrogens for the stability of this
aggregates has not been characterized. Here, we delineated
their roles by preparation of a series of insulin analogues with
selective N-methylations of peptide bond amides at positions
B24, B25, or B26. All of these N-methylated insulin analogues
showed significantly impaired binding affinities to the receptor,
confirming also the role of respective amide hydrogens in the
direct interaction/involvement with insulin receptor. System-
atic, individual N-methylations of B24, B25, and B26 peptide
bonds in studied analogue amides resulted in a wide spectrum
of reduced dimerization abilities of the analogues. Surprisingly,
the most dramatic impact on insulin dimerization capability
was exerted by theN-methylation at the B25 position, likely due
to a loss of the intramolecular -strand-hormone-core con-
necting NHB25-COA19 hydrogen bond. The subsequent
higher mobility of the -strand in this analogue severely shifts
the solution equilibrium toward the monomeric state. All
examined analogues were crystallized only as R6 hexamers,
which is the most stable form of insulin oligomers and the only
oligomeric form capable to accommodate/withstand disrupted
insulin -strands. This study helped to understand the impor-
tance and contribution of the B24NH-COB26, B26NH-COB24,
and, especially, B25NH-COA19 hydrogen bonds in the forma-
tion and stabilization of insulin dimers. The behavioral, func-
tional, and structural correlations presented here providemuch
evidence that clearly supports and further validates the SMB
model of insulin allostery. A better understanding of the struc-
ture-function relationships in the association-dissociation
pathways of this hormone is important for the understanding of
its physiology but may also facilitate development of better,
more controlled insulin for clinical applications.
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How insulin engages its primary binding site on the
insulin receptor
John G. Menting1*, Jonathan Whittaker2*, Mai B. Margetts1, Linda J. Whittaker2, Geoffrey K.-W. Kong1, Brian J. Smith1,3,
Christopher J. Watson4, Lenka Zˇa´kova´5, Emı´lia Kletvı´kova´5, Jirˇı´ Jira´cˇek5, Shu Jin Chan6, Donald F. Steiner6, Guy G. Dodson4{,
Andrzej M. Brzozowski4, Michael A. Weiss2, Colin W. Ward1 & Michael C. Lawrence1,7
Insulin receptor signalling has a central role inmammalian biology,
regulating cellular metabolism, growth, division, differentiation
and survival1,2. Insulin resistance contributes to the pathogenesis
of type 2 diabetes mellitus and the onset of Alzheimer’s disease3;
aberrant signalling occurs in diverse cancers, exacerbated by cross-
talk with the homologous type 1 insulin-like growth factor receptor
(IGF1R)4. Despite more than three decades of investigation, the
three-dimensional structure of the insulin–insulin receptor complex
has proved elusive, confounded by the complexity of producing the
receptor protein.Here we present the first view, to our knowledge, of
the interaction of insulin with its primary binding site on the insulin
receptor, on the basis of four crystal structures of insulin bound to
truncated insulin receptor constructs. The direct interaction of insu-
linwith the first leucine-rich-repeatdomain (L1)of insulin receptor is
seen to be sparse, the hormone instead engaging the insulin receptor
carboxy-terminal a-chain (aCT) segment, which is itself remodelled
on the face of L1 upon insulin binding. Contact between insulin and
L1 is restricted to insulin B-chain residues. The aCT segment dis-
places the B-chain C-terminal b-strand away from the hormone core,
revealing themechanism of a long-proposed conformational switch in
insulin upon receptor engagement. This mode of hormone–receptor
recognition is novel within the broader family of receptor tyrosine
kinases5. We support these findings by photo-crosslinking data that
place the suggested interactions into the context of the holoreceptor
andby isothermal titration calorimetry data that dissect the hormone–
insulin receptor interface. Together, our findings provide an explana-
tion for a wealth of biochemical data from the insulin receptor and
IGF1R systems relevant to the design of therapeutic insulin analogues.
Insulin comprises two chains (A and B) containing three a-helices
(residues A1–A8, A12–A18 and B9–B19) constrained by one intra-
and two interchain disulphide bonds6 (Fig. 1a). The insulin receptor is
a disulphide-linked (ab)2 homodimer; the extracellular portion of
each ab protomer contains six domains (L1, CR, L2, FnIII-1, FnIII-2
and FnIII-3) and an insert domain (ID) within FnIII-27 (Fig. 1b). The
a-chain component of the ID is terminated by a segment termed aCT,
spanning residues 704–719 (using the numbering of the insulin
receptor exon 112 isoform8). Two surfaces of insulin are understood
to interact with the insulin receptor9,10. The first consists predomi-
nantly of hormone-dimerizing residues and contacts the primary
binding site on the receptor (site 1; dissociation constant (Kd)
,6.4 nM) comprising the aCT segment from one insulin receptor
a-chain and the central b-sheet of L1 (L1–b2) of the other a-chain
within the insulin receptor dimer11–14 (Supplementary Fig. 1a). The
second consists predominantly of hormone-hexamerizing residues
and is proposed to interact with a secondary insulin receptor site (site 2;
Kd ,400 nM) at the junction of FnIII-1 and FnIII-2 of the insulin
receptor a-chain opposite to that contributing L1 to site 1 (Sup-
plementary Fig. 1a)7,9–11,13–15. Structural study of the insulin receptor
and IGF1R ectodomains is difficult; their large size, flexible multido-
mainmorphology and extensive glycosylation and disulphide bonding
posing challenges in production and crystallization. Only three ecto-
domain structures exist: those of the apo-insulin receptor7,12 and the
L1–CR–L2 fragments of insulin receptor16 and IGF1R17 (3.7 A˚, 2.3 A˚
and 2.6 A˚ resolution, respectively); none is in complex with ligand.
We present here the first view of the insulin–site 1 interaction on the
basis of four crystal structures (complexes A, B, C and D) varyingly
using the L1–CR construct IR310.T (Fig. 1c) and the L1–CR–L2–
(FnIII-1)–aCT(704–719) homodimeric construct IR593.aCT (Fig. 1d),
which has aCT(704–719) linked to FnIII-1. Complex A (3.9 A˚ reso-
lution) contains human-insulin-bound IR310.T in complex with a
Fab fragment from monoclonal antibody 83-7 (ref. 7) and exogen-
ous aCT(704–719) peptide. Complex B (4.3 A˚ resolution) is the same
as complex A but uses the high-affinity, truncated insulin analogue [D-
ProB26]-DTI-NH218. Complex C (4.4 A˚ resolution) is the same as com-
plex B but uses the longer peptide aCT(697–719). Complex D (4.4 A˚
resolution) contains bovine insulin bound to IR593.aCT in complex
with a Fab fragment from monoclonal antibody 83-14 (ref. 7).
The limited diffraction of these crystals necessitated the use of the
following: (1) weak data at the diffraction limit (a process validated by
the half-data set Pearson correlation coefficient CC1/2 criterion19,20 and
ultimately by the evident quality (see below) of the resultant electron-
density difference maps (EDDMs)); (2) B-factor-sharpened EDDMs
in model building21; and (3) dynamic ‘reference-structure’ and ‘jelly-
body’ restraints during individual atomic-coordinate refinement
whereby we exploited the known higher-resolution structures of the
underlying fragments22,23. Molecular replacement located the insulin
receptor and Fab domains and generated a clear solution for the
insulin three-helix ‘core’ structure within each complex, positioning
the core identically on the respective L1–b2 surfaces. The strongest
feature in the resultant EDDMs was a common, helical-like structure
lying adjacent to the insulin B-helix on the L1–b2 surface that, upon
B-factor sharpening, exhibited side-chain density of distinctive sizes
and at spacing consistent with an a-helix. In complex D, this feature
was connected to the C-terminal strand of FnIII-1, allowing its unam-
biguous interpretation as aCT and restricting its prima facie sequence
register to an ambiguity of at most one residue unit, with one alter-
native strongly favoured. We confirmed our register assignment
objectively by devising a broad-window analysis of sequence fit
both to the higher-resolution EDDM of complex A and to the profiled
residue environments within that complex. Crystallographic pro-
cessing and refinement statistics are provided in Table 1 and Sup-
plementary Table 1, with further detail in Methods.
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The structures of the insulin-bound site 1 assembly within com-
plexes A and D are shown in Fig. 1e, f, respectively; those within
complexes B and C are effectively isomorphous with complex A
(Fig. 1g). The Fab-complexed forms of the IR310.T and IR593.aCT
monomers are shown in Supplementary Fig. 2a, b, respectively. As
prepared and crystallized, complex D contains a dimer of IR593.aCT
homodimers crosslinked by four insulins; further description of this
assembly is provided in Supplementary Fig. 2c–e. Despite the non-
native connection of aCT to FnIII-1 in IR593.aCT (Fig. 1d), the insu-
lin-bound site 1 assembly within complex D is also superimposable on
that of complex A (Fig. 1g). Refinement of these complexes provided
EDDMs that revealed side-chain bulk for all components within the
observed site 1 interface (Fig. 1h). The mode of insulin–site 1 inter-
action emerging from these structures is as follows. The insulin B-helix
(B7–B21) engages the C-terminal end of the L1–b2 strands; the insulin
A-chain has no interaction with L1 (Fig. 1e, f). Both chains interact
extensively with aCT. Notably, the aCT helix is, with respect to its
apo-insulin receptor counterpart, both displaced on the L1–b2 surface
andC-terminally extended to include residues 711–715 (see Fig. 2a and
further discussion below). Residues B22–B30 are not resolved in these
structures, but, critically, the aCT helix occupies volume that would
otherwise contain insulin residues B26–B30 if the latter retained their
receptor-free conformation (see Fig. 2b and Supplementary Fig. 3a).
Displacement of residues B26–B30 from the insulin core confirms a
long-speculated24 induced fit upon insulin receptor binding (Sup-
plementary Fig. 1b). In contrast, the helical core of insulin seems, as
far as can be discerned at the described resolution, closely similar to
that of uncomplexed hormone (Supplementary Fig. 3b). The models
suggest that the two most critical hormone-engaging residues in aCT
are (1) His 710, which inserts into a pocket formed by invariant10
insulin residues ValA3, GlyB8, SerB9 and ValB12; and (2) Phe 714, which
occupies a hydrophobic crevice formed by invariant insulin residues
Table 1 | X-ray diffraction data collection statistics
Complex A, data set 1 Complex A, data set 2 Complex B Complex C Complex D
Human insulin1 IR310.T–
83-71 aCT(704–719)
Human insulin1 IR310.T–
83-71aCT(704–719)
[D-ProB26]-DTI-NH21 IR310.T–
83-71aCT(704–719)
[D-ProB26]-DTI-NH21 IR310.T–
83-71aCT(697–719)
Bovine insulin 1
IR593.aCT/83-14
Space group P23 P23 P23 P23 I2
Cell dimensions
a, b, c (A˚)
a, b, c (u)
168.15, 168.15, 168.15
90, 90, 90
168.91, 168.91, 168.91
90, 90, 90
169.49, 169.49, 169.49
90, 90, 90
169.23, 169.23, 169.23
90, 90, 90
118.15, 140.10, 190.02
90, 95.04, 90
Completeness (%) 99.8 (99.8)* 98.3 (99.5) 99.7 (100.0) 98.5 (98.1) 87.7 (84.9){
Resolution (A˚) 59.5–4.0 (4.1–4.0) 46.8–3.9 (4.0–3.9) 29.6–4.3 (4.53–4.3) 29.5–4.30 (4.54–4.3) 56.3–4.4 (4.5–4.4)
Rmerge 0.156 (2.36) 0.089 (1.57) 0.188 (2.69) 0.101 (1.09) 0.206 (1.31)
{Rpim 0.039 (0.57) 0.048 (0.83) 0.067 (0.97) 0.053 (0.59) 0.143 (0.89)
I/sI 11.5 (1.6) 9.0 (1.0) 7.8 (1.0) 8.2 (1.4) 2.8 (0.8)
Redundancy 17.3 (17.4) 4.1 (4.2) 8.8 (8.8) 4.4 (4.3) 2.9 (2.8)
1CC1/2 0.998 (0.580) 0.998 (0.342) 0.996 (0.330) 0.997 (0.438) 0.980 (0.232)
Each data set was collected from a single crystal.
*Highest-resolution shell statistics are shown in parentheses.
{Data completeness was compromised by radiation damage.
{Rpim, precision indicating merging R-factor30.
1CC1/2, Pearson correlation coefficient between independently merged halves of the data set19. Highest-resolution shell CC1/2 values are significant at at least P50.001.
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Figure 1 | Structure of insulin, insulin receptor and the site 1 complexes.
a, Insulin. InsA, A chain; InsB, B chain. b, Insulin receptor. CR, Cys-rich
domain; FnIII-1, FnIII-2, FnIII-3, first, second and third fibronectin type III
domains; ID, insert domain; L1, L2, first and second leucine-rich-repeat
domains; TK, tyrosine kinase; TM, JM, transmembrane and juxtamembrane
segments. c, d, IR310.T and IR593.aCT domain structure, respectively.
e, f, Insulin-bound site 1 in complexes A and D, respectively. Blue, red spheres,
observed chain termini; orange sphere, FnIII-1–aCT junction. g, Overlay of
insulin-bound site 1 in complexes A (coloured as in e), B (red), C (green) andD
(white). h, Sample 2Fobs2 Fcalc map volumes (Bsharp52160 A˚
2; contours5
1.1–1.5s) for complex A.
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GlyA1, IleA2, TyrA19, LeuB11, ValB12 and LeuB15 (Fig. 2c). Asn 711 is
directed towards GlyA1, ValA3 and GluA4. The hydrophobic face of
aCT comprising Phe 705, Tyr 708, Leu 709, Val 712 and Val 713
engages a non-polar groove on L1-b2 formed by Leu 36, Leu 37,
Leu 62, Phe 64, Phe 88, Phe 89, Val 94 and Phe 96 (Fig. 2d). Direct
interaction between the insulin B-chain B9–B19 helix and L1 seems
to be limited: ValB12 is positioned between Phe 39, Phe 64 and Arg 65,
whereas TyrB16 adjoins Phe 39 (Fig. 2e). Detailed rotameric and
atomic level detail of the above interactions is precluded by the
limited diffraction.
Relocation of aCT upon hormone binding is supported by recent
studies indicating that residues buried beneath aCT in the apo-
ectodomain may directly contact insulin25, and that peptide substitu-
tions in theaCT segment upstreamof Phe 705 that increase the affinity
of the segment for L1 concomitantly impair insulin binding12. To
investigate further, we used complex C to test whether the relocation
observed in complexesA, B andD is a consequence of aCT truncation,
as in the apo-insulin receptor the visible interaction of aCTwith L1–b2
begins at Glu 697. It is not—the relocation persists in complex C
(Fig. 1g) with no detectable ordering of residues 697–704.
We validated our interpretation of the aCT engagement with L1–b2
and insulin further by isothermal titration calorimetry (ITC). First,
Ala-substituted aCT(704–719) peptides were titrated against the L1–
CR–L2 construct IR485 (ref. 16). Second, insulin was titrated against
IR485 pre-saturatedwithAla-substituted aCT(704–719) (Supplemen-
tary Tables 2 and 3 and Supplementary Fig. 4). Individual F705A and
L709A substitutions significantly impaired aCT binding to IR485,
supporting their modelled engagement with L1–b2. In contrast, indi-
vidual H710A, N711A and F714A substitutions significantly impaired
insulin binding, supporting their modelled engagement with insulin.
These data are summarized schematically in Fig. 3a. An apparent
exception is V713A, which affects insulin but not aCT affinity, des-
pite Val 713 being modelled as engaged with L1–b2. However, this
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Figure 2 | The insulin–site 1 interaction. a, Altered disposition of aCT with
respect to that in apo-insulin receptor12. b, Superposition (via the A- and
B-chain helices) of receptor-free insulin onto the insulin–site 1 complex,
indicating steric clash of the B-chainC-terminal segment (green) withaCT. See
also Supplementary Fig. 3a. c, Interaction (at the bulk side-chain level of detail)
between aCT(704–719) and insulin. View direction is parallel to L1–b2 surface
(cyan); white shading shows insulin surface. d, e, Interaction (at the bulk side-
chain level of detail) between L1 and aCT and between L1 and insulin B-chain
helix, respectively. Panels based on complex A.
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Figure 3 | Insulin interactions in L1–CR–L2 mini-insulin receptor and
holo-insulin receptor. a, Helical wheel representation of ITC-derived insulin
affinities for IR485 in the presence of Ala-substituted aCT(704–719) (red,
.1003 reduction upon Ala substitution; green, .103 reduction; grey,
,103 reduction; open circle, not determined). b, Reducing gel autoradiograms
obtained from holo-insulin receptor after photo-crosslinking of aCT helix to
bound 125I-[TyrA14]-insulin. Arrowed band indicates crosslinked insulin
receptor a-chain–insulin A chain. Colours indicate crosslinking efficiency (red,
strong; green, medium; blue, weak; grey, none). c, d, Qualitative crosslinking
efficiency from b mapped onto aCT segment within the site 1 complexes.
e, Helical wheel representation of crosslinking data presented in b–d.
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observation aligns with the disorder of Val 713 in the apo-insulin
receptor ectodomain structure12; the interaction of Val 713 with L1–
b2 may thus instead be required to stabilize the critical11 insulin-
engaging residue Phe 714 at the terminus of the aCT helix.
The insulin–site 1 interactions described here are further supported
by a ‘photo-scan’ of the holo-insulin receptor aCT segment, wherein
individual aCT residues were successively substituted by the photo-
activatable residue para-azido-Phe (Pap) and then exposed to ultra-
violet light to probe covalent interaction with [125I]-TyrA14 insulin25.
Strong crosslinking was observed for photo-probes at sites 711 and
714, medium at sites 707 and 710, and weak at sites 713 and 715; no
crosslinking was observed at sites 705, 706, 708, 709 or 712 (Fig. 3b).
This photo-crosslinking efficiency pattern in holo-insulin receptor
exhibits a marked correlation with and supports the insulin–site 1
juxtaposition described above (Fig. 3c–e).
Complexes B and C probedwhether the stableb-turn at B24–B26 in
receptor-free [D-ProB26]-DTI-NH218 might result in ordering of
residues B22–B26 upon binding site 1—it did not, as these residues
remained unresolved. We investigated the insulin B-chain C-terminal
strand further by seeking to photo-crosslink individual Pap probes at
B24 and B25 to the truncated L1–CR–L2 construct IR46826 in the
presence of an aCT peptide. In both holo- and ectodomain insulin
receptor complexes, these probes respectively crosslink to L1 and
aCT27,28. We observed photo-crosslinking for PapA3, PapA8 and
PapB16 (as in holo-insulin receptor27) but not for PapB24 or PapB25
(Supplementary Fig. 5). We thus propose that full stabilization of
B22–B30 upon detachment from the hormone core requires the
presence of the FnIII domains.
Superposition of the site 1 complexed assembly onto the L1 domain
in the apo-insulin receptor ectodomain structure (Supplementary
Fig. 6) shows that the insulin surface proposed10 to bind site 2 overlays
the FnIII-1–FnIII-2 junction of the alternative ab protomer, that is,
the proposed site 2 itself. However, significant steric clash is present,
indicating that insulin bridging of sites 1 and 2 requires relative
displacement of the FnIII-1 and FnIII-2 domains away from the
L1–CR module. Such change would alter the relative location of the
membrane-proximal FnIII-3 domains, potentially initiating signal
transduction13.
Concordance of our structures with the extensive biochemical
literature of this system is presented in Supplementary Discussion.
Briefly, the structures are consistent with alanine scanning mutagen-
esis of the insulin receptor L1 domain, revealing now that of the ‘hot-
spot’ residues, the set Gln 34, Leu 36, Leu 37, Phe 64, Phe 88, Phe 89
and Glu 120 contact the aCT segment whereas only Phe 39 contacts
insulin. The structural engagement of insulin receptor residuesHis 710
and Phe 714 with insulin concords with (1) alanine scanning mutage-
nesis of the insulin receptor ectodomain; (2) hydrogen/deuterium
exchange studies of the closely related type 1 insulin-like growth factor
receptor (IGF1R); and (3) the lack of hormone binding by insulin
receptor chimaeras and IGF1R chimaeras containing the aCT seg-
ment from the insulin-receptor-related receptor, which has threonine
at the residue equivalent to insulin receptor Phe 714 (IGF1R Phe 701).
Our structures are also consistent with mutational analysis of insulin,
showing now that the hotspot residues GlyA1, IleA2, ValA3, TyrA19,
GlyB8 and LeuB11 make contact with the key aCT residues His 710
and Phe 714 (Fig. 2c). Although residues GlyB23, PheB24 and PheB25
are unresolved here, evidence is presented for the likely repositioning
of the B-chain C terminus into the volume between the aCT segment,
the L1–b2 surface and the adjacent CR domain; such repositioning
rationalizes the enhanced affinity of analogues containing D-amino-
acid substitutions at B24.
Our structural and biochemical findings provide groundbreaking
insight into the primary insulin–insulin receptor interaction. Parti-
cularly important in binding is the aCT segment, which is without
known counterpart in other mammalian receptor tyrosine kinases5,
although it is conserved among metazoan insulin receptor and
IGF1R. The concomitant structural re-arrangements of hormone
and receptor in our model rationalize long-standing anomalies in
clinical insulin variants associated with diabetes29 and define new
structural targets for novel therapeutics targeting these receptors.
METHODS SUMMARY
IR310.T was produced by proteolysis of an engineered mini-receptor precursor
cIR485 expressed from a stable Chinese hamster ovary Lec8 cell line and purified
by ion-exchange and size-exclusion chromatography (SEC), followed by combina-
tion with 83-7, re-purification by SEC and finally combination with excess aCT
peptide and insulin (or analogue). Crystallization conditions for IR310.T-derived
complexes A, B and C were 0.9–1.1M tri-sodium citrate, 0.1M imidazole-HCl
(pH 8.0)1 0.02% sodium azide (NaN3). IR593.aCT was expressed from a stable
Chinese hamster ovary Lec8 cell line followed by insulin affinity chromatography
and then SEC of the resultant bovine insulin complex. Samples were combined
with 83-14 and re-purified by SEC. The crystallization condition for the
IR593.aCT-derived complexDwas 9%polyethylene glycol 3350, 200mMproline,
100mMHEPES-NaOH (pH7.5). Diffraction data were collected at theAustralian
Synchrotron (beamline MX2) and Diamond Light Source (DLS; beamline I24).
Structures were solved by molecular replacement. Introduction of Pap residues
into the aCT segment used orthogonal tRNA/amber suppression technology.
Mutant holoreceptors were expressed transiently using co-transfected 293PEAK
rapid cells in Pap-containing medium. Cell detergent lysates were then subjected
to wheat-germ agglutinin chromatography; eluates containing the receptor were
concentrated before photo-crosslinking to 125I-[TyrA14] insulin. Photo-crosslinked
products were resolved by gel electrophoresis and auto-radiographed. IR468 was
produced by transient expression in HEK293 cells. 125I-photo-activatable insulin
analogues were incubated with IR468 in the presence of 1025M aCT(703–719)–
Myc and then photo-crosslinked. Samples were resolved by gel electrophoresis
and auto-radiographed. For ITC, Ala-substituted aCT peptides (80 mM concen-
tration) were titrated into a sample cell containing IR485 (10 mM concentration);
and zinc-free porcine insulin (32–48 mMconcentration)was titrated into a sample
cell containing IR485 (4–6mMconcentration) pre-incubatedwithAla-substituted
aCT peptide (103molar concentration). All samples were in Tris-buffered saline
(pH8.0) plus azide (TBSA).
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
Cloning, production and purification of IR310.T.High yield and correct fold-
ing of IR310.T was achieved by design of a thrombin-cleavable version of IR48516
(termed cIR485) for use as precursor, followed by production and purification
protocols for cIR485 similar to those described for IR48516. A 1,741-nucleotide
base fragment of insulin receptor was synthesized (DNA2.0) and inserted into the
HindIII–XbaI sites of the vector pEE14 (Lonza). The fragment encoded a protein
cIR485 (‘cleavable’ IR485) which consists, in order, of (1) the 27-residue insulin
receptor native signal sequence; (2) residues 1–310 of the insulin receptor a-chain
(the L1–CR module); (3) a thrombin cleavage site SSSLVPRGSSS; (4) residues
311–485 of the insulin receptor a-chain (the L2 domain); (5) an enterokinase
cleavage site DDDDK; and (6) a c-Myc purification tag EQKLISEEDLN31 (see
Supplementary Fig. 7). A 106-nucleotide-base non-coding fragment 59-GTCG
ACGGTACCCCGGGGAATTAATTCCGGGGGCCGCCTCGGAGCATGACC
CCCGCGGGCCAGCGCCGCGCGCTCTGATCCGAGGAGACCCCGCGCTC
CCGCAGCC-39 was included between the HindIII site and the region expressing
the signal peptide; bases 29–106 of this fragment correspond to those immediately
upstream of the human insulin receptor coding region. CHO Lec8 cells (CRL-
1737; ATCC)32 were transfected with the cIR485-containing expression vector
using Lipofectamine 2000 (Life Technologies). Selection was undertaken in the
presence of methionine sulphoximine (MSX), with cIR485 production monitored
via western blot with monoclonal antibodies 83-733 and 9E1034. Production scale-
up, performed under contract by CSIRO, was in spinner flasks (New Brunswick
Scientific) containing DMEM/F12 medium (Life Technologies) supplemented
with 10% fetal bovine serum (FBS; Life Technologies) plus 25mM MSX. The
medium was supplemented with 0.8mM butyric acid (Sigma-Aldrich) during
the last week of the production phase. A total of 50 l of culture supernatant was
collected; harvests were filtered (0.2mm cutoff) and then concentrated 10-fold
(30 kDa cutoff) after addition of 0.1mM phenylmethanesulphonylfluoride
(PMSF; Sigma-Aldrich) and 0.02% sodium azide (NaN3). Accumulated super-
natant harvests were adjusted to pH8 by addition of 3M Tris-HCl (pH 8.5).
Initial purification of cIR485 was by 9E10 antibody affinity chromatography
and size-exclusion chromatography (SEC) using procedures effectively identical
to those described for purification of IR48516. Purified cIR485 in Tris-buffered
saline (24.8mM Tris-HCl pH8.0, 137mM NaCl, 2.7mM KCl) plus 0.02% NaN3
(TBSA) was then incubated overnight at 37 uC with 0.25 units human thrombin
(Roche) per mg of cIR485 in the presence of 10mM CaCl2. Completion of pro-
teolysis was assessed by SDS–PAGE, which revealed bands corresponding to the
estimated molecular mass of the IR310.T fragment and the insulin receptor L2
domain (51 kDa and 30 kDa, respectively; Supplementary Fig. 8a). Western blot-
tingwithmonoclonal antibody 83-7 confirmed that the CR domainwas contained
in the upper band alone. The sample was diluted 8-fold in buffer A (10mM
ethanolamine-HCl, pH9.61 0.02% NaN3), centrifuged for 5 min at 17,000g to
remove particulates and then loaded onto a Mono Q 5/50 GL column (GE
Healthcare). The sample was eluted with a 60 column-volume gradient of buffer
A to buffer B (10mM ethanolamine-HCl, 400mM NaCl, pH 9.61 0.02% NaN3;
Supplementary Fig. 8b) and the fractions assessed by SDS–PAGE. Fractions con-
taining IR310.T were pooled, concentrated and re-run in TBSA on a Superdex
200 10/300 column (GE Healthcare). The chromatogram exhibited three over-
lapping peaks, probably arising from multimerization (Supplementary Fig. 8c).
SDS–PAGE of fractions revealed the presence of three closely spaced bands, which
we attributed to varying glycosylation (Supplementary Fig. 8d). The final yield of
IR301.T was,0.5mgml21 of cell culture.
Large-scale production and purification of Fab 83-7. A hybridomal cell line
expressing monoclonal antibody 83-733 was a gift from K. Siddle. Large-scale
production and purification of monoclonal antibody 83-7 and preparation
of Fab 83-7 from monoclonal antibody 83-7 were based on protocols des-
cribed previously7. In particular, monoclonal antibody 83-7 was proteolysed with
dithiothreitol-activated papain (Sigma-Aldrich) at 37 uC. Proteolysis was stopped
by adding iodoacetamide (IAA; Sigma-Aldrich) and the reaction mixture then
passed down a Superdex 200 26/60 column (GEHealthcare). Fractions containing
83-7 F(ab9)2 were isolated and reducedwithmercaptoethylamine (Sigma-Aldrich)
and then alkylated with IAA, followed by further SEC and cation-exchange chro-
matography on Mono S (GE Healthcare).
Production of Fab 83-7-complexed IR310.T. IR310.T was mixed with a slight
molar excess of Fab 83-7 and the complex purified by SEC using a Superdex
S200 10/300 column (GE Healthcare) in TBSA buffer. Fractions containing the
complex of IR310.T/Fab 83-7 were then pooled, concentrated and exchanged into
10mM HEPES-NaOH (pH 7.5)1 0.02% NaN3 for crystallization screens.
Cloning, production and purification of IR593.aCT. CHO Lec8 cells stably
expressing IR593.aCT were obtained from CSIRO. These cells were derived by
co-transfection with both the linearized expression plasmid pEE14 (Lonza) and
a pEF puromycin plasmid (Springer Labs). The pEE14 expression plasmid
contained, inserted between its HindIII–XbaI sites, a fragment encoding (in order)
the 27-amino-acid residue insulin receptor signal sequence, insulin receptor resi-
dues 1–593 and insulin receptor residues 704–719 (see Supplementary Fig. 9). The
106-nucleotide-base non-coding fragment described above was also included here
between the HindIII site and the start codon. Selection was undertaken in the
presence of puromycin, with IR593.aCT production monitored via europium-
labelled insulin binding assays35. Production scale-up, performed under contract
by CSIRO, was in spinner flasks (New Brunswick Scientific) containing DMEM/
F12 medium (Life Technologies) supplemented with 10% FBS plus 10mgml21
puromycin. Accumulated supernatant batches were adjusted to pH8 by addition
of 3MTris-HCl (pH8.5). PMSFwas added to 0.1mM concentration andNaN3 to
0.02%. The culture supernatant was filtered (0.2mm cutoff), concentrated 10-fold
(10 kDa cutoff) and pumped through a Sephacryl S100 column (GE Healthcare)
onto an in-house manufactured bis-Boc-insulin MiniLeak medium resin column
(Kem-En-Tec)36. The latter was eluted with bovine insulin in TBSA. PMSF was
again added to 0.1mM concentration and the eluates concentrated for Superdex
S200 26/60 or S200 10/300 (GEHealthcare) SEC. The SECprofiles showed a single
major peak corresponding to the insulin-complexed IR593.aCThomodimer and a
further peak corresponding to excess bovine insulin (Supplementary Fig. 8g). At
higher concentrations, an additional peak appeared corresponding to a dimer of
IR593.aCT homodimers (Supplementary Fig. 8h). Contents of fractions were
analysed by SDS–PAGE (data not shown). The final yield of IR593.aCT was
,0.4mg l21 of cell culture supernatant.
Large-scale production and purification of Fab 83-14. A hybridomal cell line
expressing Mab 83-1433 was a gift from K. Siddle. Cells were grown in 950 cm2
roller bottles at 37 uC in 5% CO2 (balanced with air) at 10 r.p.m., using approxi-
mately 300ml H-SFM medium supplemented with 5% fetal calf serum (FCS).
Typically, 2–3 l of cell culture at a viable cell density of 2–33 106cellsml21 was
achieved. Cells were then pelleted (5min, 350g) and re-suspended in serum-free
medium. The culture was collected when cell viability dropped below 30% (after
5–7 days). Monoclonal antibody 83-14 from collected supernatant was captured
using a ProSep-vA column (Millipore). Monoclonal antibody 83-14 was proteo-
lysed with dithiothreitol-activated papain (Sigma-Aldrich) at 37 uC. Proteolysis
was stopped by adding IAA and the reaction mixture containing Fab 83-14 was
then passed down a Superdex 200 26/60 column. Final purification of Fab 83-14
was by cation-exchange chromatography on a MonoS column (GE Healthcare).
Purification of the IR593.aCT1Fab 83-141 insulin complex.The IR593.aCT
protein was combined with an excess of bovine insulin and Fab 83-14 and then
re-subjected to SEC. The SEC profiles (Supplementary Fig. 8i) showed a major
peak with a molecular mass corresponding to that of a dimer of Fab-complexed
IR593.aCThomodimers and a shoulder ofmolecularweight corresponding to that
of an Fab-complexed IR593.aCT homodimer, as well as peaks corresponding to
excess Fab 83-14 and insulin. Fractions corresponding to the higher molecular
mass component of themajor peakwere pooled and then concentrated in a 10mM
HEPES-NaOH (pH7.5)1 0.02% NaN3 buffer for crystallization.
Production of IR468-containing media. A DNA fragment encoding the signal
peptide plus residues 1–468 of human insulin receptor was inserted into the
HindIII–XbaI sites of the vector pcDNA3.1zeo(1) (Life Technologies) and
then transiently transfected into HEK293 cells. Cells were grown in Dulbecco’s
modified Eagle’s medium (Life Technologies) supplemented with 10% FCS for
72 h after transfection; media containing IR468 were then collected and stored at
220 uC until used.
Crystallization and diffraction data collection of complexesA toD.Complexes
A, B, C and D are as defined in Table 1. Complexes A, B and C were prepared for
crystallization by combining the Fab 83-7 bound IR310.T (final concentration
3.5mg ml21) with a 1.53molar ratio of aCT peptide (Genscript) and 33molar
ratio of human insulin (Sigma-Aldrich) or [D-ProB26]-DTI-NH2 in 10mM
HEPES-NaOH (pH 7.5) 1 0.02% sodium azide (NaN3). [D-Pro
B26]-DTI-NH2
was prepared as described previously37. A single crystallization condition for
complex A was detected using a sparse-matrix 792-condition screen (CSIRO
Collaborative Crystallization Centre) and optimized manually to 0.9–1.1M tri-
sodium citrate, 0.1M imidazole-HCl (pH 8.0)1 0.02%NaN3 for all complexes A,
B and C. An initial crystallization condition for complex D at 2.0mgml21 was
detected in a similar 792-condition screen and optimized manually to 9%
PEG3350, 200mM proline, 100mMHEPES-NaOH (pH7.5). For data collection,
the complexA andB crystals were cryo-protected by transfer to paraffin oilHR403
(Hampton Research), the complex C crystal by progressive increase of the
precipitant concentration to saturated tri-sodium citrate, and complex D crystal
by addition of 20% glycerol to the crystallant solution. All crystals were cryo-
cooled by plunging into liquid nitrogen and maintained at ,100K during data
collection. Data set 1 for the complex A crystal and the data set for the complex D
crystal were collected at beamline MX2 at the Australian Synchrotron38
(l5 0.95369 A˚). The remaining data sets were collected at beamline I24 at the
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Diamond Light Source (l5 0.96860 A˚). Diffraction data were processed with
XDS39 and CCP440. Resolution limits were assessed on the basis of the significance
of CC1/2 at the P5 0.001 level19. Data processing statistics are provided in Table 1.
Structure solution and refinement of complex A. PHASER41 located within the
asymmetric unit a single copy each of the L1–CRmodule and the variable module
of 83-7 (using data set 1). The 83-7 constant module was not located and ulti-
mately presumed disordered. TLS parameters and individual restrained isotropic
B-factors were then refined using autoBUSTER42, followed by atomic coordinate-
only refinement, yielding Rxpctwork/R
xpct
free 5 0.368/0.363 (where R
xpct is the
crystallographic R-factor reported by autoBUSTER, computed using the expecta-
tion value of Fcalc instead of the value itself)43. The difference density maps con-
tained four helix-like features encompassing the first, third, fourth, fifth and
seventh highest peaks in themap (the secondhighest peak being glycan conjugated
to Asn111; Supplementary Fig. 10a). These features lay adjacent to the L1–b2
surface, and PHASER then positioned the three insulin helices as a rigid entity
onto three of these (TFZ5 11.4). Correctness of this solution was verified by
exhaustive six-dimensional real-space search using ESSENS44 (Supplementary
Fig. 10b). The structure was then refined further, yielding Rxpctwork/R
xpct
free5
0.320/0.339. The remaining helix-like feature in the above difference map (the
first and fifth highest peaks) revealed clear side-chain protrusions upon negative
B-factor map sharpening21, spaced consistent with an underlying a-helix
(Supplementary Fig. 10c). We concluded that it arose from the aCT peptide as
there were no further sources of peptide in the crystallization sample. A ten-
residue poly-alanine a-helix was then docked into this feature using ESSENS;
the best fit was adequately discriminated from lower-scoring fits and visual inspec-
tion confirmed the direction of the helix as judged by protruding side-chain
density (Supplementary Fig. 10c). A procedure was then devised to assign, in an
objective fashion, the sequence register to this 10-residue segment, based on
compatibility of individual residue side chains both with sharpened difference
electron density and with their surrounding protein environment. (1) Fit to dif-
ference density used a method designed not only to assess the fit of atoms within
the density, but also to penalize the existence of volumes of positive difference
density into which no atoms had been placed. Briefly, voxels corresponding to the
aCT feature were excised from the B-factor-sharpened21 map using CHIMERA45
(cutoff level 5 0.16 e2 A˚23) and placed within a rectangular grid volume large
enough to allow a.8 A˚ buffer zone around the feature. All grid points outside of
the feature were set to 0 e2 A˚23, with the resultant map being termed Mobs.
Coordinates for residues 1, 2 and 10 of the fitted poly-alanine helix were then
deleted from the model, as the density associated with them displayed poorer
a-helical geometry. Ten alternatives, corresponding to all possible alignments of
sub-sequences of aCT(704–719) with the heptameric poly-alanine structure, were
then assessed. Rotamers for each residuewithin each of these tenmodelswere then
assigned manually using COOT46 based on visual inspection of the fit of the trial
rotamer to the density at the corresponding site inMobs. The ten individualmodels
were then ‘real-space-refined’ within COOT to achieve optimal fit toMobs, main-
taining tight helical restraints. An electron density mapMcalc, on the same grid as
Mobs, was then generated (using SFALL within CCP4) for each heptamer model
in isolation, with the B-factors of all main-chain atoms being set to 10 A˚2 and of
all side-chain atoms set to 20 A˚2 to allow for subsequent comparison with a
sharpened map. All grid points within Mcalc with r, 0.45 e
2 A˚23 were set to
0 e2 A˚23. Correlation coefficients CC5 (,xy.2,x.,y.)/![(,x2.2,x.2)
(,y2.2,y.2)] between Mobs and each Mcalc were then calculated using
MAPMAN47. Each CCwas then ‘normalized’ by dividing its value by the CC value
calculated for the underlying poly-alanine heptamer, and the quotient termed the
trial sequence’s ‘density score’. The heptamer with trial register 705–711 was seen
to have the highest density score (Supplementary Table 4). (2) Compatibility of
residue side-chain environmentwithin the L1–aCT–insulin interface was assessed
as follows. For each of the ten trial heptamer (real-space refined)models described
above, an ‘environment score’ was generated using VERIFY3D48 to assess com-
patibility with the surrounding L1–b2 and insulin surfaces. Trial register 705–711
again scored highest (Supplementary Table 4). A ‘combined score’ was then com-
puted as the product (density score)3 (environment score) to assist assessment of
lower-ranked trial registers (Supplementary Table 4). The next highest combined
score was for trial register 709–715, which is related to trial register 705–711 by a
one-turn translation along the helix, effectively maintaining hydrophobic-to-
hydrophobic docking with the L1 surface. However, register 709–715 was judged
to be most unlikely, as it would bring Pro 716 and Pro 718 into the remaining
C-terminal region of the helix. We concluded that register assignment 705–711
was correct, given that it rankedhighest on all criteria. The assignment alignedwith
that assesseddirectly from theEDDMs for complexD,wherein theaCTsegment is
directly attached to the C-terminus of FnIII-1 and the ambiguity of assignment
strictly limited.Nine sugar residueswere also included atN-linked sites 16, 25, 111,
225 and 25516,49. Final refinement was against data set 2, using local structural
similarity restraints (LSSRs)22 against Protein Data Bank (PDB) structures 2HR7-
A (L1-CR), 1IL1-B (83-7 light chain) and 1FNS-H (83-7 heavy chain), yielding
Rxpctwork/R
xpct
free5 0.264/0.292 (see Supplementary Table 1). Ramachandran stat-
istics are: favoured region 91%, acceptable region 5% and disallowed region 4%.
Structure solution and refinement of complexes B andC.These structureswere
solved independently. MOLREP50 was used to locate the L1–CR/83-7 fragment
and the structure then refinedwithREFMAC523. [D-ProB26]-DTI-NH2 (PDB entry
2WRW)was then located usingMOLREP, its position being effectively identical to
that in the native insulin complex (complex A). The aCT segment from the wild-
type insulin complex was fitted in the final electron density maps using COOT.
Final refinement gave Rwork/Rfree5 0.289/0.349 and Rwork/Rfree5 0.289/0.335,
respectively (Supplementary Table 1). Ramachandran statistics for both com-
plexes are: favoured region 89%, acceptable region 7% and disallowed region 4%.
Structure solution and refinement of complex D. Molecular replacement with
PHASER located sequentially two copies each of a module consisting of Fab 83-14
in complex with the FnIII-1 domain, an L1–CR module and an L2 domain, using
searchmodels derived fromPDBentry 3LOH12. The assemblywas subject to rigid-
body and TLS refinement using autoBUSTER, followed by individual restrained
isotropic B-factor and coordinate refinement, subject both to LSSRs to PDB entries
2HR7-A (L1-CR-L2), 3LOH-E (FnIII-1), 1PLG-H (83-14 heavy chain) and
2VXU-M (83-14 light chain) and to non-crystallographic symmetry (NCS)
restraints, yielding Rxpctwork/R
xpct
free5 0.308/0.299. Difference electron density
analysis revealed: (1) two helix-like features of electron density, each connected
to a respective insulin receptor residue Thr 593 and lying on the L1–b2 surface of
an adjacentmonomer, thus identifiable as the aCT segment of IR593.aCT; and (2)
two clusters of three helix-like features, each cluster lying adjacent to a respective
one of the above aCT segments and putatively identifiable as insulin. Insulin was
then docked into each of the above putative insulin–aCT clusters of features by
means of an exhaustive six-dimensional ESSENS search. The highest scoring
solution in each instance overlaid insulin accurately onto the respective three-
helix cluster (Supplementary Fig. 10d) and was well discriminated from lower
scoring solutions; the pose of insulin andaCTwith respect to L1–b2 was effectively
identical at the two NCS related sites. The two insulins were then included in the
model followed by further refinement. COOT was then used to position poly-
alanine a-helices into the respective density features corresponding to the aCT
segment (sharpened by the application of a negative B-factor), followed by muta-
tion of the sequence to that of aCT residues 704–715. Assignment of the aCT
register presented nomore than a single residue prima facie ambiguity (depending
on theway inwhich residues at the FnIII-1–aCTpeptide junctionwere built). One
alternative was strongly favoured, aligning independently with that determined
for complexes A, B and C above. Residues B5–B7 of each insulin could be built
into electron density following a path similar to that seen in certain high-affinity
insulin analogues18. Further crystallographic refinement was then undertaken
with autoBUSTER, yielding final Rxpctwork/R
xpct
free5 0.244/0.260 (Supplemen-
tary Table 1). Ramachandran statistics are favoured region 88%, acceptable
region 7% and disallowed region 5%.
Holoreceptor photo-crosslinking. Production and photo-crosslinking of deriva-
tized holoreceptors were performed as described previously25.
Photo-crosslinking of Pap-derivatized insulins to IR468. Photo-activatable
insulin derivatives PapA3-Ins, PapA8-DKP-Ins, PapB16-DKP-Ins, PapB24-DKP-
Ins, [Pap-B25]-DP-Ins were synthesized as described28,51 and iodinated using the
chloramine-T oxidation method. aCT(703–719)-Myc peptide was synthesized
in-house. 125I-photo-activatable insulin analogues were incubated overnight at
4 uC with IR468 and 1025M aCT(703–719)-Myc in 100mM HEPES (pH7.5),
100mM NaCl, 10mM MgCl2, 0.05% bovine serum albumin, 0.025% Triton
X-100. One aliquot was exposed to short-wavelength ultraviolet light (Minera-
light UVG-54) for 30 s at 1 cm and a second aliquot treated with 0.2mM disucci-
nimidyl suberate (DSS; Pierce). Samples were diluted with Laemmli sample buffer,
resolved on 10% Tricine SDS-PAGE and auto-radiographed.
Isothermal titration calorimetry (ITC). ITC analysis of insulin binding to
IR310.T and its Fab 83-7 complex followed protocols identical to those described
previously52. The affinity of zinc-free human insulin for IR310.T in the presence
of a 103 molar ratio of aCT(704–719) was determined to be Kd5 30nM
(Supplementary Fig. 8e) and the affinity of zinc-free human insulin for
IR310.T–Fab 83-7 in the presence of a 103 molar ratio of aCT(704–719) to be
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Structural Integrity of the B24 Site in Human Insulin Is
Important for Hormone Functionality*□S
Received for publication, January 3, 2013, and in revised form, February 20, 2013 Published, JBC Papers in Press, February 27, 2013, DOI 10.1074/jbc.M112.448050
Lenka Zˇáková‡, Emília Kletvíková‡, Václav Veverka‡, Martin Lepsˇík‡, Christopher J. Watson§, Johan P. Turkenburg§,
Jirˇí Jirácˇek‡1, and Andrzej M. Brzozowski§2
From the ‡Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2,
166 10 Prague 6, Czech Republic and the §York Structural Biology Laboratory, Department of Chemistry, The University of York,
Heslington, York, YO10 5DD, United Kingdom
Background: The structure of the C-terminal B21-B30 chain of insulin bound to the insulin receptor remains
undetermined.
Results: The structures of B24-modified insulins were determined.
Conclusion: The integrity of PheB24 but flexibility of B25-B30 insulin residues are important for receptor binding.
Significance: The knowledge of the receptor-bound structure of insulin is important for the design of new insulin receptor
agonists.
Despite the recent first insight into the insulin-insulin recep-
tor complex, the structural role of the C terminus of the B-chain
of insulin in this assembly remains unresolved. Previous studies
have suggested that this part of insulin must rearrange to reveal
amino acids crucial for interactionwith the receptor. The role of
the invariant PheB24, one of the key residues of the hormone, in
this process remains unclear. For example, the B24 site func-
tionally tolerates substitutions to D-amino acids but not to L-a-
mino acids.Here,we prepared and characterized a series of B24-
modified insulin analogues, also determining the structures of
[D-HisB24]-insulin and [HisB24]-insulin. The inactive
[HisB24]-insulin molecule is remarkably rigid due to a tight
accommodation of the L-His side chain in the B24 binding
pocket that results in the stronger tethering of B25-B28 residues
to the protein core. In contrast, the highly active [D-HisB24]-
insulin is more flexible, and the reverse chirality of the B24C!
atom swayed the D-HisB24 side chain into the solvent. Further-
more, the pocket vacated by PheB24 is filled by PheB25, which
mimics the PheB24 side and main chains. The B253B24 down-
shift results in a subsequentdownshift ofTyrB26 into theB25 site
and the departure of B26-B30 residues away from the insulin
core. Our data indicate the importance of the aromatic L-amino
acid at theB24 site and the structural invariance/integrity of this
position for an effective binding of insulin to its receptor.More-
over, they also suggest limited, B25-B30 only, unfolding of the C
terminus of the B-chain upon insulin activation.
Human insulin is a 51-amino acid hormone that regulates
blood glucose levels and affects lipid/protein metabolism and,
to some extent, the life span. Insulin exerts its actions through
binding as a monomer to the (!")2-homodimeric, tyrosine
kinase-type insulin receptor (IR) (1).
Insulin is the final product of an extensive processing from
single-chain preproinsulin (2) and consists of an A-chain
(GlyA1-AsnA21) and B-chain (PheB1-ThrB30) that are linked by
two interchain disulfide bridges (CysA7-CysB7 and CysA20-
CysB19). In addition, the A chain includes an intrachain CysA6-
CysA11 disulfide bond. Insulin is capable of dimerization at low
micromolar concentrations (3), and the presence of divalent
metal ions leads to the formation of insulin hexamers that rep-
resent the storage form of this hormone (2). There is over-
whelming evidence that monomeric insulin, which dissociates
from its storage forms, must undergo structural changes upon
binding to IR. Mainly, the C-terminal !B22-B30 part of the
B-chain has to rearrange to reveal amino acids that are crucial
for the effective formation of the hormone-receptor interface
(LeuB11, ValB12, and LeuB15 on the B chain and GlyA1, IleA2,
ValA3, and GlnA5 on the A chain) (4, 5) and that are obstructed
by the C-terminal"-strand in the dimeric and hexameric forms
of the hormone (6, 7). The importance of the B-chain C-termi-
nal residues in IR binding has also been demonstrated by their
critical role in negative cooperativity (8). The changes at the C
terminus are likely accompanied by the reorganization of the N
terminus of the B-chain (B1-B8), which adopts one of the con-
formations ranging from the so-calledT-state (extended) to the
R-state (!-helical) folds (9). The current understanding of the
three-dimensional insulin structure upon binding to the IR is
based mostly on inactive storage (hexamers, dimers) states of
the hormone (9–11). Our recent structural and functional
study of the insulin-IR complex (5) provided the first insight
into the mode of insulin binding to its receptor, although the
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structural features of the B21-B30 residues (and the B-chain N
terminus) have not been determined. Nevertheless, the
obtained structural data suggest that the!B25-B30 chain in the
IR-complex must acquire a different conformation from that
regularly found in a receptor-free state.
TheNMR structures of themonomeric form of insulin, facil-
itated by mutations (12–14) or truncations of the B-chain (15,
16), have confirmed both the conformations known from the
inactive forms of the hormone and the intrinsic mobility of the
N andC termini of the B-chain. Systematic photo-cross-linking
mapping of the photo-activated surface of insulins in com-
plexes with the IR have provided further insight into the role of
the individual hormone side chains for stability of the insu-
lin-IR interface (17, 18). These experiments indicated direct
contacts of B24/B26 and A1-A8 side chains with the IR, sug-
gesting the detachment model of insulin activation (18). This
model postulates a radical departure of the !B22-B30 chain
from the core of the hormone and its insertion between the IR
domains.
However, our recent studies on highly active (!200–450%)
insulin analogues led to the identification of their structural and
functional signatures, which suggest that less dramatic rear-
rangements of the B25-B30 residues may be required for an
“active” (i.e. as in IR complex) form of the hormone (19). The
main feature of these high affinity analogues is a so-called “B26-
turn,” which is stabilized by a formation of the B24CO-NHB27
hydrogen bond and trans-cis isomerization of the B25-B26 pep-
tide bond. Contrary to the detachment model, in which the
whole B22-B30 chain is fully separated from the insulin core,
the PheB24 side chain in the B26-turn-activation model is
invariantly anchored in the hydrophobic cavity (as in the wild-
type insulin) lined up by ValB12, LeuB15, and CysB19, with only
B26-B30 residues departing from an “inactive,” i.e. "-strand-
like, conformation.
The invariant PheB24 is one of the key residues in the insulin
molecule. Its peculiar role in the “activation process” of the
hormone is further supported by lack of tolerance at this site for
any L-amino acid substitutions, whose introduction leads usu-
ally to a complete or very significant loss of the binding affinity
(20). Only SerB24 (7–15%) (21, 22) and LeuB24 (!10–50%) (23–
29) insulin analogues retained some activity. Interestingly, such
intolerance for L-amino acidmutations is evenmore striking, as
incorporation of D-amino acids at the B24 site (except D-Pro
(30) and, to a lesser extent, D-Phe(p-ethyl) (31)) results in an
increase of insulin affinity to the IR (30). Moreover, the loss of
chirality at the B24 C! atom, resulting from “racemic”-like
mutations by an achiral side chain-containing amino acid
(!-aminoisobutyric acid), also diminishes insulin activity (30).
However, a complete loss of the B24 side chain combined with
the lack of B24C! chirality is relatively well tolerated in the
GlyB24 analog (!22–78% affinity) (21, 30, 32). Interestingly,
whereas D-Phe at theB24 site in full-length insulin enhances the
affinity (140–180%) (21, 30), the same substitution in the trun-
cated analog des-pentapeptide(B26-B30)-insulin-B25-amide
(itself equipotent with human insulin) significantly reduces
binding affinity (8%) (33). Similarly, a distinct negative effect
(1% binding affinity) was found for GlyB24 in des-pentapep-
tide(B26-B30)-insulin-B25-amide (32).
The insulinmolecule can be considered the result of complex
functional and evolutionary development. The small size of this
hormone, the proximity of its key side chains, and the compact-
ness of the long range (allosteric) intramolecular interactions
combined with the t complex behavior of this protein (chal-
lenging bio-synthesis, processing, storage, activation of the
monomer, “induced fit” etc.), gives each of its amino acids a
multi-faceted and convoluted function. Therefore, the role of
the invariant PheB24 should be considered in a wider context of
its molecular contributions, for example, toward conforma-
tional switching during hormone activation, facilitation of
proper disulfide pairing, and hormone self-assembly (17).
Here, we provide an explanation of the role for the PheB24 site
in the context of insulin structure and function by studying the
effects of its substitutions by a combination of functional, struc-
tural (NMR, x-ray), and computational molecular dynamics
(MD) approaches. Systematic substitutions of chiral (L/D)
amino acids and structural main chain constraints inducing
(Pro and Sar3) amino acids resulted in four novel B24-substi-
tuted analogues, whose functional and structural relationships
have been established. Furthermore, the possible cooperative
character of B24 and B26 sites in insulin-IR interactions and
their impact on insulin affinity was investigated in three double
(D-HisB24, GluB26) insulin mutants.
EXPERIMENTAL PROCEDURES
Materials—2-Chlorotrityl chloride resin, protected amino
acids, and reagents for solid-phase synthesis of peptides were
purchased from Novabiochem Merck (Laufelfingen, Switzer-
land). Fmoc-Lys(Pac)-OH (fluorenylmethoxycarbonyl-Lys-
(phenylacetyl)-OH) was prepared as described previously (34).
TPCK (L-1-tosylamido-2-phenylethyl chloromethyl ketone)-
treated trypsin was purchased from Sigma, and penicillin G
acylase was from Fluka. Human [125I]monoiodotyrosylA14-in-
sulin was purchased from Perkin Elmer Life Sciences. Human
insulin was purchased from Sigma. All other chemicals and
solvents were obtained from Sigma.
Peptide Synthesis and Enzymatic Semisynthesis—The syn-
theses of peptides and the semisyntheses of analogueswere per-
formed according to Záková et al. (34). The identity of the pep-
tides and analogues was confirmed with an FTMS mass
spectrometer LTQ-orbitrap XL (Thermo Fisher).
Receptor Binding Studies—Receptor binding studies with
plasmamembranes prepared from epididymal adipose tissue of
adult male Wistar rats were performed according to Záková et
al. (35). Competitive binding curves were plotted using
GraphPad (San Diego, CA) Prism 5, comparing the best fits for
single-binding site models. The half-maximal inhibition values
of binding of 125I-insulin to the receptor (IC50) were obtained
from nonlinear regression analysis. The only exception was
[ProB24]-insulin, which was tested for binding to the insulin
receptor in membranes in IM-9 lymphocytes according to the
procedure that we described recently in Morcavallo et al. (36).
The binding data for [ProB24]-insulinwere analyzedwith Excel
software using a one-site fitting program developed in the lab-
3 The abbreviations used are: Sar, sarcosine; r.m.s.d., root-mean-square
deviations.
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oratory of Dr. Pierre DeMeyts (A. V. Groth and R. M. Shymko,
Hagedorn Research Institute, Denmark, a kind gift of Pierre De
Meyts) and GraphPad Prism 5, and the dissociation constant
was determined. The dissociation constant of human 125I-insu-
lin was set up to 0.3 nM. Receptor binding assays were per-
formed under conditions excluding the depletion of free ligand.
X-ray Studies—Crystallization of [HisB24]-insulin was per-
formed using in-house insulin crystallization screens covering
most of the reported crystal insulin growth parameters. Crys-
tallization conditions, data collections, and refinement and
models statistics are given in supplemental Table S1. X-ray data
were processed by HKL2000 (37) and XDS, andmodel building
and refinement were performed using the CCP4 suite of pro-
grams (38) and COOT (39). Crystal structures were solved
using Molrep (40) with B1-B6- and B23-B30-truncated insulin
hexamer or hexamer-derived monomer as a model (PDB code
1mso) (41) and refined by Refmac 5.6 (42). The figures were
made using CCP4 mg (38). For structural comparisons of the
dimer interfaces, the best defined dimers (referred here as
monomers A-B and C-D) from the relevant structures were
superimposed on the B9-B19 and D9-D19 C! atoms using the
LSQKAB program from the CCP4 suite.
NMR Spectroscopy and Structure Calculations—NMR spec-
tra were acquired from 0.35-ml samples of 0.2–0.5 mM insulin
analogues in a 20%d3-acetic acid (pH 1.9) or 25mMdeuterated-
Tris buffer (pH 8.0) containing 5%D2O, 95%H2O.All theNMR
data were collected at 25 °C on a 600MHz Bruker Avance spec-
trometer equipped with a triple-resonance (13C,1H,15N) cryo-
probe. A series of homonuclear spectra were recorded to deter-
mine the sequence-specific resonance assignments for
[HisB24]-insulin and [D-HisB24]-insulin, in particular, two-di-
mensional TOCSY (two-dimensional total correlation spec-
troscopy) spectra with a 55-ms mixing time, two-dimensional
double quantum filtered COSY spectra, and two-dimensional
NOESY spectra, whichwere acquiredwith anNOEmixing time
of 200 ms.
The family of converged structures for [HisB24]-insulin and
[D-HisB24]-insulin was initially calculated using Cyana 2.1 (43).
The combined automated NOE assignment and structure
determination protocol was used to automatically assign the
NOE cross-peaks identified in two-dimensional NOESY spec-
tra and to produce preliminary structures. Subsequently, five
cycles of simulated annealing combined with redundant dihe-
dral angle constraints (Redac) (44) were used to produce the
sets of converged structures with no significant restraint viola-
tions (distance and van der Waals violations #0.2 Å), which
were further refined with two cycles of restrained molecular
dynamics simulated annealing using AMBER (45). Initial
energy minimization (2000 steps) was followed by 15 ps of sim-
ulated annealing in a vacuum and 20 ps of simulated annealing
using a generalized Born solvent model (46). The 30 structures
with the lowest AMBER energy andwith no distance constraint
violation greater than 0.2Åwere selected. Analysis of the family
of structures obtained was carried out using the programsMol-
mol (47) and PyMOL (The PyMOL Molecular Graphics Sys-
tem, Version 1.5.0.4, Schrödinger, LLC).
Molecular Dynamics Simulations—Two starting structures
(A-B and C-D monomers) of the wild-type human insulin for
simulation runs were derived from the high resolution 1mso
crystal structure (41). The MD simulations of [HisB24]-insulin
and [D-HisB24]-insulin analogues were based on pH 8.0 NMR
structures of the analogues obtained in this work. Details of the
structure preparation before MD simulation runs are shown in
the supplemental information. The insulinmonomerswere sol-
vated in a box of TIP3P water molecules (48) extending 11 Å
from the protein. TwoNa$ counterions were added to neutral-
ize the charge. The systems were relaxed in several steps before
MD (for details, see the supplemental information). The MD
was run in periodic boundary conditions using AMBER (45)
and comprised three stages: warming, equilibration, and pro-
duction runs. In the first stage, the temperature was raised
gradually from 10 to 300 K over 25 ps. The equilibration stage
was run for 200 ps, and a production of 50 ns length ensued at
300 K and 1 atm. Three trajectories for each case were simu-
lated using different starting conditions (random number gen-
erator seed for assigning the initial velocities), and only the
most structurally stable ones according to the rootmean square
deviations (r.m.s.d.) were chosen for further analyses. All the
bond lengths were constrained using the SHAKE algorithm
(49), which allowed a time step of 2 fs. The frames were saved
every 5 ps. The analyses of the MD trajectories included meas-
urements of the positional fluctuations of insulin residues,
selected interatomic distances, and backbone r.m.s.d. with
respect to the starting structure.
RESULTS
Binding Affinities of Analogues
Seven new insulin analogues have been prepared by enzy-
matic semisynthesis. Their binding affinities, presented here in
two groups for single-B24 and double-B24/B26-substituted
analogues, are shown in Table 1, with the corresponding bind-
ing curves provided in supplemental Fig. S1. We consider here
the [D-HisB24, GluB26, LysB28, ProB29]-insulin as a “double-
mutant” as the LysB287 ProB29 swap does not have any impact
on binding affinity (50). This swap was introduced into this
analog to promote its monomeric behavior (51) for solution
NMR studies.
In the group of B24-single substituted analogues,
[D-HisB24]-insulin displays the highest binding affinity of
!212% compared with wild-type insulin. In contrast, its L-a-
mino acid analog, [HisB24]-insulin, has an only very low IR
affinity of 1.5%. Mutations with an expected impact on confor-
mation of themain chain yielded a [SarB24]-insulin analogwith
highly reduced affinity (6.3%), whereas[ProB24]-insulin was
inactive (0.16%).
In the second group of analogues, two “positive” hormone
mutations (D-HisB24 and GluB26, each individually with higher
IR affinity) were combined to elucidate their simultaneous
effect on binding affinity. The high biological activity of the
[GluB26]-insulinwas already reported (52), but the actual bind-
ing affinity data were not available. Therefore, the [GluB26,
LysB28, ProB29]-insulin was prepared as a reference molecule,
and it confirmed the high affinity (193%) of this analog. Surpris-
ingly, the simultaneous combination of the positive mutations
of the B24 and B26 sites, D-HisB24 and GluB26, respectively,
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abolished the individual affinity gains, having a detrimental
effect on the affinities of both double analogues ([D-HisB24,
GluB26]-insulin with 2.8% affinity and [D-HisB24, GluB26,
LysB28, ProB29]-insulin with 1.8% binding affinity).
X-ray Structure of [HisB24]-insulin
This analog gave crystals only under monomeric conditions
(pH 3.0, see supplemental Table S1) with one molecule in the
asymmetric unit. Despite relatively high resolution data, the
monomer of this analog displayed a high degree of disorder
(supplemental Fig. S2). Only the ValB2-GluB21 part of the
B-chain was defined in the electron density maps with the
GluB21 side chain being fully disordered. The position of the
A-chain C-terminal AsnA21 also could not be allocated. The
B2-B6 B-chainN terminus adopts a T-R “intermediate” confor-
mation observed in other monomeric x-ray structures of insu-
lin analogues (19) and some of its dimeric forms (53) as well.
The total disorder of B22-B30 chain (hence the lack of B25NH-
COA19 hydrogen bond) results in the conformation of the
A-chain observed in some other monomeric analogues (19, 54)
(movement from the wild-type insulin T-state conformation,
i.e. away from the B24-B30 chain, and !38o rotation of the
A1-A9 helix around A2C! axis). In addition, the lack of the
B23CO-NHA21 hydrogen bond did not allow clear localization
of the A-chain C-terminal AsnA21, which is also missing in the
model. The TyrB16 is flipped toward the “empty” B24 site and is
stabilized by a close (!3.55 Å) van der Waals contact with the
ValB12 side chain. The remains of the B19-B22 turn (B19-B21
main chain) adopt a conformation not observed in other insu-
lins (close towardTyrB16 side chain). However, itmay represent
one of the few alternative directions of the B20-B30 chain that
cannot be traced and refined in this analog.
NMR Structures of [HisB24]-insulin and [D-HisB24]-insulin
Analogues
NMR spectra for both HisB24 and D-HisB24 analogues were
acquired at pH 1.9 and pH 8.0 to address the issues related to
the pKa of the insulin side chains and potential disruptive influ-
ence of the buffering systems (55).
Both analogues provided good quality NMR spectra under
acidic conditions (20% d3-acetic acid, pH 1.9), which is indica-
tive of a monomeric behavior for the modified insulin mole-
cules. The essentially complete sequence-specific assignment
of 1H NMR resonances was obtained for [HisB24]-insulin and
[D-HisB24]-insulin using a combination of two-dimensional
homonuclear experiments. The detailed resonance assign-
ments are shown in supplemental Tables S2 and S3. The chem-
ical shift values for H#2 from the side chains of three histidines
(at positions B5, B10, and B24) in the acidic pH were indicative
of their double-protonated (charged) state (56). In addition, a
significant line-broadening of the 1HN NMR signals of several
residues (ThrA8, SerA9, CysA11, LeuB6, andGlyB8) was observed,
suggesting the presence of chemical exchange due to the
isomerization of the adjacent disulfide bonds in the NMR time
scale. Because of limited solubility and susceptibility to aggre-
gation, it was not possible to obtain reasonable quality NMR
data for L- and D-HisB24 analogues in aqueous solution at pH 7.
However, the analogues were fully soluble and predomi-
nantly monomeric at pH 8.0 up to a concentration of 0.5 mM.
Nevertheless, a significant proportion of the HN signals were
not present in the NMR spectra due to a rapid exchange of the
amide hydrogens with the solvent at basic pH. Consequently,
the number of assigned resonances for both analogues was sig-
nificantly lower at this pH. In particular, 91.0% (95.1% exclud-
ing HN) resonances could be assigned for [HisB24]-insulin and
86.5% (93.0% excludingHN) resonances for [D-HisB24]-insulin.
The assignments obtained for analogues at pH 8.0 are shown in
supplemental Tables S4 and S5. Because of the extensive over-
laps of the NMR signals in certain spectral regions, the number
of resonances that could not be unambiguously assigned was
higher in the [D-HisB24]-insulin analog. The chemical shift val-
ues of the B24 histidine side chains for both analogues suggest
their mono-protonated (neutral) state under basic conditions.
The 1H resonance assignments obtained for [HisB24]-insulin
and [D-HisB24]-insulin under acidic and basic conditions
allowed automated assignment of the NOEs identified in two-
dimensional NOESY spectra using protocols described under
“Experimental Procedures.” The numbers of observed NOE
TABLE 1
Values of IC50, Kd, and the relative binding affinities of human insulin and insulin analogues
Analogue
IC50"
S.E.a, (n)
Kd"
S.E.,
(n) Potencyb
nM nM %
Single B24-substituted analogues
Human insulin 0.89% 0.06 (3) NDc 100% 7
Human insulin ND 0.39% 0.01 (6) 100% 3
[HisB24]-insulin 59.5% 6.2 (3) ND 1.5% 0.16
[D-HisB24]-insulin 0.42% 0.04 (3) ND 212% 20
[SarB24]-insulin 14.1% 2.4 (5) ND 6.3% 1.1
[ProB24]-insulin ND 240% 7 (5) 0.16% 0.005
Double B24/B26-substituted analogues
[D-HisB24,GluB26]-insulin 31.5% 2.9 (4) ND 2.8% 0.26
[D-HisB24,GluB26,LysB28,ProB29]-
insulin
49.8% 3.9 (4) ND 1.8% 0.14
[GluB26,LysB28,ProB29]-insulin 0.46% 0.06 (3) ND 193.0% 25
a IC50 values represent the concentrations of insulin or the analogues that cause half-maximal inhibition of binding of human [125I]monoiodotyrosylA14-insulin to IR. Each
value represents the mean% S.E. of multiple determinations (n).
bRelative receptor binding affinity (potency) is defined as (IC50 or Kd of human insulin/IC50 or Kd of analogue)& 100.
cND, Not determined.
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peaks, distance constraints, and structural statistics for
obtained structures are shown in supplemental Table S6.
The 1H chemical shifts values for both analogues display a
high degree of similarity for the parts of the molecule further
from the introduced modification at the position B24, as illus-
trated by the calculated chemical shift differences for HN and
H! at pH 1.9 and 8.0 shown in supplemental Table S7. The
significant differences were found for the HN chemical shift
values from residues at positions B20-B26 at pH 1.9 and B23-
B27 at pH 8.0. Interestingly, only a very limited number of the
NOE contacts between the side chains of aromatic residues
(HisB24, PheB25, TyrB26) from theC-terminal part of theB-chain
and hydrophobic core of insulin were observed in the NOESY
spectra acquired at pH 1.9. However, an extensive network of
these contacts re-emerged in the NOESY spectra obtained at
pH 8 (Fig. 1).
The solution structures calculated from the NMR data for
[HisB24]-insulin and [D-HisB24]-insulin at pH 1.9 and pH 8.0
are shown in Fig. 2. Detailed analysis revealed that A-chain of
both analogues adopts a characteristic helix-turn-helix confor-
mation independently of the pH. As expected, the N-terminal
!-helix of A-chain (A1-A6) is not very well defined at pH 8.0
due to an insufficient number of NOE contacts involving back-
bone amide hydrogens, which are key for stabilization of the
local helical conformation in proteins. The effect is more evi-
dent for [D-HisB24]-insulin (Fig. 2D). In addition, the overall
appearance of the [D-HisB24]-insulin structure was affected by
a significantly lower number of NOE peaks observed in the
NOESY spectrum, which resulted in a reduced number of the
non-redundant distance constraints (supplemental Table S7).
Under acidic conditions (pH 1.9), the C-terminal parts of the
B-chain (B21-B30) were found disordered in both analogues
despite a well defined central!-helix (B9-B20). Hence,medium
to long range NOE contacts were not identified between resi-
dues B21 and B30 and the rest of the molecule (Fig. 2,A andC).
At pH 8.0, theNOEpattern indicating the reestablishment of
the contacts between the core hydrophobic residues and the
C-terminal loop of the B-chain was identified in the NOESY
spectra of both analogues (Fig. 1) before the structure calcula-
tion. However, the overall organization of the pH 8.0 NMR
structures (Fig. 2, B and D) of these analogues revealed signifi-
cant differences in the conformations of their respective
B-chains (Fig. 3).
The overall feature of the [HisB24]-insulin pH 8.0 NMR
structure is its well ordered and defined character. Detailed
analysis of the [HisB24]-insulin structure revealed that the his-
tidine side chain is very well accommodated and stabilized in
the B24 pocket not only by typical, wild-type-like nonpolar
interactions (with ValB12 and LeuB15) but by new hydrogen
bonds aswell (Fig. 3A). The protonatedB24 imidazoleN#2 atom
forms a strong (2.9- 3.2 Å) hydrogen bond (calculated between
heteroatoms) with ValB12 CO, whereas the deprotonated imid-
azole N$1 atom forms a weaker and transient hydrogen bond
(3.4- 3.9 Å) with TyrB26 NH. Subsequently, the TyrB26 side
chain is shifted closer to the core of the molecule compared
with its position in human insulin, and subsequently its OH
group is engaged in hydrogen bonds with GlyB8 CO and/or
GlyB8 NH (3.8–8.8 and 3.3–9.9 Å, respectively). However, the
observed ranges suggest that these hydrogen bonds may be
transient or mediated by water molecules, as observed in
human insulin (57). The shift of TyrB26 side chain also enables
its C-H %-like stacking contact with ProB28 side chain. All new
interactions that involve B24-B28 residues result in a very firm
stabilization of the B21-B30"-strand, its tethering into the ana-
log core, and the increased overall compactness of this protein.
In contrast to the ordered and compacted structure of the
[His]-insulin analog, parts of the [D-His]-insulin structure at pH
8.0 are not fully defined. This is despite similar and clear rees-
tablishment of contacts between the insulin hydrophobic core
and the C-terminal loop of B-chain at pH 8.0, which were also
FIGURE 1. The side chains of the aromatic residues from the C-terminal loop of B-chain re-establish the interaction with themethyl groups from the
protein core under basic conditions. Panel A shows a region from the two-dimensional NOESY spectrumof [HisB24]-insulin acquired at pH 1.9 showingNOE
cross-peaks between aromatic andmethyl hydrogens. The limited number of NOEs originates mainly from the contacts involving TyrA14, TyrA19, HisB5, and
HisB10 with the adjacent methyl side chains. Panel B shows the data obtained for [HisB24]-insulin at pH 8.0. The additional NOE cross-peaks are from the
contacts between the aromatic rings (HisB24 and TyrB25) and methyl groups (LeuB11 and LeuB15).
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undefined in this analog at pH 1.9. The incorporation of the
D-form of the His residue at the B24 site had a profound impact
on the organization of the main chain and side chains in this
region (Fig. 3B). This substitution changed the local B24-back-
bone topology, where the D-chirality of the B24C! swayed the
D-HisB24 away from the insulin core. The uprooting of the His
side chain from the PheB24 pocket had, in turn, profound con-
sequences on the B24 down- and upstreamparts of the B-chain.
Most remarkably, the cavity of the His-depleted PheB24 hydro-
phobic pocket was filled again by the PheB25, which mimics the
“missing” D-His side chain. This retractile change of the “regis-
ter” along the B23-B30 strand results in subsequent structural
downshift of the TyrB26 into the B25 site. Here, the TyrB26 fol-
lows the PheB25-typical outward conformation. In addition, in
contrast to the [HisB24] analog pH 8.0 structure, the B27-B30
residues depart from the insulin molecule core revealing previ-
ously fully buriedValB12 andLeuB15 (supplemental Fig. S3). The
N-terminal arms of the B-chains (B1-B6) were found in the
T-like states in both analogues, as in solution structures of
monomeric insulins (7).
MDof theWild-type Insulin and [HisB24]- and [D-HisB24]-
insulin Analogues
Overall Structural Stability—The 50-ns MD trajectories of
the A-B and C-D insulin monomers derived from the 1mso
dimer of human insulin (41) became stable after 20 ns with a
r.m.s.d. oscillation!2.5 or 3 Å from the starting x-ray structure
(Fig. 4A).
The backbone r.m.s.d. of the [HisB24]-insulin 50-ns trajec-
torywasmore stablewith r.m.s.d. oscillating!2Å from the first
NMR structure. The hydrogen bond pattern of [HisB24]-insu-
lin observed in the NMR structure of this analog (N#2-ValB12
CO of 2.9–3.2 Å and N$1-TyrB26 HN of 3.4- 3.9 Å) was fully
preserved throughout the whole simulation run. In contrast,
the [D-HisB24]-insulin trajectory departed very significantly
from the startingNMR structure (up to r.m.s.d. of!5- 6 Å) and
appeared stable only after 40 ns at a higher plateau of 2.6 Å (Fig.
4B).
Segment Movements—To understand the movements of the
C terminus of the B-chain (residues B24-B28) in relation to the
insulin rigid core (B7-B19 central !-helix), five representative
distances (B24C!-B15C!, B25C!-B15C!, B26C!-B12C!,
B27C!-B11C!, and B28C!-B8C!) between these structural ele-
ments were measured in [HisB24]-insulin, [D-HisB24]-insulin,
and in A-B and C-D monomers of human insulin in the course
of theMD production runs. The C! atoms of residues B26-B28
in the wild-type A-B insulin monomer (supplemental Fig. S4A)
displayed significant movements; however, the B24 and B25 C!
atoms remained relatively stable. Smaller shifts in the initial
part of the simulation were observed in the case of wild-type
C-Dmonomers (supplemental Fig. S4B); however, they tend to
converge to the A-B-like r.m.s.d. after 20 ns. All selected dis-
tances in the [D-HisB24]-analog displayed relatively high flexi-
bility in the course of MD runs (Fig. 5B). In contrast, the B24-
B28 chain in [HisB24]-insulin was very rigid (Fig. 5A) without
any significant movements (cf. Fig. 4B).
Residue Flexibility—Positional fluctuations of the wild-type
insulin and analog residues over the 50-nsMD simulation runs
are shown in supplemental Fig. S5. The largest flexibility
FIGURE 2. The solution structures of the [HisB24]-insulin and [D-HisB24]-insulin analogues. Structures are represented by best-fit superpositions of the
protein backbone for 30 converged structures. TheA-chain is colored in red, and the B-chain is in black in all structures. Panel A shows [HisB24]-insulin at pH1.9,
whereas panel B contains a set of structures obtained for the same analog at pH 8.0. [D-HisB24]-insulin structure at pH 1.9 is shown in panel C and at pH 8.0 in
panel D. The positions of histidine side chains are colored in blue. The N and C termini of the insulin A and B chains are marked as NA-chain, CA-chain (in red) and
NB-chain,CB-chain (in black), respectively. The C-terminal part of the B-chain (residues B21-B30), which is found flexible in both analogues under acidic conditions,
reestablished extensive contacts with the protein core in the basic environment.
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('500) is concentrated on theN andC termini of the B-chain in
both the A-B and C-D monomers of human insulin. The
[HisB24]-insulin yielded the most stable structures (supple-
mental Fig. S5A). This trend, increased residue flexibility of the
human insulin and [D-His]-insulin (supplemental Fig. S5B) and
lower flexibility of [His]-insulin, was observed throughout the
entirety of the insulin molecule.
DISCUSSION
The three aromatic amino acids PheB24, PheB25, and TyrB26
from the C-terminal part of the B-chain are some of the key
residues identified in human insulin. These residues are impor-
tant for both formation of the dimer interface of the hormone
(3) and its interactions with IR (18, 20). Considering the pro-
longed absence of structural description of the B22-B30-
chain-IR interface (5), we focused here on a more systematic
probing of the role of PheB24 aromatic side chain and chirality of
its C! atom for the structure and function of the hormone.
Extensive and complex data emerging fromother studies on the
B24 site are summarized in supplemental Table S8. Focusing on
FIGURE 3. An overlay of the B-chain of human insulin (PDB code 1mso
(41), in gray) with the B-chain of [HisB24]-insulin (panel A, in coral) or
[D-HisB24]-insulin (panel B, in coral) analogues (representative NMR
structures at pH 8. 0). Only the positions of Phe/HisB24, PheB25, and TyrB26
side chains are shown. Dashed lines in panel A indicate selected hydrogen
bonds stabilizing the structure of [HisB24]-insulin.
FIGURE 4.Backbone r.m.s.d. of human insulinmonomers A-B (in red) and
C-D (in blue) derived from 1mso dimer (41) (panel A) and [D-HisB24]-in-
sulin (in red) and [HisB24]-insulin (inblue) (panelB) derived fromtheirpH
8.0 NMR structures (this work) during 50 nsMD simulation runs.
FIGURE 5. The changes in five representative distances (B24C!-B15C! in
black, B25C!-B15C! in red, B26C!-B12C! in blue, B27C!-B11C! in green,
and B28C!-B8C! in yellow) were measured in [HisB24]-insulin (panel A)
and [D-HisB24]-insulin (panel B) in the course of 50-ns MD runs.
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the B24 site, we have tested its functional and structural
response to (i) an alternative polar aromatic side chain (His), (ii)
inverse C! chirality (D-His), and (iii) structural main chain
restrains (Pro, Sar) on hormone structure and function. The
histidine side chain was selected for its partially aromatic char-
acter, similar size to phenylalanine side chain, and its imidazole
hydrogen-bond formation potential. The possible functional
cooperativity between B24 and B26 sites in insulin-IR interac-
tions was further investigated in a double [D-HisB24, GluB26]-
insulin mutant and its variant ([D-HisB24, GluB26, LysB28,
ProB29]-insulin) (Table 1).
The replacement of PheB24 by any L-amino acid disrupts
insulin biological activity and affinity (supplemental Table S8).
The binding affinities of non-aromatic LeuB24, SerB24, and
AlaB24 insulin analogues do not exceed 20% in most cases.
Interestingly, the simultaneous loss of the side chain and chi-
rality at the B24 position (i.e. GlyB24]-insulin) is relatively well
tolerated, yielding affinities in the range of 22–78%. In contrast,
the replacement of PheB24 by D-amino acids enhances binding
affinity in most of the analogues (i.e. [D-AlaB24]-insulin, 150%;
[D-PheB24]-insulin, 140–180%), with an exception for the
D-ProB24 analog. Double B24/B26 mutants followed this trend
as the [D-TyrB24, PheB26]-insulin possesses 163% affinity
([PheB26]-insulin itself displays 45% binding affinity (3, 58)),
whereas its L-amino acid variant [TyrB24, PheB26]-insulin is
inactive (2%). Interestingly, the incorporation of an achiral
amino acid derivative with a pair of methyl groups attached to
the C! carbon atom, !-aminoisobutyric acid, at the B24 site
results in an!-aminoisobutyric acid B24-insulin analogwith no
potency (0.3%).
Therefore, the high affinity (212%) of the [D-HisB24]-insulin
and weak binding of [HisB24]-insulin (1.5% affinity) obtained
here were in agreement with trends observed in available data.
However, they did not provide immediate explanation of the
binding pattern observed in B24-site insulin mutants. There-
fore, a comprehensive structural characterization of [HisB24]-
and [D-HisB24]-insulins was undertaken in this study. NMR
structures were determined in parallel at acidic and basic pH
values (i.e. pH!1.9 versus pH 8.0) to avoid possible bias result-
ing from the pHandbuffer effects on insulin conformation (55).
Additional insights were obtained from theoretical MD
simulations.
Indeed, the crystal and NMR structures of [HisB24]-insulin
and [D-HisB24]-insulin analogues obtained here provide ratio-
nal explanation of the importance of an aromatic invariance of
the B24 site and underline the conservation of the structural
integrity of the PheB24 and its pocket for an effective hormone
functionality.
The striking feature of both the crystal and NMR structures
of [HisB24]- and [D-HisB24]-insulins is the widespread disor-
der of B20-B30 chains at pH 1.9 compared with their well- and
reasonably ordered conformations at pH 8.0 (Fig. 2). A similar
disorder of the B20-B30 part of insulin has been observed in
acidic pH NMR structures of other B24 mutants such as
[GlyB24]-insulin (7, 59), [GlyB24,GluB16, desB30]-insulin (55)
and in [D-AlaB24]-insulin (17). Hence, it is possible that this
phenomenon arises from the structurally deleterious effects of
lowpHand/or acetic acid on some insulin analogues (55).How-
ever, it cannot be excluded that disorder of [HisB24]-insulin
and [D-HisB24]-insulin analogues at pH 1.9 arise from the
repulsive effect of the doubly protonated HisB24 that cannot be
accommodated in the B24 hydrophobic cavity. Therefore, we
focused here on analysis of more physiological pH 8.0-derived
insulin structures and their defined conformations.
The NMR spectra at pH 8.0 yielded a well ordered and com-
pact structure of [HisB24]-insulin (Fig. 2B). Its main feature is a
stable accommodation of the N#2-monoprotonated imidazole
ring inserted in the B24 hydrophobic cavity. Interestingly, the
histidine side chain is accommodated there even more firmly
than the phenyl moiety of PheB24 as it thrusts into the cavity
!1.2 Å deeper than the PheB24 phenyl ring of the wild-type
insulin. This HisB24-related compactness of the structure is a
likely result of the combination of the combined effects of the
still-present aromatic character of the B24 imidazole with its
hydrogen bond-forming capability. In addition to close van der
Waals imidazole B24-LeuB15 contacts, the side chain of HisB24
is anchored firmly by strong B24N#2-COValB12 and weaker
B24N$1-NHTyrB26 hydrogen bonds (Fig. 3A). This tight
engagement of HisB24 within the B24 cavity has a precipitous
effect on the remaining part of the B25-B30 chain, which is also
pulled back close to the core of the hormone. This insulin-
wrapping conformation of the B-chain is further stabilized by
GlyB8CO/NH-OHTyrB26 direct hydrogen bonds and wedging
of the TyrB26 phenyl ring between ProB28 and IleA2. This
“immobilization” and tethering of the B24-B30 chain into the
[HisB24]-insulin core at pH 8.0 are likely reasons for the low
affinity of this analog and of its monomeric behavior.
The “over-conservation” of the B24-B30-fold observed in
[HisB24]-insulin is in contrast with the radical rearrangement
of the B20-B30 chain in the [D-HisB24]-insulin at the same,
high pH 8.0 (Fig. 2D). Such rearrangement is a result of the
pull-out of the histidine side chain from the Phe B24 pocket by
the inverse chirality of the D-HisB24 C! atom and subsequent/
simultaneous filling-up of the emerging empty cavity by
another available aromatic side chain that is provided here by
PheB25. The locations of PheB24 and PheB25 aromatic rings in
the wild-type and [D-HisB24]-insulins, respectively, are very
similar, with a remarkable conservation of the position of the
C! atoms that differ by only !0.55 Å in both analogues (Fig.
3B).
The compensatory capability of the PheB25 to act as PheB24
structural substitute has also been observed in the pH 8.0 NMR
structure of [GlyB24, GluB16, desB30]-insulin in which both
the side chain of the B24 residue and the chirality of its C! atom
have been removed (55). In contrast, the NMR structure of
[D-AlaB24]-insulin (17) indicated disorder of the B20-B30 part
of the molecule. However, due to a lack of some NMR experi-
mental detail there (e.g. pH at which the NMR spectra were
measured), we suppose that the significant mobility of this
chain in [D-AlaB24]-insulin arise from the use of low pH (deu-
terioacetic acid) in these NMR experiments (17). The “down-
register” shift of the B24-B30 chain in [D-HisB24]-insulin is
structurally propagated there on both sides of the B24 site. For
example, the B19-B22 "-turn is lost in favor of a larger bulge,
TyrB26 occupies PheB25 position, and the B26-B30 chain
departs from the insulin core. Importantly, these large scale
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structural rearrangements are correlated with the high affinity
of this analog. Furthermore, it is not excluded that the
B263B25 downshift observed in [D-HisB24]-insulin contrib-
utes also to the high affinity of this analog because Glendorf et
al. (60) reported [TyrB25]-insulin with a high binding affinity
(285%).
The NMR/x-ray experimental structural evidence about
[HisB24]- and [D-HisB24]-insulins was confirmed by MD sim-
ulations. First, it was established that the overall mobility and
dynamics of the wild-type insulin does not depend on slightly
different starting models (i.e. A-B versus C-D monomers
derived from the human insulin dimer, PDB code 1mso) (41).
Although the C terminus of the B-chain detached sooner from
the insulin core in the A-B monomer compared with the C-D
one (cf. the overall r.m.s.d. in Fig. 4A), both simulations con-
verged to stable plateaus of similar r.m.s.d. after an !20-ns-
long run. The reason for this delayed detachment in the C-D
monomer is possibly due to the salt bridge between theGlyA1N
and ThrB30 O atoms present in the x-ray structure only in this
monomer and persisting in the MD up to four ns. In addition,
our simulations agreed with previous insulin MD studies (61,
62); all of the simulations indicate the same range of insulin
mobility and partial, approximately B25-B30, detachment of
the B-chain from the hormone core. Second, the MD simula-
tions also fully agreed with the distinct NMR conformational
stabilities of [HisB24]- and [D-HisB24]-insulins. The r.m.s.d. for
[HisB24]-insulin are strikingly invariant and steady, in contrast
with the higher r.m.s.d. of [D-HisB24]-insulin that indicates its
increased mobility that exceeds the dynamics of the wild-type
insulin (Fig. 4B). Third, the analysis of selected distances
between the key regions of the hormone indicates the detach-
ment of the B25-B30 B-chain in the wild-type and [D-HisB24]-
insulin but conservation of the B24 C! region (Fig. 5).
Direct correlation of the affinities of [HisB24]- and
[D-HisB24]-insulin with their contrasting structural features
observed here, i.e. “gluing” of the B24-B30 chain to insulin core
versus “liberation” of the B25-B30 chain, respectively, confirm
the established consensus about the detachment of the B-chain
needed for insulin activation upon its binding to the IR. How-
ever, the scale of the detachment of the B20-B30 chain in this
process is still not determined. It is debatable whether a full
unfolding of the approximately B22-B30 chain is needed for
insulin activation (18) or whether the effective engagement of
the hormonewith IR can be achieved by amoremodest reshap-
ing of the B25-B30 residues in a form similar to that observed in
B26-turn containing high affinity analogues (19). The high
affinity of the [D-HisB24]-insulin and its structural persistence
for conservation and occupation of the PheB24 cavity by an aro-
matic moiety suggest that the PheB24 side chain may remain in
place upon insulin activation. Themaintenance of theB24 “aro-
matic” cavity in a very mobile and reshaped, but still highly
active, analog is in concordance with the strict preservation of
the B24 side chain in high affinity analogues in which it was
considered as one of the crucial invariant side chain pivots (19).
In addition, it appears that [D-HisB24]-insulin, with its less rigid
andmore flexible structure, is better primed than native insulin
for the detachment and activation of the approximately B25-
B30 C-terminal "-strand upon binding to the IR.
The need for the structural invariance of the B24 C! atoms is
supported further by the low affinities of [ProB24]-insulin and
[SarB24]-insulin analogues (Table 1 and supplemental Table
S8) that contain the main chain constraining amino acids (63).
The ProB24 and SarB24 substitutions not only result in the
absence of aromatic side chains, but their specific dihedral
angles impose restrictions on moderate flexibility at the B24
site, likely excluding any B253B24-like compensatory struc-
tural downshift observed in highly active [D-HisB24]-insulin. In
contrast, the dihedral &/' angles of glycine and D-amino acids
at the B24 site allow for a rearrangement of insulin molecule
that leads to an effective IR binding. The structural vulnerabil-
ity of the main chain at the B24 site and the sensitivity of its C!
chirality are, therefore, expressed in both aromatic pulldown
(B253B24) structural rearrangements andmaintenance of the
position of this atom. These underline the need for an overall
conservation of the phenylalanine-like character of this site.
However, it cannot be excluded that the low affinities of
[ProB24]-insulin and [SarB24]-insulin analogues may result
from the loss of B24 amide hydrogens, whichmay be important
for IR binding (3).
Despite the progress in understanding the roles of individual
substitutions at the B24 site, the negative-cooperative effects of
double B24/B26 mutations in [D-HisB24, GluB26]- and
[D-HisB24, GluB26, LysB28,ProB29]-insulins, which abolish
affinity gains of single site replacements at the B24/B26 sites,
are less obvious. The only one available NMR structure of
[D-HisB24, GluB26, LysB28, ProB29]-insulin determined at pH
1.9 that shows large scale disorder of the B-chain (data not
shown) observed in “acidic” structures of [HisB24]- and
[D-HisB24]-insulins, and the structural effect of double
[D-HisB24,GluB26] mutation remains unclear. However, the
low affinity of the [D-HisB24,GluB26]-mutants may result from
the unfavorable replacement of PheB25 aromatic ring by glu-
tamic acid side chain if the B253 B24 downshift takes place in
this analog as well as in [D-HisB24]-insulin. If such rearrange-
ment does occur there, theGluB26-side chain should occupy the
position of theB25 phenyl ring inwild-type insulin, hencemim-
icking the PheB253 GluB25 mutation, which is most likely fully
detrimental as observed in the case of similar PheB253Asp B25
substitution (64). In contrast, the B253B24 downshift in high
affinity [D-HisB24]-insulin is compensated by the move of
another aromatic TyrB26 side chain into the B25 position. It is
also possible that the GluB26 side chain follows the TyrB26 sol-
vent-pointing conformation observed in [D-HisB24]-insulin
and, therefore, is capable of forming hydrogen bonds to also
solvent-exposed D-HisB24 and neighboring AsnA21 or ThrB30.
These interactions altogether can have a negative effect on IR
binding due to the over-stabilization of this region.
In summary, our data rationalize the positive effects of D-a-
mino acid substitutions at the B24 site. They indicate the
importance of the aromatic character of the B24 side chain for
insulin activity, which is demonstrated by the B253B24 “res-
cue” downshift of PheB25 into the B24 site. They also underline
the invariance of the position of the B24C! atom for effective IR
binding. Moreover, they also provide supporting evidence for a
limited, B25 onward, unfolding of theC terminus of the B-chain
during hormone activation in disfavor of its full (B22-B30)
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detachment. However, the actual nature of PheB24 engagement
with IR requires further insulin-IR complex studies.
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